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 i 
Abstract 
 
Adenomatous Polyposis Coli (APC) is a multifunctional tumour suppressor protein and 
a negative regulator of the β-catenin Wnt signalling pathway. APC also contributes to 
numerous other pathways for normal cell growth and differentiation including cell 
migration, mitosis, and DNA repair and replication. Mutations in the APC gene occur in 
~80% of colorectal cancers (CRCs) and typically give rise to a truncated protein lacking 
C-terminal sequences which display altered mobility, subcellular localisation and 
function. APC gene mutation is one of the earliest events in the progression of inherited 
and sporadic CRC and initiates subsequent deregulation of key cellular pathways. 
Previous studies from this laboratory identified a new subcellular localisation for APC 
at the mitochondria, an intriguing finding given that many crucial aspects of 
mitochondrial function are also reported to be deregulated in carcinogenesis.  In 
particular, the efficient distribution of mitochondria throughout the cell is essential for 
their ability to perform site-specific tasks including effective ATP dispersal, and there is 
a growing body of evidence which suggests that alterations in this process contribute to 
cancer progression. This thesis seeks to investigate the hypothesis that APC plays a role 
in the anterograde transport of mitochondria, and that this process is disrupted by CRC-
associated APC mutations.  
 
The above hypothesis is first tested and initially validated in Chapter 3, where 
observations from immunofluorescence microscopy of fixed cells revealed that the 
typical uniform spread of mitochondria throughout the cytoplasm was disrupted 
following siRNA-mediated loss of wild-type APC. These cells displayed a strong 
perinuclear accumulation of mitochondria after APC silencing, indicative of disruption 
to mitochondrial transport. Further analysis of other membrane bound organelles 
following loss of wild-type APC indicated that this phenomena was specific to 
mitochondria, and not a by-product of microtubule destabilisation. These findings were 
consolidated by the use of immunoprecipitation and proximity ligation assay protein-
binding studies that revealed APC interacts at the mitochondria with Miro and Milton, 
crucial protein components of the primary mitochondrial transport complex.  
 
Chapter 4 explores the implications of APC mutation on mitochondrial transport and 
identifies the C-terminal region of APC, commonly lost in CRC, as the Miro/Milton 
 ii 
binding domain. In support of this notion, analysis of fixed cells by 
immunofluorescence microscopy showed that C-terminal deletion of APC in mutant cell 
lines severely impaired mitochondrial localisation at the cell periphery. This correlated 
with binding studies which indicated that the association of mutant APC with 
Miro/Milton was compromised. Both mitochondrial distribution and the APC-
Miro/Milton interaction could be recovered in CRC cell lines upon reconstitution of 
wild-type APC, thereby providing a direct link between APC and Miro/Milton-mediated 
mitochondrial localisation. 
 
In Chapter 5, mitochondria are tracked in real time in live cells to investigate the 
mechanism by which APC regulates transport to the cell periphery. Compared to 
mitochondria in control cells, a striking decrease in anterograde motility was observed 
following silencing of wild-type APC. The velocity or rate of mitochondrial transport, 
on the other hand, remained unaffected once transport had commenced, indicating a 
specific role for APC in the initiation of mitochondrial transport. This finding correlates 
with experiments in fixed cells which demonstrated that loss of APC reduced 
mitochondrial localisation at dynamic regions of the cell membrane, suggesting that 
APC may act as a mitochondrial chaperone to deliver targeted ATP supplies to the cell 
periphery, possibly for cell migration. The nature of the APC-Miro/Milton interaction is 
examined in more detail in Chapter 6, where a series of proximity ligation assay-based 
protein binding studies show that both loss of wild-type APC, and APC C-terminal 
deletion, disrupts the association between Miro and Milton. These preliminary findings 
suggest that APC may stabilise the Miro/Milton interaction, potentially acting in a 
scaffolding capacity.   
 
The identification of a new role for APC in the transport of mitochondria opens up a 
new route through which CRC-associated APC mutations may contribute to the 
carcinogenic process. Pathways contributing to mitochondrial dysfunction are 
increasingly being targeted in the treatment of numerous cancer types, and these 
findings could offer an additional range of protein drug targets.   
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1.1 Background 
Colorectal Cancer (CRC) is the second most common cancer diagnosed in Australia and 
in 2012 approximately 16,000 new cases were reported (1). CRC primarily affects 
patients over the age of 75 and results in ~ 4,000 deaths each year (1). The high 
incidence and mortality rate of CRC is also observed world-wide with 1,369,000 and 
694,000 cases respectively reported in 2012 (2). Development of colon cancer results 
from an accumulation of gene mutations (activating mutations in oncogenes and 
inactivating mutations in tumour suppressor genes) that promote genomic instability 
and cellular transformation. Mutation of the gene encoding the tumour suppressor, 
adenomatous polyposis coli (APC), occurs in 80% of CRC and is one of the earliest 
events in the progression of sporadic colon cancer (3-5). APC was first identified as the 
mutated protein responsible for familial adenomatous polyposis (FAP), an autosomal 
dominant disease carrying a germ line APC mutation and characterised by the formation 
of colorectal polyps. This inherited mutation primes the other APC gene allele for a 
‘second hit’ in the form of a somatic mutation, which can predispose patients to a high 
risk of early CRC (6-8).  
 
It is not surprising that APC mutation is a driving force behind carcinogenesis given its 
multiple roles in the deregulation of key cell growth and differentiation pathways, 
which are disrupted following loss of C-terminal functional domains. This includes 
altered APC function as a negative regulator of the Wnt signalling pathway, where it 
contributes to β-catenin degradation (9, 10). APC truncation also impacts its numerous 
other functions at locations throughout the cell, including the nucleus, plasma 
membrane, centrosome and the mitochondria (11, 12).  
 
The subcellular localisation of APC at the mitochondria was initially identified in this 
laboratory, and it was shown that APC mutants preferentially accumulate at 
mitochondria to stabilise Bcl-2 and protect cells against apoptosis (13). The notion that 
APC, a potent tumour suppressor, localised to the mitochondria was intriguing given the 
growing body of evidence implicating mitochondrial dysfunction in the carcinogenic 
process (reviewed in 14). Like APC, the ability of mitochondria to utilise elements of 
the cytoskeleton to shuttle around the cell and perform site-specific tasks is key to many 
of its essential cellular processes, which include the delivery of ATP to bio-
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energetically demanding regions, and modulation of calcium signals (reviewed in 15, 
16, 17). With this in mind, it is perhaps unsurprising that alterations to transport of 
mitochondria have been linked to cancer progression (18, 19).  
 
The primary aim of this thesis was to test the novel hypothesis that APC plays a 
functional role in regulating transport of the mitochondria. Therefore, this literature 
review provides background on our current understanding of APC biology, localisation 
and function, and describes how CRC-associated APC truncations contribute to 
deregulation of normal cellular processes which lead to tumourigenesis. The second part 
of this chapter will cover key aspects of mitochondria biology, with an emphasis on 
mitochondrial transport and function and how these are altered and/or contribute to the 
development of cancer.  
1.2 The APC tumour suppressor protein 
APC is a large (310 kDa, 2843 amino acids) protein comprised of multiple protein 
interaction sites and functional domains that contribute to normal cell function. These 
include regulation of Wnt signalling and cytoskeletal organisation. In particular, the 
coiled armadillo repeat (Arm) domain is a primary binding site for several important 
APC partners, whilst the ‘basic’ domain and C-terminal regions mediate both direct and 
indirect associations with the cytoskeleton (Figure 1.1). These wide range of protein 
contact sites are critical to the intracellular shuttling of APC, and it has been proposed 
that the Arm domain drives the mobility and targeting of APC within the cell whilst the 
C-terminal half of APC is important for its scaffolding role in assembly of large protein 
complexes (Section 1.2.1, and reviewed in  12).  
 
APC mutations commonly occur in a central region known as the mutation cluster 
region (MCR) (Figure 1.1) and give rise to a truncated protein which lacks the C-
terminal sequence (20). In FAP patients, MCR mutations typically cause the most 
severe phenotypes, presenting >5000 polyps (21). In sporadic CRCs the most common 
truncation is located in the MCR at amino acid 1309 (Figure 1.1). These mutations 
cause an alteration in APC localisation and function, which compromises APC’s tumour 
suppressive function and drives CRC carcinogenesis (see Section 1.2.2). 
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Figure 1.1: Functional domains and protein binding sites of the APC tumour 
suppressor. 
Wild type APC is comprised of 2834 amino acids and contains numerous functional 
domains and protein binding sites. APC truncating mutations often occur in the 
mutation cluster region (MCR), most commonly at amino acid 1309. Loss of C-terminal 
functional domains is a driving force behind CRC carcinogenesis. (*) The APC C-
terminal association with Miro/Milton will be investigated in this thesis. 
 
1.2.1 APC protein localisation, interactions and function 
The dynamic nature of APC enables it to shuttle throughout the cell, performing 
numerous tasks at distinct subcellular locations outside of its best known role in β-
catenin degradation (via regulation of Wnt signalling). Highlighted in Figure 1.2, these 
site-specific tasks include organisation of microtubules and actin filaments at the cell 
membrane, regulation of the DNA repair and damage response in the nucleus and 
regulating microtubule dynamics at the centrosome (11, 12). The recent finding that 
APC also targets to the mitochondria (13), was the foundation of this study. Based on 
the multidirectional targeting of APC, compounded by its ability to regulate the 
cytoskeleton and numerous protein interactions, APC can be considered as a mobile 
scaffolding protein. 
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Figure 1.2: APC localisation to distinct sub-cellular compartments is altered by C-
terminal truncating mutations. 
Wild-type APC can be detected at microtubule dependent protrusions and actin ruffles 
where it accumulates strongly, as well as microtubules, cell:cell junctions, 
mitochondria, the centrosome and the nucleus. C-terminal truncating mutations alter 
APC localisation, and disrupt its site-specific functions. This study focuses on the 
recently defined mitochondrial localisation of APC and investigates a novel role in 
microtubule-dependent mitochondrial transport.  
 
1.2.1.1 Regulation of APC localisation 
As alluded to above and outlined in Figure 1.2, APC is a dynamic, highly mobile 
protein that shuttles between multiple regions in the cell including the nucleus, plasma 
membrane, mitochondria and centrosome where it performs a variety of site-specific 
tasks. This localisation is mediated through a number of pathways which are facilitated 
by both internal signalling sequences and protein-protein interactions (Figure 1.1). For 
example, the N-terminal region of APC comprises critical signal sequences through 
which it is translocated in and out of the nucleus. The nuclear export signal (NES) binds 
to the major export receptor CRM1, to facilitate transport through the nuclear pore 
complex from the nucleus to the cytoplasm (22, 23), whilst the nuclear localisation 
signal (NLS) facilitates transport into the nucleus through its association with Importin 
receptors (24). An additional Arm-domain mediated pathway for APC nuclear import 
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has been identified, and is stimulated by an association with B56α (25). Arm-domain 
targeting of APC to both the centrosome and mitochondria has also been reported, 
though this is not well defined (13 and Lui and Henderson, unpublished). 
 
Targeting of APC to the cell membrane is also partially dependent on the Arm domain 
and its association with the kinesin-2 adaptor protein, KAP3A. This association was 
shown to be necessary, but not sufficient, for APC accumulation at microtubule plus-
ends (26). Deletion mapping further showed that the minimal APC sequence required to 
target APC to cellular protrusions is APC(1-2226), and that this is partly aided by an 
interaction with β-catenin (27). Whilst this mechanism has yet to be fully elucidated, it 
may be regulated in part by GSK-3β-dependent phosphorylation of APC and β-catenin, 
which has been shown to promote detachment of APC from microtubules (28), and β-
catenin destruction (Section 1.2.1.2). These studies provide a logical explanation for the 
innovative live cell timelapse work of Mimori–Kiyosue and colleagues (29), which 
showed that APC travels in clusters along microtubules of living cells. Striatin, another 
Arm-domain binding protein has also been reported to target APC to the cell periphery, 
specifically to cell-cell junctions (30) in an actin-dependent manner. The main context 
for interpreting these studies revolved around explaining how APC is recruited to the 
cell periphery, including the ends of microtubules, membrane protrusions/clusters and 
actin ruffles. However, as will be discussed later (Section 1.4), this thesis will 
investigate the potential novel role of APC as a chaperone for the microtubule-
dependent transport of mitochondria to the membrane. 
 
CRC-associated APC truncations typically impact its role as a mobile scaffold by 
altering its subcellular localisation (see Figure 1.2), in particular cytoskeletal retention 
at the plasma membrane is lost (10, 12, 27). Other important APC targeting domains, 
such as the primary NES and the Arm domain, are located within the N-terminus and 
thus retained in most cancer mutant forms of APC (Figure 1.1), which have been shown 
to be highly mobile within the cell (31). Truncated APC mutants have also been shown 
to accumulate preferentially and more strongly than wild-type APC at mitochondria 
(13). APC must be correctly targeted to specific compartments or structures within the 
cell in order to fulfil its specific roles in normal cell growth and differentiation (Section 
1.2.1.2 - 1.2.1.4). Hence alteration in APC localisation, combined with loss of co-factor 
binding, can disrupt this ability to act as a mobile scaffold, contributing to 
Chapter 1 
7 
carcinogenesis through loss tumour suppressive activity. This is discussed in detail in 
Section 1.2.3.  
1.2.1.2 The role of APC in Wnt Signalling 
Wnt Signalling 
APC is a negative regulator of Wnt signalling, a pathway that relays signals from the 
plasma membrane to the nucleus (via β-catenin), leading to the activation of specific 
genes important for embryogenesis, normal cell growth and differentiation (5, 10, 32, 
33). This pathway is reviewed in detail elsewhere (9, 32, 34, 35), and summarised in 
Figure 1.3. Briefly, under normal cellular conditions, Wnt signalling is turned off and 
APC, Axin, glycogen synthase kinase (GSK-3β) and casein kinase 1α (CKIα) form a 
complex (the ‘destruction complex’) that phosphorylates β-catenin, marking it for 
ubiquitination and ultimately degradation. However, upon association of a Wnt ligand 
with the Frizzled / LRP5/6 receptor complex at the plasma membrane, the destruction 
complex is inactivated, and Wnt signalling activated. This occurs through the 
recruitment and phosphorylation of regulatory protein Dishevelled to the receptor 
complex, in turn signalling LRP5/6 phosphorylation and the recruitment of Axin to the 
cell membrane. Free from degradation, β-catenin accumulates in the cytoplasm, where it 
can translocate to the nucleus, and interact with and trans-activate members of the T cell 
factor (TCF)/lymphoid enhancer factor (LEF) family of transcription factors, TCF1, 
TCF3, TCF4 and LEF1 to promote transcription of Wnt target genes.  
 
APC interactions with Wnt proteins 
To regulate β-catenin degradation, APC closely associates with core proteins in the 
destruction complex including β-catenin, Axin and GSK-3β, along with B56α, a subunit 
of the negative regulatory protein phosphatase 2A (PP2A) (36). These associations are 
outlined in Table 1.1.   
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Table 1.1: Interactions of APC with Wnt proteins. 
Protein Partner Binding Domain(s) Reference 
β-catenin 15 and 20 amino acid repeat domains. These domains are 
subject to GSK-3β and CKIα phosphorylation to enhance β-
catenin binding. 
(37-39) 
Axin SAMP domains (conserved 16 amino acid repeats) 
20R2 domain (20 amino acid repeat number 2) 
(40-42) 
GSK-3β The central region of APC (37) 
B56α Arm domain (25) 
 
 
 
 
 
Figure 1.3: The Wnt signalling pathway.  
(A) In the absence of a Wnt ligand, β-catenin levels are tightly regulated by the multi-
protein destruction complex, which phosphorylates β-catenin, targeting it for 
proteosomal degradation. (B) Activation of the Frizzled / LRP5/6 receptor complex by a 
Wnt ligand turns Wnt signalling on, causing dissociation of the destruction complex and 
subsequent translocation of β-Catenin into the nucleus to stimulate transcription of Wnt 
target genes.  
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The role of APC in the destruction complex 
APC was initially proposed to function as a scaffold for assembly of the β-catenin 
destruction complex, whereby its interactions with β-catenin and Axin were suggested 
to offer stability to the complex and promote phosphorylation of β-catenin by the Axin-
bound kinases GSK-3β and CKIα. More recently several other models have been 
proposed. One model suggests that APC enhances the turnover of β-catenin at the 
destruction complex, wherein phosphorylation of its 20 amino acid repeats increases its 
affinity for binding to β-catenin, thereby displacing it from Axin. This would leave Axin 
free to interact with another β-catenin molecule (43, 44). An alternate model proposes 
that APC promotes β-catenin ubiquitination (45, 46), whilst another suggests that APC 
regulates Axin localisation by restricting Dishevelled-mediated Axin recruitment to the 
plasma membrane (47). A number of reviews (9, 10) discuss these models in much 
greater detail. It is possible that these mechanisms are not mutually exclusive, and that 
APC contributes to β-catenin degradation through multiple pathways.  
 
Other mechanisms by which APC regulates transcription of Wnt target genes 
APC is also reported to inhibit TCF-dependent transcription of Wnt target genes 
through several alternate pathways. Studies from this laboratory and others suggested 
that APC can regulate accumulation of β-catenin in the nucleus by facilitating its 
nuclear export back to the cytoplasm for degradation (11, 22, 48, 49). Furthermore, 
studies also indicate that APC can directly interact with the transcription repressor, C-
terminal binding protein (CtBP), to form a complex with additional co-factors, blocking 
TCF mediated transcription (50, 51). 
 
1.2.1.3 APC and cytoskeletal organisation 
As previously mentioned, APC closely associates with cytoskeletal networks through 
both direct binding and indirect associations with binding partners (see Table 1.2 and 
Figure 1.1), which assist in mediating its localisation at the cell membrane and, in turn, 
its site-specific cytoskeletal regulatory functions. In particular, APC accumulates at the 
distal ends of microtubules where it contributes to microtubule stabilisation at the cell 
cortex, and also at actin ruffles where it contributes to actin organisation and 
polymerisation (52-54). The ability of APC to associate with microtubules, actin and a 
wide range of regulatory partners at the plasma membrane facilitates cross-talk and co-
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ordination between the two networks (54). This is essential in the regulation of cell 
polarity and highlights its unique role as a mobile scaffold. APC has also been reported 
to organise intermediate filaments during cell migration (55) through a direct Arm-
dependent association. The mechanism for this process has not yet been determined.  
 
 
Table 1.2: Cytoskeletal interactions of APC. 
Cytoskeletal Element Adaptor APC Domain Reference 
Actin 
Direct Basic domain (56) 
ASEF Arm domain (57) 
IQGAP1 Arm domain (58) 
Dlg C-terminal region (59) 
Striatin Arm domain (30) 
Microtubule 
Direct  Basic domain (60) 
KAP3A Arm domain (26) 
EB1 C-terminal region (61) 
RanBP2 APC (1211-1859)  (62) 
Intermediate filaments Direct Arm domain (55) 
 
 
APC and microtubule protrusion formation 
The localisation of APC in clusters at the distal ends of microtubules contributes to the 
stability and lifespan of microtubules in vivo and in vitro (28, 60, 63). Stabilised 
microtubules drive the formation of microtubule-dependent protrusions that are 
important for directing cell migration (reviewed in 64). This is reflected by studies 
showing that loss of APC correlates with decreased protrusion formation (27) and 
directed cell migration (65) in vitro. Inactivation of APC was also demonstrated to 
block cell migration in vivo along the crypt-villus axis in APC flox mice (66). 
 
The capacity of APC to stabilise microtubules is mediated directly through the ‘basic’ 
domain, and indirectly through an association with the +tip protein, end binding protein 
1 (EB1) (28, 63, 67). The literature suggests that the APC-EB1 interaction stabilises 
microtubules by capping microtubule plus ends, for which several co-factors have been 
implicated including Amer2, mDia and KIF17 (68-70). Intriguingly, the APC-EB1 
association has also been reported to promote microtubule assembly and polymerisation 
from the centrosome in vitro and in vivo (71), though precisely how this occurs requires 
further investigation. 
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APC and actin organisation and polymerisation 
APC also localises to actin ruffles and lamellipodia at the cell membrane to organise 
actin filaments and promote polymerisation, crucial for cell migration. One way APC 
achieves this is through an interaction with IQ motif containing GTPase activating 
protein 1 (IQGAP1), which is proposed to crosslink microtubules and actin filaments, 
thereby stabilising actin and promoting cell migration (58). Another study has indicated 
that a direct association with actin can also crosslink microtubules and actin filaments 
by competing for APC ‘basic’ domain binding (72).  
 
APC has been implicated in the organisation of the actin cytoskeleton through 
stimulation of ASEF, a Rac-specific guanine nucleotide exchange factor, which it 
activates by binding to the ASEF N-terminal region and relieving negative regulation 
(57, 73). In turn ASEF stimulates Rac reorganisation of the actin cytoskeletal network, 
promoting formation of lamellipodia and membrane ruffling (57). Furthermore, in 
MDCK cells, ASEF stimulation is reported to decrease E-cadherin cell-cell adhesion, 
thereby promoting cell migration (73). A study by Okada and colleagues (56), indicates 
that the ‘basic’ domain of APC is also directly involved in actin nucleation. APC is 
reported to dimerise and recruit actin monomers for polymerisation, further highlighting 
its multifunctional role as a protein scaffold. 
 
APC and cell polarity 
Establishing cell polarity is important for determining direction of cell migration, and 
requires the stabilisation and anchoring of microtubules to the basal cortex in addition to 
centrosome reorientation. In migrating cells, the dynein/dynactin complex has been 
shown to be essential in exerting mechanical forces on stabilised microtubules to induce 
centrosome reorientation (64). APC’s ability to capture, stabilise and crosslink 
microtubules with actin is important for microtubule anchorage to the actin-rich cortex 
(74). Moreover, microtubule bound APC has been shown to interact with the polarity 
anchoring protein disks large homolog 1 (DLG1) via its C-terminal region (59) at the 
basal plasma membrane. This process has been implicated in cell polarisation of 
astrocytes (75). It has been demonstrated that DLG1 associates with the dynein/dynactin 
complex to induce centrosome reorientation (76), though this process is poorly 
understood. The wide range of cytoskeletal connections APC is able to make at the cell 
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membrane (Table 1.2), and co-factors involved, could very well promote the 
microtubule anchoring ability of the APC-DLG1 association.  
 
Away from the cell membrane, APC has also been implicated in centrosome 
reorientation and positioning at the nuclear envelope where it was proposed to tether 
microtubules through an interaction with Nup153 (77). Collin and colleagues (77) 
suggest that the APC/Nup153 complex serves as an anchor for microtubules emanating 
from the centrosome. An interaction with the mobile Nup, Ran binding protein 2 
(RanBP2/Nup358), was also implicated in cell polarity by binding and driving APC 
towards the cell cortex in a kinesin-dependent manner (62), presumably where it can 
promote microtubule stabilisation and anchoring.  
 
APC at the centrosome and mitotic spindle 
APC has been linked to other facets of centrosomal function including duplication, 
centrosome microtubule nucleation and mitosis and chromosome segregation (12, 78). 
APC accumulates strongly at the centrosome, and while its role in interphase is poorly 
understood, during mitosis APC helps stabilise formation and orientation of the mitotic 
spindle. APC has been detected at kinetochores and the mitotic spindle during mitosis 
(79) and, it was suggested that APC is involved in mediating the attachment of 
kinetochores to the plus ends of the spindle microtubules, an essential step in mitosis 
and for the integrity of chromosome segregation (80). 
1.2.1.4 The role of APC in other cellular functions 
APC and DNA replication and repair 
In the nucleus, APC binds to A/T rich DNA sequences through a number of central and 
C-terminal amino acid regions (81). Furthermore, several studies indicate that APC is 
involved in DNA replication contributing to cell cycle progression from G1 to S phase 
(82, 83). Whilst it is unclear whether the ability of APC to directly bind DNA 
contributes to this, an interaction with replication protein A subunit 32 (RPA32) at 
chromatin is known to be involved. APC promotes the ATR kinase-dependent 
phosphorylation of RPA32 and other co-factors, particularly in response to DNA 
replication stress, which can contribute to the re-initiation of S-phase progression (82). 
A specific function for APC in DNA repair has also been described whereby binding to 
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DNA polymerase β and Fen-1 causes the blockage of base excision repair, the most 
common pathway for damaged DNA abasic repair (84). 
 
APC and the mitochondria  
APC has long been associated with regulation of apoptosis (12, 85), for instance 
through blocking Wnt-mediated repression of caspase 3 and 7 expression (86). In 2008, 
APC was first reported to display a specific localisation at the mitochondria, and was 
found to interact with the anti-apoptotic protein, Bcl-2 (13). Whilst the significance of 
the wild-type APC-Bcl-2 interaction is not clear, APC truncating mutants were shown 
to preferentially accumulate at mitochondria and stabilise Bcl-2 levels, protecting cells 
against apoptosis. This is discussed further in Section 1.2.2.4. APC localisation at the 
mitochondria was later confirmed in a study by Qian and colleagues (87), which also 
implicated APC in regulation of apoptosis. Caspase-cleaved forms of APC were shown 
to bind to distinct isoforms of the hTID-1 apoptotic regulator, and differentially 
modulate apoptosis. This thesis will focus on a new role for APC at mitochondria, 
implicating it in mitochondrial transport and as a consequence the regulation of ATP 
dispersal and calcium buffering within the cell (Section 1.4).  
1.2.2 APC dysfunction in colorectal cancer 
As discussed previously (Section 1.2.1.1), a primary effect of APC truncation is an 
alteration in subcellular localisation, which results in a net loss of APC cytoskeletal 
retention, and an increase in APC motility (11). It is also possible that mutant APC 
acquires additional cancer-promoting activities. Studies in vivo and in vitro show that 
APC mutations exert a dominant-negative effect in systems where only one APC allele 
is mutated, or when mutant APC is overexpressed. This may be due to the ability of 
APC to dimerise through its N-terminal region, thereby allowing mutant APC to bind to 
and inhibit wild-type APC in a dominant negative manner (88, 89). Alternatively, in 
cells with heterozyogous alleles the truncated forms of APC might compete with wild-
type APC to initiate assembly of protein complexes but fail to complete the process due 
to an inability to bind C-terminal-specific partners.   
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1.2.2.1 Deregulation of Wnt signalling and proliferation 
The most well known characteristic of cells expressing mutant APC is defective control 
of Wnt signalling. Loss of both the SAMP and 20R2 Axin binding domains, 
compromises formation of the destruction complex and stabilises β-catenin, which 
accumulates and translocates to the nucleus to form stable constitutively active 
complexes with the TCF/LEF1 transcription factors. This leads to the unregulated 
transcription of proliferative oncogenic Wnt target genes such as c-myc, cyclin D1 and 
fibronectin, which drives cell transformation and cancer (reviewed in 10, 33, 37, 90, 
91). Exactly how the β-catenin destruction complex is compromised has yet to be fully 
determined. One possibility is that the complex formed is insufficient to induce β-
catenin degradation thereby inhibiting the required phosphorylation or ubiquitination. 
The contribution of deregulated Wnt signalling in tumourigenesis has been reviewed 
extensively (5, 10, 32, 33, 92), and its clinical importance is highlighted by the 
continuous research and development into indentifying new drug targets for this 
pathway (93). 
1.2.2.2 Cell migration 
Loss of APC cytoskeletal retention at actin ruffles and the distal ends of microtubules 
following C-terminal truncation impacts on the site-specific scaffolding functions of 
APC at the cell membrane (27, 31, 94), despite the fact that the APC N-terminal half 
retains the capacity to bind microtubule/actin regulators such as IQGAP1 and ASEF, 
and the kinesin complex (KAP3A).  A major effect of APC mutation is the disruption of 
cell polarity which in non-adherent cells means a lack of centrosome positioning to 
allow for direction of motion during cell migration. This disruption is most likely due to 
loss of microtubule stabilisation and anchoring at the basal cortex (74, 95), and to APC 
mutants which act in a dominant negative manner to cause a more random movement of 
cells (96). For example, the overexpression of truncated APC fragments in Vero cells 
(APC wild-type) was found to impair centrosome orientation (58). Furthermore, cells 
expressing mutant APC against a background of one or two wild-type copies of APC 
displayed a distinct loss of directional preference in numerous experimental models 
(96). In particular, enterocytes in the small intestine of APC (Min/+) mice (a mouse 
model for CRC containing APC 1-850/WT) experienced a sharp decrease in migration 
along the crypt-villi axis in comparison to control mice  (96). Cell retention at the base 
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of colonic crypts has been observed on multiple occasions in colonic adenomas of 
humans and APC (Min/+) mice (97-99). Retention in the colonic crypt is favourable for 
carcinogenic transformation given that this region is highly proliferative, and therefore 
the opportunity to acquire further selective advantages is increased. 
 
Somewhat paradoxically, studies by Kawasaki and colleagues (73, 100) found that 
mutant APCs were more efficient than wild-type APC in stimulating the activity of the 
Rac1-exchange factor ASEF. This was proposed to trigger Rac-dependent cytoskeletal 
reorganisation and loss of E-cadherin at cell:cell junctions, in turn promoting cell 
migration. In a separate study, restoration of wild-type APC expression in SW480 (APC 
1-1337) CRC cells caused recovery of E-cadherin at the cell:cell junctions, correlating 
with an increase in cell adhesion (101). These studies suggest that APC mutants not 
only mediate tumourigenesis by causing loss of function, but in specific instances can 
cause a gain of function. It is however hard to predict the effect ASEF stimulation might 
have on the speed of cell migration in the context of the colonic crypt, where 
directionality of movement is also vital.  
1.2.2.3 Chromosome segregation and CIN 
Defects in chromosome segregation are most often caused by chromosome mis-
alignment, or inefficient chromosome separation during mitosis and result in aneuploidy 
(multiple copies of chromosomes). This phenotype has been demonstrated to promote 
chromosomal instability (CIN) (102, 103), a hallmark of many CRCs, and has been 
shown to correlate with APC mutation in the embryonic stem cells of APC (Min/+) 
mice (79, 104). Aberrant chromosome segregation can result from defective spindle 
formation and attachment to kinetochores during mitosis in APC-mutant cells (80, 104). 
One study proposed that overexpression of APC(1-1450) in HEK 293 cells (APC wild-
type) interrupts spindle-kinetochore attachments and interferes with chromosome 
segregation in a dominant-negative fashion (80), an effect mediated by competitive 
inhibition of the interaction between endogenous wild-type APC and EB1 (105). These 
defects allow cells to bypass the normal spindle checkpoint and result in chromosome 
mis-segregation, chromosome instability and cancer (102, 103). 
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1.2.2.4 Apoptosis 
Cells expressing mutant APC often are more resistant to the apoptotic impact of 
different drugs. In particular, in mutant APC CRC cell lines treated with HDAC 
inhibitors or 5-FU, this apoptotic resistance is reversible upon reconstitution of wild-
type APC (106, 107). These findings have been attributed to a number of APC 
pathways, both Wnt-dependent and –independent.  
 
Increased accumulation of β-catenin following APC truncation affects apoptosis at a 
transcriptional level. Wnt signalling has been shown to induce the expression of pro-
survival proteins Survivin and Akt (modulates Bax, BAD and caspase 9), and repress 
expression of pro-apoptotic caspases 3 and 7, thereby promoting cell survival (86, 107, 
108). Furthermore, constitutively active β-catenin was reported to translocate to the 
mitochondria and associate with pro-survival protein Bcl-2, somehow promoting cell 
survival (109, 110). Previous studies in this laboratory showed that APC truncating 
mutants accumulate strongly at the mitochondria in comparison to wild-type, where 
they associate with and possibly stabilise Bcl-2 (13).  Knockdown of APC in SW480 
(APC 1-1337) cells was shown to cause mitochondrial outer membrane 
permeabilisation and stimulate apoptosis, which correlated with a loss of Bcl-2. This is 
intriguing particularly as APC(1-1337) retains β-catenin binding, however,  it is yet to 
be determined if these two pathways are linked.  
 
1.3  Mitochondria 
Mitochondria are highly dynamic cell organelles encased by a unique double membrane 
structure consisting of the highly folded cristae of the inner mitochondrial membrane 
(IMM) and a simpler outer mitochondrial membrane (OMM). In addition to this, 
mitochondria have their own genome (mtDNA) and protein synthesis machinery to 
translate proteins essential for their specific cellular functions, of which ATP synthesis 
is the most well known (17, 111). As highlighted in Section 1.3.1, mitochondria 
perform a range of other critical cellular functions including regulation of calcium 
buffering and apoptosis, and are a reactive site for numerous metabolic pathways such 
as the Krebs cycle. Like APC, the motile, dynamic nature of mitochondria is critical for 
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targeting to different subcellular locations to perform site-specific tasks. This subsection 
aims to highlight the mechanisms and importance of tightly regulated mitochondrial 
dynamics (transport and morphology) (Sections 1.3.2 and 1.3.3), and will outline how 
disruptions to these pathways can promote tumourigenesis and other disease phenotypes 
(Section 1.3.4). 
1.3.1 Mitochondrial function 
The most prominent role of mitochondria is ATP synthesis whereby mitochondria 
convert nutrient derived molecules into energy by oxidative phosphorylation (Section 
1.3.1.1). The mitochondria also house crucial metabolic enzymes in the IMM and 
mitochondrial matrix, thereby mediating other metabolic pathways including the citric 
acid cycle (Krebs cycle), fatty acid oxidation, the urea cycle and heme and iron sulphur 
cluster synthesis. Parts of the steroid, ketone, cardiolipin, dolichol and ubiquinone 
synthesis pathways are also housed in the mitochondria (17, 112-116). Aside from 
metabolism, mitochondria also regulate calcium buffering (Section 1.3.1.2) and 
apoptosis (Section 1.3.1.3). This section will briefly summarise some of these functions 
in order to provide a better context for understanding the implications of disrupted 
mitochondrial dynamics. 
1.3.1.1  ATP production by oxidative phosphorylation 
Mitochondria convert fuel in the form of NADH and FADH2 derived from nutrient 
catabolism into energy (ATP) through a process known as oxidative phosphorylation 
(117-120). The machinery required for this process is embedded in the IMM and 
comprises the multi-protein electron transport chain complexes (Complexes I-IV), 
electron carriers (Coenzyme Q and Cytochrome C) and ATP synthase. Briefly, electrons 
from NADH and FADH2 are transferred into Complex I and Complex II respectively, 
after which they move through the electron transport chain, undergoing a series of redox 
reactions to release free energy until they reach Complex IV and reduce oxygen to water 
(see Figure 1.4A). The free energy released is used to pump protons through Complexes 
I, III and IV, in turn creating a proton gradient. Protons diffusing back along the 
gradient power ATP synthase, in turn driving the phosphorylation of ADP into ATP 
(Figure 1.4A). 
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Figure 1.4: Functional roles of mitochondria 
(A) ATP production. Electrons enter the electron transport chain following the 
oxidation of NADH and FADH2 at Complex I and Complex II, respectively, and are 
shuttled by the electron carriers Coenzyme Q (Co-Q) and Cytochome C (Cyt-C) to 
Complexes III and IV respectively, and used to reduce oxygen to water. As the electrons 
move through the electron transport chain they undergo a series of redox reactions, 
releasing free energy which is harnessed to pump protons through Complexes I, III and 
IV across the inner mitochondrial membrane (IMM) into the intermembrane space 
(IMS), creating an electrochemical gradient across the membrane. This energy is 
utilised to generate ATP through the movement of protons back along the gradient into 
the matrix through ATP synthase, which phosphorylates ADP. (B) Calcium buffering. 
Calcium uptake into the mitochondria is chiefly regulated by the voltage dependent 
anion-selective channel (VDAC) and the mitochondrial calcium uniporter (MCU) over 
the OMM and IMM, respectively. Calcium release is primarily mediated by the 
mitochondrial Na
+
/Ca
+
 exchanger (mNCX) and the Na
+
/Ca
+
 exchanger isoform 3 
(NCX3) for the IMM and OMM, respectively. (C) Intrinsic apoptosis. In the absence of 
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apoptotic signalling, pro-apoptotic mediators BAK/BAX and their activating BH3-only 
proteins are sequestered at the mitochondria by anti-apoptotic mediators including 
BCL-2 and BCL-XL. When apoptosis is stimulated, anti-apoptotic sequestration is 
relieved allowing BAK/BAX, stimulated by BH3-only proteins to dimerise, form 
permeable pores and release apoptotic signalling proteins. Release of Cytochrome C 
(Cyt-C) in particular, activates Apaf-1, stimulating the formation of the apoptosome and 
in turn cleavage of executioner caspases.   
 
1.3.1.2  Calcium buffering 
The ability of mitochondria to sequester and release calcium is essential for regulating 
calcium availability and signalling in the cytoplasm. Uptake of calcium into the 
mitochondria also regulates cellular ATP synthesis by increasing H
+
 extrusion over the 
IMM, and can trigger apoptosis by opening the permeability transition pore (15, 121-
123). Influx of calcium into the mitochondria is primarily mediated by the voltage 
dependent anion-selective channel (VDAC) and the mitochondrial calcium uniporter 
(MCU) over the OMM and IMM, respectively, as highlighted in Figure 1.4B (124-126). 
The MCU is a gated, highly selective ion channel which relies on the negative 
membrane potential generated by the electron transport chain to facilitate calcium 
uptake. Reflecting the low affinity/high capacity nature of the MCU, mitochondria have 
a specific role in buffering calcium microdomains, localised sites within the cytoplasm 
with a high calcium ion concentration, usually formed in the vicinity of Ca
2+
 ion 
channels (for example at the plasma membrane). This is different to the calcium uptake 
mechanisms of the ER, which more effectively buffer lower levels of calcium (127). 
Calcium release on the other hand, is chiefly mediated by the mitochondrial Na
+
/Ca
+
 
exchanger (mNCX) and the Na
+
/Ca
+
 exchanger isoform 3 (NCX3) for the IMM and 
OMM respectively (Figure 1.4B and 128, 129) . 
1.3.1.3  Regulation of apoptosis 
Mitochondria are crucial in the regulation of the intrinsic apoptotic pathway, which 
relies on proteins released from the mitochondria into the cytoplasm to initiate 
apoptosis. Mitochondrial outer membrane permeabilisation (MOMP) is a key event in 
this process, which is tightly regulated by the interplay between Bcl-2 family proteins 
(reviewed in 16, 130, 131-133). Briefly, the Bcl-2 protein family consists of anti-
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apoptotic mediators such as Bcl-2 and Bcl-XL, and the pro-apoptotic mediators 
including Bax and Bak and their activating BH3-only proteins. Once activated, pro-
apoptotic mediators Bax and Bak cluster to form protein permeable pores in the OMM, 
facilitating the release of apoptotic signalling proteins from the intermembrane space 
(IMS). The pro-survival Bcl-2 proteins are thought to inhibit this process directly by 
sequestering Bax and Bak, and indirectly by sequestering BH3-only proteins. Whilst the 
mechanism by which Bax and Bak form these permeable pores has yet to be fully 
elucidated, current evidence suggests that they homo-dimerise, then multimerise with 
lipids from the OMM to form a pore complex (132). This process is summarised in 
Figure 1.4C. As described previously (Section 1.2.3.4), APC may influence this process 
through its ability to stabilise Bcl-2 at mitochondria (13), perhaps indirectly reducing 
Bax dimerisation, and as a result MOMP.  
 
Pro-apoptotic proteins released from the mitochondria activate caspase-dependent 
apoptotic pathways, where hundreds of target endonuclease and protease substrates are 
cleaved, causing cell death. The most well documented of these is Cytochome C, which 
binds to the procaspase-activating adaptor Apaf-1 causing it to form a heptameric 
structure known as the apoptosome, which kick-starts a signalling cascade to activate 
the executioner caspases-3 and -7 (see Figure 1.4C and review 134). Over an extended 
period of time, MOMP has also been shown to cause cell death independently of 
caspase activation. This is most likely due to a progressive loss of mitochondrial 
function following loss of OMM integrity, including release of soluble components of 
the electron transport chain (135, 136).  
1.3.2 Mitochondrial transport 
Mitochondria move across cytoskeletal networks, frequently engaging in rapid bi-
directional movement, interspersed between periods of stationary docking. This 
dynamic transport is key to the ability of mitochondria to redistribute in response to 
cellular signals, enabling them to perform highly site-specific tasks, such as ATP 
provision and modulation of calcium buffering (see Section 1.2.3.3). Mitochondrial 
transport has most often been studied in neuronal cells due to their unique cellular 
architecture, which requires long distance transport through the axon from the cell body 
towards the synaptic terminal (137, 138). Disruption to this process has been shown to 
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contribute to a number of neurological conditions (139-141). More recent studies 
however, highlight the crucial nature of mitochondrial transport in other cell types, 
particularly in the context of regulated cell migration (18, 19, 142).  
1.3.2.1 Miro/Milton/KIF5 mitochondrial transport 
The Miro/Milton/KIF5 transport complex is the primary means of microtubule-
dependent mitochondrial transport within the cell. Miro and Milton were originally 
identified by genetic screening of Drosophila retinal neurons devoid of axonal and 
terminal mitochondria (143, 144). Miro and Milton have since been shown to be 
evolutionarily conserved in mammals, with two orthologues identified for each protein, 
Miro-1/Miro-2 and Milton-1/Milton-2 that are expressed in a wide variety of cell and 
tissue types (143, 145-147). Miro is a mitochondrial transmembrane protein, to which 
Milton associates at the surface of the OMM. Milton then functions as an adaptor to link 
the mitochondria to the KIF5 kinesin motor to facilitate anterograde transport along 
microtubules (148-150). Milton is reported to associate with all three KIF5 subtypes, 
the neuronal-specific KIF5A/KIF5C and the ubiquitous KIF5B, demonstrating the 
importance of this complex for basic cellular function. This importance is further 
highlighted by the absence of mitochondria in the axons and synaptic terminal of 
Drosophila harbouring mutant Miro, Milton or KIF5 (143, 144, 151). Moreover, live 
cell studies show that disruption of Miro and Milton by siRNA silencing or use of a 
dominant-negative significantly diminishes the pool of motile mitochondria (152-154). 
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Miro/Milton binding domains 
Key Binding Domain Reference 
 
 
Miro/Milton dMiro: 1-574, dMilton: 1-750 
hMilton-2: 476-700,  
hMiro-1: N-terminal region 
(149, 150) 
 
Milton/KIF5 dMilton: 138-450, dKIF5: 810-891 
hMilton-2: 124-283, hKIF5C: 336-957 
(149, 155) 
 
 
Milton/OGT hMilton-1: 658-672 (156) 
 
 
Miro/Mito hMiro-1/2: 593-615 (148) 
 
 
Milton/Mito dMilton: 847-1116 (149) 
 
Miro/Milton sites of post-translational modification 
Key Modification Site Reference 
 
 
 
 
     
Phosphorylation Ser 156/182 (hMiro-1/dMiro),  
Ser 324 (dMiro), Thr 325 (dMiro) 
(152, 157) 
 
 
 
 
 
 
 
O-GlcNA-
cetylation 
Ser 447 (hMilton-1), Ser 829 (hMilton-1), 
Ser 830 (hMilton-1), Ser 938 (hMilton-1) 
(156) 
 
 
 
 
 
 
 
Calcium binding 
(EF hands) 
184-219 (hMiro-1), 304-339 (hMiro-1)  
 
Figure 1.5: Miro/Milton mitochondrial transport complex binding and 
modification domains.  
The schematic outlines sites of protein interaction and post-translational modification in 
the Miro/Milton complex, as currently defined in the literature (see figure key for 
explanations). The + ends of microtubules are stable caps at the growing ends that 
become tethered at the plasma membrane in interphase cells. Anterograde transport of 
proteins means outward movement from nucleus toward the plasma membrane. 
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The Miro/Milton complex is regulated by metabolic fluctuations in calcium levels (153, 
158, 159) and glucose availability (156), which target the action of Miro and Milton, 
respectively. These and other regulatory post-translational modifications are discussed 
below, and the current knowledge pertaining to the Miro/Milton/KIF5 complex 
modification and binding domains is outlined in Figure 1.5. Intriguingly, Milton can 
also localise at mitochondria independently of Miro, for which a target domain has been 
identified (149). It is possible that this Milton/mitochondria association contributes to 
complex stability, however this has not been investigated. Furthermore it is unclear 
from the literature if Miro and Milton interact directly and without the assistance of 
other co-factors. A number of co-factors (detailed in Table 1.3) have already been 
reported to associate with the core components of the Miro/Milton/KIF5 complex 
including hypoxia up-regulated mitochondrial movement regulator (HUMMR), Alex3 
and Mitofusin 2 (Mfn2). When inactivated, by shRNA (HUMMR and Alex3) or 
expression of dominant negative mutants (Mfn2) these proteins were shown to suspend 
anterograde (membrane-directed) transport of mitochondria, highlighting their ability to 
regulate the transport complex and in turn providing a regulatory link to hypoxic, non-
canonical Wnt and mitochondrial fusion–dependent pathways (160-162).  
 
Table 1.3: Miro/Milton complex co-factors.  
Co-factor Association Mechanism Reference 
HUMMR 
Miro-1/2 
 
Induced by HIF-1α to facilitate anterograde 
mitochondrial transport under hypoxic 
conditions. 
(160) 
Alex3 
Miro-1/2 
Milton-2 
Associates with Miro/Milton in a Ca
2+
-
dependent manner to promote mitochondrial 
transport. Targeted for proteosomal 
degradation via the non-canonical Wnt 
signalling pathway.  
(161, 163) 
Mfn2 
Miro-1/2 
Milton-1/2 
A regulator of mitochondrial fusion 
demonstrated to associate with Miro/Milton 
and promote mitochondrial transport. 
(162) 
 
 
Calcium Sensitivity 
The role of mitochondria in the site-specific buffering of intracellular calcium (Section 
1.3.1.2) is highlighted by the Miro-regulated, calcium-dependent suppression of 
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mitochondrial transport (158, 164). When intracellular calcium levels are elevated, 
calcium binds to Miro’s EF-hand motifs (helix-loop-helix structural domains that bind 
calcium), causing a conformational change that facilitates mitochondrial detachment 
from microtubules (153, 158, 159). The mechanism by which this conformational 
change disrupts mitochondrial transport is somewhat controversial. Wang and Schwarz 
(153) report that calcium binding to the EF-hand motifs (see Figure 1.5) results in Miro 
binding and blocking the KIF5 motor domain, causing the entire complex to dissociate 
from the microtubule. On the other hand, findings by MacAskill and colleagues (159) 
suggest that Miro binds KIF5 independently of Milton, and that elevated calcium 
disrupts this interaction causing Miro/Milton detachment from KIF5. Some of these 
differences may be attributed to the use of different cell types and Miro/Milton 
homologs in these studies. However, further investigation is required to fully elucidate 
the mechanism by which Miro-calcium binding alters the complex.  
 
Post-translational modification 
Mitochondrial transport is also subject to post-translational regulation whereby Miro 
and Milton are modified by Pten-induced kinase-1 (PINK1)/Parkin pathways and O-
linked N-acetylglucosamine transferase (OGT), respectively (Figure 1.5). The 
PINK1/Parkin pathway targets Miro for proteosomal degradation, thereby blocking 
mitochondrial transport. The mechanism is unclear. PINK1 was originally reported to 
phosphorylate Miro-1/2 at Ser 156, priming it for ubiquitination and subsequent 
proteosomal degradation in a Parkin-dependent manner (152), however this was later 
disputed by others (165). A number of other PINK1-dependent phosphorylation sites 
have since been identified in Drosophila Miro (Ser 324, Thr 325) (157). It is possible 
that if these phosphorylation sites are conserved in human Miro orthologues, Parkin 
ubiquitination may occur by this means. A recent study by Birsa and colleagues (166) 
contributes further to this controversy, by suggesting an alternate mechanism whereby 
Parkin-dependent ubiquitination of Miro is sufficient to inhibit mitochondrial transport 
prior to its degradation. Whilst degradation was delayed for several hours following 
ubiquitination, this modification did not affect the integrity of Miro/Milton binding 
(166). 
 
OGT has been demonstrated to bind directly to, and catalyse the O-GlcNAcylation of 
Milton, in turn disrupting mitochondrial transport. As OGT is stimulated by glucose 
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flux, this modification is proposed to assist in ATP production by pausing mitochondrial 
movement to enable uptake in glucose microdomains (156). O-GlcNAcylation of 
Milton does not affect formation of the Miro/Milton/KIF5 complex, and the mechanism 
by which mitochondrial transport is disrupted is unknown (156). 
1.3.2.2 Other mitochondrial transport mechanisms 
Numerous mechanisms independent of the Miro/Milton complex are also used to 
transport mitochondria throughout the cell. For the most part, these mechanisms are not 
functionally redundant and contribute to different facets of mitochondrial transport. For 
example, a number of mechanisms identified for microtubule-based transport have been 
found to be specific to neuronal cells (Table 1.4). Furthermore, the actin and 
intermediate filament networks have also been implicated in mitochondrial transport, 
enabling mitochondria to reach regions of the cell not accessible by microtubules. Other 
mitochondrial motor protein complexes involved in regulating microtubular anterograde 
transport of mitochondria are described in Table 1.4. In the retrograde direction 
however, only cytoplasmic dynein has been implicated. Interestingly, both Miro (167, 
168) and Milton (169) have been shown to interact with the dynein motor and 
contribute to retrograde movement. A number of MAP proteins, outlined in Table 1.4 
have also been shown to regulate mitochondrial transport.  
 
Mitochondrial transport across the actin and intermediate filament networks is poorly 
defined. Mitochondrial transport is primarily actin-based in yeast, however there is 
increasing evidence implicating this mode of transport in higher eukaryotes. In 
particular, the actin-based motor proteins Myosins V, VI and XIX have been shown to 
regulate mitochondrial transport (Table 1.4). Actin-dependent transport may be 
important for facilitating transport to microtubule-scarce regions of the cell and perhaps 
shuttling detached mitochondria back to microtubules. This notion is in line with 
findings that actin-based transport is primarily short range (170-172). The role of 
intermediate filaments in transporting mitochondria is even less clear. Cells with 
defective keratin and neurofilament networks have been shown to display aberrant 
mitochondrial distribution (173, 174) and mitochondrial transmembrane protein Plectin 
1b has been proposed to link mitochondria to these intermediate filament networks 
(175).
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Table 1.4: Mechanisms of mitochondrial transport 
Cytoskeleton Motor Adaptor/Cofactors Mechanism References 
Microtubule 
(anterograde motor 
transport) 
KIF5A/B/C 
Miro/Milton 
(Mfn2, Alex3) 
Mitochondrial transmembrane protein Miro attaches to the 
KIF5 motor complex through the adaptor protein Milton.  
Section 
1.3.2.1 
KIF5B/C RanBP2 
RanBP2 associates directly with KIF5 and relieves its auto-
inhibition, thereby stimulating motor activity. 
(176, 177) 
KIF5B Syntabulin 
Syntabulin targets to the OMM, and directly binds KIF5 to 
drive mitochondrial transport in neuronal processes. 
(178) 
KIF1Bα KBP 
KBP localises to mitochondria and binds directly to the motor 
domain of KIF1Bα where it is suggested to increase kinesin 
motor activity.  
(179, 180) 
KLP6 KBP 
Kinesin KLP6 stimulates mitochondrial transport through an 
undefined mechanism, possibly facilitated by its association 
with KBP. 
(181) 
Microtubule 
(retrograde motor 
transport) 
Cytoplasmic 
Dynein 
Miro 
Milton 
Cytoplasmic dynein drives retrograde mitochondrial transport.  (182) 
 
 
Table continued over page.  
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Cytoskeleton Motor Adaptor/Cofactors Mechanism References 
Microtubule 
(other) 
- MAP1B 
MAP1B negatively regulates retrograde mitochondrial transport 
possibly by competing for motor proteins in neuronal axons. 
(183) 
- Tau 
Tau negatively regulates anterograde mitochondrial transport 
possibly by competing for motor proteins in neuronal axons. 
(183, 184) 
- Syntaphilin 
Syntaphilin is a Ca
2+
 induced anchor, used to immobilise 
mitochondria by displacing KIF5 from Miro/Milton. Specific 
for axonal mitochondrial transport. 
(185, 186) 
Actin 
Myosin V ? 
Myosin V disrupts anterograde and retrograde transport, 
possibly by competing with microtubule motor proteins for 
mitochondrial cargo. 
(187) 
Myosin VI ? 
Myosin VI disrupts anterograde and retrograde transport, 
possibly by competing with microtubule motor proteins for 
mitochondrial cargo. 
(187) 
Myosin XIX Direct 
Myosin XIX associates directly with mitochondria to facilitate 
actin-based transport. 
(188) 
Intermediate 
filament 
- Plectin 1b 
Plectin 1b, a mitochondrial transmembrane protein, links 
mitochondria to intermediate filaments. Loss of Plectin 1b 
caused defects in mitochondrial dynamics which may be due 
defects in mitochondrial transport.  
(175) 
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1.3.2.3  The functional relevance of mitochondrial transport 
Regulation of mitochondrial transport is essential for the site-specific functionality of 
mitochondria, namely its dispersal of synthesised ATP (Section 1.3.1.1), and buffering 
of calcium (Section 1.3.1.2). Targeting of mitochondria to subcellular regions with high 
bioenergetic demands is a much more effective method of ATP supply compared to the 
random diffusion of ATP through the cytoplasm, and has been reported to be 
particularly relevant at the cell membrane for cell migration, and the synaptic terminal 
of neurons for the generation of action potentials (18, 19, 142, 189). Likewise, close 
proximity to calcium micro-domains and the cell periphery is required to facilitate rapid 
calcium uptake (15, 127, 190). Aberrant mitochondrial transport has been linked to a 
number of neurodegenerative diseases including Alzheimer’s, and Parkinson’s diseases 
(139), and more recently, increased risk of metastasis in cancer (18, 19). These disease 
phenotypes are reviewed in more detail in Section 1.3.4.  
1.3.3 Mitochondrial Fission/Fusion Dynamics 
Mitochondrial morphology is not static. Rather, mitochondria continuously undergo 
fission and fusion events in response to numerous cellular signals allowing them to exist 
as both tubular networks and discrete puncta. These processes are primarily regulated 
by the opposing actions of the core fission/fusion machinery (described in Section 
1.3.3.1), and are important for many aspects of normal cellular function including 
mitophagy and maintenance of mtDNA fidelity (see Section 1.3.3.2). Fission/Fusion 
dynamics are intimately linked with mitochondrial transport dynamics. For example, 
defective mitochondrial transport can affect the ability of mitochondria to move 
together for fusion, and apart for fission. Furthermore, excessive fission or fusion has 
been demonstrated to respectively increase or decrease the speed of mitochondrial 
transport (19). As such, it is unsurprising that aberrant mitochondrial fission/fusion 
dynamics have been linked to similar neurodegenerative and cancer disease phenotypes 
as defective mitochondrial transport. This is described in more detail in Section 1.3.4.  
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1.3.3.1 Mechanisms of fission/fusion 
Mitochondrial fission and fusion is maintained by the actions of a set of dynamin 
related GTPase proteins, comprised of fusion mediators Mitofusin1/2 (Mfn1/2) and 
Optic atrophy 1 (OPA1), and fission mediator Dynamin related protein 1 (DRP1). These 
proteins are in turn regulated by various effector proteins and signals in response to 
cellular demands (Table 1.5). The mechanisms of mitochondrial fission/fusion have 
been reviewed extensively (191-195) and are summarised below.  
 
 
 
 
Figure 1.6: Mechanisms of mitochondrial fission and fusion.  
The schematic outlines core mechanisms of mitochondrial fission/fusion. Fusion 
requires coordination between the OMM and IMM. Mfn1/2 on opposing OMMs 
dimerise and promote fusion.  OPA1 regulates IMM fusion which requires both long, 
and shorter cleaved isoforms to be effective. Fission is regulated by DRP1, a 
cytoplasmic protein which requires mitochondrial recruitment via a receptor protein. 
When fission is stimulated, DRP1 oligomerises and forms a ring structure which 
constricts around the mitochondria. Regulatory proteins indicated on the schematic are 
summarised in Table 1.5. 
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Fusion 
Effective mitochondrial fusion requires coordination of both the OMM and IMM, 
primarily relying on Mfn1/2 and OPA1, respectively (196). The two mitofusins, Mfn1 
and Mfn2, are anchored in the OMM (197, 198), where they homo- or hetero-dimerise 
with Mfn1/2 anchored in the OMM of opposing mitochondria, acting as a tether (see 
Figure 1.6). The mitofusins then attach to the opposing mitochondrial membranes, after 
which a GTPase-dependent conformational change causes OMM fusion (191, 199). 
Mfn2 also contributes to mitochondrial tethering to the ER (200), and to mitochondrial 
transport (Table 1.3). Regulation of Mfn1/2 activity is outlined in Table 1.5. The fission 
regulator OPA1 is responsible for IMM fusion and cristae remodelling (191, 201, 202). 
Whilst the mechanism is unclear, OPA1 is reported to undergo alternate splicing (Table 
1.5) to produce a range of protein isoforms required for effective fusion (203-205).  
  
Fission 
Key to the regulation of mitochondrial fission is the GTPase protein, DRP1. DRP1 is 
primarily cytoplasmic, but when activated it translocates to the mitochondria where it 
oligomerises, forming a helical ring structure which, when hydrolysed, constricts 
mitochondria to induce fission (206, 207). Numerous other proteins have been reported 
to contribute to fission, however these mainly function to regulate DRP1 activation or 
localisation at the OMM in response to different cellular signals. These effectors are 
summarised in Table 1.5 and primarily act through post-translational modification or as 
DRP1 receptors. ER tubules have also been proposed to contribute to fission by 
wrapping around mitochondria at fission sites (208). Other players, including 
Endophilin B, MTP18 and GDAP1 have been implicated in controlling mitochondrial 
fission but their role is less clear (209-211). 
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Table 1.5: Regulation of the core mitochondrial fission/fusion machinery 
Target Cofactor(s) Regulation Mechanism References 
Mfn 
1/2 
MUL1 
Parkin 
Ubiquitination 
Targets Mfn2 to the proteasome for degradation, inhibiting fusion. (212-214) 
MIB ? Blocks Mfn1 through an unknown mechanism, inhibiting fusion.  (215) 
BAX ? Targets Mfn2 to promote fusion through an unknown mechanism. (216) 
Phospholipase D ? Targets Mfn1/2 to promote fusion through an unknown mechanism. (217) 
OPA1 
OMA1 
Yme1L 
Proteolytic 
cleavage 
Regulates cleavage of long forms of OPA1 into short forms. (218, 219) 
Prohibitin-2 
Higd-1a 
Protection from 
proteolytic 
cleavage 
Protects against accelerated cleavage of long forms of OPA1. (220, 221) 
DRP1 
FIS1 Receptor 
Recruits DRP1 to the OMM, promoting fission. Also proposed to 
inactivate Mid51. 
(222, 223) 
MFF Receptor Recruits DRP1 to the OMM, promoting fission. (224) 
Mid49/Mid51 
(MIEF2/1) 
Receptor 
Recruits DRP1 to the OMM where it inhibits DRP1’s GTPase function, 
blocking fission. 
(223, 225, 
226). 
MARCH5 
(MITOL) 
Ubiquitination 
Unclear, may positively regulate fission by promoting DRP1 at fission 
sites, rather than marking for proteasomal degradation. 
(227, 228) 
PARKIN Ubiquitination Targets DRP1 to the proteasome for degradation, inhibiting fission. (229) 
PKA Phosphorylation Blocks DRP1 translocation to the mitochondria, inhibiting fission. (230, 231). 
Calcineurin Dephosphorylation Stimulates DRP1 translocation to the mitochondria, promoting fission. (232) 
MUL1 SUMOylation Stabilises DRP1 at the OMM, promoting fission.  (233, 234) 
SENP5 DeSUMOylation Blocks DRP1 translocation to the mitochondria, inhibiting fission. (235) 
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1.3.3.2 The functional relevance of mitochondrial fission/fusion dynamics 
Mitochondrial fission and fusion dynamics have been implicated in mtDNA fidelity, 
mitophagy, apoptosis and other processes including regulation of ATP production 
(236), speed of mitochondrial transport (19) and mitochondrial inheritance during 
mitosis (237). The importance of mitochondrial fission/fusion dynamics is highlighted 
by the numerous disease pathologies which present when these dynamics are 
compromised, primarily in neurodegenerative diseases such as Charcot-Marie-Tooth 
(CMT) and Parkinson’s disease (Section 1.3.4) 
 
mtDNA fidelity (mitochondrial homogenisation) 
The fusion of mitochondria is essential in maintaining a homogenous mitochondrial 
population (238). When mitochondria undergo fusion, their contents including mtDNA, 
metabolites and enzymes are able to be exchanged (239, 240). This is particularly 
important for mtDNA which encodes crucial enzymes in the electron transport chain, 
and is prone to damaging mutations as a result of its close proximity to sites of ROS 
production. Unlike nuclear DNA, the mtDNA genome is polyploid, therefore thousands 
of copies are present per cell. Furthermore, mutations are usually recessive and can 
accumulate at high levels without effecting mitochondrial function (241, 242). Mixing 
of mitochondrial contents therefore allows for damaged mtDNA to be exchanged for 
complimentary healthy mtDNA (239, 240). However, defective mitochondria with 
severely damaged mtDNA are quarantined and primed for mitophagy, as detailed 
below. 
 
Mitophagy and autophagy 
Mitophagy is a specific type of autophagy which targets mitochondria for degradation, 
often assisting in mitochondrial quality control through the quarantine and removal of 
dysfunctional mitochondria (243). Mitochondrial fission is essential for separating 
defective mitochondria from the healthy population, a process which is regulated 
through the PINK/Parkin mitophagy pathway. In this pathway, PINK1 is targeted to 
damaged, depolarised mitochondria and recruits Parkin to the OMM, where it poly-
ubiquitinates OMM proteins targeting them for degradation (244, 245), and 
subsequently stimulating mitophagy (246). Mfn2 in particular is targeted by Parkin in 
this process, decreasing fusion and tipping the balance towards fission (247). 
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Fission/Fusion dynamics have also been reported to play a role in cell survival during 
starvation-induced autophagy. Starvation induces PKA activation, stimulating the 
phosphorylation of DRP1, consequently inhibiting mitochondrial translocation, and 
fission (230, 231). The subsequent mitochondrial elongation has been reported to 
protect mitochondria from autophagosomes, possibly through steric hindrance, thereby 
allowing autophagic cells to maintain ATP production and hence, viability (248). 
 
Apoptosis  
Mechanisms mediating induction of apoptosis and mitochondrial fission/fusion 
dynamics often intersect as these pathways share many common proteins (see Table 
1.5). As such, it is hard to elucidate if mitochondrial morphology plays a role in the 
apoptotic response, or if any apoptotic changes are secondary effects caused by 
modulation of common machinery. For example, the apoptotic response is associated 
with extensive mitochondrial fission which occurs immediately prior to release of 
Cytochrome C. Alterations to DRP1 activity by stimulating its translocation to the 
OMM inducing mitochondrial fragmentation, or through expression of a dominant-
negative mutant inducing mitochondrial elongation have been demonstrated to 
respectively increase and decrease the sensitivity of cells to apoptotic stimuli (230, 249, 
250). However, extensive mitochondrial fission has been observed in many cases not 
pertaining to apoptosis (summarised in 251). Moreover, it is unclear whether 
mitochondrial fission is required for the apoptotic process, or is simply a by-product of 
other apoptotic pathways mediated by DRP1. This is presently a subject of controversy 
within the literature (252, 253). This topic and further examples pertaining to other 
proteins in the fission/fusion machinery are reviewed in more detail elsewhere (251, 
254). 
1.3.4 Mitochondrial dysfunction in disease 
The mitochondria are a cornerstone of normal cell function, playing the central role in 
cellular metabolism (Section 1.3.1). As a result, mitochondrial dysfunction has wide-
reaching effects. Neurodegenerative diseases in particular are often associated with 
aberrant mitochondrial function due to the high bioenergetic demands, and the unique 
morphology of neuronal cells (Section 1.3.4.1). Mitochondrial dysfunction has also 
been increasingly linked to numerous cancer types (Section 1.3.4.2). Other pathologies 
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associated with defective mitochondrial function include the mitochondrial cytopathies, 
like MELAS syndrome, which is characterised by defects in the electron transport 
chain, and Type II diabetes (255-257). 
1.3.4.1  Neurodegenerative disease 
In neurodegenerative disease pathologies, disrupted mitochondrial transport, extensive 
fragmentation and loss of mtDNA fidelity (a common effect of aberrant fission/fusion 
dynamics – Section 1.3.3.2) are commonly observed (139-141). Neurons are highly 
sensitive to these defects due to their high metabolic demands, long post-mitotic life 
spans and far reaching processes over which mitochondria need to be shuttled. 
Dysfunctional mitochondria affect many aspects of normal neuronal function, for 
example at synaptic terminals where mitochondria are required to supply ATP for 
neurotransmission, and buffer calcium influxes for maintenance of neuroplasticity 
(258).  
 
The neuromuscular disorder, Charcot-Marie-Tooth (CMT) subtype 2A for example, is 
specifically caused by a point mutation in Mfn2, which causes mitochondrial 
fragmentation and mtDNA damage leading to motor axon degeneration (259). Another 
neurological disease, autosomal dominant optic atrophy (ADOA) type 1, is often caused 
by a mutation in OPA1 and affects retinal ganglion cells in the optic nerve (260). The 
retinal ganglion cells of patients with ADOA display extensive mitochondrial 
fragmentation and are more sensitive to apoptosis, leading to degeneration which 
impairs sight and can lead to blindness. A growing body of evidence also indicates that 
mitochondrial dysfunction is a key feature of Parkinson’s disease (PD) and, certain 
subtypes have been linked to mutations in proteins that influence mitochondrial 
transport and morphology. Mutations in PINK/Parkin (see Section 1.3.2.1, Table 1.5), 
are often observed in autosomal recessive juvenile PD, and directly impact 
mitochondrial distribution and quality control (257, 261). Aberrant expression of 
mitochondrial fission/fusion proteins and altered kinesin dynamics have also been 
observed in Alzheimer’s and Huntington’s diseases (139, 257, 261). 
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1.3.4.2  Cancer 
Defective mitochondria were first linked to carcinogenesis as the cause of the “Warburg 
effect”, a commonly observed phenotype whereby tumour cells display increased rates 
of ATP generation by glycolysis in the cytosol as an alternate method to production by 
oxidative phosphorylation (262). Since then, many aspects of mitochondrial dysfunction 
have been found to contribute to tumourigenesis, and due to the interlinked nature of 
metabolic and mitochondrial regulatory pathways often aberrations in one pathway can 
cause a knock-on effect resulting in defects in numerous others. Excessive mtDNA 
genome mutation and defective mitophagy, mitochondrial biogenesis, and metabolic 
signalling have all been observed in tumour cells. The complex interplay between these 
pathways frequently results in aberrant ROS production, ATP production and metabolic 
signalling, often switching on pathways that promote growth, cell survival and even 
alterations in nuclear DNA fidelity. These pathways are reviewed extensively in the 
literature (14, 263, 264).  
 
A growing body of evidence suggests that defective mitochondrial transport and 
fission/fusion dynamics play a significant role in cancer formation. The heterogenic 
nature of tumours means that preference for particular defects could depend on many 
factors including tissue type, stage of carcinogenesis and location within the tumour. As 
previously discussed, mitochondrial transport and fission/fusion dynamics are 
intimately linked, for simplicity however they have been split in the subsections below.  
 
Mitochondrial transport 
Recent studies have linked perturbations in mitochondrial transport to aberrant cell 
migration, a hallmark of cancer cells (18, 19). These studies indicate that mitochondria 
in metastatic breast, and prostate cancer cell lines preferentially cluster at the leading 
edge of migrating cells, and contribute to increased migration speed, directional 
persistence and invasion, which can be attenuated by disrupting the mitochondrial 
transport complex (18). Mitochondria localised at the cell periphery in metastatic breast 
cancer cells were directly implicated in supplying the ATP required for the 
polymerisation of F-actin, and lamellipodia formation in cell migration (19). On the 
other hand, mitochondrial localisation away from the cell periphery, in the perinuclear 
region, is also reported to be favourable for carcinogenesis. In a study by Al-Mehdi and 
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colleagues (265), mitochondrial clustering around the nucleus was observed to create an 
oxidant-rich nuclear environment by releasing ROS. This elevated nuclear ROS was 
then shown to cause oxidative base DNA damage, stimulating the transcription of 
growth signalling proteins like vascular endothelial growth factor (VEGF).  
 
Mitochondrial fission/fusion dynamics 
Aberrant expression of mitochondrial fission and fusion proteins have been observed in 
numerous cancer types (14, 140, 266). However, the outcome of defective 
morphological dynamics can vary. For example, up-regulation of DRP1 tips the 
morphological balance towards fission, and has been reported in several cancer types 
where it was linked to increased mitochondrial motility, and a loss of mtDNA fidelity, 
electron transport chain defects, and subsequently increased ROS production, which are 
all favourable in cancer progression. However, electron transport chain defects reduce 
ATP production and extensive mitochondrial fission is reported to promote apoptosis; 
neither is favourable for tumourigenesis (19, 140, 266). On the other hand, hypoxia-
induced mitochondrial fusion is also reported to be favourable to cancer progression, 
with links to cancer cell survival and higher rates of ATP production (14, 140, 267). The 
paradoxical nature of mitochondrial fission/fusion dynamics in carcinogenesis is likely 
due to the heterogeneity in tumour cells, suggesting that the preferred mitochondrial 
morphology for cancer growth is determined on a cell-by-cell basis.  
 
1.4 Rationale and summary of study 
Evidence in the literature supports a mitochondrial transporter or chaperone role for 
APC; (1) APC is a large mobile scaffold than can not only stimulate assembly of protein 
complexes (e.g. the β-catenin destruction complex), but also influence the localisation 
of other proteins (e.g. β-catenin) (Section 1.2.1). (2) APC associates with mitochondria 
in both mutant and full-length forms (Section 1.2.1.4). (3) Mitochondria are highly 
dynamic and transported to the plasma membrane by kinesin complexes that sometimes 
include known APC-binding partners, such as RanBP2 (Section 1.3.2). (4) Both APC 
and mitochondria have been linked to cell migration and shown to be directed along 
microtubules to the membrane (Sections 1.2.1.3, 1.3.2.3). When considered together, 
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these and other facets of the biology of APC and mitochondria suggested a potential 
role for APC in the transport of mitochondria.  
 
The hypothesis, that APC plays a novel role in the anterograde transport of 
mitochondria was investigated and shown to be true. In Chapter 3, loss of APC wild-
type is demonstrated to cause uniformly spread mitochondria to redistribute towards the 
perinuclear region, a finding consolidated by identification of mitochondrial transport 
proteins Miro and Milton as novel APC binding partners. Chapter 4 identifies the C-
terminal region of APC as the Miro/Milton binding domain and focuses on the 
implications of CRC-associated APC truncation on its mitochondrial transport 
capabilities. APC mutation is found to correlate strongly with defective mitochondrial 
transport to the cell periphery, which is restorable by expression of wild-type APC. The 
dynamics of APC-dependent mitochondrial transport are addressed in Chapter 5, where 
live cell imaging is used to determine that APC is specifically involved in the initiation 
of anterograde mitochondrial transport. The nature of the association between APC and 
Miro/Milton is investigated further in Chapter 6, where preliminary studies suggest that 
APC stabilises the interaction between Miro and Milton, perhaps in a scaffolding 
capacity. 
 
There is 
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2.1  Materials 
2.1.1 Cell Lines 
All cell lines used in this study are outlined in Table 2.1. All cell lines were obtained 
from the American Type Culture Collection (ATCC) unless otherwise stated. 
 
Table 2.1: Cell lines and source 
Cell Line APC Status Source 
U2OS Wild type Human epithelial osteosarcoma 
HDF1314 Wild type Human dermal fibroblast 
NIH 3T3 Wild type Mouse embryonic fibroblast 
Hela Wild type Human epithelial cervical cancer 
SW480 (1-1337) Human epithelial colorectal 
adenocarcinoma 
HT-29 (1-853/1-1555) Human epithelial colorectal 
adenocarcinoma 
HCT116 Wild type Human epithelial colorectal 
adenocarcinoma 
LIM 1215 Wild type Human epithelial colorectal 
adenocarcinoma 
Inducible HEK 293 
(1-2843) 
Wild type, 
inducible wild type. 
Human embryonic kidney. Inducible 
APC cells created and supplied by (268). 
Inducible HEK 293 
(1-1309) 
Wild type, 
inducible (1-1309) 
Human embryonic kidney. Inducible 
APC cells created and supplied by (268) 
 
2.1.2 Antibodies and Dyes 
Primary antibodies, secondary antibodies and dyes used in this study are outlined in 
Table 2.2, Table 2.3 and Table 2.4, respectively.  
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Table 2.2: Primary antibodies 
Antibody 
Target 
Clonality 
Dilution 
IP Supplier 
IF WB Duo 
α-Actin Monoclonal 1:1000 - -  Sigma-Aldrich 
APC (Ab1) Monoclonal - 1:100 -  Calbiochem 
APC (Ab5) Monoclonal - - - Y Calbiochem 
APC (Ab7) Monoclonal 1:100 - 1:400  Calbiochem 
APC (C20) Polyclonal - - - Y Santa Cruz 
APC (H290) Polyclonal 1:400 1:500 1:2000  Santa Cruz 
β-Catenin Monoclonal 1:100 1:2000 1:1000  BD Biosciences 
β-Catenin Polyclonal 1:100 - 1:1,000  Santa Cruz 
BRCA1 Polyclonal - - 1:300  Calbiochem 
DRP1 Monoclonal 1:800 1:1000 1:10000  BD Biosciences 
EB1 Monoclonal 1:200 1:500 -  BD Biosciences 
58k Monoclonal 1:150 - -  Abcam 
Fis1 Polyclonal 1:400 - 1:2000  Gift* 
GFP Monoclonal 1:1000 1:1000 1:100000  Roche 
GFP Polyclonal 1:1000 1:1000 - Y Invitrogen 
HSP70 Monoclonal 1:1000 1:1000 -  Pierce 
IgGr Polyclonal - - - Y Sigma-Aldrich 
IgGm Monoclonal - - - Y Sigma-Aldrich 
IQGAP1 Polyclonal 1:200 - 1:400  Santa Cruz 
KAP3A Monoclonal 1:200 - -  BD Biosciences 
KIF5 Monoclonal - - 1:600  Millipore 
LAMP-1 Monoclonal 1:100 - -  BD Biosciences 
Milton 2 
(TRAK2) 
Polyclonal 1:100 1:100 1:500 Y Sigma-Aldrich 
Miro 1 
(RHOT1) 
Polyclonal 1:100 1:500 1:300  Sigma-Aldrich 
Mfn2 Polyclonal 1:500 1:1000 1:2000  Gift* 
OPA1 Monoclonal 1:500 1:1000 1:5000  BD Biosciences 
PCNA Monoclonal - - 1:500  BD Biosciences 
RanBP2 Monoclonal 1:100 1:500 1:2000 Y Santa Cruz 
RanBP2 Polyclonal 1:500 - 1:2000  Santa Cruz 
Topo II Monoclonal - 1:500 -  Calbiochem 
α tubulin Monoclonal 1:1000 1:1500 -  Sigma-Aldrich 
γ-tubulin Monoclonal 1:200 - -  Abcam 
IF: Immunofluorescence, WB: Western Blot, Duo: Duolink, IP: Immunoprecipitation. 
Antibodies marked with (*) were generously gifted by Dr Mike Ryan.  
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Table 2.3: Secondary antibodies 
Antibody 
Dilution 
Supplier 
IF WB 
AlexaFluor 405 anti-mouse 1:400 - Molecular Probes 
AlexaFluor 405 anti-rabbit 1:400 - Molecular Probes 
AlexaFluor 488 anti-mouse 1:500 - Molecular Probes 
AlexaFluor 488 anti-rabbit 1:500 - Molecular Probes 
AlexaFluor 594 anti-mouse 1:2000 - Molecular Probes 
AlexaFluor 594 anti-rabbit 1:2000 - Molecular Probes 
HRP-conjugated anti-mouse - 1:10000 Sigma-Aldrich 
HRP-conjugated anti-rabbit - 1:10000 Sigma-Aldrich 
IF: Immunofluorescence, WB: Western Blot. 
 
Table 2.4: Dyes 
Dye Dilution, IF Supplier 
CMX-Ros 1:10000 Molecular Probes 
ER Tracker 1:500 Molecular Probes 
Hoechst 33258 (200 g/ml) 1:200 Sigma-Aldrich 
IF: Immunofluorescence 
2.1.3 Small interfering RNA (siRNA) 
Small interfering RNAs (siRNA) used are outlined in Table 2.5. 
 
Table 2.5: siRNA target sequences 
Target Gene siRNA Target Sequence Source 
scrambled 
sequence 
control siRNA AAT TCT CCG AAC  GTG 
TCA CGT 
QIAGEN- 
custom made 
scrambled 
sequence 
control siRNA Non-targeting nucleotides Santa Cruz 
(sc-367007) 
APC APC2 AAC GAG CAC AGC GAA 
GAA TAG 
QIAGEN- 
custom made 
APC APCd AGG GGC AGC AAC TGA 
TGA AAA 
QIAGEN- 
custom made 
APC 
(mouse) 
mAPC AAG GAC TGG TAT TAT 
GCT CAA 
QIAGEN- 
custom made 
APC 
(mouse) 
mAPC-red 
(AlexaFluor® 555) 
AAG GAC TGG TAT TAT 
GCT CAA 
QIAGEN- 
custom made 
EB1 EB1 Pool of 3-5  siRNA nucleotides Santa Cruz 
(sc-35258) 
RanBP2 RanBP2 Pool of 3-5 siRNA nucleotides Santa Cruz 
(sc-36381) 
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2.1.4 Plasmids 
Plasmid DNA constructs used in this study are outlined in Table 2.6 below.  
 
Table 2.6: Plasmids and sources 
Gene Construct Tag Source 
APC 
APC WT pCMV Dr Bert Vogelstein* (91) 
APC WT GFP Dr Angela Barth *(269). 
APC (1-1309) pCMV Dr Bert Vogelstein* (91) 
APC (1-1309) EGFP Dr Myth Mok (Chinese 
University of Hong Kong) 
APC (1-302) EGFP Dr Manisha Sharma (27) 
APC (334-900) EGFP Dr Manisha Sharma (27) 
APC (1379-2080) GFP Dr Mariann Bienz* (49) 
APC (2226-2644) EGFP Dr Manisha Sharma (27) 
APC (2650-2843) EGFP Dr Manisha Sharma (27) 
Mito targeting 
sequence (COX8) 
Mito GFP2 Evrogen (Moscow, Russia) 
Miro (RHOT) 
Miro-1 EGFP Dr Mike Ryan* (270) 
Miro-2 EGFP Dr Mike Ryan* (270) 
Milton (TRAK) 
Milton-1 EGFP Dr Mike Ryan* (270) 
Milton-2 EGFP Dr Mike Ryan* (270) 
WT: Wild type.  Sources marked with (*) kindly supplied plasmids as gifts.  
2.1.5 Drugs 
Drug treatments performed in this study are outlined in Table 2.7. 
 
Table 2.7: Drug target action 
Drug Target Action Dosage 
/Time 
Solvent Supplier 
Calcimycin 
(A23187) 
Cation ionophore selective for Ca
2+
, 
Mn
2+
 and Mg
2+
. Used in this study to 
increase intracellular Ca
2+
 
concentrations. 
20 µM 
/5 min 
DMSO Sigma-
Aldrich 
Latrunculin 
A 
Binds actin monomers to prevent 
polymerisation into F-actin. 
0.5 nM 
/1 h 
DMSO Sigma-
Aldrich 
Nocodazole Binds to β-tubulin sub-units to prevent 
polymerisation into microtubules. 
33 µM 
/1 h 
DMSO Sigma-
Aldrich 
Tetracycline An antibiotic used in this study to 
induce APC fragment expression in 
inducible HEK cell lines. 
4.5 nM 
/16h 
H2O Sigma-
Aldrich 
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2.1.6  Other Reagents 
Other reagents used in this study are outlined in Table 2.8. 
 
Table 2.8: Reagents 
Reagent Supplier 
Acetic acid Fisher Scientific 
Acetone Merck  
Acrylamide solution 40% Merck  
Agar Amresco 
Agarose  Amresco  
Ammonium persulphate (APS)  Sigma-Aldrich 
Ampicillin  Calbiochem  
Bacto-agar  Oxoid  
Bacto-tryptone  Oxoid  
Bacto-yeast extract  Amresco  
Blastocidin Sigma-Aldrich 
Boric Acid Astral Scientific 
Bovine serum albumin (BSA) Sigma-Aldrich 
Bromophenol blue Sigma-Aldrich 
Calcium chloride (CaCl2) Sigma-Aldrich 
Chromotography paper Whatman 
Deoxycholate Biomedicals Inc. 
Dulbecco’s Modified Eagle Medium 
(DMEM)  
Sigma-Aldrich 
Duolink α-rabbit probes O-link Biosciences 
Duolink α-mouse probes O-link Biosciences 
Duolink amplification Red O-link Biosciences 
Duolink amplification Green O-link Biosciences 
Duolink Mounting Media O-link Biosciences 
Dimethyl Sulphoxide (DMSO)  Amresco  
ECL Western blotting detection reagents  GE Healthcare  
Ethanol (absolute)  Merck  
Ethylenediaminetetra-acetic acid (EDTA)  Amresco  
Fetal bovine serum (FBS) ThermoTrace  
Fugene HD  Promega  
Glucose (20%)  Amresco  
Glutamine (200 mM)  SAFC biosciences  
Glycerol  Amresco  
Glycine  Amresco  
HEPES buffer (1 M)  SAFC Biosciences  
Hydrochloric acid (HCl) AJAX chemicals 
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Hygromycin B Sigma-Aldrich 
Isopropanol  Amresco  
K2 Transfection Biontex 
Kanamycin  Boehringer Manheim  
Lipofectamine  Life Technologies  
Manganese (II) chloride (MnCl2) AJAX chemicals 
Magnesium chloride (MgCl2) AJAX chemicals  
Magnesium sulphate (MgSO4) AJAX chemicals  
β-mercaptoethanol  Sigma-Aldrich 
Methanol (absolute)  Fronine  
Nitrocellulose membrane Millipore 
Nonidet P-40 (NP-40)  Roche  
Opti-MEM
TM
 reduced serum medium Life Technologies 
Penicillin G (500 U/mL)/Streptomycin 
sulphate (5000 μg/ml)  
CSL Biosciences  
Polyethylenimine (PEI) Sigma-Aldrich 
Phosphate Buffered Saline (PBS, distilled) Lonza Biowhitttaker 
Poly-L-lysine Sigma-Aldrich 
Ponceau S Sigma-Aldrich 
Potassium acetate AJAX chemicals 
Potassium chloride (KCl) AnalaR 
Potassium phosphate (KH2PO4) Sigma-Aldrich 
Precision Plus Dual colour standards BioRad 
Protease inhibitor cocktail tablets 
(complete)  
Roche  
Protein-A-sepharose beads  GE Healthcare  
Rubidium chloride (RbCl) Sigma-Aldrich 
Skim milk powder Diploma 
Sodium chloride (NaCl) Sigma-Aldrich 
Sodium dodecyl sulphate (SDS; 20%)  Amresco  
(Di)Sodium phosphate (Na2HPO4) AJAX Chemicals 
TEMED  Amresco  
Tris  Amresco  
Triton-X-100  Astral Scientific 
Trypsin JRH Biosciences  
Tween-20  Astral Scientific 
Vectashield mounting medium  Vector Laboratories  
Water (distilled) Baxter Laboratories 
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2.2 Methods 
2.2.1 Bacterial culture 
2.2.1.1 Overnight bacterial culture 
2-yeast tryptone (2-YT) medium or agar was prepared as per Appendix 2.1. Agar plates 
were streaked with a bacterial glycerol stock (prepared as 2.2.1.2) in a sterile 
environment using an inoculation loop, and then incubated for 14-16 h at 37°C. A single 
colony from the agar plate was used to inoculate 2-YT media containing the appropriate 
antibiotic (ampicillin or kanamycin, 50 µg/ml), and incubated at 37°C for 14-16 h at 
250 rpm (revolutions per minute). 
2.2.1.2 Freezing bacterial cultures as glycerol stocks 
Bacterial glycerol stocks were created by adding 300 µl of sterile glycerol (50%) to 700 
µl of an overnight E.coli culture in a cryovial, then vortexed. Cultures were snap-frozen 
on dry ice and stored at -80°C. 
2.2.1.3 Preparation of XL10-gold or BL-21 competent cells 
A single colony of XL10-gold or BL-21 cells was incubated in 5 ml 2-YT medium 
without antibiotic at 37°C and shaken at 250 rpm for 14-16 h. This was used to 
inoculate 250 ml 2-YT medium supplemented with MgSO4 (20 mM) and further 
incubated at 37°C, 250 rpm until the OD600nm = 0.8 – 1.0. The cells were centrifuged at 
1,000 xg/5 min/4°C, prior to discarding the supernatant and resuspending in 100 ml cold 
TFB1 buffer (Appendix 2.1). Following 5 min incubation on ice, cells were once more 
centrifuged at 1000 xg/5 min/4°C. The supernatant was discarded and the cells 
resuspended in 10 ml TFB2 buffer (Appendix 2.1). Cells were incubated on ice for a 
further 15-50 min then either transformed immediately or aliquoted and stored at -80°C 
for later use. 
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2.2.1.4 Heat shock transformation of XL10-gold or BL-21 cells 
β-mercaptoethanol (4 µl) was added to 100 µl of XL10-gold or BL-21 cells (prepared as 
2.2.1.3) prior to a 10 min incubation on ice with gentle agitation every 2 min. Plasmid 
DNA (50 ng) was then added to the cells and mixed gently before further incubation on 
ice for 30 min. Cells were subjected to a 90 s heat pulsation in a water bath at 42°C and 
then cooled on ice for 2 min. Warmed 2-YT medium (900 µl) was added to the cells 
which were then incubated at 37°C, shaking at 250 rpm for 1 h. Cells were centrifuged 
at 358 xg for 2 min, and most of the medium removed, leaving ~100 µl. The cell pellet 
was resuspended in this remaining medium, plated onto 2-YT agar plates containing the 
appropriate antibiotic (ampicillin or kanamycin, 50 µg/ml) and incubated at 37°C for 
14-16 h. 
2.2.2 Preparation of plasmid DNA 
2.2.2.1 Plasmid midi-preps 
Plasmid DNA preparations were obtained using the PureYield™ Plasmid Midi-Kit 
(Promega) according to the manufacturer’s instructions. Briefly, a 50 ml overnight 
culture (see 2.2.1.1) was centrifuged at 10,000 xg for 10 min and the supernatant 
discarded. The bacterial pellet was then resuspended in Cell Resuspension Solution (3 
ml), after which Cell Lysis Solution (3 ml) was added. The bacterial solution was gently 
mixed by inversion and incubated at RT for 4 min. Neutralisation Solution (5 ml) was 
added to the lysed cells and mixed gently by inversion, before incubation at RT for 3 
min in an upright position.  
 
The following centrifugation steps utilising the PureYield™ Clearing and Binding 
Columns were performed using a centrifuge with a swinging bucket rotor. A 
PureYield™ Clearing Column was placed in a 50 ml Falcon tube and the lysate poured 
into the column, where it was allowed to filter through for 5 min prior to centrifugation 
at 1,500 xg for 5 min. A PureYield™ Binding Column was placed in a new 50 ml 
Falcon tube and the filtered lysate was poured into the column before further 
centrifugation at 1,500 xg for 5 min. Endotoxin Removal Wash (5 ml) was added to the 
Binding Column which was then subjected to centrifugation at 1,500 xg for 5 min 
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before the flow-through was discarded. Column Wash (20 ml) was added to the Binding 
Column and centrifuged at 1,500 xg for 5 min, after which the flow-through was 
discarded and the column re-centrifuged at 1,500 xg for 10 min to remove excess liquid.  
 
To elute the DNA, the PureYield™ Binding Column was placed into a new 50 ml 
Falcon and nuclease-free water (600 µl) was dropped onto the middle of the column 
membrane. This was subjected to centrifugation at 1500 xg for 5 min, after which the 
DNA-containing filtrate was transferred into an Eppendorf tube for storage at -20°C. 
2.2.2.2 Quantification of plasmid concentration 
Plasmid DNA concentration was determined using the Warburg-Christian method on a 
Beckman DU-64 spectrophotometer. 5 µl DNA was diluted in 45 µl nuclease-free water 
and ultraviolet radiation absorbance at 260nm (A260) and 280nm (A280) was 
measured. A ratio between A260:A280 in the range of 1.8-2.0 indicates that the plasmid 
DNA is highly purified. The DNA concentration was determined from the A260 value 
using the formula described below. 
 
DNA concentration (ng/μl) = A260 x dilution factor x 50 ng/μl constant 
2.2.3 Cell culture 
All cell lines used in this thesis are described in Table 2.1 and were subject to routine 
mycoplasma testing. All cell culture was performed in a laminar flow hood. 
2.2.3.1 Propagation of cell lines 
All cell lines were grown as adherent cells in 25 cm
2
, 75 cm
2
 or 150 cm
2 
flasks, unless 
otherwise stated. U2OS, Hela, SW480, HT-29, HCT116, LIM 1215, HDF1314 and NIH 
3T3 cells were maintained in supplemented DMEM (Appendix 2.1) and cultured at 
37°C with 5% CO2. HEK293 (APC-WT) and HEK293 (APC-1309) cells were 
maintained in supplemented DMEM containing 15 g/ml blasticidin and 150 g/ml 
hygromycin B and cultured at 37°C with 5% CO2.  
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To propagate cell lines, the culture media was removed and the cells were washed with 
distilled phosphate buffered saline (PBS, Appendix 2.1). Cells were detached from the 
flask and collected following a 5-10 min incubation period at 37°C with 5% CO2 in 
trypsin, after which they were placed in new cell culture medium. The cells were then 
either added to a new flask for continued propagation or seeded into the appropriate 
vessel for experiments (specifics outlined in the methods section for each chapter). Cells 
were discarded after passage 22.  
2.2.3.2 Freezing cells 
Cells grown to 80% confluence at a low passage number were collected using trypsin 
(as per 2.2.3.1), and centrifuged at 500 xg for 5 min after which the cell pellet was 
resuspended in Fetal Bovine Serum (FBS) supplemented with 10% DMSO. The cell 
suspension was aliquoted into cryovials on ice, and placed at -80°C for freezing prior to 
storage in liquid nitrogen 
2.2.3.3 Reviving cells from liquid nitrogen stocks 
Stocks were thawed at 37°C in a sterile water bath and added to 5 ml Dulbecco’s 
Modified Eagle Medium (DMEM) which had been pre-warmed to 37°C. The cells were 
subjected to centrifugation at 500 xg for 5 min, after which the cell pellet was 
resuspended in 5 ml supplemented DMEM, transferred into a 25 cm
2
 flask and placed in 
an incubator at 37°C with 5% CO2. 
2.2.3.4 Transfection of cell lines with plasmids or siRNA 
A number of transfection methods were used in this study to transfect the siRNA and 
plasmid DNA (described in Table 2.5 and Table 2.6 respectively), into cells which had 
been seeded at least 12 h prior. Transfection of siRNAs was typically performed on 
cells at ~50% confluence with Lipofectamine (Lipofectamine 2000), whilst transfection 
of plasmid DNA was typically performed on cells at ~70% confluence with 
polyethylenimine (PEI). Following treatment with transfection reagents, cells were 
incubated at 37°C and 5% CO2, for 72 h for siRNA transfection or 48 h for plasmid 
DNA transfection. The typical concentration for plasmid DNA transfection was 1-2 
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µg/ml, however under certain conditions this amount was reduced. This is discussed 
further in the relevant results chapters. 
 
The protocol for both Lipofectamine and PEI is identical. Lipofectamine or PEI was 
diluted in serum-free OptiMEM
TM
 medium and incubated for 5 min at RT. In a separate 
tube, siRNA or plasmid DNA was diluted in serum-free OptiMEM
TM
 medium. The 
Lipofectamine or PEI mixture was then slowly added to the siRNA/Plasmid DNA 
mixture and incubated at RT for 20 min, before it was diluted in DMEM and added to 
the cell culture. Following a 6 h incubation period at 37°C and 5% CO2, the culture 
medium was removed and replaced with supplemented DMEM.  Reagent volumes used 
for typical transfection are outlined below. 
 
PEI and Lipofectamine Transfection Reagents 
 
Tube 1 
3 µg siRNA OR 1-2 µg Plasmid 
DNA 
100 µl serum-free OptiMEM
TM
 
Tube 2 
3 µl Lipofectamine OR PEI 
100 µl serum-free OptiMEM
TM
 
 
DMEM 
1 ml 
The above protocol describes the components required for a single well in a standard 6-
well tissue culture plate. Reagents were scaled up and down according to size of vessel. 
 
The protocol for transfection of plasmid DNA with Fugene HD is as follows; Fugene 
HD and plasmid DNA were diluted in serum-free OptiMEM
TM
 medium, incubated at 
RT for 20 min, diluted in DMEM and added to the cell culture. The medium was 
changed after a 6 h incubation period at 37°C and 5% CO2, and replaced with 
supplemented DMEM.  Reagent volumes used for typical transfection are outlined 
below. 
Fugene Transfection Reagents 
 
Tube 1 
1-2 µg Plasmid DNA 
4 µl Fugene 
100 µl serum-free OptiMEM
TM
 
DMEM 
2 ml  
 
 
The above protocol describes the components required for a single well in a standard 6-
well tissue culture plate. Reagents were scaled up and down according to size of vessel. 
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The protocol for transfection of plasmid DNA with the K2 transfection system is as 
follows; The K2 multiplier reagent was diluted in supplemented DMEM, added to the 
cell culture and incubated for 2 h at 37°C and 5% CO2. K2 transfection reagent was 
diluted in serum-free OptiMEM
TM
 medium and, in a separate tube, plasmid DNA was 
diluted in serum-free OptiMEM
TM
 medium. The K2 mixture and the plasmid DNA 
mixture were then slowly mixed together and incubated at RT for 20 min, before being 
added to the cell culture containing the multiplier reagent. Following a 24 h incubation 
period at 37°C and 5% CO2, the medium was removed and replaced with supplemented 
DMEM. Reagent volumes used for typical transfection are outlined below. 
 
K2 Transfection Reagents 
 
Tube 1 
1-2 µg Plasmid DNA 
100 µl serum-free OptiMEM
TM
 
Tube 2 
3 µl K2 transfection reagent 
100 µl serum-free 
OptiMEM
TM
 
DMEM 
1 ml  
30 µl multiplier 
 
The above protocol describes the components required for a single well in a standard 6-
well tissue culture plate. Reagents were scaled up and down according to size of vessel. 
2.2.3.5 Drug Treatments 
All drugs were aliquoted and stored according to the manufacturer’s instructions and 
diluted to the desired concentration just prior to administration. To determine the 
dosage, drug concentrations were optimised by titration using functional concentrations 
and treatment times from the literature. The optimal concentration and treatment time 
for each drug used in this study is described in Table 2.7 and experimental specifics 
outlined where relevant in the results chapters.  
2.2.3.6 Wound Healing Assays 
Confluent cells grown on coverslips coated with Poly-L-Lysine (1 mg/ml) were 
wounded with a 0.8 mm (PrecisionGlide, BD) needle and washed twice with PBS prior 
to the addition of new DMEM. Subsequent fixation/immunostaining or live cell 
imaging was performed 5 h after wounding.   
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2.2.4 Preparation of slides for immunofluorescence microscopy 
2.2.4.1 Application of Dyes by Molecular Probes® 
Application of dyes by Molecular Probes® (Life Technologies) occurred prior to 
fixation. Cells were incubated for 15 min at 37°C and 5% CO2 with the desired dye 
diluted (Table 2.4) in DMEM warmed to RT, at a volume sufficient to cover the slide. 
Cells were either fixed immediately afterwards, or if they were to be subjected to live 
cell microscopy, washed 3 times with PBS, covered in supplemented DMEM and 
immediately processed.  
2.2.4.2 Standard fixation 
Cells for analysis by immunofluorescence microscopy were grown on glass cover-slips 
(Menzel-gläser) in 6-well tissue culture plate (Nunc) or, if Duolink PLA was required 
(see Section 2.2.8), in 8-well chamber slides with silicone wells (Lab-Tek). Prior to 
fixation, the cell medium was removed from the well and the slide washed 3 times with 
PBS. A sufficient volume of chilled (-20°C) methanol:acetone (1:1) was applied to 
cover the slide which was then incubated at -20°C for 5 min. After fixation, the slide 
was washed 3 times with PBS. 
2.2.4.3 Immunostaining 
This protocol is for fixed cells grown on coverslips in a 6-well tissue culture plate; for 
the Duolink counter-staining protocol, see Section 2.2.8.5. Cells were blocked with 3% 
bovine serum albumin (BSA) - PBS (1 ml/well) for 40 min, after which cells were 
incubated for 1 h with the desired primary antibodies (Table 2.2) diluted in 3% BSA-
PBS in a volume sufficient to cover the slide. Slides were then washed 3 times with 
PBS before incubation with secondary antibodies and/or Hoechst dye diluted (Table 2.3, 
Table 2.4) in 3% BSA-PBS for 1 h. Coverslips were washed 3 times with PBS and 
mounted on glass slides using Vectashield mounting media and sealed with clear nail 
polish. For basic immunofluorescence microscopy analysis, slides were viewed using an 
upright Olympus Fluorescent BX40 system at 40x and 60x magnification. For more 
advanced analysis and image capture, the inverted Olympus IX71 DeltaVision core 
deconvolution microscope was used (see Section 2.2.5). Slides were stored at 4°C. 
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2.2.5 Acquisition by DeltaVision microscopy 
The Olympus IX71 DeltaVision core deconvolution microscope equipped with a 
CoolSNAP HQ
2
 camera was used for advanced image capture and live cell imaging at 
40x, 60x and 100x magnification. 
2.2.5.1 Fixed cell 
Collected images were further resolved using SoftWorx deconvolution software 
(Version 3.7.1; Applied Precision) and where required, sequential transverse optical 
sections (z-stack images) were taken which could be rendered into 3-D projections 
(more detail in relevant chapters). Analysis of immunofluorescence images for 
localisation assays, mitochondrial distribution and morphology, and Duolink PLA is 
described in Sections 2.2.6, 2.2.7 and 2.2.8 respectively. 
2.2.5.2 Live cell 
For live cell experiments, cells were seeded in 2-well chamber slides coated with Poly-
L-lysine and grown until they reached the desired confluence. To visualize 
mitochondria, cells were either transfected with pGFP2-mito or stained with CMX-Ros. 
Cells subject to imaging were maintained inside the chamber at 37°C and 5% CO2. The 
protocol for live cell imaging, including optimisation and post-acquisition analysis is 
described in greater detail in Chapter 5. 
2.2.6 Localisation assays 
2.2.6.1 Preparation of cells  
Cells grown on glass cover-slips in 6-well tissue culture plates were fixed, 
immunostained and imaged as outlined in Section 2.2.4 and 2.2.5. 
2.2.6.2 Analysis of localisation 
The DeltaVision imaging software, SoftWorx was used to assess colocalisation between 
different proteins and mitochondrial markers (mitochondrial dye CMX-Ros or antibody 
HSP-70) stained with alternate colours. Colocalisation was deemed positive if the 
Chapter 2 
53 
staining patterns of the proteins or markers showed at least a partial overlap and, as red 
and green fluorophores (i.e. AlexaFluor® 594 and AlexaFluor® 488 respectively) were 
typically used, this was usually identified by the production of a yellow colour in the 
merged image.  
2.2.7 Mitochondrial distribution and morphology assays 
2.2.7.1 Preparation of cells 
Cells grown on glass cover-slips in 6-well tissue culture plates were fixed, 
immunostained and imaged as outlined in Sections 2.2.4 and 2.2.5. During 
immunostaining, mitochondria were marked using CMX-Ros or α-HSP70. If possible, 
the nucleus and cell membrane were also stained using Hoescht or a cytoplasmic marker 
(i.e. α-tubulin or IQGAP1) respectively. If however, this was outside the limitations of 
3-colour staining, the DIC channel (white light) was used to detect the nucleus and cell 
membrane.  
2.2.7.2 Analysis of mitochondrial distribution 
To quantify mitochondrial distribution, the localisation of mitochondria in cells was 
scored by eye into one of three 'zones' starting at the nucleus and radiating out to the cell 
membrane. These zones constituted 33% (zone 1), 66% (zone 2) and 100% (zone 3) of 
the cytoplasmic area and mitochondria were scored according to which zone they 
extended into (see Figure 2.1 for examples across a number of cell lines). 
 
Differences in morphological features across the cell lines analysed meant that in some 
cells, certain parameters had to be put in place for mitochondrial scoring. These are 
described in Table 2.9. Furthermore as SW480 is a biclonal cell line expressing two 
morphologically distinct cell types that are round or elongated, additional parameters to 
those outlined in Table 2.9 were observed. Elongated cells typically presented a higher 
number of mitochondria in zone 3 compared to round cells and appeared more sensitive 
to toxicity associated with certain experimental procedures such as siRNA treatment. To 
avoid selecting out a single population whilst scoring, it was ensured that equal numbers 
of round and elongated cells were scored, and results pooled.  
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Figure 2.1: Mitochondrial distribution scoring method.  
Cells were scored into one of three cellular ‘zones’ according to how far they radiated 
from the nucleus to the cell membrane. Cells relevant to each zone are marked (*). For 
cell line specific parameters see Table 2.9. 
 
Table 2.9: Cell line specific parameters for scoring mitochondrial distribution.  
Cell Type Cell Lines Mitochondrial Distribution Scoring 
Parameters 
Large epithelial  U2OS, Hela N/A 
Small epithelial SW480, HT-29, 
HCT116, LIM 
1215 
Scoring zones are very narrow due to size of 
cell. Mitochondria that do not touch the 
nucleus are at least considered 'zone 2'. In 
'zone 3' cells, the mitochondria typically 
touch the cell membrane. 
Fibroblast HDF1414, NIH 
3T3 
Mitochondria must enter the cell extensions 
and protrusions typically observed in 
fibroblasts to be considered 'zone 3'. 
Chapter 2 
55 
2.2.7.3 Analysis of mitochondrial morphology 
To analyse mitochondrial morphology, cells were classified according to the size of the 
majority of mitochondria within the cell. Individual mitochondria were determined by 
eye to be either a puncta (~<2 µm) or a rod (~ ≥2 µm) according to their length (Figure 
2.2). Cells presenting a mitochondrial population where ~>66% were puncta was 
classified as “punctate”, whilst cells with ~>66% of the population as rods was 
classified as “rods”. Cells which fell into neither category (i.e. <66% puncta and <66% 
rods) were classified as “mixed”. Examples can be seen in Figure 2.2 below. 
 
 
Figure 2.2: Mitochondrial morphology scoring method.  
The morphology of individual mitochondria was classified as puncta or rods (A). Cells 
were classified according to the majority mitochondrial population (B). 
 
2.2.8 Duolink Proximity Ligation Assay (PLA) 
2.2.8.1 Rationale 
Duolink PLA utilises specifically designed “PLA” probes, species-specific secondary 
antibodies joined to a short oligonucleotide sequence, which attach to the primary 
antibodies of target proteins. If the target proteins are in close proximity (<40 nm), 
following the addition of ligase, PLA probes are able to hybridise. Addition of 
polymerase then facilitates rolling-circle amplification of the probe oligonucelotides 
which attach to a complementary fluorophore to generate a quantifiable signal for 
visualisation of protein-protein interactions in the cell. This is represented in Figure 2.3. 
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For each interaction, the primary antibodies used were also tested on their own for 
background control. 
 
Figure 2.3: Rationale for Duolink PLA  
Circles represent target proteins of interest attached to the respective primary antibody 
(purple and green symbols). Blue and yellow symbols represent secondary PLA probes 
with oligonucleotides attached. Red dots are fluorophores. 
 
 
 
Prior to this study, the Duolink technique had not been previously used in this lab, 
hence a number of control experiments were undertaken to confirm the reliability and 
specificity of the assay. For negative controls, neither the APC/BRCA1 interaction 
(shown to be negative by IP) nor the Miro/PCNA interaction (proteins localised to 
separate cell compartments), produced PLA signals above background level in U2OS 
cells (Supplementary Figure S2.1). For a positive control, the APC/β-Catenin 
interaction was successfully shown to produce PLA signals above background across a 
number of cell lines (Supplementary Figure S2.2). A positive control for ectopically 
expressed GFP-tagged constructs was also undertaken whereby U2OS cells transfected 
with the β-Catenin binding domain, pGFP-APC(1379-2080), were shown to produce 
GFP/β-Catenin PLA signals, ~6.8-fold higher than cells transfected with pGFP alone 
(Supplementary Figure S2.3). 
2.2.8.2 Preparation and fixation of cells for Duolink PLA 
Cells were grown to 80% confluence on 8-well chamber slides (Lab-Tek) coated with 
Poly-L-Lysine (1 mg/ml) then fixed with methanol:acetone (1:1) as per Section 2.2.4.2. 
Chamber wells were removed from the slides prior to commencement of Duolink PLA 
(2.2.8.3). 
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2.2.8.3 Duolink PLA 
Duolink was performed using the Duolink In-Situ PLA kit (O-link Biosciences) as per 
the manufacturer’s instructions. Aside from the primary antibodies, all reagents used 
were provided by the Duolink In-Situ PLA kit and all incubations were carried out at 
37°C in a light-proof humidity chamber. Cells were incubated in Duolink Blocking 
Buffer for 40 min, followed by incubation with the desired primary antibodies (Table 
2.2), diluted in Duolink Diluent for a further 60 min. The slides were submerged in a 
Coplin jar and gently washed in Duolink Buffer A (Appendix 2.1) by rocking (2 x 5 
min). Cells were then incubated with Duolink PLA probes (1:5) diluted in Duolink 
diluent for 60 min, before further washing with Duolink Buffer A (2 x 5 min).  
 
Ligation was facilitated by incubation with ligase (1:40), diluted in a Duolink Ligation 
Reaction Solution for 30 min. Slides were washed with Duolink Buffer A (2 x 2 min). 
Polymerisation was facilitated by incubation with polymerase (1:80), diluted in Duolink 
Polymerisation Reaction Solution (contains fluorophores which hybridise to amplified 
signal) for 100 min. Slides were then washed using Duolink Buffer B (Appendix 2.1) (2 
x 10 min). If further immunostaining (2.2.8.4) was not required, slides were washed in 
Duolink Buffer B 0.01% (1 x 2 min), mounted using the Duolink Mounting Media 
containing DAPI, sealed with nail polish and stored at -20°C until further processing 
(2.2.8.5). 
2.2.8.4 Duolink PLA with ectopically expressed GFP-tagged constructs 
When required, transfection of GFP-tagged constructs was undertaken as described in 
Section 2.2.3.4, however the amount of plasmid DNA transfected was scaled down to 
30-50% of its usual concentration. This was to reduce the high levels of background 
which occur when cells are flooded with GFP. Duolink PLA was performed as 
described in 2.2.8.3, using an antibody against GFP to detect interactions with the 
transfected construct and an endogenous target protein. The GFP signal for transfected 
cells was usually dampened when using Duolink PLA; therefore, following completion 
of the assay, the Duolink counterstaining protocol (Section 2.2.8.5) was employed using 
the same species GFP antibody, to identify transfected cells expressing modest levels of 
GFP. All Duolink PLA’s with cells expressing ectopic GFP-tagged constructs were 
performed in parallel with cells expressing GFP alone. 
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2.2.8.5 Immunostaining after Duolink PLA 
Upon completion of Duolink PLA (Section 2.2.8.3), the slide was washed in Duolink 
Buffer A (2 x 2 min). The desired primary antibody was then diluted (Table 2.2) in 
Duolink diluent and added to the appropriate well where it was incubated in a light-free 
environment for 1 h. The slide was again washed in Duolink Buffer A (2 x 2 min) 
before the appropriate secondary antibody (Table 2.3) diluted in Duolink diluent was 
added to the appropriate well and incubated in a light-free environment for 1 h. The 
slide was then washed in Duolink Buffer A (2 x 2 min), followed by 0.01 % Duolink 
Buffer B (1 x 2 min) after which the slides were mounted using Duolink mounting 
media as per 2.2.8.3. 
2.2.8.6 Analysis and quantification of Duolink PLA 
Slides were analysed by immunofluorescence microscopy using the DeltaVision core 
microscope with fluorescent images captured at 40x and 60x magnification as described 
in 2.2.5. Captured images showed PLA signals, visualized as dots, in clear focus. In 
some cell lines (SW480 and HT-29) it was not possible to achieve this on a single focal 
plane, so z-stack images were acquired. The PLA signal for each cell was scored 
manually using an overlay of the DIC channel (white light) to define the periphery of 
each cell whilst scoring the dots within. 
 
Where localisation of PLA signals to mitochondria needed to be verified, sequential 
transverse optical sections (z-stack images) of cells stained with CMX-Ros were 
acquired in 0.2 µm incremental steps. Images were then rendered into 3-D projections 
using SoftWorx software. PLA signals were considered to be localised to mitochondria 
if >50% overlapped with mitochondrial staining.  
2.2.9 SDS-PAGE and Western Blot analysis of proteins 
2.2.9.1 Protein extraction 
Cells were washed with PBS, then detached and collected from the flask using trypsin 
(Section 2.2.3.1). The cell suspension was then pelleted by centrifugation at 500 xg, for 
5 min at 4°C, washed in PBS and re-centrifuged. Next, cells were resuspended in either 
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RIPA or HUNT buffer (approximately 80 µl for a confluent 25 cm
2
 flask; for recipes 
see Appendix 2.1) and incubated on ice for 30 min to promote cell lysis. Insoluble 
components were removed by centrifugation at 14,000 xg for 12 min at 4°C, after which 
the supernatant was collected. 
2.2.9.2 Quantification of protein cell lysates 
The Bradford assay was used to quantify the protein concentration of cell extracts. BSA 
standards (0, 2, 4, 6 µg/ml) were diluted in Protein Assay Dye Reagent (1x) (Bio-Rad), 
and measured at 595 nm with a DU 800 spectrophotometer to create a standard curve. 
Samples were diluted in the Protein Assay Dye Reagent (1x) (1 µl/ml) and measured at 
595 nm. The standard curve was used to determine the protein concentration of the 
sample. 
2.2.9.3 Resolving proteins by SDS-PAGE  
Cell lysates or immunoprecipitation samples (see Section 2.2.10) were suspended in 4x 
Laemmli buffer and denatured by boiling for 6 min at 95°C. Proteins were resolved by 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) using a 
Mini-Protean II® Electrophoresis System (Bio-Rad). The gel apparatus was prepared by 
pouring freshly made separating gel (Table 2.10) between two glass plates, leaving ~1.5 
cm at the top for coverage with 100% isopropanol. The percentage of acrylamide used 
for the separating gel varied depending on the size of the protein of interest. Following 
gel polymerization (~20 min), the isopropanol was removed and freshly made stacking 
gel (Table 2.11) was used to fill the rest of the apparatus. A comb was inserted into the 
stacking gel at the top of the apparatus to create wells for loading the protein samples, 
which was then removed after polymerization (~20 min). The samples were loaded into 
the gel (for concentrations see relevant chapters) and resolved via electrophoresis at 100 
V for 2 h in running buffer (Appendix 2.1), or until the sample ran to the end of the gel. 
Precision Plus Dual Colour Standards (Bio-Rad) were used as molecular size standards. 
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Table 2.10: Separating Gel for SDS-Page 
Reagent 10% A 7.5% A 5% A 
Poly-Acrylamide Stock (4:1, 40%) (ml) 10 7.5 5 
H2O (ml) 14.55 17.05 21.6 
1 M Tris, pH 8.7 (ml) 15 15 15 
20% SDS (µl) 200 200 200 
10% APS (µl) 200 200 200 
TEMED (µl) 40 40 40 
A: Acrylamide 
 
Table 2.11: Stacking Gel for SDS-Page 
Reagent  
Poly-Acrylamide Stock (4:1, 40%) (ml) 1.25 
H2O (ml) 7.4 
1 M Tris, pH 6.8 (ml) 1.25 
20% SDS (µl) 50 
10% APS (µl) 100 
TEMED (µl) 20 
 
2.2.9.4 Resolving proteins by SDS-Agarose gel electrophoresis 
As APC is a very large protein (~320 kDa), occasionally it was resolved using SDS-
agarose gel electrophoresis rather than traditional SDS-PAGE methods. To prepare the 
gel, 2.5% agarose was melted in Tris Borate EDTA buffer (TBE, Appendix 2.1), after 
which 10% SDS was added and the solution poured into a gel apparatus until full. A 
comb was inserted immediately into the top of the apparatus, which was removed 
following gel polymerization (~20 min). The samples, denatured in Laemmli buffer 
(Appendix 2.1) as in Section 2.2.9.3, were loaded into the gel (for concentrations see 
relevant chapters), and resolved via electrophoresis at 100 V in running buffer (see 
2.2.9.3) until the Plus Dual Colour Standards marker was separated (~40 min). 
2.2.9.5 Western blot transfer – Acrylamide gel 
Following SDS-PAGE (Section 2.2.9.3), the gel and components of the transfer 
apparatus were equilibrated in transfer buffer (Appendix 2.1). To construct the transfer 
apparatus, the gel and a nitrocellulose membrane (Millipore) were sandwiched between 
two pieces of chromatography paper (Whatman 3MM) and two sponges and placed 
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inside a Mini-Trans-Blot® cell (Bio-Rad) according to the manufacturer’s instructions. 
The Mini-Trans-Blot® cell, along with an ice-block and magnetic stirrer, were placed 
into the transfer chamber which was filled with transfer buffer. The proteins on the gel 
were transferred to the membrane at 100 V for 1-3 h, depending on the protein size. 
Protein transfer was confirmed using Ponceau S stain (1 min incubation with 
membrane, Appendix 2.1), after which the membrane was stored in PBS at 4°C until 
immunoblotting.  
2.2.9.6 Western blot transfer – Agarose gel 
Following SDS-Agarose separation (Section 2.2.9.4), the gel and components of the 
transfer apparatus were equilibrated in Tris Buffered Saline (TBS, Appendix 2.1) 
supplemented with 10% SDS. The transfer apparatus was assembled as follows: from 
bottom to top – 3 cm paper towel, 3 x chromatography paper (Whatman 3MM), 
nitrocellulose membrane (Millipore), agarose gel, 2 x chromatography paper. The 
transfer apparatus was then placed over a tank containing TBS supplemented with 10% 
SDS and covered with a salt bridge made from chromatography paper which was 
anchored into each side of the tank. The gel was transferred onto the membrane 
overnight at RT. 
2.2.9.7 Immunoblotting 
Membranes were rinsed with TBS supplemented with 0.2% Tween-20 (TBST) and 
blocked for 1 h in 3% skim milk powder made up with TBST (3% skim milk/TBST). 
The membrane was incubated with the desired primary antibodies diluted to the relevant 
concentrations (Table 2.2) in 3% skim milk/TBST, for 1 h at RT. This was followed by 
3 x 10 min washes with TBST. The secondary HRP-conjugated antibody was diluted to 
the relevant concentration (Table 2.3) in 3% skim milk/TBST and applied to the 
membrane for 1 h at RT after which the membrane was subjected to 3 x 10 min washes 
with TBST. 
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2.2.9.8 Immunodetection by ECL 
ECL reagents (GE Healthcare) were combined (1:1), added to the membrane and 
incubated for 1 min. Excess reagent was removed and the membrane developed by film 
or detected on a ChemiDoc MP imaging system (BioRad). 
 
For film development, the membrane was covered in cling film and placed in an X-
omatic cassette (Dupont cronex), where it was exposed to film (X-OMat BT, Kodak or 
Amersham Hyperfilm ECL, GE Healthcare) at various time intervals. Films were 
developed using a CP1000 X-Ray film processor (AGFA). 
 
For ChemiDoc development, the membrane was placed inside the ChemiDoc MP 
imaging system and developed using the ECL detection protocol at various time 
intervals. 
2.2.10 Detection of protein interactions by immunoprecipitation (IP) 
2.2.10.1  Protein extraction for immunoprecipitation 
Cells were harvested and lysed as per Section 2.2.9.1, and cell lysates quantified for 
protein concentration using the Bradford assay as per Section 2.2.9.2.  
2.2.10.2  Preparation of protein A-sepharose beads 
Protein A-Sepharose beads (GE Heathcare) were washed 3 times in the relevant IP lysis 
buffer (RIPA or HUNT, see Section 2.2.9.1). Once the beads had sedimented after the 
final wash, the lysis buffer was removed until the volume of beads to buffer was 1:1. 
2.2.10.3  Addition of primary antibody 
Cell lysates (700 µg – 2 mg protein) suspended in ~700 µl of lysis buffer were 
incubated with 2 µg of the primary antibody of interest or IgG control overnight, at 4°C, 
with continuous end over end mixing. It was ensured that enough lysate was reserved 
for the input (~10% of IP samples), which was suspended in 4x Laemmli buffer 
(Appendix 2.1), boiled at 95°C for 6 min and stored at -20°C until further processing. 
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2.2.10.4  Addition of beads 
30 µl of Protein A-sepharose bead suspension (2.2.10.2) was added to the cell lysate 
mixture (2.2.10.3) and incubated for 2 h at 4°C, with continuous end over end mixing to 
allow protein attachment to the beads. The beads were pelleted by centrifugation at 500 
xg for 2 min at 4°C after which the supernatant was removed. The beads were then 
washed in 700 µl lysis buffer on ice and re-centrifuged at 500 xg for 1 min at 4°C. The 
wash procedure was repeated twice more. The supernatant was removed following the 
final wash and the beads resuspended in 30 μl of 4x Laemmli buffer (2.2.9.3) and boiled 
at 95°C for 8 min to remove the immunocomplexes from the beads and to denature the 
protein. The mixture was centrifuged at 16,000 xg for 1 min and the supernatant 
removed and subjected to gel electrophoresis (Section 2.2.10.5). 
2.2.10.5  Resolving and developing immunoprecipitation 
Immunoprecipitation samples (2.2.10.4) and the input (2.2.10.3) were loaded into an 
agarose or acrylamide gel then resolved and developed as per Section 2.2.9. 
2.2.11 Statistics and Graphs 
All experimental data was compiled in Microsoft Excel.  
2.2.11.1  Statistical analysis 
Microsoft Excel was used to complete basic statistical analysis such as mean, median 
and standard deviation. GraphPad Prism (version 5.0) was utilised to perform statistical 
comparisons between different samples using an unpaired T-test, for data with normal 
distribution, or a Mann-Whitney U-test, for data without normal distribution.  
2.2.11.2  Graphs 
Bar graphs were generated using Microsoft Excel and typically showed mean ± standard 
deviation. Box-and-whisker plots and dot plots were generated in GraphPad Prism 5. 
For box-and-whisker plots the data presented is median (line), upper/lower quartile 
(box), min/max (error bars with 95% C.I).  
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Appendix 2.1 General Buffers and Culture Medium 
2-YT Medium  
2-YT Medium consisted of Bacto-tryptone 15 g, Bacto-yeast extract 10 g and NaCl 5 g. 
Components were dissolved in 1 L distilled water and autoclaved.  
 
2-YT Agar 
For preparation of agar plates, 15 g bacto-agar was added to 2-YT medium prior to 
autoclaving and left to cool to 50°C. In a sterile environment, antibiotic was then added 
before the solution was poured into sterile petri dishes (~20 ml/dish) and set at room 
temperature (RT). 
 
4x Laemmli Buffer  
125 mM Tris-HCl pH 6.8, 20% glycerol, 10% β-Mercaptoethanol, 5% SDS and 0.005% 
Bromophenol Blue.  
 
Duolink Buffer A 
0.01 M Tris pH 8.0, 0.15 M NaCl and 0.05% Tween 20. Buffers made up with sterile 
H2O, filtered and stored at 4°C.  
 
Duolink Buffer B 
1 M Tris pH 7.5 and 0.1 M NaCl. Buffers made up with sterile H2O, filtered and stored 
at 4°C.  
 
HUNT Buffer 
50 mM Tris pH 7.5, 100 mM NaCl and 0.5% NP-40. Made up in PBS with fresh 
cocktail protease inhibitor (Roche) added just prior to use. 
 
Phosphate Buffered Saline (PBS) 
137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4,1.8 mM KH2PO4. Made up with H2O 
and adjusted to pH 7.4 
 
Ponceau S Stain  
5% Acetic Acid and 0.01 g Ponceau S, made up with H2O. 
 
RIPA Buffer 
1% NP-40 , 0.5% deoxycholate and 0.1% SDS. Made up in PBS with fresh cocktail 
protease inhibitor (Roche) added just prior to use. 
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Running Buffer  
Tris 2.5 mM, glycine 25 mM, and SDS 0.001%. Made up with H2O. 
 
Supplemented DMEM 
Dulbecco’s Modified Eagle Medium (DMEM ) supplemented with 20 mM HEPES, 4 
mM L-Glutamine, 10 % FBS, 100 units/ml Penicillin and 100 µg/ml Streptomycin. 
Medium was stored at 4°C and brought to RT prior to use.  
 
Transfer Buffer 
Tris 25 mM, glycine 192 mM, methanol 20%. Made up with H2O. 
 
Tris Borate EDTA Buffer (TBE 10x) 
890 mM Tris, 890 mM Boric Acid and 20 mM EDTA. Made up with H2O and adjusted 
to pH 8.3. Dilute with H2O for a 1x stock. 
 
Tris Buffered Saline (TBS) 
50 mM Tris and 150 mM NaCl. Made up with H2O and adjusted to pH 7.6 
 
TFB1 Buffer 
30 mM Postassium acetate, 10 mM CaCl2, 50 mM MnCl2, 100 mM RbCl and 15% 
glycerol. Made up with sterile H2O and stored at 4°C. 
 
TFB2 Buffer  
8.8 mM HEPES, 75 mM CaCl2, 10 mM RbCl and 15% glycerol. Made up with sterile 
H2O and stored at 4°C. 
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Appendix 2.2 Supplementary Figures 
 
 
  
 
Supplementary Figure S2.1: Duolink Negative controls  
(A-B) U2OS cells were subject to Duolink PLA using antibodies against (A) BRCA1 
and APC (mAb), or (B) Miro-1 and PCNA to visualise interactions between the proteins 
of interest. Representative images are shown and scoring quantification of PLA signals 
per cell as seen in the dot-plots (mean ± S.D), reveal negative interactions between 
BRCA1/APC and Miro-1/PCNA. 
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Supplementary Figure S2.2: Duolink Positive Control - APC interacts with β-
Catenin  
(A-B) U2OS, SW480 and HCT116 cells were subjected to Duolink PLA using 
antibodies against APC (APC2, pAb) and β-Catenin (mAb) to visualise interactions 
between the two proteins. (A) Representative images are shown and scoring 
quantification of PLA signals is visualised in the (B) dot-plot (mean ± S.D).  
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Supplementary Figure S2.3: Ectopic Duolink positive control - GFP APC(1379-
2080) interacts with β-Catenin.  
(A-C) U2OS cells transfected with pGFP and pGFP APC(1379-2080) were subjected to 
Duolink PLA using antibodies against GFP (mAb) and β-Catenin (pAb). 
Counterstaining using GFP (mAb) and subsequent analysis  and PLA signal scoring by 
immunofluorescence microscopy revealed a positive interaction between GFP 
APC(1379-2080) and β-Catenin relative to GFP control as indicated by the (A) 
representative images,  (B) dot-plot (mean ± S.D)  and (C) table (n, number in sample; * 
fold change relative to GFP control; IQR, inter-quartile range; SD, standard deviation). 
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The dynamic behaviour of mitochondria is essential for many aspects of normal cell 
function, providing a means for its metabolic roles in ATP generation and calcium 
buffering, to be conducted in a finely controlled, site-specific manner. Despite the 
critical nature of mitochondrial motility, the regulatory mechanisms behind this process 
have yet to be fully elucidated. In this chapter a novel role for the tumour suppressor 
APC in the regulation of mitochondrial transport is presented. Analysis of U2OS, 
HDF1314 and NIH 3T3 cell lines by immunofluorescence microscopy revealed that 
siRNA-mediated silencing of wild-type APC caused the typically branched 
mitochondrial network, uniformly spread throughout the cytoplasm to completely 
redistribute to the perinuclear region, in a manner reminiscent of disrupted 
mitochondrial transport.  Treatment of U2OS cells with the microtubule toxin 
nocodazole, mimicked the mitochondrial redistribution induced by APC, indicating that 
microtubule based transport of mitochondria may be effected. Distribution of other 
membrane bound cell organelles following loss of APC was unchanged, as was 
mitochondrial distribution following loss of EB1, the binding partner through which 
APC stabilises microtubules, thus indicating that this phenomena was specific to 
mitochondria, and not a secondary effect of microtubule de-stabilisation. Screening by 
immunofluorescence microscopy identified potential associations between APC and 
proteins from the primary mitochondrial transport complex Miro/Milton, which could 
be confirmed by immunoprecipitation assays in U2OS cells. Finally, Duolink in situ 
PLA was used to finely map the localisation of endogenous APC-Miro/Milton 
immunocomplexes to the mitochondria in both U2OS and Hela cells in 3-D rendered 
models, consistent with the localisation of mitochondrial transport complexes. Together, 
these results indicate a new role for APC in the microtubule-dependent distribution of 
mitochondria towards the cell periphery through an interaction with the Miro/Milton 
mitochondrial transport complex.  
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3.1 Introduction 
APC is a large protein with multiple binding domains that facilitate protein-protein 
interactions integral to its role as a tumour suppressor protein and its capacity to 
regulate pathways for cell growth and differentiation (Section 1.2.1). The ability of APC 
to shuttle throughout the cell, to associate with the cytoskeletal microtubule and actin 
networks, and localise to different cellular compartments (Section 1.2.1.1) is also 
essential for this multifunctional nature. Previous studies from our group determined for 
the first time a new subcellular localisation of APC at the mitochondria, wherein it was 
found to bind and regulate the anti-apoptotic factor Bcl-2 (13). In this study we present 
a completely new and unexpected function of APC at the mitochondria, defined by its 
association with the Miro/Milton mitochondrial transport complex to facilitate 
distribution of mitochondria along microtubules.  
  
Mitochondria are primarily known for playing a pivotal role in providing energy in the 
form of ATP to the cell through a process known as oxidative phosphorylation. 
However, mitochondria are also key to a number of other essential cell functions such 
as apoptosis and calcium buffering (15-17). Critical to these processes is the dynamic, 
motile nature of mitochondria, which allows for quick redistribution to different regions 
of the cell in response to cellular signals, for example, movement towards 
bioenergetically demanding sites, like the cell periphery to provide ATP for cell 
migration. The importance of regulated mitochondrial transport is discussed further in 
Section 1.3.2, and Chapters 4 and 5. 
 
Transport of mitochondria is primarily facilitated by kinesin and dynein-dependent 
movement across the microtubule network towards the plus and minus ends, 
respectively (271). However, mitochondria have also been reported to associate with a 
number of myosin motor proteins for short range transport along actin filaments, 
particularly in neurons (170, 171). For finely regulated transport, mitochondria rely on a 
number of motor protein adaptor complexes, from which the most well defined is the 
Miro/Milton complex that drives kinesin dependent anterograde mitochondrial transport 
along microtubules (for details on other mitochondrial transport mechanisms see 
Section 1.3.2.2.) This complex was originally identified from genetic screens in 
Drosophila with impaired mitochondrial transport (143, 144), and since then has been  
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found to be evolutionarily conserved in mammals, with two orthologues identified for 
each protein, Miro-1/Miro-2 and Milton-1/Milton-2 (145, 146). Miro is a mitochondrial 
transmembrane protein which through the adaptor Milton, is attached to the KIF5 
kinesin motor (148-150).  
 
The close association of APC with both the microtubule and actin networks has been 
widely reported (see Section 1.2.1.3 for more details). With this in mind, we show for 
the first time that APC loss specifically disrupts microtubule-based distribution of 
mitochondria at the cell periphery in epithelial and fibroblastic cell lines. It is proposed 
that this occurs due to a change in the Miro/Milton/KIF5 mitochondrial transport 
complex which is shown to interact with APC.  
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3.2 Methods 
3.2.1 Cell culture 
U2OS, Hela, HDF1314 and NIH 3T3 cells were cultured in DMEM under standard 
conditions as outlined in Section 2.2.3. For mitochondrial distribution and co-
localisation experiments, cells were seeded on glass coverslips in 6 well trays, and for 
Duolink PLA experiments cells were seeded in 8-well chamber slides coated with poly-
L-lysine. For experiments using fixed cells, cells were grown to 70-80% confluence 
prior to fixation. Cells to be subjected to western blotting were seeded in 150cm
2
 flasks 
for immunoprecipitation assays and 25cm
2
 flasks for siRNA knockdown experiments. 
The transfection of plasmid DNA for transient expression or siRNAs for gene silencing 
in cells is described in Section 2.2.3.4. 
3.2.2 Cell fixation and staining for immunofluorescence microscopy 
Cells were seeded for at least 24 h, fixed with methanol-acetone, probed with relevant 
antibodies and mounted for immunofluorescence microscopy as outlined in Section 
2.2.4. If addition of CMX-Ros or ER-tracker for detection of mitochondria or the 
endoplasmic reticulum respectively was required this occurred prior to fixation. 
Concentrations and any further specifications for all antibodies and dyes used in this 
chapter are outlined in Table 2.2, Table 2.3 and Table 2.4. 
3.2.3 Immunofluorescence cell image acquisition and processing 
Slides were analysed using the Olympus IX71 DeltaVision Core deconvolution 
microscope equipped with a CoolSNAP HQ
2
 camera for general image capture (Section 
2.2.5). Images collected were further resolved using SoftWorx deconvolution software. 
For scoring of co-localisation experiments, 200 cells were analysed over 2 independent 
experiments as outlined in Section 2.2.6. For mitochondrial distribution experiments, 
300 cells were scored over 3 independent experiments, with the exception of the 
nocodazole and latrunculin A experiments (Figure 3.3) where 200 cells were analysed 
over 2 experiments. Analysis of mitochondrial distribution experiments and Duolink 
PLA is further described in Section 3.2.4.1 and 3.2.8 respectively.  
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3.2.4 Quantification of cell organelle distribution 
Post-image acquisition, cells treated with control or APCd siRNA and stained with 
various cell organelle markers were analysed for organelle distribution. Organelle 
distribution was analysed by marking the nucleus with Hoechst and the cell membrane 
with IQGAP1, then determining by eye, which of three cellular 'zones', between the 
nucleus and cell membrane the organelle was able to extend to (see example Figure 
M3.1). This method was further developed for subsequent experiments looking at 
mitochondrial distribution. 
 
Figure M3.1: Organelle distribution scoring method 
Schematic indicates scoring ‘zones’ under which organelles are classified. An organelle 
is classified into a zone depending on how far it extends from the nucleus towards the 
cell membrane. For example, golgi staining in this U2OS cell indicates that it is 
localised to the zone 1 cellular region.  
 
3.2.4.1 Quantification of mitochondrial distribution  
To quantify mitochondrial distribution, the same principle used to score organelle 
distribution was implemented and cells were scored into three 'zones' radiating from the 
nucleus to the cell membrane. These zones constituted 33% (zone 1), 66% (zone 2) and 
100% (zone 3) of the cytoplasmic area and mitochondria were scored according to 
which zone they reached. Figure M3.2 below shows examples of distribution scoring in 
U2OS cells, however, more detailed scoring parameters, including important features 
taken into account in the analysis of other cell lines is described in Section 2.2.7.  
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Figure M3.2: Mitochondrial distribution scoring method 
Cells were scored into one of three cellular ‘zones’ radiating from the nucleus towards 
the cell membrane. Classification was dependant on extension from the nucleus. 
 
3.2.5 Drug treatments 
Under sterile conditions, sub-confluent cells were treated with nocodazole (33µM), 
latrunculin A (0.5 nM) or DMSO for 1h at 37°C prior to fixation as outlined in Section 
2.2.3.5 and Table 2.7. 
3.2.6 Immunoprecipitation assays 
For immunoprecipitation experiments, cells transfected with pGFP, pGFP Miro-1 and 
pGFP Milton-2 were collected and lysed with HUNT buffer as outlined in Section 
2.2.9.1. Immunoprecipitation was carried out as described in Section 2.2.10, using 
antibodies against GFP (pAb, Invitrogen), APC (C20, pAb, Santa Cruz) and IgGr (pAb, 
Sigma-Aldrich) to pull-down target proteins prior to samples being subjected to SDS-
PAGE and western blot analysis. Immunoprecipitation experiments were repeated a 
minimum of 3 times.  
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3.2.7 Western blot analysis 
With the exception of the samples for immunoprecipitation assays described above 
(Section 3.2.6), cells were collected, lysed using RIPA buffer and processed as 
described in Section 2.2.9.1. Samples (immunoprecipitates or ~30µg total cell lysate) 
were separated by SDS-PAGE using 5% (for detection of APC) or 7.5% acrylamide 
gels, and transferred onto a nitrocellulose membrane (see Sections 2.2.9.3-2.2.9.6). 
Western blots were probed as described in Section 2.2.9.7, using primary antibodies as 
per the figure legends. Dilutions for these antibodies and subsequent secondary 
antibodies are outlined in Table 2.2 and Table 2.3, respectively. Immuno-blots in this 
chapter were developed on film using ECL (See Section 2.2.9.8). 
3.2.8 Duolink Proximity Ligation Assay (PLA)  
Duolink PLA (Olink Biosciences) is a relatively new assay designed to detect protein 
interactions in situ. Briefly, as the rationale for this method is described in detail in 
Section 2.2.8.1, species specific "PLA" probes act as secondary antibodies which are 
conjugated to short oligonucleotide sequences. The PLA probes attach to primary 
antibodies of target proteins, and if these proteins are in close proximity (<40nm), the 
PLA probes ligate and undergo rolling circle amplification, which is then able to attract 
a complementary fluorophore and generate a quantifiable signal which can be visualised 
using immunofluorescence microscopy. This is summarised in Figure M3.3. 
 
 
 
Figure M3.3: Rationale for 
Duolink PLA 
Purple and green circles 
represent target proteins of 
interest attached to the 
respective primary antibody. 
Blue and yellow symbols 
represent secondary PLA probes 
with oligonucleotides attached. 
Red dots are fluorescent probes 
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For Duolink PLA experiments in this chapter, primary antibodies against APC (Ab7, 
mAb, Merck), Miro-1 (pAB, Sigma-Aldrich) and Milton-2 (pAB, Sigma-Aldrich) were 
used at concentrations outlined in Table 2.2, to visualise APC/Miro-1 and APC/Milton-
2 protein interactions by Duolink PLA in cells pre-stained with CMX-Ros. Following 
image capture, PLA signals were quantified manually, by scoring the number of PLA 
signals per cell using a DIC channel overlay to determine the boundaries of each cell 
(see Section 2.2.8.6). Unless stated in the figure legend, Duolink PLA experiments in 
this chapter obtained data from at least 2 independent experiments per condition. The 
number of cells scored is outlined in the supplementary figures for each experiment.  
 
U2OS and Hela cells are very flat, therefore in most cases mitochondria sit on single 
plane, enabling PLA signals in focus to be scored for mitochondrial localisation from 
single stack images. Data from PLA/mitochondrial colocalisation studies was collected 
across 2 independent experiments, with the number of cells scored outlined in the 
relevant supplementary figures. To further verify mitochondrial localisation in 5-10 
cells/sample, z-stack images of cells stained with CMX-Ros were acquired, rendered 
into 3-D projections and PLA signals scored for mitochondrial localisation. This is 
described in detail in Section 2.2.8.6. 
3.2.9 Graphs and statistics 
All graphs and statistics used to display and analyse results in this chapter are outlined 
in Section 2.2.11. 
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3.3 Results 
3.3.1 Loss of wild-type APC alters the cellular distribution of 
mitochondria but not of other microtubule-associated organelles 
Previous work from our group described the first detection of APC at mitochondria 
(13). As mitochondria primarily utilise the microtubule network for transport 
throughout the cytoplasm, and APC is known to bind and stabilise microtubules (28), 
we next investigated the possibility that APC has a role in regulating the transport of 
mitochondria and other membrane bound organelles which associate with microtubules 
including the endoplasmic reticulum, golgi, lysosomes and centrosomes (272). U2OS 
osteosarcoma cells were treated with control siRNA or APC-specific siRNA to silence 
APC expression prior to fixing and visualising specific cell organelles (Figure 3.1A,B). 
Analysis by immunofluorescence microscopy revealed a dramatic redistribution of 
mitochondria from the cell membrane toward the perinuclear region following silencing 
of APC.  In comparison, loss of APC did not appear to alter the localisation of the 
endoplasmic reticulum, golgi, lysosomes and centrosomes (for more detail, see 
Supplementary Figure S3.1), suggesting a specific role for APC in the transport of 
mitochondria.  
3.3.2 Loss of wild-type APC induces a redistribution of mitochondria 
from the cell membrane to the perinuclear region 
To elucidate a potential role for APC in the transport of mitochondria, U2OS cells were 
again treated with either control or APC (APCd and APC2) siRNAs, stained with the 
mitochondrial marker CMX-Ros and fixed cells analysed by immunofluorescence 
microscopy. Mitochondria in control cells were uniformly distributed throughout the 
cell from the nucleus to the cell membrane, whereas after loss of APC most cells 
displayed distinct mitochondrial clustering around the nucleus (Figure 3.2A). 
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To quantify this perinuclear shift, mitochondria were scored according to their position 
in one of three cellular zones spanning from the perinuclear region (zone 1) to the 
region bordering the cell membrane (zone 3) (see schematic in Figure 3.2B). Scoring 
analysis confirmed that loss of full length APC elicited a ~300% increase in the 
population of cells with mitochondria clustering in the perinuclear region (zone 1) 
relative to control cells (control= 17%, APCd=52%, APC2= 50%) (P<0.001; Figure 
3.2C). Conversely, as expected, the population of cells displaying spread out 
mitochondria (zone 3) significantly decreased following the loss of APC (control= 46%, 
APCd=13%, APC2= 23%) (P<0.001). APC knockdown efficiency was confirmed by 
microscopy and western blot analysis (Figure 3.2A,D). 
 
To confirm that the perinuclear shift of mitochondria following APC siRNA treatment 
was not specific to U2OS cells, HDF1314 human fibroblasts and NIH 3T3 mouse 
fibroblasts were also treated with control or APC (APCd or mAPC1) siRNAs and 
stained with CMX-Ros and antibodies against APC. Fixed cells were analysed by 
immunofluorescence microscopy. Loss of APC elicited a dramatic redistribution of 
mitochondria to the perinuclear region (zone 1) in both HDF1314 cells (control= 8%, 
APCd=29%) (P<0.001) and NIH 3T3 cells (control= 13%, mAPC1=42%) (P<0.001) 
(Figure 3.2E-F), mimicking the results obtained in U2OS cells.  
 
CMX-Ros is an effective mitochondrial dye which accumulates depending on 
mitochondrial membrane potential. The fluorescence intensity of the CMX-Ros stain 
was not altered upon treatment with APC siRNA (see mitochondria staining Figure 3.2), 
indicating that the mitochondrial redistribution observed was not a secondary effect of 
mitochondrial membrane depolarisation. Importantly, an antibody against mtHSP70 was 
used as an alternate mitochondrial marker and confirmed the significant redistribution 
of mitochondria caused by knockdown of APC (Supplementary Figure S3.2). 
 
In addition to inducing mitochondrial perinuclear clustering, loss of APC in U2OS, 
HDF1314 and NIH 3T3 cells also appeared to cause mitochondria to decrease size, and 
to become less filamentous and more punctate, suggesting that mitochondrial fission 
and fusion dynamics may also be affected. Mitochondrial fission/fusion and transport 
dynamics are intimately linked; they share a number of protein regulators and often if 
one pathway is disrupted, the other is also affected. In Chapter 7 (Section 7.6), the 
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appearance of punctate mitochondria following APC knockdown is further examined to 
determine if this is evidence of APC controlling mitochondrial fission/fusion dynamics, 
or if it is an indirect consequence of disrupting mitochondrial transport. 
 
 
 
 
 
 
 
Figure 3.1: Loss of APC alters transport of select microtubule associated 
organelles.  
(A) Sub-confluent U2OS cells were treated with control or APC (APCd) siRNA and 
stained with dyes CMX-Ros (red) or ER tracker (green), or probed with antibodies 
against 58k, LAMP-1 or γ-tubulin (green) to detect mitochondria, endoplasmic 
reticulum, golgi, lysosomes and centrosomes respectively. Cells were co-stained with 
Hoechst and IQGAP1 (not shown) to indicate the nucleus (blue) and cell membrane 
(represented by dotted line) respectively and scored for changes in organelle distribution 
by immunofluorescence microscopy. (B) APC knockdown was confirmed by western 
blot analysis with Topo II as a loading control.  
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Figure 3.2: Loss of wild-type APC induces a redistribution of mitochondria in 
U2OS, HDF1314 and NIH 3T3 cells. 
(A) APC was silenced in U2OS cells by siRNA (APCd or APC2), and mitochondrial 
distribution was analysed by immunofluorescence microscopy after staining for 
mitochondria (CMX-Ros), APC (H290) and microtubules (α-tubulin). The cell 
membrane is represented by the dotted line. (B) The distribution of mitochondria in 
different “zones” was scored according to the (C) schematic, revealing a significant 
redistribution of mitochondria from the cell periphery (zone 3) towards the perinuclear 
region (zone 1) when APC is knocked down. (D) Loss of APC was confirmed by 
western blot analysis. (E) HDF1314 and NIH 3T3 cells were treated with APCd siRNA 
or mouse APC1 (mAPC1) siRNA respectively and mitochondrial distribution analysed 
by immunofluorescence after staining for mitochondria and APC. (F) Scoring revealed a 
similar shift in mitochondrial distribution following loss of APC.  Significant 
differences for zone 1 distribution relative to controls, as determined by an unpaired T-
test, are indicated (***, P<0.001, % mean ± S.D).    
Chapter 3 
82 
3.3.3 Destruction of the microtubule network by nocodazole induces a 
redistribution of mitochondria towards the perinuclear region, similar 
to that caused by loss of APC. 
Mitochondria utilise the microtubule network and, to a lesser extent, actin filaments to 
move throughout the cell. APC is associated with both these cytoskeletal networks (52-
54). Therefore, mitochondrial localisation was assessed following the disruption of the 
microtubule and actin networks through treatments with nocodazole and latrunculin A, 
respectively. Treatment with nocodazole induced a redistribution of mitochondria 
towards the perinuclear region (DMSO= 23%, nocodazole = 43%) (P<0.01), similar to 
that observed upon loss of APC (Figure 3.3A-B). In comparison, at an identical time 
point, disruption of the actin network by latrunculin A, at a concentration that disrupted 
actin filaments but did not impair microtubule integrity, had no effect on mitochondrial 
distribution (Figure 3.3C-D). However, whilst mitochondrial spread was unaffected in 
latrunculin A treated cells (zone 1 mitochondria: DMSO = 17%, latrunculin A = 15%) 
(P>0.5), the mitochondria did appear to be more aggregated and less filamentous. This 
may be due to alteration in the preferentially short-range movements of mitochondria 
along actin filaments, as opposed to the long range trafficking that occurs along 
microtubules (170, 171, 271), or simply a secondary effect resulting from changes in 
cell shape and structure after actin depolymerisation.   
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Figure 3.3: Nocodazole but not latrunculin A treatment induces a redistribution of 
mitochondria in U2OS cells.  
(A, C) Sub-confluent cells were treated with DMSO (control), nocodazole or latrunculin 
A and analysed by immunofluorescence microscopy after staining for mitochondria 
(CMX-Ros) and microtubules (α-tubulin) or actin (α-actin). (B) Distribution scoring 
revealed a significant (**, P<0.01) shift of mitochondria towards the zone 1 perinuclear 
region following destruction of the microtubule network by nocodazole, which was (D) 
not observed (n.s., not significant) upon disruption of the actin network by latrunculin A 
(% mean ± S.D). Statistical significance determined by unpaired T-test. 
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3.3.4 Mitochondrial redistribution following loss of APC is specific, 
and not due to microtubule destabilisation  
As APC has an important role in microtubule stabilisation (28), it was important to 
ensure that mitochondrial redistribution following loss of APC was not a secondary 
effect or consequence of microtubule network disruption. APC is known to interact with 
EB1 to bind and stabilise the plus-ends of microtubules (67, 70, 71). Therefore, the 
impact of EB1 knockdown on mitochondria was assessed. Unlike APC siRNA 
treatment, EB1 knockdown did not alter mitochondrial distribution in HDF1314 cells 
(Figure 3.4A-C) (zone 1 mitochondria: control = 10%, EB1 = 6%) (P>0.5) despite what 
looked like a slight disorganisation of the microtubule network when EB1 siRNA 
treated cells were stained with α-tubulin (Figure 3.4D). 
 
 
Figure 3.4: Loss of microtubule cap protein EB1 does not induce mitochondrial 
redistribution in HDF1314 cells.   
(A) Sub-confluent cells were treated with control or EB1 siRNA, stained with CMX-
Ros (mitochondria, red), Hoechst (blue) and an antibody against EB1 (green) and 
analysed by immunofluorescence microscopy. Cells displaying EB1 knockdown are 
indicated by *, and the cell membrane indicated by the dotted line. (B) Efficacy of EB1 
siRNA knockdown was confirmed by immunostaining (% mean ± S.D). (C) 
Mitochondrial distribution  was scored and no significant changes (unpaired T-test) in 
distribution were observed (n.s., not significant, mean ± S.D) following loss of EB1 
despite the slight microtubule disorganisation observed in the (D) representative images 
stained with α-tubulin (green) and Hoechst (blue). 
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Immunostaining of α-tubulin before and after treatment with APC siRNA also revealed 
only a slight disruption to the microtubule network (Figure 3.2A), especially when 
compared to the complete obliteration and consequential mitochondrial redistribution 
seen upon treatment with nocodazole (Figure 3.3A-B). Additionally, transport of other 
membrane bound organelles which move along microtubules including the endoplasmic 
reticulum, golgi, lysosomes and centrosomes were unaffected by silencing of full length 
APC in U2OS cells (Figure 3.1) implying that the microtubule network in general 
retains organelle transport functionality in the absence of APC. 
3.3.5 Mitochondria and APC co-localise with a number of potential 
co-factors including the Miro/Milton mitochondrial transport complex 
To determine if APC may be interacting with known transport complexes to assist 
mitochondrial movement, a number of co-localisation studies were undertaken. Firstly, 
mitochondria were assessed for co-localisation with APC and other binding proteins 
known to traffic along microtubules (Figure 3.5). This data was then compared to co-
localisation observed with known mitochondrial transport factors Miro (100%) and 
Milton (92%) and mediators of mitochondrial fission/fusion Mfn2 (100%), OPA1 
(100%), DRP1 (97%) and Fis1 (100%) (Figure 3.5). Mitochondrial co-localisation of 
KAP3A (13%), a kinesin adaptor protein which connects APC with the KIF3 kinesin 
complex (26), and β-catenin (6%), were both found to be relatively low in comparison 
to the proteins known to regulate mitochondrial morphology. In contrast, RanBP2, 
reported to interact with APC to assist in the regulation of cell polarity (62), showed 
substantially higher rates of mitochondrial colocalisation (88%). This is unsurprising as 
RanBP2 has previously been found to have a role in mitochondrial transport (176), 
however, this is believed to be independent of Miro/Milton transport. In addition, 
mitochondrial co-localisation of APC was analysed using two different APC-specific 
antibodies, Ab7 and H290. The strikingly different level of co-localisation between the 
two antibodies indicates that Ab7 (13%) is not as effective as H290 (45%) in detecting 
mitochondrial-localised APC, either because it has a lower affinity, or because the 
epitope is masked when APC is associated with mitochondria. 
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Figure 3.5: Mitochondrial colocalisation with potential co-factors in U2OS cells. 
(A) Sub-confluent cells were stained with CMX-Ros (mitochondria) and Hoechst (blue) 
and probed with antibodies against APC (Ab7 and H290), Miro-1, Milton-2,  Mfn2, 
OPA1, DRP1, Fis1, RanBP2 (pAb), KAP3A and β-Catenin. (B) Cells were scored for 
co-localisation with mitochondria by immunofluorescence microscopy (% mean ± S.D).  
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The endogenous forms of the potential co-factors were then analysed for co-localisation 
with APC (Figure 3.6) in U2OS cells. As expected, RanBP2, KAP3A and β-catenin all 
showed a high level of co-localisation with APC (84%, 91% and 94% respectively). 
More unexpected however, was the equally high level of co-localisation observed 
between APC and the mitochondrial transport proteins Miro and Milton (89% and 90% 
respectively), particularly in the perinuclear region and cell membrane protrusions.  
 
Mitochondrial fusion proteins Mfn2 and OPA1 also indicated a high level of co-
localisation with APC (83% and 87% respectively), whilst in contrast, DRP1 (23%) and 
Fis1 (7%) showed little. Given the high level of APC colocalisation with these fusion 
proteins, and the appearance of punctate mitochondria following the loss of APC 
(Figure 3.2A), the possibility that APC may modulate mitochondrial morphology 
through an interaction with these proteins is examined further in Chapter 7. The 
possibility that APC may regulate mitochondrial transport in association with RanBP2 
is also investigated in more detail in Chapter 7. 
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Figure 3.6: APC colocalisation with potential co-factors in U2OS cells.  
(A) Sub-confluent cells were probed with antibodies against APC (Ab7 and H290) and 
either Miro-1, Milton-2, Mfn2, OPA1, DRP1, Fis1, RanBP2 (pAb), KAP3A or β-
Catenin. (B) Cells were scored for co-localisation with APC by immunofluorescence 
microscopy (% mean ± S.D). Note: use of both monoclonal (Ab7) and polyclonal APC 
(H290) antibodies were required for co-localisation studies. Despite reduced efficiency 
in detecting mitochondrial APC with Ab7, this antibody clearly co-stained with Miro-1 
and Milton-2.  
  
Chapter 3 
89 
3.3.6 Specificity of Miro-1 and Milton-2 antibodies 
Prior to further investigation, Miro-1 and Milton-2 antibodies were tested for specificity 
in cell staining experiments. pGFP-tagged Miro-1, Miro-2, Milton-1 or Milton-2 
transfected U2OS cells were stained with CMX-Ros and probed with antibodies against 
GFP and either Miro-1 or Milton-2. Although these were the best commercially 
available antibodies against Miro-1 and Milton-2, immunofluorescence microscopy 
suggests that the Miro-1 antibody was not homolog specific and stained GFP-Miro-2 
with a higher immunofluorescence intensity than untransfected cells (Supplementary 
Figure S3.3). The same was true for Milton-2 staining of pGFP-Milton-1 transfected 
cells relative to those not transfected. For the sake of simplicity, the Miro-1 antibody 
and detection of proteins Miro-1 and Miro-2 stemming from the use of this antibody 
will now be referred to as Miro, unless a specific pGFP-tagged ortholog has been 
transfected and detected using GFP antibodies (not the Miro-1 antibody). The same 
principle will be applied for the use of the Milton-2 antibody.  
3.3.7 APC interacts with the Miro/Milton mitochondrial transport 
complex 
APC co-localisation with Miro and Milton combined with the mitochondrial transport 
alterations observed upon APC knockdown suggested the possibility of interaction 
between these proteins. Immunoprecipitation assays in U2OS cells revealed that 
antibodies against APC were able to pull down GFP-tagged Miro-1 and Milton-2, but 
not GFP alone (Figure 3.7A, Supplementary Figure S3.4) in transfected cells. Pull-
downs in the reverse direction however were less successful. Whilst initial experiments 
found that GFP antibodies were able to pull down GFP-tagged Miro-1 and endogenous 
APC in U2OS cells transfected with pGFP Miro-1, the APC pull down could not be 
repeated (Supplementary Figure S3.4). Furthermore, whilst GFP Milton-2 could also be 
pulled down by GFP antibodies in cells transfected with pGFP Milton-2, APC could not 
(Figure 3.7A; Supplementary Figure S3.4). It is possible that the inability of the GFP 
antibody to pull-down APC in pGFP Miro-1 and Milton-2 transfected samples is due to 
some steric hindrance/masking of the GFP epitope when Miro/Milton are bound to 
APC. It could also be due to the difficult nature of APC detection by western blot 
resulting from the large size of the protein (~310kDa) and the low sensitivity of 
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antibodies available, such that low levels of APC are difficult to detect. APC antibodies 
could also pull down GFP Milton-2 and endogenous Miro in HEK 293 APC-inducible 
cell lines (Supplementary Figure S4.2) discussed further in Chapter 4.  
 
To complement the immunoprecipitation assay data we employed an in situ Duolink 
Proximity Ligation Assay (PLA; for details of the assay see Methods Section 3.2.8), 
using antibodies targeting endogenous APC and either Miro or Milton to detect 
potential interactions in U2OS cells. In line with the IP assays, APC/Miro and 
APC/Milton PLA experiments yielded a positive result, averaging ~25 and ~19 PLA 
signals per cell, respectively (Figure 3.7B-C). This was significantly higher than control 
samples that used a single antibody per reaction (PLA signal/cell APC= 0.7, Miro= 0.7, 
Milton= 0.8) (see Supplementary Figure S3.5 for more details). Similar positive and 
specific Duolink PLA results between APC/Miro and APC/Milton were observed in 
repeat experiments in Hela cells, with PLA signal/cell averaging ~47 and ~18, 
respectively, which was well above the signal from the single antibody controls (PLA 
signal/cell APC= 4.4, Miro= 5.1, Milton= 2.5).  (Figure 3.7B-C, see Supplementary 
Figure S3.5 for more details). 
 
Specificity of the APC/Miro interaction by PLA was confirmed by treating U2OS cells 
with APC siRNA (APCd) prior to performing the assay. The efficiency of APC 
knockdown was ~60% (Figure 3.6D). As observed in Supplementary Figure S3.6, the 
PLA signal was significantly reduced by ~45% upon silencing of APC (APC/Miro PLA 
signal/cell: control siRNA= 21.8, APC siRNA= 12.1).  
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Figure 3.7: APC interacts with the Miro/Milton mitochondrial transport complex 
in U2OS and Hela cells 
(A) U2OS cells transfected with pGFP, pGFP Miro-1 or pGFP Milton-2 were 
immunoprecipitated by antibodies against GFP (pAb) and APC (C20, pAb) and 
analysed by western blot to detect GFP/GFP Miro-1/GFP Milton-2 (GFP, mAb) and 
APC (Ab1). The APC antibody successfully captured GFP Miro-1 and GFP Milton-2, 
indicative of a positive interaction between APC and Miro-1/ Milton-2. The GFP 
antibody also captured APC in cells transfected with pGFP Miro-1, however a similar 
pull down was not observed in cells transfected with pGFP or pGFP Milton-2. (B-C) 
Duolink PLA confirmed this interaction in situ in U2OS and Hela cells using antibodies 
against APC, Miro and Milton. Scoring from analysis by immunofluorescence 
microscopy, indicate a positive PLA signal between APC/Miro and APC/Milton as 
observed in the (B) box-and-whisker plot and (C) representative images.  
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3.3.8 APC/Miro and APC/Milton complexes localise to the 
mitochondria 
After establishing novel interactions between APC with Miro and Milton, we next 
confirmed that these protein complexes actually localise to the mitochondria. This is 
critical if they are to be functionally linked to mitochondrial transport. Preliminary 
immunofluorescence co-localisation studies were employed by staining U2OS cells 
transfected with pCMV-APC with CMX-Ros and antibodies against APC, Miro or 
Milton. Microscopic analysis revealed that APC and Miro appeared to co-locate with 
mitochondria in regions throughout the cell, including cell protrusions (Figure 3.8A). 
Similar co-localisation between APC and Milton at mitochondria was observed (Figure 
3.9A).  
 
Next, to study the position of actual APC/Miro and APC/Milton complexes, more 
detailed localisation studies were performed in U2OS and Hela cells utilising Duolink 
PLA assays counterstained for Mitochondria (CMX-Ros) (for n cells analysed see 
Supplementary Figure S3.5B). In U2OS cells ~52% of APC/Miro complexes localised 
to mitochondria (Figure 3.8C) which was verified by 3D image projections obtained 
from z-stacks (Figure 3.8B). Co-localisation (46%) of APC/Milton PLA signals was 
also observed at mitochondria in U2OS cells, and was verified using 3D image 
projections (Figure 3.9B-C). The similarity in the degree of mitochondrial colocalisation 
for APC/Miro and APC/Milton PLA signals is consistent with the idea that APC forms 
a complex with Miro and Milton. Comparable results were also observed in Hela cells 
which indicated 58% of Miro/APC and 49% of Milton/APC complexes were detected at 
mitochondria, where localisation could again be confirmed by 3D image projections 
(Figure 3.8D-E, Figure 3.9D-E). 
 
APC/Miro and APC/Milton PLA signals at mitochondria mostly appeared to be 
localised to the outer edge of the mitochondria, which is consistent with the formation 
of the Miro/Milton transport complex on the surface of the outer mitochondrial 
membrane. To confirm this, electron microscopy would be required. Furthermore, 
whilst these PLA signals did not appear to preferentially localise to any distinct 
mitochondrial shape or size, they did seem to localise more frequently to the ends of 
individual mitochondria, rather than the middle. This was more noticeable when the 
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mitochondria were rod shaped, rather than punctate. Finally, APC/Miro and 
APC/Milton PLA signals at mitochondria were observed throughout the entire cell, 
from the perinuclear region to the tips of cell protrusions, as would be expected for 
complexes involved in mitochondrial transport.  
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Figure 3.8: APC interacts with Miro at mitochondria in U2OS and Hela cells 
(A) Sub-confluent U2OS cells were transfected with pCMV-APC, stained with CMX-
Ros (mitochondria), probed with antibodies against APC (Ab7) and Miro and analysed 
for colocalisation by immunofluorescence microscopy. pCMV-APC, Miro and 
mitochondria were observed to co-locate at the perinuclear region (#1) and at cell 
protrusions (#2). (B-E) Mitochondria were stained using CMX-Ros in U2OS and Hela 
cells prior to utilising Duolink PLA to detect interactions between APC and Miro. 
Scoring (C,E) of immunofluorescence images, revealed APC/Miro PLA signals 
colocalised with mitochondria in both cells lines (% mean ± S.D), as observed in the 
(B,D) representative 3D projections.  
Chapter 3 
95 
Figure 3.9: APC interacts with Milton at mitochondria in U2OS and Hela cells 
(A) Sub-confluent U2OS cells were transfected with pCMV-APC, stained with CMX-
Ros (mitochondria), probed with an antibodies against APC (Ab7) and Milton and 
analysed for colocalisation by immunofluorescence microscopy. pCMV-APC, Milton 
and mitochondria were observed to co-locate at the perinuclear region (#1) and at cell 
protrusions (#2). (B-E) Mitochondria were stained using CMX-Ros in U2OS and Hela 
cells prior to utilising Duolink PLA to detect interactions between APC and Milton. 
Scoring (C,E) of immunofluorescence images, revealed APC/Milton PLA signals 
colocalised with mitochondria in both cells lines (% mean ± S.D), as observed in the 
(B,D) representative 3D projections.  
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3.4 Discussion 
APC is a critical regulator of many pathways in normal cell growth and differentiation. 
Here a new role for APC in the regulation of anterograde mitochondrial transport is 
described for the first time. The motile nature of mitochondria is essential for swiftly 
providing energy to cell compartments with high bioenergetic demands, such as 
membrane protrusions and lamellipodia for cell migration.  Loss of APC caused a 
specific redistribution of mitochondria away from the cell periphery towards the 
perinuclear region which, upon further investigation, correlated strongly with an 
interaction between APC and the Miro/Milton transport complex. This protein complex 
is responsible for transport of mitochondria toward the plus-ends of microtubules at the 
cell periphery, and a novel regulatory role for APC in this process will be discussed.  
3.4.1 APC has a novel and specific role in the subcellular localisation 
of mitochondria. 
APC localises at several cellular compartments, moves along cytoskeletal tracks and has 
been reported to interact with a number of motor proteins and adaptors involved in 
vesicle transport (Section 1.2.1). Therefore, it is perhaps not surprising to find that APC 
has a role in cell organelle transport. The finding that loss of APC disrupts 
mitochondrial localisation (Figure 3.2) correlates with its previous detection at 
mitochondria (13). Perturbations in mitochondrial distribution following APC 
knockdown, presumably through altered transport (this is demonstrated more directly in 
Chapter 5), were found to be quite specific and other organelles were not affected by the 
loss of APC (Figure 3.1).   
 
Mitochondrial transport is mediated by a limited number of motor proteins that interact 
with a wide range of adaptors to ensure that transport of cargo is highly regulated (273, 
274). Whilst some kinesins bind directly to their cargo, most organelles bind kinesins 
indirectly through a unique set of adaptor proteins (273). For example, in addition to 
mitochondria, KIF5 is also involved in the microtubule-dependent transport of 
lysosomes and the endoplasmic reticulum (275, 276), both of which associate with a 
different set of adaptor proteins that they use to attach to KIF5 (277, 278). When APC 
expression was silenced, there were no observable alterations in the transport of either 
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of these organelles. This indicates that APC loss is not causing havoc with the general 
microtubule-transport systems of the cell and, consequently, is likely to be affecting 
with some specificity the movement of mitochondria through its interaction with the 
Miro and Milton adaptor proteins. 
 
APC was previously reported to bind to KAP3A, a component of the KIF3 kinesin 
adaptor complex, by which APC was proposed to be transported in a plus-end directed 
fashion along microtubules (26). The KIF3/KAP3A complex has been reported to drive 
the transport of cell organelles, in particular the golgi and lysosomes (279, 280). 
However, as no changes in distribution for these organelles were observed upon APC 
knockdown, and as APC has not been reported to localise to these structures, it is 
unlikely that APC contributes to these processes (other implications of the APC/KAP3A 
association are discussed in Chapter 7). 
 
In addition to the mitochondria, APC also localises to the centrosome where it has been 
implicated in centrosome reorientation and cell polarisation (281). In this regard we 
observed no clear changes in centrosome positioning following the siRNA knockdown 
of APC in sub-confluent U2OS cells (Figure 3.1), whereas others reported that loss of 
APC in  polarised migrating fibroblasts disrupted centrosome re-orientation and in turn 
cell polarity in scratch wound assays (75). Whilst these results may point to another role 
for APC in transporting cell organelles, evidence from the literature suggests that the 
disruption of centrosome localisation in migrating cells was due more to destabilisation 
of microtubules, rather than APC association with a motor protein (75). 
 
3.4.2 Evidence for APC transport of mitochondria along microtubules 
Mitochondria are highly dynamic in nature and utilise the cytoskeleton for movement 
throughout the cell. As discussed in Section 1.3.2, kinesin and dynein motors are 
primarily used to transport mitochondria long distances across microtubules whilst 
myosin motors typically provide a means for short range transport along actin filaments. 
APC itself can associate directly and indirectly with both the microtubule and actin 
networks, and such cytoskeletal interactions are crucial for its role in regulating cellular 
processes such as co-ordinating cell polarity, stabilising microtubules, promoting F-
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actin assembly, and promoting cell adhesion and/or migration (for more information see 
Section 1.2.1.3). The discovery that APC binds to the microtubule-dependent 
Miro/Milton complex indicates that APC could stimulate mitochondrial transport via its 
association with the microtubule system, rather than the actin cytoskeleton.  
 
In this study, loss of APC induced a perinuclear clustering of mitochondria, 
characteristic of disruption to anterograde microtubule-based transport. This is because 
unlike actin, which forms a lattice-like network cross-linked in many directions, 
microtubules form a polarised, radial network, anchored to a central point known as the 
microtubule organising centre (MTOC) at the centrosome, typically located close to the 
nucleus. Mitochondria in the cell lines observed thus far (Figure 3.2) typically form 
branching networks throughout the entire cell. The shift in localisation of mitochondria 
towards the perinuclear region observed following APC knockdown suggests that their 
transport along a polarised, radial network emanating from a point close to the nucleus 
has been disrupted, more consistent with disruption of movement along microtubules 
rather than along actin filaments which have no central point or polarisation.  
 
To further demonstrate that the influence of APC on mitochondrial distribution was 
more likely linked to microtubules than actin, cells were exposed to drug treatments to 
depolymerise microtubules and actin filaments using nocodazole (282) and latrunculin 
A (283), respectively (Figure 3.3). Treatment with nocodazole caused mitochondria to 
shift towards the perinuclear region, in a manner similar to, though less severe, than that 
observed when APC was silenced. On the other hand, treatment with latrunculin A 
induced no such shift, even though mitochondria looked slightly aggregated and 
irregular, perhaps due to disruption of short range transport. These results support the 
notion that APC transport of mitochondria is microtubule based rather than actin based. 
 
The above points when considered together with the binding of APC to the Miro/Milton 
complex, strongly implicate APC in microtubule based transport of mitochondria. 
However, one cannot rule out an alternative pathway whereby APC might transport 
mitochondria along actin. Disrupting plus end-directed long range mitochondrial 
transport mechanisms, such as Miro/Milton, would mask any additional disruptions to 
short range actin transport. In this context, it is intriguing to note that unpublished data 
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from our laboratory suggests that APC interacts with several myosin motors (discussed 
further in Chapter 7). 
3.4.3 APC interacts with the Miro/Milton mitochondrial transport 
complex to move mitochondria in the anterograde direction 
Mitochondrial perinuclear clustering is often observed in cases where anterograde 
mitochondrial transport has been disrupted. In line with current literature, our results in 
U2OS, HDF1314 and NIH 3T3 cells (Figure 3.2) are reminiscent of  experiments in 
Hela cells where siRNA disruption of Miro-1/Miro-2 expression resulted in a dramatic 
mitochondrial redistribution from the cell periphery to the perinuclear region (165). This 
phenomena was also observed in mouse cells following disruption of KIF5B gene 
expression (284). In the study by Tanaka et al. (284), mitochondria in control cells 
displayed a branching network throughout the cell, whereas in KIF5B disrupted cells 
the mitochondria were clustered around the nucleus. Therefore the loss of expression of 
proteins in the Miro/Milton complex result in a very similar perinuclear redistribution of 
mitochondria to that observed following APC disruption in this study, providing 
correlative evidence for a functional link between APC and the Miro/Milton complex.  
 
The interaction detected here between APC and the Miro/Milton complex is novel, and 
now explains an earlier observation showing co-localisation between APC and KIF5 in 
mouse colon cancer epithelial cells (285). Intriguingly the previous study noted 
APC/KIF5 co-localisation at cell membrane regions, similar to that observed here 
between APC and Miro (Figure 3.8A) and APC and Milton (Figure 3.9A). The loss of 
KIF5 was also reported to reduce APC localisation at the cell periphery (285). 
Furthermore, APC has been reported to modify KIF5 in Drosophila neurons, thereby 
linking it to vesicle transport (286) in neurons, suggesting a more general and potential 
functional link between APC and KIF5 in different cell types and species. 
Unfortunately, due to antibody limitations at the time of the study, an interaction 
between APC and KIF5 was unable to be confirmed, though it should be noted there is 
no evidence in the literature to suggest that Miro or Milton associate with any other 
kinesin proteins. These previous findings, combined with the careful 3-D mapping of 
APC/Miro and APC/Milton complexes to the outer mitochondrial membrane in this 
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study, support a role for APC in regulation of Miro/Milton/kinesin transport of 
mitochondria toward the cell membrane.  
3.4.4 Summary  
These findings indicate a new role for APC as a regulator of mitochondrial transport. 
APC binds to the Miro/Milton complex at mitochondria, which in turn facilitates 
microtubule-based transport in the anterograde direction towards the cell membrane 
periphery. The truncation of APC, a common feature in ~80% of colorectal cancers, 
severely disrupts many of its cellular pathways, including its association with 
microtubules and it’s regulation of Wnt signalling. How APC truncation impacts on 
mitochondrial transport, and what physiological effects this has on cellular function is 
investigated in subsequent chapters (Chapter 4). Other implications for APC-dependent 
mitochondrial transport will also be discussed, with a particular focus on how 
localisation of mitochondria at the cell membrane may contribute to the functionality of 
APC in cell migration (Chapter 5). Furthermore, specifics regarding how APC mediates 
the Miro/Milton transport complex are examined throughout (Chapters 4-6). 
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3.5 Supplementary Figures 
 
Supplementary Figure S3.1: Loss of APC effects transport of select microtubule 
associated organelles 
Sub-confluent U2OS cells were treated with control or APC (APCd) siRNA and stained 
with  ER tracker or probed with antibodies against 58k, LAMP-1 or γ-tubulin to detect 
endoplasmic reticulum, golgi, lysosomes and centrosomes respectively, as visualised in 
Figure 3.1. Cells were scored (% mean ± S.D) for changes in organelle distribution by 
immunofluorescence microscopy. Significance was determined using an unpaired T-test 
(n.s, not significant). 
 
 
Supplementary Figure S3.2: Loss of wild-type APC induces a redistribution of 
mitochondria in U2OS stained with HSP70 
(A) U2OS cells were treated with APCd siRNA, stained using antibodies against HSP70 
(mitochondria) and APC (H290) and analysed by immunofluorescence microscopy. 
Scoring (B) of mitochondrial distribution (% mean ± S.D) revealed a significant (***, 
P<0.001, determined using an unpaired T-test) increase in zone 1 perinuclear clustering 
following silencing of APC.   
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Supplementary Figure S3.3: Miro-1 and Milton-2 antibodies are not homolog 
specific.  
Sub-confluent U2OS cells transfected with pGFP Miro-1, pGFP Miro-2, pGFP Milton-1 
or pGFP Milton-2 were stained with CMX-Ros, and probed with antibodies against 
GFP and either Miro-1 or Milton-2.  
 
Supplementary Figure S3.4: Additional immunoprecipitation blots - GFP Miro-1 
and GFP Milton-2 can be immunoprecipitated using an APC antibody 
U2OS cells transfected with pGFP, pGFP Miro-1 or pGFP Milton-2 were 
immunoprecipitated by antibodies against GFP (pAb) and APC (C20, pAb) and 
analysed by western blot to detect GFP/GFP Miro-1/GFP Milton-2 (GFP, mAb) and 
APC (Ab1). The APC antibody successfully pulled down GFP Miro-1 and GFP Milton-
2, whilst no pull down was observed for the GFP control. APC pull down by GFP was 
not observed in cells transfected with pGFP, pGFP-Miro-1 or pGFP Milton-2.  
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Supplementary Figure S3.5: APC interacts with Miro and Milton in U2OS and 
Hela Cells - Expanded Duolink Data  
(A-B) Interactions between APC and Miro/Milton were visualised in situ using Duolink 
PLA as described in Figure 3.7. Scoring indicates a positive signal between APC and 
Miro, and APC and Milton as shown in the (A) dot-plots (mean ± S.D) and (B) table (n, 
number in sample; IQR, inter-quartile range; SD, standard deviation). 
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Supplementary Figure S3.6: Loss of APC decreases the APC/Miro Duolink PLA 
signal in U2OS cells.  
(A-E) Cells were treated with control or APC (APCd) siRNA prior to performing 
Duolink PLA using antibodies against APC and Miro. (A) Analysis by 
immunofluorescence microscopy and subsequent scoring visualised in the (B) dot plot 
(mean ± S.D) and (C) box-and-whisker plot revealed that the APC/Miro PLA signal was 
reduced by ~45% upon loss of APC. (D) Knockdown was confirmed by western blot 
and further details are outlined in the (E) table (n, number in sample; IQR, inter-quartile 
range; SD, standard deviation). 
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APC is involved in many areas of normal cell growth and differentiation such as Wnt 
signalling, mitosis, cell migration and cytoskeletal regulation. These processes are mis-
regulated by C-terminal truncating APC mutations. In Chapter 3 a novel role for APC in 
the regulation of mitochondrial transport was proposed, whereby APC binds the 
Miro/Milton complex to transport mitochondria along microtubules toward the cell 
periphery in a kinesin-dependent manner. To determine if this function of APC is 
disrupted by truncating mutations, mitochondrial distribution patterns were interrogated 
in a number of CRC cell lines harbouring mutant or wild-type APC. In CRC cells 
expressing mutant APC (SW480 and HT-29), mitochondria were more frequently 
clustered around the nucleus, indicative of impaired anterograde mitochondrial 
transport. In comparison, mitochondrial distribution in CRC cell lines expressing wild-
type APC (HCT116 and LIM1215) were uniformly distributed throughout the cell 
extending towards the cell membrane, similar to that observed in epithelial and 
fibroblastic cells in Chapter 3. Furthermore, in mutant APC cells, siRNA-mediated 
knockdown of APC did not elicit any mitochondrial redistribution, suggesting that 
truncated APC was compromised in its ability to transport mitochondria. This idea was 
supported by recovery of mitochondrial transport to the cell periphery after 
reconstitution of wild-type APC in mutant HT-29 cells. Immunoprecipitation and 
Duolink PLA analysis indicated that truncated APC mutants were defective in binding 
to Miro/Milton, a finding consistent with mapping of the Miro/Milton-binding site to 
the C-terminal region (2650-2843) of APC. These results suggest that truncation of 
APC disrupts its capacity to bind Miro/Milton, in turn blocking mitochondrial transport 
to the cell periphery. This could result in impaired mitochondrial distribution and 
compromise site-specific functions such as distribution of ATP and calcium buffering, 
contributing to the carcinogenic process.  
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4.1 Introduction 
APC regulates pathways of cell growth and differentiation including Wnt signalling, 
spindle formation, chromosome segregation, the DNA repair and damage response, cell 
polarization and cell migration (Section 1.2.3 and 8, 52, 287, 288). This multifunctional 
nature makes APC a critical tumour suppressor protein as highlighted by the fact that 
mutations in the APC gene occur in ~80% of CRCs and are one of the earliest events in 
the progression of sporadic CRC. APC was first identified as the critical gene mutated 
in familial adenomatous polyposis (FAP), an autosomal dominant disease carrying a 
germ line APC mutation and characterised by colorectal polyps and a high risk of early 
CRC (3-5). A gene mutation in one APC allele can cause FAP, whereas a ‘second hit’ in 
the form of a somatic mutation in the remaining allele predisposes patients to increased 
risk of cancer (7, 8). 
 
The majority of APC mutations localise in a central area known as the mutation cluster 
region and in general produce a premature stop codon resulting in a truncated APC 
protein (the most common is a mutation at amino acid 1309), which lacks C-terminal 
sequences (20). This often results in loss of APC function which is followed by tumour 
formation. Aberrant β-catenin signalling and in turn continuous transcription of Wnt 
target proteins is most commonly associated with mutant APC driven tumourigenesis 
(Section 1.2.3.1 and 3, 5), however a number of other alterations in chromosome 
stability, cell polarity and cell migration (Sections 1.2.3.2 - 1.2.3.4 and 54, 96, 289) 
contribute to this process. 
 
The previous chapter presented a new role for APC in the anterograde transport of 
mitochondria, through an interaction with the Miro/Milton mitochondrial transport 
complex. Mitochondria are known to be dysfunctional in cancer cells and several 
aspects of this have been studied including defective metabolism, mitochondrial 
genome mutations, increased ROS production and alterations in fission/fusion dynamics 
(Section 1.3.4.2 and 14, 263, 264). Disrupted mitochondrial transport however, has 
more often been studied in the context of neurological disorders, where, in normal 
neurons mitochondria are required to travel long distances between the cell body and 
the axon terminal (Section 1.3.4.1 and 139, 256, 257). The importance of precise 
regulation of mitochondrial transport and how disruption contributes to carcinogenesis 
Chapter 4 
108 
is only just coming to light. In particular, recent studies in epithelial cells link 
mitochondrial distribution to cancer cell migration and invasion (18, 19). Other cell 
signalling pathways known to be disrupted during cell transformation include aberrant 
gene transcription of growth factors and calcium signalling, which have also been 
reported to be partially dependent on mitochondrial distribution (see Section 1.3.1.2) 
 
Prior studies in this laboratory have shown that APC mutants display increased 
mitochondrial localisation (13), which correlated with a protective influence against 
apoptosis through regulation of Bcl-2, thereby promoting the survival of cancer cells. In 
this chapter, the truncation of APC in CRC cell lines is shown to disrupt its interaction 
with the Miro/Milton mitochondrial transport complex through loss of a critical C-
terminal binding region, leading to an apparent cessation of mitochondrial anterograde 
transport which could be restored upon wild-type APC expression. These results, when 
viewed in the context of current literature indicate a new pathway by which mutant APC 
loss of function may contribute to CRC carcinogenesis. 
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4.2 Methods 
4.2.1 Cell culture 
U2OS osteosarcoma cells, and the colorectal cancer cell lines SW480, HT-29, HCT116 
and LIM1215 were cultured in DMEM under standard conditions as outlined in Section 
2.2.3. Stable inducible HEK293 cell lines (APC-WT) and (APC-1309) were cultured in 
DMEM containing 15 g/ml blasticidin and 150 g/ml hygromycin B under standard 
conditions. APC protein expression was induced by the addition of 2 ng/ml tetracycline 
16 h prior to subsequent processing. For mitochondrial distribution and co-localisation 
experiments, cells were seeded on glass cover slips in 6-well tissue culture plates, and 
for Duolink PLA experiments, cells were seeded in 8-well chamber slides coated with 
poly-L-lysine. Cells were grown to 70-80% confluence prior to fixation. For western 
blotting experiments, cells were seeded into 150 cm
2 
flasks for immunoprecipitation 
assays and 25 cm
2 
flasks for siRNA knockdown experiments. Further details can be 
found in Section 2.2.3.1. 
 
The transfection of plasmids and siRNAs for transient expression or gene silencing in 
cells is described in Section 2.2.3.4. In Duolink PLA assays utilising GFP-tagged 
constructs, the amount of plasmid transfected was significantly reduced (more details 
Section 2.2.8.4). For siRNA treatments in CRC cell lines SW480, HT-29, HCT116 and 
LIM1215, APC siRNAs (APCd and APC2) were pooled to increase efficacy of the 
knockdown. 
4.2.2 Cell fixation and staining for immunofluorescence microscopy 
Cells were seeded for at least 24 h, fixed with methanol-acetone, probed with relevant 
antibodies and mounted for immunofluorescence microscopy as outlined in Section 
2.2.4. If detection of mitochondria was required, the addition of the MitoTracker dye, 
CMX-Ros, occurred prior to fixation. Concentrations and any further specifications for 
all antibodies and dyes used in this chapter are outlined in Table 2.2, Table 2.3 and 
Table 2.4. 
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4.2.3 Immunofluorescence cell image acquisition and processing 
Slides were analysed using the Olympus IX71 DeltaVision Core deconvolution 
microscope equipped with a CoolSNAP HQ
2
 camera for general image capture. The 
images collected were further resolved using SoftWorx deconvolution software. For 
mitochondrial distribution experiments, 300 cells were scored over 3 independent 
experiments with the exception of the HT-29 reconstitution assay (Figure 4.2) where 
200 cells were scored over 2 independent experiments. Analysis of mitochondrial 
distribution experiments and Duolink PLA experiments is further described in Section 
4.2.4 and Section 4.2.7, respectively. 
4.2.4 Quantification of mitochondrial distribution 
Mitochondrial distribution was scored into three ‘zones’ spanning outwards from the 
nucleus towards the cell membrane as described in Section 2.2.7.2. It should be noted 
that additional parameters were taken into account when scoring certain cell lines used 
in this chapter, in particular the smaller colorectal cancer cells. This is outlined in Table 
2.9. For analysis of mitochondrial distribution in HT-29 cells expressing GFP, GFP 
APC-WT and GFP APC-1309 (Figure 4.2), only cells displaying a modest level of 
transfection were scored, to avoid complications stemming from the microtubule 
bundling observed when GFP APC-WT is overexpressed. 
4.2.5 Immunoprecipitation assays 
Immunoprecipitation experiments were performed as described in Section 2.2.10. Cells 
used for these assays were treated as follows: SW480 cells transfected with plasmids 
that express GFP, GFP Miro-1 and GFP Milton-2 (Figure 4.3), and HEK293 stable cell 
lines induced with tetracycline (Supplementary Figure S4.2, pg138), were collected and 
lysed with HUNT buffer (Appendix 2.1). U2OS cells transfected with plasmids that 
express GFP and GFP-APC fragments (1-302, 1379-2080 and 2650-2843) (Figure 4.6) 
were collected and lysed with RIPA buffer. Collection and lysis of cells is described in 
Section 2.2.9.1. Immunoprecipitation experiments were carried out using antibodies 
against GFP (pAb, Invitrogen), APC (C20, pAb, Santa Cruz), APC (Ab5, mAb, Merck), 
Miro-1 (pAb, Sigma-Aldrich), Milton-2 (pAb, Sigma-Aldrich), IgGm (mAb, Sigma-
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Aldrich) and IgGr (pAb, Sigma-Aldrich), to pull-down target proteins prior to samples 
being subjected to SDS-PAGE and western blot analysis. Immunoprecipitation 
experiments were performed at least twice. 
4.2.6 Western blot analysis 
Cells were collected, lysed using RIPA buffer and processed as described in Section 
2.2.9.1. Samples (immunoprecipitates or ~30 µg total cell lysate) were separated by 
SDS-PAGE using 5% (for detection of APC), 7.5% or 10% acrylamide gels, and 
transferred onto a nitrocellulose membrane (see Sections 2.2.9.3-2.2.9.6). Western blots 
were probed as outlined in Section 2.2.9.7, using primary antibodies as per the figure 
legends. Dilutions for these antibodies and subsequent secondary antibodies are outlined 
in Table 2.2 and Table 2.3. Immunoblots in this chapter were developed on film using 
ECL, with the exception of those in Figure 4.6 and Supplementary Figure S4.1 which 
were developed using ECL and the BioRad ChemiDoc Imaging System (see Section 
2.2.9.8). 
4.2.7 Duolink Proximity Ligation Assay (PLA) 
Duolink PLA experiments in this chapter employed primary antibodies against APC 
(Ab7, mAb, Merck), Miro-1 (pAB, Sigma-Aldrich) and Milton-2 (pAB, Sigma-Aldrich) 
at concentrations outlined in Table 2.2, to visualise protein interactions between 
APC/Miro and APC/Milton in cells pre-stained with CMX-Ros (more detail in Section 
2.2.8). Duolink PLA in cells expressing GFP-APC constructs also used an antibody 
against GFP (mAb, Roche) to visualise protein interactions between transiently 
expressed APC sequences and endogenous Miro or Milton (Section 2.2.8.4). Following 
image capture, PLA signals were quantified manually, by scoring the number of PLA 
signals per cell using a DIC channel overlay to determine the boundaries of each cell 
(Section 2.2.8.6). Unless stated in the figure legend, Duolink PLA experiments were 
performed at least twice for each sample. The number of cells scored is outlined in the 
supplementary figures for each experiment. 
 
Duolink PLA in cells expressing GFP-tagged APC constructs were compared to control 
cells expressing GFP alone as a frame of reference for background signal. For these 
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experiments, only cells expressing a modest level of the transfected plasmid were 
scored to minimise artefacts caused by overexpression. Low levels of transfection were 
more readily detected by counterstaining Duolink experiments with GFP (mAb) and the 
appropriate secondary antibody (as described in 2.2.8.5) following PLA. In exception to 
the above rule, transfected cells used for the competition Duolink PLA assay (Figure 
4.9) were selected for mid-range expression of GFP-tagged construct. 
4.2.8 Graphs and statistics 
All graphs and statistics used to display and analyse results in this chapter are outlined 
in Section 2.2.11.  
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4.3 Results 
4.3.1 APC dependent relocalisation of mitochondria is disrupted by 
truncating APC mutations in colorectal cancer cell lines 
Colorectal cancers display a high incidence of APC C-terminal truncating mutations 
which often lead to disruption of APC function (4, 5, 11). In Chapter 3 it was shown 
that silencing of full-length APC caused a novel perinuclear redistribution of 
mitochondria, revealing a role for APC in the normal cellular spread of mitochondria. 
To investigate whether this activity is altered by truncations of APC typically observed 
in cancer, mitochondrial distribution was analysed in a number of colorectal cancer cell 
lines expressing either mutant (SW480(APC 1-1337) and HT-29(APC 1-853/1555)) or 
wild-type APC (HCT116 and LIM1215) (see schematic Figure 4.1A). Distribution was 
quantified as previously described in Chapter 3, where mitochondria were scored 
according to their position in one of three cellular zones radiating from the perinuclear 
region (zone 1) to the region bordering the cell membrane (zone 3) (see schematic in 
Figure 4.1B). 
 
Mitochondria in colorectal cancer cell lines retaining wild-type APC (HCT116 and 
LIM1215) were frequently spread throughout the cell cytoplasm, reaching towards the 
plasma membrane (zone 3), in a similar manner to that observed in U2OS, HDF1314 
and NIH 3T3 cell lines (Figure 3.2). However, this was less often the case for SW480 
and HT-29 mutant APC cell lines, where mitochondria were more frequently clustered 
around the perinuclear region (zone 1), implying that truncation of APC may disrupt its 
ability to facilitate anterograde transport of mitochondria (Figure 4.1C-D). Furthermore, 
siRNA-mediated knockdown of wild-type APC induced a significant redistribution of 
mitochondria away from the cell periphery, towards the perinuclear region in HCT116 
cells (zone 1 mitochondria: control=18%, APCd/APC2=28%) (P>0.01) and LIM1215 
cells (zone 1 mitochondria: control=15%, APCd/APC2=23%) (P>0.01). However, no 
such change in mitochondrial distribution was observed when mutant APC was silenced 
in SW480 (zone 1 mitochondria: control=37%, APCd/APC2=35%) (P>0.5) and HT-29 
cell lines (zone 1 mitochondria: control=32%, APCd/APC2=35%) (P>0.5), consistent 
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with the idea that mutant truncated APC is unable to assist in driving mitochondria 
towards the cell periphery. 
 
 
Figure legend over page. 
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Figure 4.1: Loss of truncated APC in colon cancer cell lines does not induce 
redistribution of mitochondria  
(A) The mutation status of APC in colon cancer cell lines SW480, HT-29, HCT116 and 
LIM1215 is outlined in the schematic. (B-D) These cell lines were treated with control 
or APCd/APC2 pooled siRNA for 72 h, stained with CMX-Ros Mitotracker and 
counterstained with APC antibody (H290) and Hoechst. Mitochondrial distribution was 
analysed by immunofluorescence microscopy and scored as described in the (B) 
schematic. (C) Results are indicated on the bar graph with significant differences 
relative to siRNA control indicated for each cell line (**, P<0.01; n.s., not significant,  
% mean ± S.D). Significance determined using unpaired T-test. (D) Representative 
images are shown (dotted line represents the cell membrane). (E) Knockdown of APC 
(control (c) and APC siRNAs) was confirmed by western blot analysis with the use of 
α-tubulin as a loading control.  
 
4.3.2 Mitochondrial localisation towards the plasma membrane is 
rescued by reconstitution of wild-type APC in mutant APC HT-29 cells 
To confirm that disruption of mitochondrial distribution in APC mutant cell lines was 
due to APC truncation alone, rather than additional defects in the mitochondrial 
transport complex, GFP-tagged APC wild-type (GFP APC-WT) was transiently 
expressed in HT-29 cells and analysed by immunofluorescence microscopy to 
determine if recovery of mitochondrial localisation at the cell periphery was possible 
(Figure 4.2). The overexpression of APC has been shown to bundle microtubules (28, 
60), which could potentially block mitochondrial trafficking, therefore only cells which 
expressed a modest level of GFP APC-WT were analysed. Mitochondrial scoring of 
these cells revealed that reconstitution of GFP APC-WT compared to GFP alone 
significantly stimulated transport of mitochondria away from the perinuclear region 
(zone 1 mitochondria: GFP=38%, GFP APC-WT=24%)(P<0.001) towards the zone 3 
cell membrane region (zone 3 mitochondria: GFP=29%, GFP APC-
WT=43%)(P<0.001), thereby at least partly correcting the mitochondrial transport 
defect observed in mutant APC cell lines (Figure 4.2). 
 
In parallel, pGFP-tagged APC truncated at amino acid 1309 (GFP APC-1309) was also 
transfected, and HT-29 cells expressing a modest level of the construct were analysed 
for mitochondrial distribution (Figure 4.2). As expected, transport of mitochondria to 
the cell periphery was not recovered, and in fact expression of GFP APC-1309 induced 
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an increase in zone 1 perinuclear clustering of mitochondria (GFP=38%, GFP APC-
1309=25%)(P<0.001). This could reflect a partial dominant effect, although was not 
consistently seen in other cell lines.  
 
 
 
 
Figure 4.2: Reconstitution of GFP APC-WT expression in HT-29 cells restores 
mitochondrial distribution to the cell periphery.  
(A) Sub-confluent HT-29 cells were transfected with plasmids expressing GFP, GFP 
APC-1309 or GFP APC-WT for 48 h, stained with CMX-Ros Mitotracker and  
counterstained with antibodies against GFP (mAb) and Hoechst (blue). Cells were 
analysed by immunofluorescence microscopy and moderately transfected cells were (B) 
scored for mitochondrial distribution as previously described. Significant differences 
relative to control, determined using an unpaired T-test, are indicated (***, P<0.001, % 
mean ± S.D).  
 
 
It is interesting to note that Miro, Milton and a number of other proteins involved in 
regulation of mitochondrial dynamics are readily detected by western blot analysis in 
SW480 and HT-29 cell lines (mutant APC) at comparable levels to that seen in U2OS, 
HDF1314 and HCT116 cell lines (wild-type APC) (Supplementary Figure S4.1A). This 
indicates that the altered steady-state distribution of mitochondria in cells with mutant 
APC is not caused by defects in expression of Miro/Milton. Furthermore, detection of 
Miro and Milton by immunofluorescence microscopy in SW480, HT-29 and HCT116 
cell lines did not reveal any unusual staining patterns (Supplementary Figure S4.1B). 
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4.3.3 C-terminal truncating mutations disrupt APC binding to 
Miro/Milton 
The above finding suggests that overexpression of wild-type APC could re-establish 
normal mitochondrial distribution, and most likely transport, in APC-mutant HT-29 
cells. This led to the hypothesis that APC truncation may disrupt its interaction with the 
Miro/Milton mitochondrial transport complex. To test this, immunoprecipitation assays 
were performed using lysates from SW480 cells expressing GFP Miro-1 and GFP 
Milton-2 (Figure 4.3A). While APC antibodies could effectively capture mutant APC, 
in contrast to experiments in U2OS cells (Figure 3.7), neither GFP Miro-1 nor GFP 
Milton-2 could be captured. In addition, mutant APC could not be detected when a GFP 
antibody was used to pull down GFP Miro-1 or GFP Milton-2 (Figure 4.3A). 
 
These results mirror those obtained in induced stable cell lines HEK293 (APC-WT) and 
HEK293 (APC-1309) transfected with pGFP Milton-2. Both wild-type and mutant APC 
were successfully pulled down by an APC antibody in these cell lines,  however only 
ectopic full-length APC was able to pull down with GFP Milton-2 and endogenous 
Miro, despite the fact that HEK293 (APC-1309) cells still contain a baseline of 
endogenous wild-type APC (see Supplementary Figure S4.2). This result is most likely 
because the majority of APC pulled down is in the truncated form, therefore any GFP 
Milton-2 or Miro attached to the wild-type would be an extremely small percentage of 
the lysate, thus very hard to detect. GFP pull down experiments in both cell lines 
successfully captured GFP Milton-2, however neither mutant APC-1309 nor wild-type 
APC-WT could be detected (Supplementary Figure S4.2). This was expected in the case 
of APC-1309, however in the case of APC-WT, lack of detection  may be due to 
reasons suggested previously in Section 3.3.7, as difficulty was also encountered 
detecting APC in GFP Milton-2 pull downs in U2OS cells. The capture of GFP Milton-
2 from cell extracts also appeared to pull down a higher molecular weight form of 
endogenous Miro in both HEK293 (APC-1309) and (APC-WT) cell lines which will be 
discussed further in Chapter 7 (Section 7.1.1).  
 
To confirm this result, Duolink PLA was used to assess interactions between APC and 
Miro or Milton in CRC cell lines that express mutant APC (SW480 and HT-29) and 
wild-type APC (LIM1215) (Figure 4.3B-C, expanded in Supplementary Figure S4.3). In 
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both SW480 and HT-29 cells, no PLA signals above background could be detected 
between mutant APC and Miro, or mutant APC and Milton. However, in LIM1215 cells 
which express wild-type APC, a positive PLA signal was observed for both APC/Miro 
and APC/Milton interactions, presenting on average ~14 and ~6 PLA signals/cell 
respectively. 
 
In addition to the analysis of endogenous APC-Miro/Milton interactions, Duolink 
assays were also used to demonstrate that APC truncation reduced the binding of 
ectopic GFP-tagged APC to the mitochondrial transporters. GFP APC-WT was 
transiently expressed in SW480 cells, and the Duolink assay identified a positive PLA 
interaction between GFP-tagged full-length APC and Miro which was ~2.8 fold 
(P<0.001) above GFP background (Figure 4.4; Supplementary Figure S4.4). In contrast 
no PLA signal above GFP background was observed in SW480 cells expressing GFP 
APC-1309 (Figure 4.4; Supplementary Figure S4.4). This result was also verified in 
U2OS cells where a positive PLA signal, ~1.8 fold above GFP baseline, was observed 
between GFP and Miro in cells transfected with GFP APC-WT, but not GFP APC-1309 
(Supplementary Figure S4.5). 
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Figure 4.3: Truncated APC does not interact with the Miro/Milton complex in 
colon cancer cell lines 
(A) SW480 (APC 1-1337) cells transfected with plasmids expressing GFP, GFP Miro-1 
or GFP Milton-2 were immunoprecipitated by antibodies against GFP (pAb) and APC 
(Ab5) and analysed by western blot to detect GFP/GFP Miro-1/GFP Milton-2 (GFP, 
mAb) and APC (Ab1). The APC antibody did not pull down GFP, GFP Miro-1 or GFP 
Milton-2 and the GFP antibody was unable to pull down APC in any of the transfected 
samples. (B-C) Duolink PLA was utilised to confirm this result in situ in SW480, HT-
29 (APC 1-853/1555) and LIM 1215 (APC-WT) cells with antibodies against APC, 
Miro and Milton. Scoring from analysis by immunofluorescence microscopy confirmed 
a negative interaction between truncated APC and Miro/Milton in SW480 and HT-29 
cells, and a positive interaction between full length APC and Miro/Milton in LIM 1215 
cells as observed in the (B) box-and-whisker plot and (C) representative images.  
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Figure 4.4: Overexpression of GFP APC-WT in SW480 cells restores the 
APC/Miro interaction as measured by Duolink.  
(A-B) pGFP, pGFP APC-WT and pGFP APC-1309 were transfected into SW480 cells 
48 h prior to fixation. Duolink PLA was performed using antibodies against GFP (mAb) 
and Miro. Slides were analysed by (A) immunofluorescence microscopy and modestly 
transfected cells scored for PLA signals as observed in the (B) box-and-whisker plot. 
Significant differences relative to GFP control, as determined using the Mann-Whitney 
U-test, are indicated (***, P<0.001; n.s., not significant). 
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4.3.4 The Miro-binding region maps to the C-terminal amino acids 
(2650-2843) of APC 
Given that C-terminal truncation of APC disrupted both APC/Miro and APC/Milton 
interactions, experiments were performed to determine if APC may associate with the 
complex through its C-terminal sequences. To identify the Miro-binding region of APC, 
a detailed mapping was performed by Duolink PLA in U2OS cells expressing a range of 
GFP-tagged APC fragments (1-302, 334-900, 1379-2080, 2226-2644, 2650-2843) as 
outlined in the schematic in Figure 4.5A and verified by western blot analysis (Figure 
4.5B). Using antibodies against Miro and GFP, cells expressing low to moderate levels 
of each fragment were assessed for in situ binding with endogenous Miro (Figure 
4.5C,D). Of the five sequences tested, only GFP APC(2650-2843) presented a PLA 
signal above GFP baseline, where the mean PLA signal/cell increased by ~3.4 fold 
(P<0.001) compared to GFP alone. The PLA reaction performed on cells using only the 
individual anti-GFP or anti-Miro antibodies produced no signal. For more details see 
Supplementary Figure S4.6.  
 
In line with findings above (Figure 4.3), the APC(2650-2843) sequence corresponds 
with the far C-terminal end of the APC protein, a section which is lost in the vast 
majority of truncating APC mutations. To confirm this interaction, U2OS cells 
expressing GFP APC(2650-2843) were immunoprecipitated with an antibody against 
GFP (Figure 4.6A). In addition to successfully capturing GFP APC(2650-2843), a 
higher molecular weight form of Miro was detected that was not observed under the 
same conditions when cells were transfected with pGFP, pGFP APC(1-302) or pGFP 
APC(1379-2080) (Figure 4.6A). The higher molecular weight form of Miro pulled 
down suggests that the APC(2650-2843) fragment may bind to a post-translationally 
modified form of Miro; this will be discussed further in Chapter 7 (Section 7.1.1). 
Unfortunately, evidence for an interaction was not achievable by reverse 
immunoprecipitation using the Miro antibody, possibly due to overlap between the 
antibody epitope and APC binding region. Colocalisation studies also indicate that GFP 
APC(2650-2843) localises to the mitochondria (Figure 4.6B), further supporting the 
notion that APC binds to the Miro/Milton complex via its C-terminal sequences, and the 
finding that truncation of APC disrupts mitochondrial transport. 
 
Chapter 4 
122 
 
 
 
Figure continued over page. 
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Figure 4.5: The Miro-binding domain of APC maps to the C-terminal sequences by 
Duolink.   
U2OS cells were transfected with pGFP, or the pGFP tagged APC fragments (1-302), 
(334-900), (1379-2080), (2226-2644) or (2650-2843) described in the (A) schematic 
which were confirmed by (B) western blot analysis. Duolink PLA was then performed 
utilising antibodies against GFP (mAb) and Miro, and transfected cells expressing 
modest levels of GFP proteins were analysed by (C) immunofluorescence microscopy. 
PLA signals per cell were scored to reveal that only GFP APC(2650-2843)  gave a 
positive interaction by Duolink when compared to the GFP background. This is 
indicated in the (D) box-and-whisker plot. Significant differences relative to GFP 
control, as determined using the Mann-Whitney U-test, are indicated (***, P<0.001;n.s., 
not significant). 
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Figure 4.6: The C-terminal sequences of APC are confirmed to interact with Miro 
by immunoprecipitation and localise to the mitochondria.  
(A) U2OS cells transfected with pGFP alone and pGFP-tagged APC fragments (1-302), 
(1379-2080) and (2650-2843) were immunoprecipitated by antibodies against GFP 
(pAb) and Miro prior to western blot analysis. Detection by GFP (mAb) revealed that 
the Miro antibody was unable to pull down any of the GFP-tagged APC fragments. 
Detection by Miro antibody however revealed that the GFP (pAb) antibody could 
successfully pull down GFP-APC(2650-2843) and a high molecular weight form of 
Miro-1 in transfected cell samples. (B) Plasmids encoding GFP and GFP APC(2650-
2843) were transfected into U2OS cells for 48 h and stained with CMX-Ros to detect 
mitochondria prior to fixation. Cells were counterstained with a GFP antibody (mAb) 
and Hoechst (blue), then analysed for co-localisation by immunofluorescence 
microscopy. 
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4.3.5 The APC C-terminal sequence also binds to Milton. 
Duolink PLA was used to confirm that GFP APC(2650-2843) also interacts with Milton 
(Figure 4.7). Scoring of PLA signals between GFP and Milton in U2OS cells 
transfected with pGFP APC(2650-2843), revealed a positive PLA signal 2.6-fold higher 
(P>0.001) than those cells transfected with GFP alone (Figure 4.7; Supplementary 
Figure S4.7), indicating that the C-terminal region of APC does indeed associate with 
Milton. 
 
 
 
Figure 4.7: The C-terminal sequences of APC also interact with Milton by Duolink 
PLA.  
(A-B) pGFP and pGFP-APC(2650-2843) plasmids were transfected into U2OS cells 
which were subjected to Duolink PLA using antibodies against GFP (mAb) and Milton. 
Slides were analysed by immunofluorescence microscopy and (A) representative cell 
images are shown. (B) Transfected cells were scored for PLA signals and the data 
quantified and compared here graphically by box-and-whisker plot. Significant 
differences relative to GFP control, determined using the Mann-Whitney U-test, are 
indicated (***, P<0.001).   
Chapter 4 
126 
4.3.6 Overexpression of the C-terminal region of APC partially 
disrupts mitochondrial transport. 
Since the C-terminal region of APC was found to interact with the Miro/Milton 
mitochondrial complex, investigation was undertaken to determine if overexpression of 
this APC fragment could disrupt mitochondrial transport. Therefore, U2OS cells were 
transfected with plasmids that expressed GFP or GFP-tagged APC fragments (1-1309), 
(334-900) and (2650-2843), counterstained with CMX-Ros to detect mitochondria, and 
scored for mitochondrial distribution by immunofluorescence microscopy. The 
overexpression of GFP APC(2650-2843) was found to stimulate a small, but significant, 
shift in mitochondrial distribution towards the perinuclear region when compared to 
GFP control cells, which was not observed in cells transiently expressing the common 
colorectal cancer truncation of APC(1-1309) or the  Arm domain of APC (334-900) 
(zone 1 mitochondria: GFP=17%, GFP APC(2650-2843)=23%)(P<0.05) (Figure 4.8). 
This result indicates that the C-terminus has some functional contribution to the APC-
dependent regulation of mitochondria.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: The overexpression of APC(2650-2843) partially disrupts 
mitochondrial distribution.  
U2OS cells transfected with pGFP, or pGFP tagged APC fragments (1-1309), (334-900) 
or (2650-2843) were fixed and stained for mitochondria (CMX-Ros). Transfected cells 
were scored for mitochondrial distribution by immunofluorescence microscopy. Results 
are represented in the bar graph (% mean ± S.D.) where significant differences for zone 
1 distribution relative to the GFP control are indicated (*, P<0.05, n.s., not significant). 
Significance determined using an unpaired T-test.   
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4.3.7 Overexpression of APC(2650-2843) does not disrupt the 
interaction between endogenous APC and Miro. 
In the above section overexpression of the APC C-terminal region induced a modest 
perinuclear redistribution of mitochondria. One explanation for why the perinuclear 
shift was not more substantial could be that overexpression of the C-terminal fragment 
was not sufficient to completely disrupt the interaction between endogenous APC and 
Miro/Milton proteins. To test this, U2OS cells expressing GFP APC(2650-2843) were 
subjected to Duolink PLA using antibodies to detect endogenous APC (Ab7 – detects 
N-terminal epitope) and Miro. In line with the hypothesis, overexpression of GFP 
APC(2650-2843) did not significantly (P>0.05) alter the binding of endogenous full-
length APC to Miro relative to the GFP control (Figure 4.9;Supplementary Figure S4.8). 
This suggests that while APC(2650-2843) may contribute, either directly or indirectly, 
to the binding between the two proteins, it alone is perhaps not sufficient for binding 
and other APC regions or a particular protein folding may be required.  
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Figure 4.9: Overexpression of APC(2650-2843) does not interrupt the endogenous 
APC/Miro interaction.  
(A-B) U2OS cells transfected with pGFP or pGFP APC(2650-2843) were subject to 
Duolink PLA using antibodies against APC and Miro. Transfected cells were analysed 
by (A) immunofluorescence microscopy and scored for PLA signals as observed in the 
(B) box-and-whisker plot. Significant differences relative to GFP control, determined 
using the Mann-Whitney U-test, are indicated (n.s., not significant). 
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4.4 Discussion  
In this chapter, the impact of APC truncations on the ability of APC to bind the 
Miro/Milton transport complex and mediate mitochondrial distribution throughout the 
cell was assessed in different CRC cell lines. Cancer-associated truncations were found 
to disrupt APC binding to the Miro/Milton complex, which was mapped to the far C-
terminal end (2650-2843) of APC (Figure 4.5, Figure 4.7). In addition, CRC cell lines 
expressing mutant APC displayed defective mitochondrial localisation patterns 
indicative of altered anterograde transport, identifying a new consequence of APC 
mutations. The implications of these observations for APC, mitochondria and cancer 
biology will be discussed. 
4.4.1 Truncating APC mutations disrupt the interaction between APC 
and the Miro/Milton complex inhibiting mitochondrial transport 
Given the disruptions observed in numerous APC functions following CRC-associated 
truncation of the protein, their effect on the ability of APC to regulate mitochondrial 
spread within a cell was addressed. This was first assessed for endogenous APC in CRC 
cell lines that express only truncated APC (SW480 and HT-29, Figure 4.1). In these cell 
lines, the proportion of cells displaying mitochondria that spread outward to the 
membrane periphery was much lower than that observed in CRC cell lines expressing 
wild-type APC (Figure 4.1). Thus, the expression of endogenous APC mutants 
correlated with disruption of mitochondrial distribution and transport. Colorectal 
cancers acquire a series of sequential gene mutations during the cell transformation 
process (3-5), hence in order to test specifically the role of APC gene mutations, ectopic 
forms of APC were expressed. These experiments revealed that in HT-29 cells the mild 
overexpression of wild-type APC, but not mutant APC-1309, rescued the defect in 
mitochondrial distribution (Figure 4.2). These results indicate that truncations in APC 
contribute to altered mitochondrial localisation, most likely through defects in transport. 
 
Consistent with the inability of mutant APC to drive membrane-directed localisation of 
mitochondria, the endogenous mutant forms of APC did not associate with Miro or 
Milton in CRC cell lines (Figure 4.3). Even when overexpressed, the APC-1309 
truncated form of APC failed to bind Miro in SW480 cells (Figure 4.4) and U2OS cells 
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(Supplementary Figure S4.5). In contrast, overexpressed GFP-tagged wild-type APC 
was found to bind to Miro in both SW480 and U2OS cells. These observations, together 
with the finding that in APC-mutant CRC cells the endogenous levels of Miro and 
Milton are not rate-limiting (Supplementary Figure S4.1), provide strong evidence that 
truncation of APC directly affects its ability to associate with the Miro/Milton complex. 
This altered association may cause perinuclear accumulation of mitochondria through 
impairment of the normal Miro/Milton-driven anterograde transport pathway, as 
proposed in Figure 4.10. 
 
 
Figure 4.10: Model 
Wild-type APC, but not truncated APC, stimulates anterograde transport of 
mitochondria through a C-terminal association with the Miro/Milton/KIF5 kinesin 
complex along microtubules. 
 
The distribution of mitochondria is also disrupted by mutations in genes that encode 
other components of the transport complex. For example, the Drosophila homologs for 
Miro and Milton were originally identified through genetic screenings of Drosophila 
with retinal neurons devoid of axonal and terminal mitochondria (143, 144). Similar 
observations were also reported in mutant KIF5 Drosophila neurons (151). Due to the 
unique architecture of neuronal cells, disrupted long range transport along the axon have 
more severe consequences than in other cell types where distances travelled are not as 
vast. As a result, published studies in other cell types are limited. However, mutation of 
KIF5 in a murine primary culture from a visceral yolk sack was reported to display 
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substantial perinuclear clustering of mitochondria compared to control cultures (284), 
mirroring what was observed in APC mutant colon cancer cell lines in this study. 
 
A sizeable population of SW480 and HT-29 cells still displayed mitochondria in 
vicinity of the plasma membrane (zone 3). It is possible that in these cells, Miro/Milton 
complexes remain transport-active even in the absence of bound APC. However, it is 
more likely that a subset of mitochondria find their way to the cell periphery through the 
action of alternate kinesin-based motor complexes that facilitate anterograde transport 
along microtubules such as the RanBP2/KIF5 and KBP/KIF1Bα complexes (Section 
1.3.2.2 and 176, 180), or potentially Myo10 motor complexes that transport 
mitochondria along actin filaments (188). For example, in HT-29 cells (APC 1-
853/1555), RanBP2 is a potential alternative transporter, as it remains stable due to the 
reported silencing of the E3 ligase Parkin (which marks RanBP2 for degradation) in this 
cell system (290, 291). These alternate pathways could remain active or even up-
regulated in the sustained absence of wild-type APC, and in turn, a less active 
Miro/Milton transport complex. The mechanism by which APC mutation disrupts 
functionality of the Miro/Milton complex is discussed further in Chapters 5 and 6, 
which look at the role APC plays in complex formation and regulation. 
4.4.2 Identification of a C-terminal sequence that mediates binding of 
APC to Miro/Milton 
Duolink PLA identified a Miro-binding site in the C-terminal sequence 2650-2843, 
located just after the “basic” domain (Figure 4.5). Miro-binding of the 2650-2843 
sequence was verified by immunoprecipitation and found to be specific (Figure 4.6; see 
Section 7.1.1 for discussion about the altered higher molecular weight form of Miro that 
bound to APC). The identification of the 2650-2843 Miro-binding sequence, which also 
bound to Milton (Figure 4.7), provides a satisfactory explanation for why APC cancer 
truncations, almost all of which lose this sequence (4), are unable to bind Miro/Milton. 
Interestingly, the overexpression of GFP APC(2650-2843) was not sufficient to disrupt 
the interaction between endogenous APC and Miro (Figure 4.9), indicating that 
additional sites within APC may contribute to Miro binding. These might be contained 
in the regions 900-1379 or 2080-2226, for which GFP fragments were not available. It 
is also possible that optimal binding is context-dependent and interrupted by segregating 
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APC into fragments, or that overexpression of GFP APC(2650-2843) is insufficient to 
displace wild type APC. Consistent with the inability of the 2650-2843 fragment to 
disrupt binding of APC to Miro, only a minor effect on mitochondrial distribution was 
observed when this sequence was overexpressed (Figure 4.8). This is a stark comparison 
to the overexpression of a dominant negative form of Miro observed in the literature, 
where anterograde mitochondrial transport is completely disrupted (148). Overall, these 
observations suggest that the 2650-2843 sequence is a key binding site for Miro, but 
may not be the only binding site, and its location at the C-terminus implies that its loss 
through gene mutation is sufficient to disrupt APC binding to Miro/Milton complexes. 
4.4.3 Disruption of mitochondrial transport by APC truncation may 
contribute to the CRC tumour cell phenotype 
The general dysfunction of mitochondria has been widely reported to contribute to 
many facets of the carcinogenic process including altered energy metabolism, cell 
viability and replicative stress (14). Whilst the more specific impact of disrupting 
mitochondrial transport has been studied in other disease phenotypes (139, 256, 257), 
the impact to the carcinogenic process is only just coming to light. In particular, recent 
studies link mitochondrial distribution to key aspects of cell function disrupted in 
carcinogenesis including cell migration (18, 19), calcium signalling (15, 292), and gene 
transcription (265). Hence, a disturbance of mitochondrial transport could represent 
another way in which truncated APC exerts its carcinogenic effect on cells. 
 
This study is not the first to link a Wnt target protein to the regulation of mitochondrial 
transport. The recently discovered protein Alex3 was found to stimulate mitochondrial 
aggregation and clustering, through an interaction with the Miro/Milton complex (163). 
Stimulation of the non-canonical Wnt signalling pathway was reported to attenuate the 
effects of Alex3, in a manner that could not be reproduced by the constitutive activation 
of β-catenin (161). Therefore it is unlikely that the Alex3 mitochondrial regulatory 
pathway is disrupted upon the aberrant β-catenin/canonical Wnt signalling observed 
following APC truncation. The relationship between APC, Alex3 and Wnt signalling in 
the context of mitochondrial transport is discussed in Chapter 7 (Section 7.2). 
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4.4.3.1 Mis-regulated ATP targeting by disruption of mitochondrial transport may 
contribute to CRC carcinogenesis 
Aberrant cell migration is a hallmark of cancer (293), and truncation of APC contributes 
to altered migration through several different pathways including disrupted microtubule 
stabilisation, actin polymerisation and cell polarity (Section 1.2.3.2 and 52, 54). Recent 
reports have indicated that mitochondrial localisation at the cell periphery is crucial for 
supplying ATP reserves required for dynamic membrane movement, and that changes in 
this process can alter cell migration in several sub-types of cancer (18, 19). It is 
therefore possible that APC mutations also impact on cell migration indirectly through 
perturbation of mitochondrial transport (this is addressed in detail in Chapter 5). 
 
ATP is the main energy source for many other cell processes for which the significance 
of mitochondrial localisation has not yet been described. These include cytoskeletal 
assembly and disassembly, signalling cascades, and DNA, RNA and protein synthesis. 
It is assumed that mitochondrial ATP plays a role in these processes under normal 
cellular conditions, as oxidative phosphorylation is the primary means of ATP synthesis 
in healthy cells. However, tumour cells, including CRC cells, display vastly increased 
rates of glycolysis, an alternate method for generating ATP, in the cytosol (the 
“Warburg effect”, reviewed in 262). Furthermore, pyruvate dehydrogenase kinase 
(PDK1), an enzyme that promotes aerobic glycolysis through inhibition of the pyruvate 
dehydrogenase (PDH) complex, and in turn oxidative phosphorylation, was recently 
identified as a Wnt target gene (294), indicating that truncation of APC may in fact 
stimulate the glycolytic pathway further through aberrant β-catenin Wnt signalling. 
Despite this, it is important for bioenergetic structures to achieve a high level of site-
specific ATP synthesis through targeting of mitochondria. Unlike energy produced by 
glycolysis, which must be obtained from non-specific ATP diffusion through the 
cytoplasm, targeted mitochondria provide a means for consistent site-specific ATP 
output and fast ADP recycling. Furthermore, it is also metabolically ~18-fold more 
efficient to produce ATP by oxidative phosphorylation than by glycolysis (295). 
 
The truncation of APC as observed in CRC cells could impact on membrane-directed 
localisation of mitochondria and ATP reserves, in addition to the supply of energy at 
other sites yet to be investigated. This is suggested not only by the range of intracellular 
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shuttling patterns of APC (11, 12) but also the recent finding that APC can bind 
different myosin motors (Lui and Henderson, unpublished) that may help traffic 
mitochondria along actin filaments, taking them to parts of the cell different to those 
targeted by microtubules (discussed further in Section 7.5.3). 
4.4.3.2 Disruption of mitochondrial transport may contribute to aberrant calcium 
signalling in CRC carcinogenesis. 
Mitochondria have an essential role in buffering calcium, a key regulator in many facets 
of cell function, though their ability to take up and release calcium in a site-specific 
manner (Section 1.3.1.2). Like other metabolites, calcium often accumulates in 
microdomains, sites within the cell cytoplasm with a localised high calcium ion 
concentration, usually formed in the vicinity of Ca
2+
 channels (for example at the 
plasma membrane, golgi and ER). Close proximity of mitochondria to these 
microdomains can facilitate the rapid uptake of calcium (reviewed in 15), however, the 
effects of mislocalised mitochondria on calcium buffering are poorly understood. One 
study does report that mitochondrial contact with the cell periphery is essential for 
extracellular calcium uptake (190). This is discussed further in the context of cell 
migration in Chapter 5 (Section 5.4.2). 
 
Impaired calcium signalling is frequently observed in cancer cells where it affects cell 
migration and proliferation (reviewed in 292, 296). Furthermore, pro-proliferative 
pathways regulated by calcium signalling are particularly sensitive in colonocytes (297). 
It is possible that disrupted mitochondrial transport could inhibit effective calcium 
buffering, in turn contributing to the aberrant calcium signalling observed in cancer 
cells. The importance of effective mitochondrial transport and distribution in calcium 
buffering is highlighted by the regulatory EF-hand motifs present in Miro, which when 
bound to calcium, cause cessation of mitochondrial transport, presumably to facilitate 
site-specific calcium buffering (153, 158). Intriguingly, Togo and colleagues (298), 
report that APC attachment to microtubules is calcium regulated. With this in mind, 
further investigation into if, and how, calcium may regulate APC-dependent 
mitochondrial transport and what effect APC mutation may have on calcium signalling 
in carcinogenesis was investigated and will be discussed in Chapter 6. 
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4.4.3.3 Perinuclear clustering of mitochondria may contribute to aberrant gene 
transcription in CRC carcinogenesis. 
Sustained perinuclear accumulation of mitochondria may also have adverse effects on 
the cell. Little is known about the physiological role of mitochondrial aggregation in 
this region, although hypoxia-induced perinuclear clustering of mitochondria in 
pulmonary artery endothelial cells was reported to create an oxidant rich nuclear domain 
due to the release of ROS from the mitochondria (265). This increased nuclear ROS can 
cause oxidative base modifications through a Hypoxia Induced Factor 1α (HIF-1α) 
dependent pathway to facilitate transcription of target genes, such as the growth signal 
vascular endothelial growth factor (VEGF). 
 
These findings are especially intriguing as high levels of HIF-1α, the transcriptional 
master regulator of hypoxia (reviewed in 299), and VEGF have been observed in colon 
tumour tissues and several colon cancer cell lines (300). Furthermore, APC truncation in 
the intestinal epithelium was shown to cause an increase in ROS through both a Rac1-
dependent pathway (301) and Wnt3a-stimulated mitochondrial biogenesis (302). It is 
possible that the perinuclear mitochondrial clustering, frequently observed in SW480 
and HT-29 mutant APC cell lines (Figure 4.1), assists in formation of an oxidant rich 
microdomain around the nucleus, even in the absence of hypoxic signals due to the 
disruption of APC-dependent mitochondrial transport. This could contribute to aberrant 
transcription of hypoxia-induced genes such as VEGF, NFκB and a variety of cellular 
adhesion molecules contributing to carcinogenesis (299). Increased ROS in close 
proximity to the nucleus could also expose the DNA to carcinogenic promoting 
mutations, whilst increased ATP from perinuclear mitochondria could provide the 
nucleus with the energy required for increased DNA transcription. 
4.4.4 Summary  
These findings indicate that C-terminal deletion of APC prevents its binding to the 
Miro/Milton complex, in turn disrupting mitochondrial transport in mutant APC CRC 
cells. Disrupted mitochondrial transport has been implicated in a number of pathways 
known to be altered in carcinogenesis including cell migration, calcium signalling and 
gene transcription. This points to a previously unreported mechanism through which 
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mutation of APC may contribute to tumourigenesis. APC mutation and mitochondrial 
localisation already have reported roles in cancer cell migration; therefore, potential 
links between these pathways will be investigated in the following chapters, along with 
the mechanism by which APC may interact with, and regulate Miro/Milton to drive 
mitochondrial transport. 
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4.5 Supplementary Figures 
 
Supplementary Figure S4.1: APC and regulators of mitochondrial dynamics in 
colon cancer cell lines 
(A) U2OS, HDF1314, SW480, HT-29 and HCT116 cells were analysed by western 
blot. Antibodies against APC (Ab1), Milton, OPA1, β-catenin (mAb), Mfn2, Miro and 
α-tubulin were used to detect endogenous levels of their respective protien in each of 
these cell lines. Protein molecular weights (kDa) are indicated in brackets. (B) Sub-
confluent HCT116, SW480 and HT-29 cells were fixed and stained with either CMX-
Ros Mitotracker (red) or antibodies against APC, Miro, Milton or α-tubulin (green), and 
analysed by immunofluorescence microscopy.  
Chapter 4 
138 
 
 
Supplementary Figure S4.2: APC antibodies can immunoprecipitate Miro and 
Milton in wild-type inducible HEK293 cells, but not mutant inducible HEK293 
cells  
Inducible HEK293 cell lines transfected with pGFP Milton-2 were treated with 
tetracycline 16 h prior to immunoprecipitation to induce expression of (APC-1309) or 
(APC-WT). Cells immunoprecipitated by antibodies against APC (Ab5), GFP (pAb), 
Milton, IgGr and IgGm, were then analysed by western blot to detect APC (Ab1), GFP 
Milton-2 (GFP, mAb) and Miro, respectively. The APC antibody was able to pull down 
endogenous and/or induced APC in both cell lines. Only in cells induced for (APC-WT) 
could the APC antibody pull down GFP Milton-2 and Miro. The GFP antibody was able 
to pull down GFP Milton-2 and Miro in both cell lines, but was unable to pull down 
APC. Protein molecular weights (kDa) are indicated. 
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Supplementary Figure S4.3: Truncated APC does not interact with the 
Miro/Milton complex - Expanded Duolink PLA data 
(A-B) Interactions between APC and Miro/Milton were visualised in situ by Duolink 
PLA in SW480, HT-29 and LIM1215 cells as described in Figure 4.3. The PLA signals 
for APC/Miro and APC/Milton are not above background in SW480 and HT-29 cells, 
indicating no interaction is present, whilst the PLA signals for APC/Miro and 
APC/Milton are are above background in LIM1215 cells indicating a positive 
interaction as shown in the (A) dot-plot (mean ± S.D, shading indicates interactions 
tested) and (B) table (n, number in sample; IQR, inter-quartile range; SD, standard 
deviation). 
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Supplementary Figure S4.4: Reconstitution of GFP APC-WT into SW480 cells 
restores the APC/Miro interaction by Duolink - Expanded Duolink PLA Data 
(A-B) Interactions between GFP and Miro were visualised in situ using Duolink PLA in 
cells transfected with pGFP, pGFP APC-WT and pGFP APC-1309, as described in 
Figure 4.4. Scoring indicates a positive signal between GFP and Miro in cells 
transfected with pGFP APC-WT, but not pGFP APC-1309, relative to pGFP control as 
shown in the (A) dot-plot (mean ± S.D, shading indicates interactions tested) and (B) 
table (n, number in sample; * fold change relative to GFP control; IQR, inter-quartile 
range; SD, standard deviation). 
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Supplementary Figure S4.5: GFP APC-WT but not GFP APC-1309 interacts with 
Miro in U2OS cells by Duolink PLA 
(A-C) Cells expressing GFP, GFP APC-WT and GFP APC-1309 were subject to 
Duolink PLA using antibodies against GFP (mAb) and Miro. Scoring analysis by (A) 
immunofluorescence microscopy indicates a positive signal, above GFP background 
between GFP APC-WT/Miro but not GFP APC-1309/Miro as indicated by the (B) dot-
plot (mean ± S.D, shading indicates interactions tested) and (C) table (n, number in 
sample; * fold change relative to GFP control; IQR, inter-quartile range; SD, standard 
deviation). 
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Supplementary Figure S4.6: The C-terminal sequences of APC interact with Miro 
– Expanded Duolink PLA Data 
(A-B) U2OS cells were transfected with pGFP and pGFP-tagged APC fragments (1-
302), (334-900), (1379-2080), (2226-2644) and (2650-2843). Duolink PLA was 
performed using antibodies against GFP (mAb) and Miro as described in Figure 4.5. 
Scoring  of PLA signals indicates that GFP APC(2650-2843) was the only GFP APC 
fragment to show a positive PLA signal above GFP background as indicated by the (A) 
dot-plot (mean ± S.D, shading indicates interactions tested) and (B) table (n, number in 
sample; * fold change relative to GFP control; IQR, inter-quartile range; SD, standard 
deviation). 
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Supplementary Figure S4.7: The C-terminal sequences of APC interact with 
Milton – Expanded Duolink PLA Data 
(A-B) U2OS cells expressing GFP or GFP APC(2650-2843) were subject to Duolink 
PLA as per Figure 4.7, using antibodies against GFP (mAb) and Milton. Scoring 
indicates that GFP APC(2650-2843)/Milton shows a positive PLA signal above GFP 
background as indicated by the (A) dot-plot (mean ± S.D, shading indicates interactions 
tested) and (B) table (n, number in sample; * fold change relative to GFP control; IQR, 
inter-quartile range; SD, standard deviation). 
 
 
 
 
 
 
Supplementary Figure S4.8: Overexpression of APC C-terminal sequences does 
not interrupt the endogenous APC/Miro interaction – Expanded Duolink PLA 
Data 
(A-B) U2OS cells were transfected with pGFP or pGFP APC (2650-2843) and Duolink 
PLA performed using antibodies against APC and Miro as described in Figure 4.9. 
Scoring indicates that GFP APC (2650-2843) did not alter the endogenous APC/Miro 
interaction as shown in the (A) dot-plot (mean ± S.D, shading indicates interactions 
tested) and (B) table (n, number in sample; * fold change relative to GFP control; IQR, 
inter-quartile range; SD, standard deviation).  
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The active transport of mitochondria throughout the cell is integral to its role in a range 
of key cellular processes, in particular at the cell periphery where accumulation of 
mitochondria provides ATP for cell migration and modulation of calcium flux. 
Positioning of mitochondria at the cell membrane requires effective anterograde 
transport along microtubules, primarily mediated through the Miro/Milton/KIF5 
complex. Chapters 3 and 4 established APC as a novel component of this complex, 
which when silenced or truncated by CRC-associated mutations disrupted mitochondrial 
transport to the cell membrane. This chapter examines the functional role of APC in 
regulating mitochondria dynamics in live cells. Wound healing experiments in confluent 
NIH 3T3 revealed strong colocalisation of APC with mitochondria at cell membrane 
protrusions associated with active migration. To better understand how loss of APC 
affects mitochondrial transport, live cell imaging was employed to track real time 
movement of GFP-labelled mitochondria in NIH 3T3 cells. The most striking 
observation was that in comparison to control cells, loss of APC significantly reduced 
mitochondrial motility, specifically by affecting the initiation of anterograde transport. 
In line with these results, a decrease in the frequency of distinct mitochondrial 
movements and a decrease in the average mitochondrial displacement and distance 
travelled were also observed. However, once mitochondrial transport commenced, no 
alteration in the velocity of transport was recorded between control and APC siRNA 
treated cells. These results indicate a specific role for APC in stimulating initiation of 
anterograde mitochondrial transport to the cell periphery, disruption of which may 
contribute to mislocalisation of ATP and the aberrant cell processes (such as migration) 
observed in CRC carcinogenesis.  
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5.1 Introduction 
The highly motile nature of mitochondria is essential for supplying targeted energy in 
the form of ATP to bioenergetically demanding areas of the cell and for optimal 
regulation of calcium buffering. Mitochondrial transport has traditionally been studied 
in neurons due to their unique cell architecture which requires long distance transport 
through the axon from the cell body towards the synaptic terminal (137, 138). 
Disruptions in this process, which prevent trafficking of mitochondria along the axon, 
deprives the synaptic terminal of the ATP required for effective synaptic firing, and in 
turn contributes to a number of neurological conditions (reviewed in 139, 140, 257). 
More recently, mitochondrial transport has been studied in other cell types including 
epithelial and lymphocytic cells (18, 19, 142). These studies shed new light on the 
importance of effective mitochondrial targeting, in particular for cell migration. 
 
At the leading edge of the cell in particular, extensive cytoskeletal remodelling is 
required for dynamic membrane deformation and the formation of membrane structures, 
such as actin-dependent lamellipodia or membrane ruffles for cell movement, and 
microtubule-dependent protrusions for cell polarisation (directionality of movement). 
Cytoskeletal remodelling requires polymerisation of actin and tubulin monomers into 
extensive F-actin and microtubule networks, which is an extremely bioenergetically 
demanding process. Moreover, transportation of membrane-associated proteins and 
other factors required for cell migration often occurs by kinesin and myosin motors 
along these cytoskeletal tracks and requires high levels of energy consumption 
(reviewed in 64). In this context, highly specific positioning of mitochondria at the 
leading edge has been shown to be essential for providing the ATP required to meet the 
energy demands to maintain cell migration (18, 19).  
 
APC targeting to the cell periphery is also essential for coordinating persistent and 
directed cell migration through a multifaceted role in regulating the actin and 
microtubule networks (see Section 1.2.1.3 and reviews 52, 54). In particular, APC binds 
to and stabilises the plus-end tips of microtubules by association with EB1, contributing 
to the maintenance of cell polarity (67, 70). APC also contributes to regulation of the 
actin network by stimulating actin polymerisation directly and through modulation of 
substrates such as the GTP exchange factor ASEF and IQGAP1 (57, 58, 72). The 
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majority of these interactions are mediated through the C-terminal “basic” domain of 
APC, and as such are lost in truncating mutations in CRC.  
 
Silencing of APC, like blocking the localisation of mitochondria to the cell periphery, 
has been reported to slow cell migration (65). Results from previous chapters indicate 
that APC regulates localisation of mitochondria to the cell periphery of sub-confluent 
cells through the Miro/Milton mitochondrial transport complex. The primary aim of this 
chapter was to experimentally confirm, for the first time, that APC drives the movement 
of mitochondria to the outer cell membrane. Here it is shown that APC contributes to 
the initiation of mitochondrial transport in the anterograde direction, towards the leading 
edge of actively migrating cells, opening up a new pathway through which APC 
controls cell migration. It is suggested that APC-dependent mitochondrial localisation at 
the cell periphery acts synergistically with APC’s cytoskeletal regulatory functions to 
stimulate cell migration, a process that may be disrupted in CRC carcinogenesis, as 
reflected by the aberrant migration of colonic epithelial cells in mouse colon crypts (66, 
99). 
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5.2 Methods 
5.2.1 Cell culture 
NIH 3T3 and HDF1314 fibroblast cells were cultured in DMEM under standard 
conditions as outlined in Section 2.2.3. For all fixed cell wound healing experiments, 
cells were seeded on glass cover slips in 6 well trays coated with poly-L-lysine and 
grown to 100% confluence. For live cell experiments, cells were seeded in 2-well 
chamber slides coated with poly-L-lysine and grown to 70-80% confluence for sub-
confluent experiments and 100% confluence for wound healing experiments. Cells to be 
subjected to western blotting were seeded in 25 cm
2
 flasks for siRNA knockdown 
experiments. For more details see Section 2.2.3.1.  
 
Under standard conditions used though out the majority of this thesis, plasmids are 
transfected for transient expression at ~70% confluence. However, due to pre-treatments 
and toxicity issues faced in live cell imaging experiments, cells had to be transfected 
with pGFP2-Mito at ~90% confluence. Following optimisation (Section 5.3.3.2, Table 
5.2) using several transfection reagents as described in Section 2.2.3.4, the K2 
transfection system was selected. Use of mouse APC siRNAs for gene silencing is also 
described in Section 2.2.3.4. 
5.2.2 Wound Healing 
Confluent cells were wounded with a 0.8 mm (PrecisionGlide, BD) needle and washed 
twice with PBS prior to the addition of new DMEM. Subsequent 
fixation/immunostaining or live cell imaging was performed 5 h after wounding.  
5.2.3 Cell fixation and staining for immunofluorescence microscopy 
Cells were seeded for at least 24 h, fixed with methanol-acetone, probed with relevant 
antibodies and mounted for immunofluorescence microscopy as outlined in Section 
2.2.4. Addition of CMX-Ros, where required, for detection of mitochondria occurred 
prior to fixation. Concentrations and further specifications for antibodies and dyes used 
in this chapter are outlined in Table 2.2, Table 2.3 and Table 2.4. 
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5.2.4 Fixed cell immunofluorescence cell image acquisition and 
processing 
Slides were analysed using the Olympus IX71 DeltaVision Core deconvolution 
microscope equipped with a CoolSNAP HQ
2
 camera for general image capture. Images 
collected were further resolved using SoftWorx deconvolution software. In wound 
healing experiments detecting mitochondrial localisation at protrusions (Figure 5.4), 
200 cells were scored over 2 independent experiments. Localisation was considered 
positive if mitochondria reached at least 75% of the protrusion length. 
5.2.5 Live cell imaging acquisition and analysis 
Live cell imaging was performed using the Olympus IX71 DeltaVision system (above) 
for image capture at 40x. Whilst imaging, NIH 3T3 cells grown in 2-well chamber 
slides (Nunc) were maintained at 37°C and 5% CO2. The following describes optimised 
conditions for each protocol (for optimisation process see Section 5.3.4). In sub-
confluent experiments, cells expressing GFP2-Mito were imaged every 5 s for 5 min. 
For wound healing experiments (Section 5.2.2), cells transfected with control or mAPC-
red siRNA, expressing GFP2-Mito were imaged every 7 s for 5 min. Three z-stack 
images were acquired in FITC and DIC channels for each time point.  
 
The MTrackJ ImageJ plug-in (303) was used to manually track randomly selected 
mitochondria in cells at protrusions and the leading edge (Figure M5.1). All 
mitochondria were tracked in one z-plane, for a minimum of 2 min, and where 
appropriate, subsequent calculations were normalized to 1 min. Tracking was 
terminated if mitochondria underwent fission or fusion, or shifted significantly out of 
focus. The raw data readout assigned co-ordinates for each time-point a single 
mitochondrion was tracked. This was processed using Microsoft Excel to calculate 
displacement for each time point, and in turn velocity and other calculations observed in 
Figure M5.1 and Table 5.3 and Table 5.4. Mitochondria were deemed to be motile if 
displacement between two consecutive time-points was >0.1 µm/s. Anterograde, 
retrograde and oscillatory transport was assigned to motile mitochondria according to 
the changes in mitochondrial displacement from the nucleus (ΔDFN) between the first 
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and final tracking points (ΔDFN +2.5 µm = anterograde, -2.5 µm = retrograde, -2.5 µm 
- +2.5 µm = oscillating). 
 
 
Figure M5.1: Tracking mitochondria using MTrackJ 
(A) The nucleus (n) and randomly selected mitochondria were manually tracked in 
ImageJ using the MTrackJ plug-in. (B) Raw data in the form of (x,y) point co-ordinates 
from MTrackJ were used to calculate different parameters of mitochondrial movement 
for each time point in Microsoft Excel (DFN, displacement from nucleus). 
 
 
Measurements for mitochondria in sub-confluent cells were obtained over two 
independent experiments (n cells: 10, n mitochondria: 73), whilst measurements for 
mitochondria in wound healing assays were obtained over three independent 
experiments (control cells: n [cells] = 18, n [mitochondria] = 202; mAPC-red cells: n 
[cells] = 18, n [mitochondria] = 189). Cells chosen for imaging in wound healing 
experiments were healthy, expressed modest GFP2-mito, did not show significant 
movement over the 5 min time period (visualised in DIC channel) and, for the mAPC-
red siRNA treated sample, displayed a clear red fluorescent signal. 
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5.2.6 Western blot analysis 
To confirm APC knockdown, cells were collected, lysed using RIPA buffer and 
processed as described in Section 2.2.9.1. Total cell lysate samples (~30 µg) were 
separated by SDS-PAGE using 5% acrylamide gels, and transferred onto a 
nitrocellulose membrane (see Sections 2.2.9.3-2.2.9.6). Western blots were probed as 
described in Section 2.2.9.7, using primary antibodies against APC (H290) and α-
tubulin. Dilutions for these antibodies, and subsequent secondary antibodies are outlined 
in Table 2.2 and Table 2.3 respectively. Immunoblots in this chapter were developed by 
ECL using the ChemiDoc Imaging System (See Section 2.2.9.8). 
5.2.7 Graphs and statistics 
All graphs and statistics used to display and analyse results in this chapter are outlined 
in Section 2.2.11. 
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5.3 Results 
5.3.1 Loss of APC slows cell migration 
APC plays a well-established and crucial role in cell polarity and migration (see Section 
1.2.1.3 and reviews 52, 53, 54) and loss of APC in mouse fibroblasts has previously 
been implicated in decreased membrane protrusion formation and cell migration (65).  
To confirm this, NIH 3T3 cells, which are known to display strong APC staining at 
microtubule-dependent protrusions (27), were treated with control or mouse APC-
specific (mAPC) siRNAs and grown to confluence. These cells were then wounded and 
5 h later fixed and analysed by immunofluorescence microscopy. In line with the 
findings by Kroboth and colleagues (65), a significant lag in cell migration was 
observed for mAPC siRNA treated cells in comparison to control (Figure 5.1), which 
appeared to correlate with a decrease in the number of cells with microtubule-dependent 
protrusions at the leading edge, and the presence of mitochondria in this region 
(described further in Section 5.3.2).  
 
 
Figure 5.1: Loss of APC slows cell migration in NIH 3T3 cells 
Cells treated with control or mAPC siRNA were grown to confluence and wounded. 
After 5 h of regrowth cells were stained with CMX-Ros Mitotracker, fixed, counter-
stained for APC (H290) and α-tubulin and analysed by immunofluorescence 
microscopy. 
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5.3.2 Mitochondrial localisation at extended cellular protrusions of 
actively migrating cells is significantly reduced upon loss of APC.  
Whilst APC may be well known to contribute to cell migration through its interactions 
with other key players like tubulin, actin, IQGAP1 and β-catenin, the importance of 
mitochondrial dynamics in cell migration is only just coming to light. Recent 
publications provide experimental evidence to show that regulated mitochondrial 
distribution is essential for proper migration of T lymphocytes (142), and that 
accumulation of mitochondria at the leading edge of epithelial breast and prostate 
cancer cells provides energy to drive cell migration (18, 19). Observations that 
mitochondrial localisation at the leading edge and cellular protrusions was lost upon 
knockdown of APC (Figure 5.1) led to further interrogation of mitochondrial staining 
patterns in this region. Detailed co-staining experiments revealed clearly that 
mitochondria co-localised with APC and its regulatory cell migration protein partners 
actin, IQGAP1, α-tubulin (microtubules) and β-catenin (Figure 5.2) at the leading edge 
of migrating NIH 3T3 cells, including at cell membrane protrusions. Mitochondrial co-
localisation at cell migratory regions with cell migration factors was also observed in 
human HDF1314 cells (Supplementary Figure S5.1) 
 
To further investigate the effect that loss of APC has on mitochondrial localisation in 
migratory cells at the cell periphery, confluent NIH 3T3 cells were treated with either 
control or mAPC siRNAs and subjected to a scratch wound assay. The cells were then 
fixed, stained for mitochondria, APC and α-tubulin and examined 5 h after regrowth 
(Figure 5.3A). Loss of APC caused a ~20% (P<0.01) reduction in the number cells with 
microtubule-dependent cellular protrusions at the leading edge of the wound (Figure 
5.3B), as well as the number of protrusions per cell (preliminary observations, data not 
shown), in agreement with previous findings (27). The remaining microtubule-
dependent protrusions in mAPC siRNA treated cells appeared to be shorter and less 
pronounced than their control siRNA treated counterparts and, mitochondrial 
localisation at the ends of these microtubules was found to decrease by >50% (P<0.001) 
after APC knockdown (Figure 5.3C). This mirrored prior results obtained in sub-
confluent cells (Figure 3.2). This APC-dependent alteration in mitochondrial 
localisation could potentially decrease the supply of energy to the cell membrane 
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required for cell migration, contributing to the observed slower rate of migration upon 
loss of APC (65, and confirmed in Figure 5.1). 
 
 
 
Figure 5.2: APC and mitochondria co-localise with components of the cell 
cytoskeleton at cell membrane protrusions in NIH 3T3 cells.  
Confluent NIH 3T3 cells wounded 5 h prior to fixation and stained with CMX-Ros 
Mitotracker were counter-stained using antibodies against APC (H290, green) and 
proteins involved in cell migration (actin, IQGAP1, α-tubulin and β-catenin, blue). 
Immunofluorescence microscopy of cells at the leading edge of the wound revealed 
colocalisation between mitochondria, APC and these cell migration factors as indicated 
by the arrows.  
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Figure 5.3: Loss of APC reduces mitochondrial localisation at cellular protrusions 
(A-C) NIH 3T3 cells treated with control or mAPC siRNA were grown to confluence 
and wounded. After 5h regrowth cells were stained with CMX-Ros Mitotracker, fixed, 
counter-stained for APC (H290) and α-tubulin and analysed by (A) 
immunofluorescence microscopy. Cells positive for APC knockdown are indicated by 
an asterisk (*). (B) Cells displaying cellular protrusions at the leading edge were scored, 
from which the (C) number of cells presenting mitochondrial localisation at these 
protrusions was determined. It was revealed that loss of APC significantly reduced the 
presence of mitochondria at cellular protrusions (indicated by arrows in panel A, and 
observed in greater detail in the zoom). Significant differences, determined using an 
unpaired T-test, are indicated (**, P<0.01; ***, P<0.001, % mean ± S.D).  (D) APC 
knockdown was confirmed by western blot analysis.   
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5.3.3 Optimisation of imaging mitochondria movement in living cells 
The above results in fixed cells and findings in previous chapters support a role for 
APC/Miro/Milton in microtubule-based mitochondrial transport towards the cell 
periphery. To investigate more directly whether APC stimulates the actual rate of 
transport of mitochondria, live cell imaging was employed to determine what impact 
loss of APC had on real time movement of mitochondria within the cell. Mitochondrial 
transport has traditionally been studied in neuronal cell lines, in the context of 
neurological disorders. Research in other cell types is limited and as a result, much of 
the mitochondrial tracking protocol had to be optimised from the outset. Firstly, as the 
study was to focus on mitochondrial transport to the leading edge in cell migration it 
was decided that a fibroblastic cell line would be used as they are ideal for wound 
healing assays, and because the mitochondria are spread out towards the protrusions 
allowing for easier tracking. NIH 3T3 cells were chosen because they are less sensitive 
to toxicity than human HDF1314 cells and as previous experimental data had already 
been collected in this cell line (Figure 5.1-Figure 5.3). Additionally, a study of 
mitochondrial transport had already been conducted in sub-confluent NIH 3T3 cells by 
another group (177), allowing for comparison of methodology and baseline transport 
results (Figure 5.4). Once optimisation in sub-confluent cells was complete, this method 
was further optimised for wound healing assays.   
5.3.3.1 Visualisation of mitochondria and image capture 
The next step was to select a marker for the visualisation of mitochondria in a live cell 
setting. Several markers, outlined in Table 5.1, were tested prior to GFP2-Mito 
selection. The interval between each time point was based on the minimum time 
required for the Olympus IX71 DeltaVision core microscope to undertake image 
capture. Initial experiments used a 5 s interval, which had to be increased to 7 s 
following external alterations to the DeltaVision settings.  
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Table 5.1: Selection of mitochondrial marker for live cell imaging 
Sub-confluent NIH 3T3 cells either transfected with 400 ng of pGFP-Mito, pGFP2-Mito 
or pTomato-Mito plasmid or stained with CMX-Ros Mitotracker (1:10000) or Green 
Mitotracker (1:5000) were subjected to live cell imaging as described in Section 5.2.5. 
Mitochondria in 4-5 cells were imaged for each marker. 
 
Marker Fluorescence Stability 
Mitochondrial 
Visualisation 
Toxicity 
GFP-Mito 
Moderate, most 
mitochondria visible to at 
least 5 min, though 
resolution poor. 
Normal at low-
moderate 
transfection levels. 
Cells look 
moderately healthy 
after image capture. 
GFP2-Mito 
Good, most mitochondria 
visible to at least 5 min 
and resolution ok. 
Normal at low-
moderate 
transfection levels. 
Cells look 
moderately healthy 
after image capture. 
Tomato-
Mito 
Poor, can no longer 
visualise after 3 minutes. 
Bright, covered in 
fluorescent dots 
which do not look 
like mitochondria. 
Cells look 
moderately healthy 
after image capture. 
CMX-Ros 
Mitotracker 
Very good, all 
mitochondria visible to at 
least 5 min (if cells do not 
die) and resolution good. 
Normal Cells often die prior 
to completion of 
image capture. 
Green 
Mitotracker 
Good, most mitochondria 
visible to at least 5 min 
and resolution good. 
Normal Cells do not look 
healthy after image 
capture. 
 
5.3.3.2 Optimisation of transfection in cells at 90% confluence 
Transfection of pGFP2-Mito for live cell imaging in sub-confluent cells was performed 
under standard conditions using PEI (Section 2.2.3.4), however difficulty was 
encountered when transfection of pGFP2-Mito was required for live cell imaging of 
wounded cells pre-treated with siRNAs. In order to reach confluence, cells needed to be 
treated with siRNAs at a higher confluence (70-75%) than normal, which meant that 
transfection occurred when the cells were verging on 90% confluence. Under standard 
conditions, this resulted in an extremely low rate of transfection. A number of reagents 
were tested (Section 2.2.3.4), before the K2 transfection system was chosen (Table 5.2).  
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Table 5.2: Selection of transfection reagent for live cell imaging in wound healing 
assays 
NIH 3T3 cells pre-treated with mAPC-red siRNA were transfected with 400ng pGFP-
Mito using the K2 transfection system. Cells were examined for transfection level of 
GFP2-Mito and the ability of the cells to reach confluence.  
 
Reagent Transfection Level Toxicity 
Lipofectamine No cells transfected. High, cells could not reach confluence. 
Fugene No cells transfected. Low. 
PEI 
5% of cells transfected. Low-moderate, cells could not reach 
confluence. 
K2 60% of cells transfected Low. 
 
5.3.4 Measurements of mitochondrial velocity in sub-confluent NIH 
3T3 cells are comparable to those in the literature 
Mitochondria were visualised in live NIH 3T3 cells following expression of a GFP2-
tagged mitochondrial peptide marker (pGFP2-Mito) and the use of time lapse imaging 
by DeltaVision live cell microscopy to track the mitochondria (Supplementary Figure 
S5.2). The optimised methodology was as described (Section 5.2.5) and tracking was 
generally performed over a 5 min period. Analysis of the acquired image data indicated 
that motile mitochondria moved with an average velocity of 10.06 µm/min. Whilst this 
is only ~45% of the speed reported in YFP-transfected control cells by Patil and 
colleagues (Table 5.3), it is still within the same order of magnitude. There are several 
variations in cell culture and transfection conditions, image acquisition and data analysis 
that could contribute to this difference in velocity. 
 
Analysis of other parameters (see Table 5.3) revealed that 75.61% of mitochondria were 
motile; this characteristic is presented as either directed movement (anterograde or 
retrograde) or oscillatory movement with no net displacement (oscillatory = 38.10%, 
anterograde = 26.19%, retrograde =9.52%). The average distance travelled (distance 
travelled over tracking time), and net displacement (distance between start-point and 
end-point), of a mitochondrion over 1 min was found to be 3.41µm and 0.83µm 
respectively, the latter of which is comparable to that found by Patil and colleagues 
(1.11µm). 
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Table 5.3: Optimised mitochondrial tracking in sub-confluent NIH 3T3 cells 
Mitochondria in sub-confluent 3T3 cells transfected with pGFP2-mito, were tracked 
using MTrackJ ImageJ plug-in. From the raw tracking data, Microsoft Excel was used 
to calculate movement parameters of randomly selected mitochondria. Displacement is 
measured as the net distance between start-point and end-point. Distance refers to total 
distance travelled during the time period measured. This data was compared to data 
from control cells in a pre-existing study by Patil et al., 2013 (177).  
 
Overall Mitochondrial Movement  Optimised Patil 2013 
% motile mitochondria  75.61 ± 2.55  
% directionality 
Stationary 26.19 ± 2.55  
Oscillating 38.10 ± 1.85  
Anterograde 26.19 ± 4.83  
Retrograde 9.524 ± 9.23  
Average Displacement (µm)  
(normalised to 1 min) 
 0.83 ± 0.03 1.11 
Average Distance (µm)  
(normalised to 1 min) 
 3.41 ± 0.10  
Motile Mitochondria  Optimised Patil 2013 
Average Velocity (µm/min)* 
*does not include stationary time points 
Total 10.06 ± 2.53 22.8 
Anterograde 10.32 ± 3.29 23.4 
Retrograde 9.86 ± 2.85 22.2 
 
5.3.5 Loss of APC decreases initiation of mitochondrial transport 
The above methodology was adapted to investigate facets of mitochondrial transport in 
actively migrating cells. NIH 3T3 fibroblasts treated with control or a red fluorescently 
tagged mAPC (mAPC-red) siRNA, were transfected with pGFP2-Mito and then grown 
to confluence and wounded. Following 5 h regrowth, cells were subjected to timelapse 
imaging by DeltaVision live cell microscopy after which mitochondria at the leading 
edge were tracked and analysed for several transport parameters over 5 min intervals 
(see Figure 5.4), as described in Section 5.2.5. 
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Figure legend over page. 
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Figure 5.4: Loss of APC reduced the initiation of anterograde mitochondrial 
transport in NIH 3T3 cells.  
NIH 3T3 cells were treated with either control or fluorescently tagged mAPC siRNA 
(mAPC-red), transfected with a fluorescently tagged mitochondrial marker (pGFP2-
Mito) and grown to confluence. Cells were wounded and 5 h later analysed by live cell 
time lapse imaging, capturing images every 7 s for a total of 5 min. Post image 
acquisition, mitochondria were selected at random for tracking manually using the 
ImageJ plug-in MTrackJ. Representative cell images are shown for ~1 min of tracking. 
Mitochondria are marked for different types of movement: stationary/oscillating 
(yellow), anterograde (green) and retrograde (red). APC silencing is indicated by red 
fluorescence. 
 
The most striking observation revealed from analysis of the timelapse images was that 
loss of APC caused a dramatic decrease (~2.3 fold reduction, P<0.01) in the overall 
motility of mitochondria (see cell images in Figure 5.4 and graphs in Figure 5.5A). 
Under control conditions, mitochondria were motile 48.4% of the time, whilst in 
comparison, only 21.3% of cells transfected with mAPC siRNA were motile. A more 
detailed analysis revealed that whilst oscillatory movements remained relatively 
constant following APC knockdown, directed mitochondrial transport was severely 
diminished. In cells targeted by the mAPC-red siRNA, the frequency of mitochondria 
displaying anterograde transport dropped significantly from 24.3% to 7.0% (P<0.05, 
Figure 5.5B). A decrease in mean retrograde transport from 8.7% to 1.7% was also 
observed, however this was not found to be significant (P>0.05, Figure 5.5B). As 
expected, the proportion of stationary cells increased after loss of APC from 49.9% to 
78.7% (P<0.01, Figure 5.5B). 
 
In line with these results, silencing of APC also significantly decreased the frequency of 
distinct mitochondrial movements (directional movement without pause) by ~50% in 
both anterograde and retrograde directions (P<0.01, Figure 5.5C). Furthermore, the 
average mitochondrial displacement and average distance travelled over the observed 
time period also significantly decreased (P<0.01, Figure 5.5D-E). These findings 
suggest that APC has a role in the initiation of long range, directed mitochondrial 
transport in migrating cells. These results are summarised in Table 5.4 and Figure 5.5, 
and reflected in the tiled cell images (Figure 5.4) and the time lapse movies 
(Supplementary Video 5.1 and 5.2) that compare control and mAPC siRNA treated NIH 
3T3 cells.  
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Table 5.4: Effect of APC loss on parameters of mitochondrial transport in 
migrating NIH 3T3 cells 
Mitochondria in migrating NIH 3T3 cells treated with control or mAPC-red and 
transfected with pGFP2-mito, were tracked using the MTrackJ ImageJ plug-in. From 
the raw tracking data, Microsoft Excel was used to calculate movement parameters of 
randomly selected mitochondria. A distinct mitochondrial movement is classified as any 
directional motion without pause. Significance determined by unpaired T-test (*, 
P<0.05; **, P<0.01; n.s., not significant). 
 
Overall Mitochondrial Movement  Control mAPC1 P-Value 
% motile mitochondria  48.44 ±5.92 21.25 ±5.32 ** 
% directionality 
Stationary 49.91 ±7.47 78.76 ±5.32 ** 
Oscillating 17.08 ±7.29 12.50 ±4.00 n.s. 
Anterograde 24.30 ±8.43 7.03 ±3.39 * 
Retrograde 8.74 ±5.43 1.70 ±1.49 n.s. 
Average Displacement (µm) 
(normalised to 1 min) 
 1.19 ±0.11 0.67 ±0.16 ** 
Average Distance (µm)  
(normalised to 1 min) 
 3.19 ±0.14 2.10 ±0.20 ** 
Motile Mitochondria  Control mAPC1 P-Value 
Average Velocity (µm/min)* 
*does not include stationary time points 
Total 9.27 ±0.39 8.82 ±0.57 n.s. 
Anterograde 8.98 ±0.19 8.99 ±0.26 n.s. 
Retrograde 10.13 ±0.76 8.75 ±0.97 n.s. 
Average Distinct Mitochondrial 
Movements  
Anterograde 0.23 ±0.03 0.13±0.07 ** 
Retrograde 0.15 ±0.04 0.09±0.03 ** 
Average Distance of  Mitochondrial 
Movements (µm) 
Anterograde 1.35 ±0.20 1.22 ±0.16 n.s. 
Retrograde 1.39 ±0.18 1.16 ±0.25 n.s. 
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Figure 5.5: Loss of APC disrupts mitochondrial motility 
(A-E) Analysis of mitochondrial tracking data from time lapse microscopy performed in 
wounded NIH 3T3 cells transfected with control or mAPC siRNA (Figure 5.4) was 
performed in Microsoft Excel from output generated by Image J plug-in MtrackJ. 
Analysis of mitochondrial motility revealed that loss of APC resulted in (A) decreased 
mitochondrial transport, particularly in the (B) anterograde direction. This correlated 
with a decrease in the (C) number of runs (mitochondrial movements without pause or 
change in direction) mitochondria made per min and a decrease in both (D) the 
displacement and (E) distance (m, normalized to 1 min to account for different 
tracking periods) travelled over the tracking period following loss of APC. Significance, 
as determined by unpaired T-tests, indicated (*, P<0.05; **, P<0.01; n.s., not 
significant, % mean ± S.D). 
 
 
5.3.6 Loss of APC does not slow the rate of mitochondrial transport 
Somewhat surprisingly, analysis of live cell data from the same experiment revealed 
that loss of APC did not significantly slow the overall rate of mitochondrial transport 
once movement had been initiated (control siRNA = 9.27 ±0.39 µm/min, mAPC-red 
siRNA = 8.82 ±0.57 µm/min, P>0.05; see Figure 5.6A, and for further details 
Supplementary Figure S5.3). This lack of difference was also reflected in the average 
velocities of transport in both anterograde and retrograde directions (Figure 5.6A). 
Furthermore, the average distance travelled during these distinct mitochondrial 
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movements (directional motion of mitochondria without pause) was not significantly 
altered by silencing of APC (Figure 5.6B). These results are summarised in Table 5.4. 
Collectively, this data suggests a specific role for APC in stimulating the initiation of 
Miro/Milton driven mitochondrial transport, rather than its ongoing velocity. 
 
 
 
 
Figure 5.6: Loss of APC has no effect on mitochondrial velocity once transport is 
initiated  
(A-B) Analysis of mitochondrial tracking data from time lapse microscopy performed in 
wounded NIH 3T3 cells that were transfected with control or mAPC siRNA (Figure 5.4) 
was performed in Microsoft Excel from output generated by Image J plug-in MtrackJ. 
Analysis of the rate of mitochondrial movement after transport had been initiated 
revealed that (A) mitochondrial velocity (m/min) remained static following APC 
knockdown, as did the (B) distance (m) individual mitochondria travelled (runs). 
Significance relative to control siRNA, determined using an unpaired T-test, is indicated 
(n.s., not significant, % mean ± S.D).  
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5.4 Discussion 
The results shown here indicate that APC is required for initiation of anterograde 
mitochondrial transport, thereby explaining the loss of mitochondrial localisation from 
cellular protrusions in actively migrating cells following APC silencing. These findings 
also explain the previously observed net shift in mitochondria away from the cell 
periphery in APC siRNA treated sub-confluent cells, which was shown to correlate with 
interaction between APC and the Miro/Milton mitochondrial transport complex. 
 
Recent studies that link mitochondrial localisation to cell migration suggest a new role 
for APC in regulating mitochondrial transport and subsequently supplying ATP to the 
cell membrane. This hypothesis could, in part, explain the decrease in protrusion 
formation and cell migration observed here and elsewhere when APC is silenced (27, 
65). C-terminal truncating APC mutations were previously (Chapter 4) shown to disrupt 
APC binding to Miro/Milton, and in turn mitochondrial transport. The potential impact 
of this on anterograde transport initiation and in turn cell migration and polarity will be 
discussed. 
5.4.1 APC appears to stimulate the initiation, rather than the velocity, 
of anterograde mitochondrial transport  
Live cell imaging data suggests a specific role for APC in the initiation of mitochondrial 
transport, rather than modulation of the rate of kinesin motor–driven translocation. 
Support for this notion primarily comes from the finding that siRNA silencing of APC 
in actively migrating NIH 3T3 cells decreased the total pool of motile mitochondria 
from 48.4% to 21.3%, whilst the velocity of the motile pool remained stable. 
Furthermore, decreased mitochondrial movement following loss of APC correlated 
directly with a drop in the incidence of distinct mitochondrial movements, and a 
decrease in mitochondrial net displacement and distance travelled over the tracking time 
period. Treatment with mAPC siRNA elicited no change in the distance travelled by 
mitochondria after transport had commenced, further indicating a very specific role for 
APC in initiation of mitochondrial transport. These results are summarised in Figure 
5.5, Figure 5.6 and Table 5.4. 
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A role for APC in “kick-starting” mitochondrial movement makes sense in the context 
of what is currently known about the mechanism of Miro/Milton-driven transport. In 
fact, there is evidence that Miro/Milton complexes function in the same way by 
stimulating mitochondrial transport initiation rather than velocity. For instance, when 
investigating Milton-1 in the axons of hippocampal pyramidal neurons, Brickley and 
Stephenson (154) observed that knockdown of Milton-1 gene expression diminished the 
pool of motile mitochondria from 36% to 16%, whilst the velocity of motile 
mitochondria remained unaltered. Moreover, silencing of Alex3, a newly discovered 
regulator of the Miro/Milton complex, also reduced mitochondrial motility but had no 
effect on velocity (163), a phenomenon likewise observed upon disruption of Miro (152, 
153). In these cases, as observed here for APC, the loss of Milton, Miro or Alex3 each 
caused a decrease in anterograde transport of mitochondria, supporting the view that 
APC is a positive regulator of the Miro/Milton/KIF5 complex. 
 
The mitochondrial motility pool most affected by mAPC siRNA treatment was that of 
anterograde transport, where mitochondrial movement decreased from 24.3% to 7.0%. 
Whilst the data from live cell analysis also indicated that the pool of mitochondria 
moving in a retrograde direction was diminished following loss of APC, this was not 
found to be statistically significant. Interestingly, both Miro (167, 168) and Milton (169) 
have been implicated in retrograde mitochondrial transport through interactions with the 
dynein motor, an association which may occur separately from APC. The mild 
alteration in retrograde transport may be due to disruption of bidirectional transport 
which has been reported to interfere with crosstalk between different motor protein 
complexes (304). Oscillatory transport movements remained static after APC silencing, 
suggesting an alternate mechanism of transport to the microtubule-dependent 
Miro/Milton system, perhaps one which is actin-based. This is in agreement with the 
notion that short-range mitochondrial transport is typically mediated by actin-motors 
(170, 171).  
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5.4.2 APC stimulates transport of mitochondria to cell membrane 
protrusions and the leading edge: Implications for cell migration. 
APC is known to regulate cell migration and polarity through specific processes such as 
promotion of F-actin assembly, centrosome re-orientation and microtubule stabilisation 
and anchoring (Section 1.2.1.3 and reviews 52, 54). These are primarily facilitated 
through APC at the cellular periphery, in particular at membrane protrusions. Recently, 
mitochondrial localisation to membrane structures such as protrusions in epithelial cell 
lines has also been found to contribute to cell migration and polarity. In this study, 
image analysis of migrating NIH 3T3 cells revealed colocalisation between APC and 
mitochondria at these membrane protrusions (Figure 5.2), suggesting a link between the 
two pathways and a potential novel mechanism through which APC may contribute to 
cell migration and polarity. 
 
In agreement with prior studies (27), loss of APC in migrating cells caused a ~20% 
reduction in the number of cells displaying protrusions (Figure 5.3B). Of those 
remaining protrusions which appeared noticeably smaller in size, a >50% depletion in 
mitochondrial co-localisation was observed (Figure 5.3C) indicating disrupted 
mitochondrial transport to the cell periphery, agreeing with previous results in sub-
confluent cells (Figure 3.2) and findings that APC loss impairs anterograde transport 
(Figure 5.5B). Previously, Desai and colleagues (18) showed that siRNA silencing of 
Miro-1 reduced mitochondria at the leading edge in MDA-MB-231 breast cancer 
epithelial cells correlating with a ~3-fold decrease in speed and directional persistence 
of cells. In the same cell line, Zhao and colleagues (19) found that blocking 
mitochondrial distribution to the leading edge reduced the size of lamellipodia in cells 
by 60%, in turn significantly slowing cell migration. This phenomenon is not limited to 
epithelial cell lines, as Campello and colleagues (142) showed that by blocking 
mitochondrial transport to the uropod, the primary migratory structure in T-cell 
lymphocytes, cell polarisation was disrupted and cell migration was reduced by >80%.  
 
Regulated cell migration requires movement at the membrane primarily mediated 
through remodelling of the actin network, and also direction (polarity) which is largely 
dependent on the microtubule network. This cytoskeletal remodelling is a 
bioenergetically demanding process, and studies by Campello, Desai and Zhao (18, 19, 
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142) indicate that mitochondria are targeted to cell migratory regions to provide the 
ATP necessary to fulfil these energy requirements (discussed further in Section 5.4.2.1). 
 
Mitochondrial contact with the cell periphery is also essential for extracellular calcium 
uptake (190), where increased [Ca
2+
]i has been shown to contribute to cell migration 
through a number of Ca
2+
 signalling pathways, contributing to focal adhesion turnover, 
actin assembly and migration directionality (reviewed in 292). In a similar manner to 
the targeted release of ATP from mitochondria, liberation of Ca
2+
 from mitochondrial 
stores, and conversely intracellular Ca
2+
  uptake, may also alter [Ca
2+
]i at the leading 
edge. Hence, APC may stimulate the membrane-directed provision of ATP and calcium 
through regulation of mitochondrial localisation. 
5.4.2.1 APC may target mitochondrial ATP to cellular protrusions and the leading edge 
to supply energy for cell migration 
The cytoskeletal remodelling that occurs in cell migration is a bioenergetically 
demanding process which is highly dependent on a constant supply of ATP (64).  Like 
other metabolites, ATP is known to accrue in microcompartments with its substrates in 
numerous areas of the cell, including the cytoskeleton where the actin and microtubule 
networks, along with numerous scaffolding proteins, create mechanical barriers to 
prevent diffusion of ATP away from target sites (reviewed in 305, 306). This function is 
facilitated by targeted localisation of mitochondria to directly supply ATP to the 
microcompartment, rather than non-specific ATP diffusion through the cytoplasm. A 
localised concentration of mitochondria allows for faster generation of ATP after 
hydrolysis through recycling of ADP back into the mitochondria for oxidative 
phosphorylation, thereby providing a continuous supply of ATP. There it is likely to 
represent a primary energy source for actin and microtubule polymerisation during cell 
migration. 
 
The polymerisation of actin subunits into F-actin mechanistically pushes the cell 
membrane forward, causing it to expand in a process catalysed by ATP hydrolysis. 
Indications that the ATP required is mitochondrial in origin come from several studies.  
In particular, uncoupling of ATP synthesis by CCCP (Carbonyl cyanide m-chlorophenyl 
hydrazone) treatment was shown to decrease F-actin polymerisation, and as a result 
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reduced lamellipodia formation in MDA-MB-231 breast cancer cells, correlating with a 
slowing of cell migration (19). This mirrors results described in T-cell lymphocytes, 
where uncoupling of ATP synthesis also reduced the rate of cell migration (142), 
however, in that study impaired migration was not attributed to altered actin 
polymerisation, but rather to an inability to activate the ATPase activity of myosin II, 
which is required for the contraction of the actin network. Thus mitochondrial ATP is 
required to catalyse a range of processes that drive cell migration. 
 
Evidence that mitochondrial ATP is required for microtubule polymerisation in the 
formation of cellular protrusions is less well defined. Findings in this chapter show that 
APC-siRNA dependent loss of mitochondria from the cell membrane correlated with a 
decrease in the number and size of protrusions (Figure 5.3). This data, combined with 
the known efficiency of mitochondrial ATP microcompartment formation suggest that 
APC may contribute to protrusion formation not only through its ability to stabilize 
microtubule bundles (70) but perhaps also via delivery of mitochondrial ATP. As 
previously described (Section 1.2.1.3), APC localises to and regulates the microtubule 
and actin networks. This raises the possibility that once APC delivers mitochondria to 
the cell periphery, it may also act as an anchor to tether mitochondria to these energy-
demanding sites, assisting in the formation of ATP microdomains. These mitochondria 
could work in synergy with APC’s other roles and act like a battery to provide a highly 
specific localised source of ATP. 
5.4.3 APC mutation may contribute to aberrant cell migration in CRC 
through disruption of mitochondrial transport 
The loss of mitochondria at the leading edge of actively migrating cells, as described in 
Section 5.4.2, deprives this region of metabolites required for effective membrane 
dynamics and motility. In Chapter 4 it was shown that APC interaction with the 
Miro/Milton mitochondrial complex was diminished in APC-mutant CRC cell lines, 
resulting in a perinuclear mitochondrial clustering similar to that observed when wild-
type APC is silenced. Given that the binding domains for Miro/Milton and numerous 
cytoskeletal binding domains are lost upon APC mutation, it makes sense that APC 
truncation affects mitochondrial targeting to the membrane. The impact of APC 
mutations on migration may not, however, always mimic that observed by complete loss 
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of APC. For instance, Kawasaki and colleagues (73) reported that C-terminal truncated 
APC mutants exhibit a gain of function to constitutively activate the Rac1 exchange 
factor ASEF in colon cancer cell lines, leading to modest stimulation of cell migration 
through regulation of actin. More recent studies (96) however, indicate that APC 
truncations most often cause erratic cell movement due to loss of polarity and 
directionality, and this is thought to be due to reduced APC-dependent formation of 
membrane protrusions, and may also be affected by loss of targeted mitochondria.  
 
Perturbations in mitochondrial transport are linked to aberrant cell migration in 
carcinogenesis (18, 19). These studies indicate that mitochondria in invasive breast and 
prostate cancer cell lines preferentially cluster at the leading edge, contributing to 
increased migration speed and invasion. Disruption of anterograde mitochondrial 
transport (described in Section 5.4.2), attenuated these invasive properties and slowed 
cell migration, and similar principles are likely to apply to a range of other cell types 
and tissues. Cells in the gut are highly proliferative and over the course of 3-5 days, 
following generation at the base of the colon crypt, they migrate upwards undergoing 
several phases of differentiation before they are shed or undergo apoptosis. 
 
 Whilst little is known about the mechanisms of colon crypt migration, experiments in 
APC (Min/+) mice (99) and inducible APC knockout mice (66), demonstrated a slowing 
of cell migration along the crypt-villus axis. In addition, Nelson and colleagues (96) 
reported that expression of truncated APC caused a loss in directional cell migration 
towards the tip of colon crypt villi. These effects were attributed to a loss of APC 
cytoskeletal regulation, however, results from this thesis support an additional 
contribution through loss of APC-dependent mitochondrial targeting. Retention of cells 
in the lower zone of colon crypts is observed and favourable in CRC as this region is 
highly proliferative. Retention also increases the opportunity to acquire further selective 
advantages, particularly given the toxic, DNA-damaging environment of the gut.   
 
In APC-mutant CRC cells, some of the metabolic demands at the periphery could still 
be met by mitochondria reaching the membrane through the action of other 
mitochondrial transport pathways (Section 1.3.2.2), however as outlined in Section 
5.4.2.1, the localisation and interaction of APC with elements of the cytoskeleton is 
likely to specifically anchor mitochondria to these regions. Similarly, energy provided 
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by glycolysis in the cytoplasm, known to be substantially heightened in mutant APC 
CRC cells (14), would not be an effective energy source.  
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5.5 Supplementary Figures 
 
Supplementary Figure S5.1: Mitochondria co-localise with components of the cell 
cytoskeleton at cell membrane protrusions in HDF1314 cells 
Confluent HDF1314 cells were wounded 5 h prior to fixation and counterstained with 
CMX-Ros Mitotracker, Hoechst and antibodies against proteins involved in cell 
migration (APC, actin, α-tubulin and IQGAP1). Analysis by immunofluorescence 
microscopy of cells at the leading edge of the wound indicated colocalisation between 
mitochondria and the cell migration factors. 
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Supplementary Figure S5.2: Mitochondrial tracking in sub-confluent NIH 3T3 
cells 
Sub-confluent cells expressing GFP2-Mito were subject to live cell, time lapse imaging 
every 5 s for a total of 5 min. Post acquisition, randomly selected mitochondria were 
manually tracked using ImageJ plug-in MTrackJ. Representative images from ~2 min of 
mitochondrial tracking are shown (mitochondrial tracks indicated in blue).  
 
 
 
 
 
Supplementary Figure S5.3: Loss of APC does not alter mitochondrial transport 
velocity in 3T3 cells 
No difference in transport velocity was observed for cells transfected with either control 
siRNA or mAPC1-red siRNA when GFP2-labelled mitochondria were tracked using 
MTrackJ. 
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5.6 Supplementary Videos 
Note for videos 
These videos are best viewed full screen, in high definition. The diagram below 
indicates how to alter these parameters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Video 5.1: NIH 3T3 cell transfected with pGFP2-Mito and control 
siRNA 
 
Please view Supplementary Video 5.1 by following this link: 
http://tinyurl.com/KateMillsVideo5-1 
 
NIH 3T3 cells were treated with control siRNA and transfected with a fluorescently 
tagged mitochondrial marker (pGFP2-Mito) whilst being grown to confluence. Cells 
were wounded and 5 h later analysed by live cell time lapse imaging, capturing images 
every 7 s for a total of 5 min, utilising the FITC and DIC channels over 3 focal planes 
(z-stack) . Post image acquisition, mitochondria were selected at random for tracking 
manually using the ImageJ plug-in MTrackJ.  The middle plane from the z-stack 
acquired was compressed into an AVI file using ImageJ at a rate of 5 frames per second. 
The video shows GFP2-mito (FITC) with and without MTrackJ tracking data on the left 
and middle respectively, as well as the cell periphery and nucleus imaged using white 
light (DIC) on the right. 
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Supplementary Video 5.2: NIH 3T3 cell transfected with pGFP2-Mito and mAPC-
red siRNA 
 
Please view Supplementary Video 5.2 by following this link: 
http://tinyurl.com/KateMillsVideo5-2 
 
NIH 3T3 cells were treated with mAPC-red (here labelled mAPC1-555) siRNA and 
transfected with a fluorescently tagged mitochondrial marker (pGFP2-Mito) whilst 
being grown to confluence. Cells were wounded and 5 h later analysed by live cell time 
lapse imaging, capturing images every 7 s for a total of 5 min, utilising the FITC and 
DIC channels over 3 focal planes (z-stack) . Post image acquisition, mitochondria were 
selected at random for tracking manually using the ImageJ plug-in MTrackJ.  The 
middle plane from the z-stack acquired was compressed into an AVI file using ImageJ 
at a rate of 5 frames per second. The video shows GFP2-mito (FITC) with and without 
MTrackJ tracking data on the left and middle respectively, as well as the cell periphery 
and nucleus imaged using white light (DIC) on the right. 
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Previous chapters established a novel role for APC in the initiation of anterograde 
mitochondrial transport facilitated through its association with the Miro/Milton 
transport complex (Chapters 3 and 5). APC binds Miro/Milton via its far C-terminal 
end, supporting the impaired mitochondrial transport observed in CRC cell lines 
expressing mutant truncated APC (Chapter 4). In this chapter, the mechanism through 
which APC interacts with the Miro/Milton complex to regulate transport is investigated 
in more detail. A series of binding studies to investigate interactions between proteins in 
the mitochondrial transport complex were conducted in U2OS (wild-type APC) and 
SW480 (APC 1-1337) cell lines. Analysis found that the knockdown of wild-type APC 
in U2OS cells, or expression of mutant APC in SW480 cells, compromised the binding 
between Miro and Milton. In comparison, the interaction between Milton and KIF5 
remained intact. These results suggest that APC mediates the association between Miro 
and Milton, potentially acting as a scaffold, whilst C-terminal deletion of APC inhibits 
complex formation and as a result disrupts mitochondrial transport. Additional 
experiments indicate that the involvement of APC in mitochondrial transport is 
independent of calcium modulation.  
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6.1 Introduction 
The anterograde shuttling of mitochondria by the Miro/Milton transport complex is a 
dynamic pathway essential to maintain the morphology, number and distribution of 
mitochondria.  As previously described (Section 1.3.2.1 and Figure 1.5), the transport 
complex consists of Miro, a mitochondrial transmembrane protein which attaches the 
mitochondria to the KIF5 kinesin motor protein through an adaptor protein, Milton 
(148-150). The roles of mitochondria in ATP production and calcium buffering are very 
site-specific (see Section 1.3.2.3). As such, fine regulation of mitochondrial distribution 
is required to respond to the constantly changing conditions within the cell, as reflected 
by the growing number of signalling pathways shown to directly affect and modify 
components of the Miro/Milton complex (Section 1.3.2.1). Many of these signalling 
pathways have yet to be fully elucidated, therefore defining the regulatory role of the 
novel Miro/Milton partner APC, a known protein scaffold (9, 12) which has a vast array 
of binding partners, may provide a stepping stone for further investigation. 
 
Post-translational modification is one mode through which the Miro/Milton complex is 
regulated. For example, following localised increases in glucose concentration, rapid 
ATP production is induced and mitochondrial transport is reported to be suspended 
through the O-GlcNAcylation of Milton by the metabolic sensor O-linked N-
acetylglucosamine transferase (OGT) (156). Miro is also susceptible to post-
translational modification via PINK1/Parkin dependent pathways which inhibit 
mitochondrial transport by promoting the phosphorylation  (152, 157) and subsequent 
poly-ubiquitination of Miro, which in turn leaves it susceptible to proteasomal 
degradation (165, 166) (for further details on post translational modifications see 
Section 1.3.2.1). 
 
A number of well-known signalling pathways and molecules also regulate 
mitochondrial transport. In particular, intracellular calcium concentrations modulate 
stability of the Miro/Milton complex, reflecting a role for mitochondria in calcium 
buffering (see Section 1.3.1.2). When intracellular calcium levels are elevated, calcium 
binds to a pair of EF-hand motifs located in the middle region of Miro, arresting 
mitochondrial transport. Whilst the exact mechanism by which this occurs is 
controversial (Section 1.3.2.1), calcium binding appears to cause a conformational 
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change in the complex, resulting in dissociation of the mitochondria from microtubules 
(153, 159). Additionally, hypoxia and the non-canonical Wnt signalling pathways have 
also been implicated in the regulation of mitochondrial transport through the HUMMR 
(304) and Alex3 (161, 163) proteins, respectively.  
 
This chapter investigates the mechanism through which APC stimulates anterograde 
mitochondrial transport, and supports a role for APC as a scaffold in assembly of the 
Miro/Milton mitochondrial transport complex. It is also shown that despite existing 
reports in the literature indicating that the association of APC with microtubules is 
calcium dependent (298), modulation of calcium did not alter the localisation of APC at 
mitochondria, or its interaction with calcium-sensitive Miro, in the experimental settings 
used here.  
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6.2 Methods 
6.2.1 Cell culture 
U2OS osteosarcoma and SW480 adenocarcinoma cells were cultured in DMEM under 
standard conditions as outlined in Section 2.2.3. For co-localisation experiments, cells 
were seeded on glass cover slips in 6 well trays, and for Duolink PLA experiments, cells 
were seeded in 8-well chamber slides coated with poly-L-lysine. Cells were grown to 
70-80% confluence prior to fixation. For live cell experiments, cells were seeded in 2-
well chamber slides coated with poly-L-lysine and grown to 70-80% confluence. For 
western blotting experiments, cells were seeded into 150 cm
2
 flasks for 
immunoprecipitation assays and 25 cm
2
 flasks for siRNA knockdown experiments. For 
more details see Section 2.2.3.1. The transfection of plasmids and siRNAs for transient 
expression or gene silencing in cells is described in Section 2.2.3.4. In Duolink PLA 
assays utilising GFP-tagged constructs, the amount of plasmid transfected was 
significantly reduced (for more details see 2.2.8.4).  
6.2.2 Drug Treatments 
Under sterile conditions, sub-confluent cells were treated with calcimycin (the calcium 
ionophore A23187, used to increase intracellular calcium) (20 µM) or DMSO (vehicle) 
for 5 min at 37°C prior to subsequent experimentation as outlined in Section 2.2.3.5 and 
Table 2.7. 
6.2.3 Cell fixation and staining for immunofluorescence microscopy 
Cells were seeded for at least 24 h, fixed with methanol-acetone, probed with relevant 
antibodies and mounted for immunofluorescence microscopy as outlined in Section 
2.2.4. If addition of CMX-Ros for detection of mitochondria was required this occurred 
prior to fixation. Concentrations and any further specifications for all antibodies and 
dyes used in this chapter are outlined in Table 2.2, Table 2.3 and Table 2.4. 
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6.2.4 Immunofluorescence cell image acquisition and processing 
Slides were analysed using the Olympus IX71 DeltaVision Core deconvolution 
microscope equipped with a CoolSNAP HQ
2
 camera for general image capture. Images 
collected were further resolved using SoftWorx deconvolution software. For co-
localisation experiments 200 cells were scored over 2 independent experiments. 
Analysis of Duolink PLA experiments is further described in Section 6.2.8. 
6.2.5 Live cell imaging acquisition and analysis 
Live cell imaging was performed using the Olympus IX71 DeltaVision system (above) 
for image capture at 40x. During imaging, U2OS cells stained with Mitotracker CMX-
Ros (1:10000, 15 min), treated with either calcimycin or DMSO were maintained at 
37°C and 5% CO2. Cells were imaged every 5 s for 2 min. Confirmation that calcimycin 
treatment decreased mitochondrial transport was obtained from observation of two 
independent experiments (n cells: 5-8 per condition). Cell data was obtained between 5 
and 15 min post calcimycin or DMSO treatment. 
 
6.2.6 Immunoprecipitation assays 
U2OS cells treated with control or APCd siRNA and untreated SW480 cells were 
collected and lysed with RIPA buffer as described in Section 2.2.9.1. 
Immunoprecipitation was carried out using Miro-1 (pAb, Sigma-Aldrich), Milton-2 
(pAb, Sigma-Aldrich) and IgGr (pAb, Sigma-Aldrich) antibodies to pull-down target 
proteins prior to samples being subjected to SDS-PAGE and western blot analysis as 
described in Section 2.2.10. Immunoprecipitation experiments in U2OS cells were 
performed twice, whilst experiments in SW480 cells were performed once. 
6.2.7 Western blot analysis 
Cells were collected, lysed using RIPA buffer and processed as described in Section 
2.2.9.1. Samples (immunoprecipitates or ~30µg total cell lysate) were separated by 
SDS-PAGE using 5% (for detection of APC) or 7.5% acrylamide gels, and transferred 
onto a nitrocellulose membrane (see Sections 2.2.9.3-2.2.9.6). Western blots were 
Chapter 6 
182 
probed as outlined in Section 2.2.9.7, using primary antibodies as per the figure legends. 
Dilutions for these antibodies and subsequent secondary antibodies are outlined in Table 
2.2 and Table 2.3, respectively. Immunoblots in this chapter were developed using the 
BioRad ChemiDoc Imaging System and ECL (see Section 2.2.9.8). 
6.2.8 Duolink Proximity Ligation Assay (PLA) 
Duolink PLA experiments in this chapter employed primary antibodies against KIF5 
(mAb, Millipore), GFP (mAB, Roche), Miro-1 (pAb, Sigma-Aldrich), Milton-2 (pAb, 
Sigma-Aldrich) and APC (mAb, Merck) at concentrations outlined in Table 2.2 to 
visualise interactions between KIF5/Milton, APC/Miro and GFP-tagged 
constructs/Miro. Following image capture, PLA signals were quantified manually, by 
scoring the number of PLA signals per cell using a DIC channel overlay to determine 
the boundaries of each cell (Section 2.2.8.6). Duolink PLA experiments were performed 
twice and the number of cells scored is outlined in the supplementary figures for each 
experiment. 
 
Duolink PLA in cells expressing GFP Miro-1 constructs were compared to control cells 
expressing GFP alone as a frame of reference for background signal. For these 
experiments, only cells expressing a modest level of the transfected plasmid were 
scored to minimise artefacts caused by overexpression (Section 2.2.8.4). Low levels of 
transfection were more readily detected by counterstaining Duolink experiments with 
GFP (mAb) and the appropriate secondary antibody (as described in Section 2.2.8.5) 
following PLA.  
6.2.9 Graphs and statistics 
All graphs and statistics used to display and analyse results in this chapter are outlined 
in Section 2.2.11. 
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6.3 Results 
APC has been reported to act as a scaffold in numerous protein complexes throughout 
the cell (12), including the well-known multi-protein β-catenin destruction complex (9). 
Previous chapters indicate that APC regulates anterograde mitochondrial transport 
through an interaction with the Miro/Milton complex, which is lost upon CRC-
associated APC mutations. Whilst it was shown that APC associates with the 
Miro/Milton complex through its C-terminal sequence, the part of the complex through 
which APC exerts its effects is unknown. To determine whether APC has a role in 
stabilising components of the Miro/Milton mitochondrial transport complex, two simple 
models were tested: (1) APC links Milton to the kinesin KIF5 (Figure 6.1A), and (2) 
APC stabilises binding of Milton to Miro (Figure 6.2A).  
6.3.1 Full-length APC is not required for the ability of Milton to 
interact with KIF5 
To assess the first model, which proposes that the APC C-terminus links Milton to KIF5 
to facilitate mitochondrial transport (Figure 6.1A), Duolink PLA was used to assess the 
Milton/KIF5 interaction in U2OS (wild-type APC) and SW480 (APC 1-1337) cell lines. 
In both cell lines, a positive PLA signal above background level was observed for 
Milton/KIF5 (PLA signal/cell: U2OS = 10.7, SW480 = 7.1) (Figure 6.1B,C, Figure 
S6.1), indicating that binding was retained between the two proteins when APC C-
terminal sequences were lost. In both cell lines, Milton/KIF complexes locate correctly 
at the mitochondria as shown by Duolink PLA and counterstained for mitochondria 
(U2OS = 41%, SW480 = 37%) (Figure 6.1D,E). Thus, the ability of Milton/KIF5 
complexes to form at mitochondria does not depend on expression of full-length APC. 
These findings do not support the model proposed in Figure 6.1A, and suggest that 
CRC-related APC mutations have no bearing on the KIF5/Miro interaction. 
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Figure legend over page. 
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Figure 6.1: Evidence that APC is not required for the ability of Milton to interact 
with KIF5 
(A) Schematic detailing the model to be tested, wherein the APC C-terminus is required 
for optimal interaction between Milton and KIF5. (B-C) Duolink PLA was utilised to 
detect interactions between KIF5 and Milton in U2OS and SW480 cell lines. Scoring 
analysis of cells by immunofluorescence microscopy revealed a positive interaction 
between KIF5 and Milton in both cell lines as observed in the (B) box-and-whisker plot 
and (C) representative images. (D-E) KIF5/Milton PLA signals were analysed by 
immunofluorescence microscopy for mitochondrial colocalisation in cells 
counterstained with  Mitotracker CMX-Ros, as observed in the (D) representative 
images and (E) scored in the bar graphs (% mean ± S.D). Milton/KIF5 PLA signals 
localised well at mitochondria in U2OS and SW480 cells. This data argues against the 
proposed model and reveals that Milton binding to KIF5 does not require full-length 
APC.   
 
 
6.3.2 Loss of APC diminishes the GFP Miro-1/Milton interaction 
The next model tested (Figure 6.2A), proposes that APC facilitates the association of 
Milton and Miro. Duolink PLA was performed in U2OS cells expressing low to 
moderate levels of GFP or GFP Miro-1, treated with either control siRNA or APC 
siRNA (Figure 6.2B-D, and Supplementary Figure S6.3 for validation of APC 
knockdown). Antibodies against GFP and Milton were used to analyse cells expressing 
GFP Miro-1 for in situ binding with endogenous Milton. As expected, in control cells 
the mean number of GFP-Miro / Milton PLA signals per cell was ~3.1 fold higher than 
cells expressing GFP alone. More intriguing however, was the finding that when treated 
with APC siRNA, the number of GFP-Miro / Milton PLA signals per cell was only ~1.3 
fold higher than GFP control (Figure 6.2B, Supplementary Figure S6.3). When samples 
were normalised and background subtracted, the data indicated that loss of APC 
reduced the number of detectable Miro/Milton complexes by ~84% (Figure 6.2C). Thus 
APC may have a role in mediating the interaction between Miro and Milton. These 
Duolink results were confirmed by immunoprecipitation assays in U2OS cells, where 
the reciprocal pull down of Miro and Milton by their respective antibodies was 
diminished in cells treated with APC siRNA (Supplementary Figure S6.4). These results 
provide supporting evidence for the model outlined in Figure 6.2A, which suggests that 
APC stabilises the interaction between Miro and Milton, possibly by acting as a 
scaffold, or by post-translational modification of Miro or Milton. 
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During immunoprecipitation experiments it was also noted that in control cells, the 96 
kDa isoform of Milton was preferentially pulled down by the Miro antibody, indicating 
that this is the form which most often interacts with Miro. Furthermore, the higher 
molecular weight form of Miro, previously observed to interact with APC (Figures S3.4 
and S4.2) and speculated to be post-translationally modified was preferentially pulled 
down by the Milton antibody, suggesting that this form also binds Milton. This is 
discussed further in Chapter 7 (Section 7.1.1). 
 
 
 
 
Figure legend over page. 
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Figure 6.2: Loss of APC disrupts the interaction between GFP Miro-1 and Milton 
in U2OS cells by Duolink 
(A) Schematic detailing the model to be tested wherein APC acts as a scaffold between 
Miro and Milton via a C-terminal interaction. (B-D) U2OS cells treated with either 
control or APC siRNAs (APCd), and transfected with pGFP or pGFP Miro-1 were 
subjected to Duolink PLA using antibodies against GFP (mAb) and Milton. Moderately 
transfected cells were selected for analysis by immunofluorescence microscopy, where 
scoring of PLA signals revealed a positive interaction between GFP Miro-1 and Milton, 
which as shown by the (B) box-and-whisker plot was significantly reduced upon APC 
knockdown. Significant differences relative to GFP control, as determined using the 
Mann-Whitney U-test, are indicated (**, P<0.01; ***, P<0.001). (C) This reduction is 
highlighted in the bar graph where the PLA/Signal per cell for GFP Miro-1/Milton 
interactions was subtracted from GFP/Milton background and normalised. This supports 
the proposed model. (D) Representative images are shown.  
 
6.3.3 APC truncation correlates with loss of the Miro/Milton 
interaction 
As loss of APC was shown to disrupt the interaction between Miro and Milton, 
investigation was undertaken to see if deletion of the Miro/Milton binding region of 
APC, by C-terminal truncation, had a similar effect (see Figure 6.3A). Duolink PLA 
assays were performed in SW480 (APC 1-1337) cells expressing low to moderate levels 
of GFP or GFP Miro-1. Analysis of GFP/Milton interactions in GFP Miro-1 expressing 
cells revealed no PLA signal above GFP background (Figure 6.3C-D, Supplementary 
Figure S6.4), indicating that ectopic Miro did not interact with endogenous Milton. 
 
This negative interaction between ectopic Miro and endogenous Milton was also 
verified with endogenous Miro in SW480 cells by immunoprecipitation assays. The 
Miro antibody was unable to pull down Milton, and the Milton antibody was unable to 
pull down Miro, even following long exposure times (Supplementary Figure S6.5), 
despite successful pull-down of their respective proteins (Figure 6.3B). These results 
suggest that APC truncation disrupts the Miro/Milton interaction, which could explain 
the disrupted mitochondrial transport observed in SW480 and other mutant APC cell 
lines. This supports the notion that the APC C-terminal region is required for APC to 
mediate an interaction between Miro and Milton. 
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Figure 6.3: Miro does not interact with Milton in SW480 mutant APC cells 
(A) Schematic detailing the model to be tested, wherein C-terminal APC truncation 
disrupts the interaction between Miro and Milton. (B) SW480 cells were 
immunoprecipitated by antibodies against Miro and Milton and analysed by western 
blot. Detection using the Miro and Milton antibodies revealed that Miro was unable to 
pull down Milton, and Milton was unable to pull down Miro. (C-D) Cells transfected 
with pGFP or pGFP Miro-1 were subjected to Duolink PLA using antibodies against 
GFP (mAb) and Milton. Moderately transfected cells were selected for analysis by 
immunofluorescence microscopy, where scoring of PLA signal revealed that the 
interaction between GFP Miro-1 and Milton did not produce a signal above GFP 
background level. This is observed in the (C) box-and-whisker plot and (D) 
representative images and supports the proposed model. Significant differences, 
determined using Mann-Whitney U-test, relative to GFP control are indicated (n.s., not 
significant). 
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6.3.4 Loss of APC does not alter the expression or mitochondrial 
localisation of Miro or Milton 
The current proposed model (Figure 6.2A) supported by preliminary data (Sections 
6.3.2 and 6.3.3) suggests that APC facilitates the interaction between Miro and Milton, 
which is lost when APC is silenced. Of course the Miro/Milton complex might also be 
diminished by loss of APC if APC regulates the expression of Miro or Milton, possibly 
by protecting the complex from their reported ubiquitination and degradation via the 
PINK1/Parkin pathway (165, 166). To exclude this possibility, western blot analysis of 
total cell extracts was performed, however the experiment revealed no changes in 
overall protein expression of Miro/Milton following the loss of APC (Figure 6.4A). 
This was confirmed by immunofluorescence microscopy, where the intensity of Miro 
and Milton staining appeared unaltered after APC siRNA treatment. Furthermore, the 
mitochondrial localisation of both proteins also remained unchanged after APC 
knockdown (Figure 6.4B-D), indicating that disruption of the Miro/Milton complex was 
not simply due to an APC-dependent relocalisation of these proteins away from 
mitochondria.  
6.3.5 Calcimycin treatment inhibits mitochondrial transport without 
altering the localisation of Miro, Milton and APC at the mitochondria 
Increased intracellular calcium has been widely reported to contribute to the cessation of 
mitochondrial transport by binding the EF-hands of Miro and, in turn, altering the 
structure of the Miro/Milton mitochondrial transport complex (153, 159). As studies in 
the literature are conflicting regarding how these structural changes affect transport, 
calcium regulation of APC in the context of the Miro/Milton transport complex was 
investigated. 
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Figure 6.4: Loss of APC does not alter mitochondrial localisation or expression of 
Miro or Milton in U2OS cells 
(A) Cells treated with control or APC (APCd) siRNA were subjected to western blot 
analysis, APC knockdown was confirmed and further detection of Milton and Miro 
revealed no changes in their expression levels following loss of APC. α-tubulin was 
used as a loading control. (B-D) Sub-confluent cells treated with control or APC 
(APCd) siRNA were stained with CMX-Ros (mitochondria) and APC (Ab7) and probed 
with antibodies against Miro or Milton. Cells were analysed by immunofluorescence 
microscopy where scoring revealed no changes in (B) Miro or (C) Milton mitochondrial 
localisation following loss of APC (% mean ± S.D). (D) Representative images are 
shown. 
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The calcium-dependent arrest of mitochondrial transport has previously been observed 
in vitro following treatment with the calcium ionophore calcimycin (153), which acts to 
increase intracellular calcium. To confirm this observation under conditions utilised in 
this thesis, sub-confluent U2OS cells stained with Mitotracker CMX-Ros were treated 
for 5 minutes with calcimycin before being subjected to timelapse imaging by 
DeltaVision live cell microscopy over a 2 minute period. Treatment with 20 µM 
calcimycin was observed to be sufficient to stall mitochondrial transport (Figure 6.5) 
without disrupting the microtubule network, indicating that this cessation of 
mitochondrial transport was not a secondary effect of microtubule depolymerisation 
(see fixed cells Figure 6.7A).  
 
 
 
Figure 6.5: Treatment with calcimycin (20 µM) inhibits mitochondrial transport.  
U2OS cells stained with Mitotracker CMX-Ros were treated with DMSO or calcimycin 
(20 µM) for 5 min prior to live cell timelapse imaging. Images were captured every 5 s 
for a total of 2 min. For each treatment, representative cell images show mitochondria at 
two time points 1 min apart. Mitochondria that remained stationary over this time point 
appear yellow in the merged images. Arrows in DMSO zoom panel indicate examples 
of motile mitochondria from T=0 s (red) to T=60 s (green). 
 
 
In line with current literature, the mitochondrial localisation of Miro and Milton 
remained unchanged following treatment with calcimycin (Figure 6.6A-C) (153). 
Mitochondrial localisation of APC also remained unchanged (Figure 6.6A,D) indicating 
that relocalisation of these transport proteins away from the mitochondria is not 
responsible for inhibition of mitochondrial transport.   
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Figure 6.6: Calcimycin treatment does not alter mitochondrial localisation or 
expression of Miro, Milton or APC in U2OS cells 
(A-D) Sub-confluent cells treated with DMSO or calcimycin (20µM) were stained with 
CMX-Ros (mitochondria) and Hoechst (blue) and probed with antibodies against Miro, 
Milton or APC (H290). Analysis by (A) immunofluorescence microscopy revealed no 
changes in (B) Miro, (C) Milton or (D) APC mitochondrial localisation following 
calcimycin treatment (% mean ± S.D). 
 
6.3.6 Calcimycin treatment does not alter APC localisation at 
microtubule clusters  
Given the calcium-sensitivity of the Miro/Milton transport complex, it is intriguing that 
APC has also been reported to be calcium regulated. A previous report (298)  suggested 
that under increased intracellular calcium concentrations induced by ionomycin (1 µM) 
treatment, APC dissociates from microtubule clusters. This is interesting as it is possible 
that this detachment of APC from microtubules could offer a mechanism by which 
mitochondrial transport is stalled when intracellular calcium concentrations rise, 
Chapter 6 
193 
particularly if APC attachment to microtubules is required for transport. In U2OS cells 
however, calcium dependent APC dissociation from microtubule clusters could not be 
verified following treatment with calcimycin at concentrations sufficient to disrupt 
mitochondrial transport (20 µM, Figure 6.5). It is possible that the calcium dependent 
APC re-localisation observed by Togo (298) is cell type specific, or that the intracellular 
levels of calcium induced by treatment with 20 µM calcimycin is not sufficient to match 
those induced by ionomycin treatment. This result does however show that APC 
dissociation from microtubules is not a contributing factor to calcium regulated 
cessation of mitochondrial transport. 
 
 
Figure 6.7: Calcimycin treatment does not alter APC localisation at microtubule 
clusters in U2OS cells  
(A-B) Sub-confluent cells treated with DMSO or calcimycin (20µM) were probed with 
antibodies against α-tubulin and APC (H290) and stained with Hoechst. Analysis by 
immunofluorescence microscopy revealed no changes in APC localisation at 
microtubule clusters following calcimycin treatment as indicated by the arrows in the 
(A) representative images, and the (B) scoring data (% mean ± S.D). 
 
6.3.7 Calcimycin treatment does not alter the APC-Miro interaction 
Although findings in this chapter indicate that the localisation of APC at microtubules 
and mitochondria is not calcium dependent (Figure 6.6 and Figure 6.7), this does not 
exclude the possibility that the interaction between APC and the calcium sensitive Miro 
is altered following spikes in intracellular calcium. In fact, the recently discovered Wnt 
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signalling protein Alex3, which also interacts with the mitochondrial transport complex, 
was reported to dissociate from Miro following increased intracellular calcium levels 
(161, 163). 
 
To determine if APC binding to Miro was regulated in a similar calcium-dependent 
manner as reported for Alex3, Duolink PLA was used to assess interactions between 
APC and Miro in U2OS cells treated with DMSO or calcimycin (Figure 6.8; Figure 
S6.6). The APC/Miro interaction produced positive PLA signals, which were almost 
identical in cells treated with DMSO or calcimycin. This finding indicates that unlike 
Alex3, the APC/Miro interaction is not calcium-dependent, and therefore it is unlikely 
to be involved in the structural alterations observed following the calcium-induced 
stalling of mitochondrial transport.  
 
 
 
 
Figure 6.8: Calcimycin treatment does not alter the APC-Miro interaction by 
Duolink 
(A-B) U2OS cells treated with DMSO or calcimycin (20µM) were subject to Duolink 
PLA using antibodies again APC (Ab7) and Miro. Scoring by immunofluorescence 
microscopy revealed that calcimycin treatment did not significantly alter the interaction 
between APC and Miro as shown in the (A) representative images and the (B) box-and-
whisker plot. Significant differences relative to DMSO control, as determined using the 
Mann-Whitney U-test, are indicated (n.s., not significant). 
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6.4 Discussion 
Data from the previous chapters describes a novel role for APC in anterograde 
mitochondrial transport through a C-terminal interaction with the Miro/Milton 
mitochondrial transport complex, which is lost in APC mutant CRC cell lines and 
proposed to lead to disrupted mitochondrial distribution. Whilst it was determined that 
APC was essential in the initiation of mitochondrial transport, the mechanism behind 
this process was previously unclear. Preliminary findings in this chapter indicate a role 
for APC in mediating or stabilising the interaction between Miro and Milton (6.4.1), 
and suggest that the influence APC has on the mitochondrial complex is independent of 
calcium regulation (6.4.2).  
6.4.1 Evidence to support a role for APC in regulating the interaction 
between Miro and Milton 
Preliminary assessments in this chapter on the influence of APC on components of the 
Miro/Milton complex, and their association with mitochondria and each other, suggest 
that APC may somehow mediate the interaction between Miro and Milton. The primary 
evidence for this hypothesis is the finding that both APC knockdown in U2OS cells and 
APC truncation in SW480 cells disrupt the association between Miro and Milton, as 
shown by both Duolink PLA and immunoprecipitation assays (Figure 6.2, Figure 6.3, 
Supplementary Figure S6.3). In contrast, APC truncation did not alter the association 
between Milton and KIF5 by Duolink in SW480 cells (Figure 6.1), suggesting that 
unlike Miro/Milton this interaction complex is independent of APC. Furthermore, the 
Milton/KIF5 PLA signal retained mitochondrial localisation (Figure 6.1D,E) in SW480 
cells, a finding that is somewhat surprising, given that Miro is thought to be the primary 
mitochondrial anchor in the Miro/Milton complex. Milton has previously been reported 
to localise to mitochondria independent of Miro (149), so it is possible that the 
Milton/KIF5 complexes localise to the mitochondria, even without transport 
functionality. This is supported by the finding that mitochondrial localisation of Milton 
is also retained following the loss of APC in U2OS cells (Figure 6.4C-D). 
 
The Miro/Milton interaction has been evolutionarily conserved from Drosophila to 
humans, and the binding sites have been mapped to the N-terminal regions for both 
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proteins (149, 150, see Figure 6.9A). It is less clear from the literature if these two 
proteins interact directly and without the assistance of other co-factors. Findings from 
this chapter identify APC as one potential co-factor important for promoting the 
Miro/Milton interaction by acting as a scaffold to tether the complex together and assist 
in its assembly (Figure 6.9B). This is not unreasonable given the known roles of APC as 
a scaffold in numerous other cellular pathways including the formation of the β-catenin 
destruction complex (9, 12). Given that there is no published evidence of direct binding 
between Miro and Milton it is possible that APC performs an adaptor role, acting as a 
bridge to link the two proteins (Figure 6.9C). Scaffold proteins have also been known to 
recruit partner proteins to specific regions of the cell. Whilst, the mitochondrial 
localisation of Miro and Milton following loss of APC remains unchanged, it remains 
possible that APC recruits additional co-factors yet to be identified to assist in complex 
formation. 
 
APC could also mediate the Miro/Milton interaction by recruiting an enzyme that post-
translationally modifies Miro or Milton to influence their association (Figure 6.9D). It 
was shown in previous chapters that APC binds to a higher molecular weight form of 
Miro, speculated to be post-translationally modified (discussed in Section 7.1.1). 
Although findings in this chapter indicate that Milton also preferentially binds a higher 
molecular weight form of Miro (Supplementary Figure S6.4), immunoprecipitation 
assays show a strong pull down of this same band by the Miro antibody in SW480 
mutant APC cells (Figure 6.3B), suggesting that this particular potential modification of 
Miro may not be APC mediated. These findings do not exclude the possibility that APC 
mediates other post-translational modifications by regulating previously defined 
modification enzymes like PINK1/Parkin and OGT (for more details see Section 
6.4.1.1), or through an entirely new pathway made possible given APC’s huge range of 
binding partners like GSK-3β. Future biochemical experiments are required to delineate 
the specific forms of Miro that bind Milton and APC. 
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Figure 6.9: The Miro/Milton mitochondrial transport complex 
(A) A schematic that outlines sites of protein interaction and post-translational 
modification in the Miro/Milton complex, as currently defined in the literature (see 
Figure 1.5A for reference details). (B-D) Evidence from this chapter suggests that APC 
is required to facilitate the Miro/Milton interaction, possibly by acting as a scaffold (B) 
or adaptor (C), or by recruiting an enzyme to post-translationally modify the complex 
(D). APC may also act by recruiting additional co-factors like bridging molecules, or 
enzymes for post-translational modification (PTM) yet to be identified. 
 
 
This investigation into the role of APC in the Miro/Milton complex is only in its 
preliminary stage, and further experimentation is needed to elucidate, which, if any, of 
the mechanisms presented (and outlined in Figure 6.9B-D) match APC’s functionality. 
This could include determining in greater detail the binding of APC, Miro and Milton 
by using a purified protein system to determine if the APC/Milton, APC/Miro and 
Miro/Milton interactions are direct, or indirect. In mutant APC SW480 cells where 
Miro/Milton binding is defective, full-length ectopic APC could be overexpressed to 
determine if, as predicted, the Miro/Milton association could be re-established. In 
addition, to determine if APC could mediate any post-translational modifications, mass 
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spectrometry could be performed on Miro/Milton and compared between cell lines with 
full length and mutant APC.  
6.4.1.1 Possible involvement of APC in Miro/Milton post-translational modification 
pathways 
As described previously (Section 1.3.2.1), numerous studies in the literature indicate 
that the mitochondrial transport complex is subject to post translational modification 
though the PINK1/Parkin mediated phosphorylation and ubiquitination of Miro (152, 
157, 165) and the OGT regulated O-GlcNAcylation of Milton (156). APC regulation of 
Miro through the PINK1/Parkin pathway is unlikely despite reports that both PINK1 
and Parkin are abnormally expressed in colon cancer cell lines (307), as these 
modifications modulate mitochondrial transport by marking Miro for proteosomal 
degradation. As shown in Figure 6.4, protein expression levels of Miro are unaltered 
following loss of APC by western blot analysis and immunofluorescence microscopy.  
 
Like PINK1 and Parkin, it was also proposed that increased rates of O-GlcNAcylation 
and OGT expression are markers for carcinogenesis (reviewed in 308), particularly 
colon cancer (309), a finding attributed to the O-GlcNAc modification of a number of 
oncogenic factors including p56, MYC, NFκB, and β-catenin. Interestingly, targeting 
OGA (O-GlcNAcase), the enzyme responsible for de-O-GlcNAcylation which is also 
reported to be upregulated in CRC, has been shown to attenuate carcinogenesis in APC 
(Min/+) mice in a mechanism independent of Wnt signalling (310). It is unclear if these 
findings impact on the reported inhibition of mitochondrial transport following the O-
GlcNAcylation of Milton in the presence of increased intracellular glucose (156), 
particularly given the highly glycolytic nature of  CRC cells. This challenge is further 
compounded since the pathways of O-GlcNAcylation and OGT/OGA in cancer are a 
relatively new field, and thus poorly understood. Further investigation is required to 
determine if APC has any role in regulating O-GlcNAcycation, or recruiting/inhibiting 
OGT/OGA to Milton. 
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6.4.2 APC regulation of the Miro/Milton mitochondrial transport 
complex is not calcium dependent. 
The cessation of mitochondrial transport through calcium regulation of the Miro/Milton 
transport complex is reflective of the role of mitochondria in calcium buffering, where 
proximity to regions of high intracellular calcium is essential for effective uptake (311). 
The literature clearly supports the modification of Miro, wherein the Miro EF-hand 
motifs bind to calcium, as a mechanism behind the disruption to mitochondrial 
transport, however, the changes in protein-protein interactions that cause dissociation of 
the Miro/Milton complex from microtubules following calcium binding is unclear (see 
Section 1.3.2.1 and 153, 159). Prior studies by Togo and colleagues (298), indicating 
that APC dissociates from microtubules in the presence of increased calcium, suggested 
that APC may contribute to this calcium regulation of mitochondria. However, 
preliminary investigations in this chapter do not support this hypothesis.  
 
When calcimycin was used to boost intracellular calcium to levels sufficient to disrupt 
mitochondrial transport (Figure 6.5), APC localisation to both the mitochondria and 
microtubules remained unchanged (Figure 6.6A,D, Figure 6.7). This was consistent 
with earlier reports that other components of the transport complex, Miro and Milton, 
remain attached to mitochondria following calcium-induced disruption of mitochondrial 
transport (153, 159, and confirmed in Figure 6.6A-C). However, indications that the 
pool of APC localised to microtubules remained unchanged following increased 
intracellular calcium, was somewhat surprising given the findings reported by Togo and 
colleagues (298). 
 
It is possible that the intracellular calcium levels required to displace APC from 
microtubules is higher than that required to inhibit mitochondrial transport. Previous 
studies into the differences between calcimycin, and ionomycin, used in the study by 
(298), indicate that ionomycin has a higher specificity for calcium ion uptake (312) and 
therefore might be more effective than the calcimycin used here. It is also possible that 
the calcium regulation of APC and mitochondrial components vary between different 
cell types and under different experimental conditions. 
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Duolink PLA experiments of calcimycin-treated U2OS cells suggest that the 
conformational change in the mitochondrial transport complex induced by calcium 
binding does not affect the Miro/APC interaction (Figure 6.8). This contrasts with the 
calcium-dependent binding observed between Miro and the newly discovered Wnt 
protein Alex3 (163) and further supports the notion that the role of APC in the 
mitochondrial transport complex is calcium-independent. These findings are still in their 
preliminary stages and further experiments are required to confirm this data. For 
example, intracellular calcium levels induced by treatment with calcimycin need to be 
monitored and Miro calcium binding needs to be confirmed at the calcimycin 
concentrations used to arrest mitochondrial transport. Experiments could also be 
confirmed using another calcium ionophore such as ionomycin, and repeated with the 
inclusion of a calcium chelator such as BAPTA-AM to determine whether the absence 
of calcium alters the activity of Miro, Milton or APC. 
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6.5 Supplementary Figures 
 
 
 
 
 
Supplementary Figure S6.1: Milton interacts with KIF5 in APC wild-type and 
mutant cell lines by Duolink– expanded Duolink data 
(A-B) Interactions between Milton and KIF5 were visualised in situ in U2OS and 
SW480 cell lines using Duolink PLA as described in Figure 6.1. Scoring indicates a 
positive signal between Milton and KIF5 in both cell lines as shown in the (A) dot-plots 
(mean ± S.D) and (B) table (n, number in sample; IQR, inter-quartile range; SD, 
standard deviation. 
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Supplementary Figure S6.2: Loss of APC disrupts the interaction between GFP 
Miro-1 and Milton in U2OS cells – expanded Duolink data 
(A-B) U2OS cells were treated with control or APC (APCd) siRNA, transfected with 
pGFP or pGFP Miro-1 and Duolink PLA performed using antibodies against GFP and 
Milton as described in Figure 6.2. Scoring indicates that treatment with APC siRNA 
disrupted the interaction between GFP Miro-1 and Milton as shown in the (A) dot-plot 
(mean ± S.D) and (B) table (n, number in sample; * fold change relative to GFP control; 
IQR, inter-quartile range; SD, standard deviation). 
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Supplementary Figure S6.3: Immunoprecipitation assays suggest that loss of APC 
in U2OS cells may disrupt the interaction between Miro and Milton 
Cells treated with control or APC (APCd) siRNA were immunoprecipitated by 
antibodies against Miro and Milton and analysed by western blot. The Miro antibody 
successfully pulled down both Miro and the 96 kDa form of Milton in cells treated with 
control siRNA, however in cells treated with APC siRNA amount of Milton pulled 
down appeared to be diminished. The Milton antibody successfully pulled down the 96 
kDa form of Milton and Miro in cells treated with control siRNA, however in cells 
treated with APC siRNA the amount of Miro pulled down also appeared to be 
diminished. The blots shown are from the same experiment, however the extract was 
run on separate gels to avoid overlapping Miro and Milton bands.  
 
 
 
Supplementary Figure S6.4: GFP Miro-1 does not interact with Milton in SW480 
mutant APC cells – expanded Duolink data 
(A-B) SW480 cells were transfected with pGFP or pGFP Miro-1 and Duolink PLA 
performed using antibodies against GFP and Milton as described in Figure 6.3. Scoring 
indicates that GFP Miro-1 and Milton did not produce a signal above GFP background 
level as shown in the (A) dot-plot (mean ± S.D) and (B) table (n, number in sample; * 
fold change relative to GFP control; IQR, inter-quartile range; SD, standard deviation). 
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Supplementary Figure S6.5: Miro does not interact with Milton in SW480 mutant 
APC cells by IP – longer time points 
SW480 cells were immunoprecipitated using antibodies against Miro and Milton and 
analysed by western blot. Whilst pull-down of their respective proteins by the Miro and 
Milton antibodies was successful, the Miro antibody was unable to pull down Milton 
and vice versa.  
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Supplementary Figure S6.6: Calcimycin treatment does not alter the APC-Miro 
interaction – Expanded Duolink Data 
(A-B) U2OS cells treated with DMSO or calcimycin (20 µM) were subject to Duolink 
PLA using antibodies against APC (Ab7) and Miro as described in Figure 6.8. Scoring 
indicates that calcimycin treatment did not alter the interaction between APC and Miro 
as shown in the (A) dot-plot (mean ± S.D) and (B) table (n, number in sample; * fold 
change relative to DMSO control; IQR, inter-quartile range; SD, standard deviation). 
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This thesis has presented the first evidence to indicate a role for APC in the anterograde 
microtubule-dependent transport of mitochondria, facilitated by the Miro/Milton/KIF5 
complex. In particular, APC was shown to stimulate the initiation of mitochondrial 
transport by stabilising the association between the mitochondrial anchor Miro and the 
kinesin adaptor Milton. APC truncation of the C-terminal end, as often observed in 
CRC, results in loss of the ‘Miro-binding domain’ and reduced both formation of the 
transport complex and mitochondrial movement towards the cell periphery. This new 
pathway of APC action, and its disruption by mutation, may explain some of the 
aberrant cell properties, such as altered polarity of migration, displayed by CRC cell 
lines and colonic crypt epithelial cells that express mutant APC.  
 
7.1 APC is a novel regulator of the Miro/Milton 
mitochondrial pathway 
Cells expressing wild-type APC were found to display mitochondria distributed 
throughout the cell in a uniformly spread manner, whereas the loss of APC shifted 
mitochondria towards the perinuclear region (Chapter 3), analogous to that observed 
when other components of the transport complex were disrupted (165, 284). The finding 
that APC associated with Miro and Milton, key proteins from the primary transport 
complex at mitochondria, consolidated this analysis. Truncation of the C-terminal ‘Miro 
binding domain’ of APC by CRC mutation inhibited APC binding to the Miro/Milton 
complex (Chapter 4), and correlated with reduced mitochondrial transport (discussed 
further in 7.2). This deficit was rescued in mutant-expressing CRC cells by 
reconstitution of wild-type APC, thus linking APC to trafficking of mitochondria to the 
cell periphery (Chapter 4). Results from live cell imaging showed that APC was 
involved specifically in the initiation of anterograde mitochondrial transport, rather than 
negatively regulating retrograde transport or altering transport velocity (Chapter 5). 
When APC expression was silenced, a larger proportion of the mitochondria became 
stationary, and this correlated with a decrease in anterograde movement, similar to that 
seen previously after loss of Miro or Milton (152-154, 163). Preliminary binding studies 
(Chapter 6) suggest that this may be due to the ability of APC to stabilise the interaction 
between Miro and Milton, the binding of which was impaired when APC was lost 
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through siRNA treatment or C-terminal truncation (summarised in Figure 7.1, ‘zoom’ 
panels). This idea is in line with APC’s scaffolding role in numerous other protein 
complexes (9, 12). The mechanism by which APC stabilises the Miro/Milton complex, 
and which of these proteins bind one another directly, are yet to be defined (see Section 
7.7 for future directions). There is also some evidence that APC binds to a post-
translationally modified form of Miro (Section 7.1.1).  
 
 
Figure 7.1: APC truncation impairs formation of the Miro/Milton/KIF5 motor 
complex, preventing anterograde transport of mitochondria.  
(A) Findings from this study implicate APC as a key regulator of membrane-directed 
mitochondrial transport. (B) Such transport is compromised when APC is mutated in 
CRC. This model speculates on how APC-dependent mitochondrial transport may 
contribute to normal cell function, and how APC gene mutations could contribute to 
CRC carcinogenesis through misregulation of these pathways.   
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7.1.1 APC may interact with a post-translationally modified form of 
Miro. 
APC may bind to a post-translationally modified form of Miro as suggested by 
immunoprecipitation of GFP-APC(2650-2843) with endogenous Miro in U2OS cells 
(Supplementary Figure S7.1). The band detected was higher (~85 kDa) than that of the 
predicted size for Miro (~75 kDa), both of which were visible in the input lane. Higher 
molecular weight bands of ectopic GFP-Miro were also observed in U2OS lysates, upon 
immunoprecipitation by wild-type endogenous APC (Supplementary Figure S7.1B). 
Furthermore an ~85 kDa endogenous form of Miro was observed in HEK293 cell 
lysates with induced expression of wild-type APC, and transfected with pGFP Milton-2, 
where antibodies against both APC and Milton appeared to preferentially capture this 
~85 kDa Miro isoform (Supplementary Figure S7.1C). Endogenous Milton also 
appeared to preferentially capture this ~85kDa Miro in U2OS cells (Supplementary 
Figure S7.1D). 
 
It is possible, that even though Miro-1 and Miro-2 are the same size and have the same 
predicted molecular weight (146), because the Miro antibody used for detection is not 
homolog specific (Supplementary Figure S3.3), the higher form detected simply results 
from the two homologs separating differently along the gel. However, as two bands are 
also clearly observed in Supplementary Figure S7.1B for ectopic GFP Miro-1 pulled 
down by APC and detected using anti-GFP, it is more likely that Miro has undergone 
some form of post-translational modification to which APC and Milton bind.  
 
APC can act as scaffold to mediate phosphorylation of β-catenin by GSK3β (reviewed 
in 9). Whilst Miro is not known to be modified by GSK3β, it can undergo post-
translational modification through the PINK1/Parkin pathway which orchestrates 
mitochondria quality control, mitophagy, and transport. PINK1 was reported to 
phosphorylate Miro, correlating with a cessation of mitochondrial transport in 
Drosophila neurons (152, 157) . Parkin on the other hand, can poly-ubiquitinate Miro 
upon membrane depolarisation, targeting it to the proteasome for degradation (165, 
166). At this stage, it is unclear whether APC or Milton actually promote modification 
of Miro or whether they selectively bind an existing post-translationally modified sub-
pool of Miro. If the modification is poly- ubiquitination, there was no evidence that 
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APC altered the stability of this form of Miro (Chapter 6), however it is worth further 
study as the preferential binding of the larger Miro isoform to APC and Milton suggests 
that it contributes to mitochondrial transport. 
 
7.2 APC truncation disrupts mitochondrial transport 
The initiation and progression of CRC primarily occurs through truncation of the C-
terminus of APC, a region known to bind to numerous other regulatory partners 
involved in normal cell function whose loss might contribute to carcinogenesis (see 
Section 1.2.3). APC truncation disrupted its association with the Miro/Milton complex, 
a finding supported by mapping of the ‘Miro-binding domain’ to APC (2650-2843). The 
effects of C-terminal deletion were reflected by the impaired mitochondrial distribution 
in mutant APC cell lines, wherein mitochondria accumulated more around the nucleus 
and less at the plasma membrane region. Reconstitution of wild-type APC recovered 
APC binding to the Miro/Milton complex, and partly restored mitochondrial transport to 
the cell periphery (Chapter 4). The results indicate that C-terminal truncation decreases 
mitochondrial transport to the cell periphery (Figure 7.1B), which may contribute to 
CRC tumourigenesis (discussed further in Section 7.3). 
 
It is possible that APC mutations contribute to alterations in mitochondrial transport 
through other pathways. For example, MacLeod and colleagues (313) indicated that in 
HT-29 CRC cells the truncated APC, but not ectopic wild-type APC, stimulates Wnt5a 
secretion in the presence of calcium. Separately, Wnt5a stimulation of the non-
canonical Wnt signalling pathway is reported to target Alex3 (a positive regulator of 
mitochondrial transport) for degradation in a concentration dependent manner, which 
could in turn inhibit mitochondrial transport (161). It is hard to reconcile these results 
given that elsewhere Wnt5a has been reported to be silenced in most CRC cell lines 
(including HT-29) by promoter methylation, whilst expressing well in normal cell types 
(314). More direct alternatives through which wild-type and mutant APC could regulate 
mitochondrial transport are discussed in Section 7.5. 
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7.3 Disruption of mitochondrial transport may 
contribute to CRC 
APC truncation mutations contribute to CRC carcinogenesis by disrupting a range of 
key tumour suppressor activities such as β-catenin turnover (leading to aberrant Wnt 
signalling, see reviews 3, 5), mitosis chromosome segregation, cell polarity and cell 
migration (see Section 1.2.3 and reviews 52, 54, 289). As shown in this study (Chapters 
4 and 6), C-terminal truncation of APC also appears to disrupt assembly of the 
Miro/Milton transport complex, and in turn affects mitochondrial movement towards 
the cell periphery. It is possible that this impairment contributes to carcinogenesis 
(Figure 7.1).  
 
One mechanism by which impaired mitochondrial transport may contribute to CRC is 
through irregular targeting of mitochondrial ATP. In particular, recent studies have 
indicated that localisation of mitochondria at the cell periphery is essential for effective 
cell migration and, that disruption to this, slows the rate by cutting off the ATP supply 
essential for F-actin and microtubule polymerisation (18, 19). Data from Chapter 5 
show that siRNA mediated loss of APC decreased the rate of cell migration, correlating 
with a loss of mitochondria at the cell periphery and microtubule-dependent protrusions. 
C-terminal deletion of APC also impaired mitochondrial movement to the cell 
periphery, suggesting that it may likewise perturb directed cell migration. This 
hypothesis is in line with studies that report a decrease in the rate of cell migration along 
the crypt-villi axis in APC (Min/+) and APC knockout mice (66, 99). Furthermore, 
disruption to microtubule polymerisation, required for maintenance of cell polarity may 
also account for the loss of directed cell migration observed in APC (Min/+) mice (96). 
Retention of cells at the base of colonic crypts may be favourable for cancer cell 
expansion and survival as this region is highly proliferative. Disruptions in the targeting 
of mitochondrial ATP reserves may further impact the numerous other regulatory 
pathways for which it supplies energy. This area requires further investigation. 
 
The disruption of mitochondrial transport may also affect calcium buffering, through the 
loss of site-specific uptake, and release of calcium by mitochondria (15) and disruption 
of mitochondrial membrane positioning for extracellular calcium uptake (190). This 
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may contribute to the aberrant calcium signalling frequently observed in cancer cells 
which disturbs regulation of cell proliferative and migratory pathways (292, 296). 
Furthermore, the perinuclear clustering, resulting from disruption of outward, 
anterograde mitochondrial movement may assist in the creation of an oxidant-rich 
nuclear domain due to the continuous release of mitochondrial ROS in a confined 
environment (265). Highly concentrated ROS in close proximity to the nucleus could 
stimulate transcription of  hypoxia-induced genes such as VEGF and NFκB, and expose 
the DNA to oxidative damage, promoting carcinogenesis (299). These mechanisms 
through which disruption to mitochondrial transport can promote carcinogenesis may 
act synergistically with aberrant pathways arising from APC truncation.  
 
7.4 Other Implications for APC in mitochondrial 
transport 
Disruption to APC-dependent mitochondrial ATP supply to the cell periphery may have 
implications not only relevant to CRC, but also to other cell and tissue processes such as 
wound healing, embryonic development and the immune response. Alternative 
outcomes are briefly outlined below. 
7.4.1 Regulation of CNS structure and function. 
APC is expressed highly in the brain, particularly in neurons (315, 316), and contributes 
to the proliferation, differentiation and process formation of various cell types in the 
CNS (317-320), through both its Wnt and cytoskeletal regulatory pathways. A previous 
study implicated APC in the modification of KIF5-mediated vesicle transport in neurons 
(286), suggesting that mitochondrial dynamics may also contribute to the regulation of 
some of these pathways. For instance, APC is enriched at the tips of growth regions in 
hippocampal neurons and retinal ganglion cells where it is involved in outgrowth and 
elongation (321, 322). It is assumed that ATP is required for this process, and in line 
with this notion mitochondrial dynamics and positioning have been shown to be 
essential for the growth rate of retinal ganglion cells (323). The ability of APC to 
localise to these areas of growth, where it regulates cytoskeletal function, may act in 
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synergy with its capacity for mitochondrial transport, to supply the energy required in 
neuronal outgrowth. Furthermore, as outlined in Section 1.3.4.1 and reviewed in (139-
141), mitochondrial transport defects are associated with numerous neurological 
diseases such as Alzheimer’s, Parkinson’s and Huntington’s diseases. Canonical Wnt 
signalling is reported to have neuroprotective effects in Alzheimer’s disease by 
preventing the permeabilisation of the mitochondrial membrane induced by β-amyloids 
(324), however APC dysfunction has not yet been reported. 
7.4.2 Regulation of development 
Mitochondrial distribution changes during embryonic development to meet specific 
demands including mediating nuclear-mitochondrial signalling, energy supply and 
segregation for proper mitochondrial inheritance. Moreover, alterations to mitochondrial 
dynamics and morphology impair embryonic development in different organisms (325). 
This is highlighted by studies demonstrating that complete loss of functional DRP1, 
OPA1 or Mfn1/2, required to mediate mitochondrial morphology were embryonically 
lethal in mice (326-328). Loss of APC in KO mice is also embryonically lethal (329, 
330), however due to its multifaceted nature, this is not surprising. APC’s role as a 
suppressor of Wnt signalling is a crucial in the regulation of development, however 
results from this study raise the possibility that it may also contribute to this process 
through regulated transport of mitochondria.  
 
7.5 APC as a potential regulator of other 
mitochondrial transport pathways 
7.5.1 APC and RanBP2 
Ran-binding protein-2 (RanBP2) was originally identified as a mobile nucleoporin 
involved in nucleocytoplasmic transport of proteins (331, 332). Since then numerous 
roles have emerged for RanBP2 in normal cell function. In particular, RanBP2 has been 
reported to stimulate anterograde mitochondrial movement through the direct 
association, and activation, of the KIF5B/C motor domain (176, 177). These studies 
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showed that overexpression of a dominant-negative form of RanBP2 in NIH 3T3 cells 
resulted in perinuclear clustering of mitochondria (176), similar to that observed 
following APC wild-type knockdown across numerous cell lines, including NIH 3T3 
(Figure 3.1). An unrelated study identified the formation of RanBP2/APC complexes in 
the maintenance of cell polarity (62), and preliminary studies confirming that RanBP2 
co-located well at mitochondria and with APC (Figure 3.5, Figure 3.6) suggested that 
further investigation is warranted to examine if this RanBP2/APC association also 
influenced mitochondrial transport.  
 
To confirm these findings, and to examine if the mutational status of APC had any 
bearing on RanBP2-mediated mitochondrial transport, U2OS (APC-WT) and SW480 
(APC 1-1377) cell lines were treated with control or RanBP2 siRNAs, and analysed by 
immunofluorescence microscopy. In U2OS cells, loss of RanBP2 induced redistribution 
of mitochondria toward the perinuclear region, as described by Cho and colleagues 
(176), although to a lesser extent (31%) than that observed after APC knockdown (52%) 
(Supplementary Figure S7.2). The loss of RanBP2 also elicited a small increase in 
perinuclear mitochondrial clustering in SW480 cells expressing mutant APC 1-1337 
(Supplementary Figure S7.2). These results suggest that if APC/RanBP2 
immunocomplexes are involved in mitochondrial transport, they operate through a 
pathway alternate to the APC/Miro/Milton complex. This notion was confirmed by 
Duolink PLA, where attempts to produce PLA-positive signals between RanBP2 and 
Miro in U2OS cells were unsuccessful (Supplementary Figure S7.3).  
 
To confirm the association between APC and RanBP2 proposed in previous studies 
(62), Duolink PLA was employed using antibodies targeting endogenous APC and 
RanBP2 to detect potential interactions. In agreement, PLA experiments showed a 
positive interaction between APC and RanBP2, with U2OS and SW480 cells yielding 
~18 and ~13 PLA signals/cell respectively (Figure Supplementary Figure S7.4A-B). 
This was confirmed by immunoprecipitation in U2OS lysates (Supplementary Figure 
S7.4C). Murawala and colleagues (62) mapped the RanBP2 binding domain to the 
middle section of APC (residues 1211-1859), however, the detection of APC/RanBP2 
complexes in SW480 (APC 1-1337) cells, suggests that this domain could be further 
isolated to the 1211-1337 region. APC/RanBP2 PLA signals did not locate at 
mitochondria (Supplementary Figure S7.4D,E) suggesting that APC and RanBP2s 
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mitochondrial transport functionality are independent of one another, or that they 
influence mitochondria transport indirectly.  
7.5.2 APC and other kinesin pathways 
APC is also reported to associate with a number of kinesin motor proteins which have 
yet to be assessed for mitochondrial transport capabilities. These include KIF17 which 
has a role in microtubule stabilisation (68), and KIF3A/B. The APC/KIF3 association is 
mediated by an APC ARM domain interaction with adaptor protein KAP3A, and was 
shown to be necessary for APC localisation at membrane clusters (26). KAP3A was 
assessed in the preliminary stages of this study as a candidate through which APC may 
mediate mitochondrial transport, however weak mitochondrial co-localisation (Figure 
3.3), and the finding that loss of mutant APC (retains KAP3A binding) did not affect 
mitochondrial distribution (Figure 4.1), makes it less likely that APC/KAP3A/KIF3 is a 
transport pathway for mitochondria. 
7.5.3 Myosin 
In addition to microtubule-dependent transport of mitochondria highlighted in this 
study, the actin network also facilitates mitochondrial trafficking through the use of 
myosin motor proteins (summarised in Section 1.3.2.2). In particular, myosin motors, 
Myosin V, Myosin VI (187) and Myosin XIX (188) have been implicated in actin-
dependent transport of mitochondria in mammalian cell lines. Whilst there are no 
existing reports in the literature suggesting APC interacts with myosin motors, 
unpublished mass spectrometry data (Lui and Henderson) identified several myosin 
isoforms as putative binding partners for APC. These findings, coupled with the close 
association APC with the actin network (Section 1.2.1.3), open up the possibility of an 
alternate actin-dependent mitochondrial transport pathway for APC. Due to the short-
range nature of actin-dependent mitochondrial movement (170, 171), it is likely that any 
loss of transport across the actin network by APC knockdown would be masked by 
disruption to its long-range microtubule-dependent actions. Further investigation is 
required to determine if APC/actin-dependent mitochondrial transport is a viable 
pathway. 
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7.6 APC in mitochondrial morphology 
Preliminary observations in Chapter 3, indicated that the mitochondrial network in 
U2OS, HDF1314 and NIH 3T3 cells became more fragmented when treated with APC 
siRNA (Figure 3.2), suggesting that loss of APC may also contribute to mitochondrial 
fission and fusion dynamics. The ability of mitochondria to fuse and divide is another 
key facet to their dynamic nature, enabling them to form large interconnected networks 
or discrete fragments/puncta in response to various cell signals (Section 1.3.3). 
Mitochondrial transport and fission/fusion dynamics are intimately linked. On a 
mechanistic level, functional transport is required to bring mitochondria into contact to 
facilitate fusion, and move mitochondria apart to facilitate fission. Furthermore, several 
regulatory proteins overlap in both mitochondrial transport and morphology pathways. 
PINK1/Parkin for example, known to post-translationally modify Miro/Milton (see 
Section 7.1.1), also ubiquitinates the fission/fusion regulatory proteins Mfn1/2, DRP1 
and Fis1, targeting them to the proteosome for degradation (229, 246). Mfn2 has also 
been implicated in axonal mitochondrial transport (162), whilst overexpression of 
Milton has been shown to induce morphological defects in mitochondria (270). This 
interconnectivity also presents itself in disease pathology, where mutations in a number 
of key fission/fusion proteins contribute to the same neurodegenerative diseases 
observed following defects in mitochondrial transport. These include Charcot Marie 
Tooth, autosomal dominant optic atrophy, Alzheimer’s disease and Parkinson’s disease 
(reviewed in 139, 140, 192).  
7.6.1 APC knockdown causes changes in mitochondrial morphology 
To confirm the fragmentation of mitochondria observed in Figure 3.2 following loss of 
APC, and to determine if C-terminal truncation had any impact, wild-type APC was 
silenced in U2OS and LIM1215 cell lines, whilst mutant APC was silenced in SW480 
and HT-29 cell lines. These cells were stained with CMX-Ros to detect mitochondria 
and analysed by microscopy. Individual mitochondria were scored as either a puncta 
(~<2 µm) or a rod (~ ≥2 µm) according to their length, and from this cells were 
assigned as either punctate (>66% puncta), mixed (<66% puncta and <66% rods) or 
rods (>66% rods). This is explained in detail in Section 2.2.7.3.  
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Scoring analysis (Supplementary Figure S7.5) revealed that U2OS cells present a 
primarily mixed morphology. LIM1215 CRC cells showed a preference for punctate 
mitochondria, however this was not as pronounced as the punctate pattern observed in 
the mutant APC CRC cell lines. Silencing of wild-type APC increased the population of 
cells displaying punctate mitochondria relative to control (Supplementary Figure S7.5). 
However, loss of mutant APC did not alter the already large proportion of cells with a 
punctate mitochondrial morphology (Supplementary Figure S7.5). These results suggest 
that if APC influences mitochondrial morphology independently from transport, this is 
mediated by sequences in the C-terminal region.  
7.6.2 Binding studies 
A of number fission/fusion regulatory proteins (Mfn2, OPA1, DRP1 and Fis1) were 
assessed for their ability to bind APC. An initial screen of these proteins for 
colocalisation with APC (Figure 3.6) revealed that both fusion proteins, Mfn2 and 
OPA1 showed a high level of colocalisation (83% and 87% respectively), while in 
contrast, DRP1 (23%) and Fis1 (7%) showed little. The use of Duolink PLA detected no 
specific PLA signal between APC and these regulators of mitochondrial morphology 
(Supplementary Figure S7.6), underscoring the specific nature of its interaction with 
Miro/Milton. 
 
7.7 Future direction, clinical implications and 
conclusion 
To further define how APC alters mitochondrial transport, the structural biology of the 
complex needs to be further investigated. This could involve determining which 
components of the transport complex bind directly to one another, through the use of 
purified protein binding assays. A proteomic approach could be used to identify any 
other co-factors involved in the formation of the complex and mass spectrometry used 
to investigate possible Miro post-translational modifications that may facilitate APC-
binding. Moreover, the impact of APC on Miro/Milton association, and on 
mitochondrial transport, should be further analysed over a broad range of cell types, and 
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in mouse models such as the APC (Min/+) mouse. Tissue samples could also be 
interrogated in a similar manner.  
 
To determine the broader impacts of this newly defined mitochondrial transport 
pathway, ATP production could be analysed in more detail to verify that loss or 
truncation of APC does slow cell migration by impairing energy supply at the cell 
periphery. One approach to this could be through immunofluorescence detection and 
analysis of an ATP substrate in actively migrating cells following APC knockdown. 
Mitochondrial localisation, and how this correlates with the distribution of cells in CRC 
organoids, or the colon crypts of normal and APC (Min/+) mice could also be 
examined.  
 
The recent development of chemotherapeutic drugs that target mitochondrial function, 
highlight the importance of understanding all pathways in carcinogenesis for the 
discovery of new drug targets. Drugs indirectly targeting mitochondrial dynamics have 
already been developed. For example, the CT20 peptide promotes mitochondrial 
aggregation and membrane hyperpolarization leading to the detachment and death of 
metastatic breast cancer cells through disruption of membrane protrusions and F-actin 
polymerisation (333). Mitochondrial ATP production has also been targeted to inhibit 
migration and invasion of cancer cells by treatment with graphene (334). Findings in 
this thesis which implicate APC in mitochondrial transport open up a new pathway 
through which APC mutation may perturb normal cell function and drive 
carcinogenesis, and in turn present a range of new protein partners which could be 
targeted for therapeutic use.  
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7.8 Supplementary Figures 
 
 
 
Supplementary Figure S7.1: APC and Milton may bind to a post-translationally 
modifed form of Miro.  
Potential post-translationally modified Miro bands are indicated by arrows in red. (A) 
U2OS cells transfected with pGFP tagged APC (2650-2843) were immunoprecipitated 
by antibodies against GFP (pAb) and Miro prior to western blot analysis. Detection by 
Miro antibody revealed that the GFP antibody could successfully pull down a high 
molecular weight form of Miro-1 in transfected cell samples (Supplementary Figure 
S4.6A). (B) U2OS cells transfected with pGFP Miro-1 were immunoprecipitated by 
antibodies against APC (C20, pAb) and GFP (pAb). Detection by GFP revealed that the 
APC antibody successfully pulled down GFP Miro-1 (Figure S3.4). (C) Inducible HEK 
293 cell lines transfected with pGFP Milton-2  were treated with tetracycline 16 h prior 
to immunoprecipitation to induce expression of (APC-WT). Cells were 
immunoprecipitated by antibodies against APC (Ab5), GFP (pAb) and Milton, then 
analysed by western blot to detect Miro. The APC and GFP antibodies were able to pull 
down a higher size band for Miro (Figure S4.4). (D) U2OS cells were 
immunoprecipitated by antibodies against Miro and Milton and analysed by western 
blot. The Milton antibody successfully pulled down a higher weight form of Miro 
(Supplementary Figure S6.4). 
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Supplementary Figure S7.2: Loss of RanBP2 induces redustribution of 
mitochondria in U2OS and SW480 cells  
(A) U2OS and SW480 cells were treated by RanBP2 siRNA, and mitochondrial 
distribution analysed by immunofluorescence microscopy after staining for 
mitochondria (CMX-Ros) and RanBP2 (pAb). The cell membrane is represented by the 
dotted line. (B) Mitochondrial distribution was scored revealing a significant 
redistribution of mitochondria from the cell periphery (zone 3) towards the perinuclear 
region (zone 1) when RanBP2 was lost. Significant differences for zone 1 distribution 
relative to controls, determined by an unpaired T-test, are indicated (*, P<0.05, % mean 
± S.D). 
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Supplementary Figure S7.3: RanBP2 does not interact with Miro by Duolink PLA.  
U2OS cells were subject to Duolink PLA using antibodies against RanBP2 (mAb) and 
Miro (pAb). Representative images are shown and scoring quantification, as seen in the 
dot-plots (mean ± S.D), revealed no PLA signal/cell above background level.  
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Supplementary Figure S7.4: APC/RanBP2 immunocomplexes do not localise to 
mitochondria.  
(A-B) U2OS and SW480 cell lines were subject to Duolink PLA using antibodies 
against APC (H290) and RanBP2 (mAb). Scoring from analysis by 
immunofluorescence microscopy, showed a positive PLA signal, between APC and 
RanBP2, above background level in both cell lines, as observed in the (A) 
representative images and (B) dot plot (mean ± S.D). (C) This interaction was 
confirmed by immunoprecipitation in lysates of U2OS cells whereby an APC antibody 
(C20) successfully captured endogenous RanBP2. (D-E) Analysis of mitochondrial 
localisation for APC/RanBP2 PLA signals in U2OS and SW480 cells pre-stained with 
CMX-Ros, indicated poor localisation for APC/RanBP2 immunocomplexes as observed 
in the (D) representative images and (E) scored in the graph.  
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Supplementary Figure S7.5: Loss of wild-type, but not truncated APC induces 
fragmentation of mitochondria.  
(A) The mutation status of APC in U2OS, LIM1215, SW480 and HT-29 is outlined the 
schematic. (B-C) These cell lines were treated with control, APCd (U2OS) or 
APCd/APC2 pooled siRNA (LIM1215, SW480, HT-29) for 72h, stained with CMX-
Ros Mitotracker and counterstained with APC antibody (H290) and Hoechst. 
Mitochondrial morphology was analysed by immunofluorescence microscopy and 
scored as described Section 2.2.7.3. (B) Results are indicated on the bar graph with 
significant differences for punctate mitochondria relative to siRNA control, as 
determined by an unpaired T-test, shown for each cell line (***, P<0.001; n.s., not 
significant, % mean ± S.D). (C) Representative images are shown (dotted line 
represents the cell membrane).  
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Supplementary Figure S7.6: APC does not interact with key regulators of 
mitochondrial fission and fusion by Duolink PLA.   
(A-D) Duolink PLA was utilised to detect interactions between APC and mediators of 
mitochondrial morphology using antibodies against APC (Ab1 or H290), and (A) Mfn2, 
(B) OPA1, (C) DRP1 or (D) Fis1. No PLA signal above background was detected for 
any interaction investigated as visualised in the representative images and dot-plots 
(mean ± S.D). 
 
 
 
 
 
 
 225 
References 
 
 
 
 
 
 
 
 
 
 
 
 
 
References 
 
 
 
  
References 
226 
1. AIHW. Cancer in Australia: in brief 2014. In: Welfare AIoHa, editor. 
Canberra2014. 
2. WHO. World Cancer Report 2014: World Health Organization; 2014. 
3. Fodde R, Smits R, Clevers H. APC, signal transduction and genetic instability in 
colorectal cancer. Nat Rev Cancer. 2001 Oct;1(1):55-67. 
4. Senda T, Iizuka-Kogo A, Onouchi T, Shimomura A. Adenomatous polyposis 
coli (APC) plays multiple roles in the intestinal and colorectal epithelia. Med Mol 
Morphol. 2007 Jun;40(2):68-81. 
5. Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev. 2007 
Feb;17(1):45-51. 
6. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 
1996 Oct 18;87(2):159-70. 
7. Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. The American 
journal of gastroenterology. 2006 Feb;101(2):385-98. 
8. Fearnhead NS, Britton MP, Bodmer WF. The ABC of APC. Hum Mol Genet. 
2001 Apr;10(7):721-33. 
9. Stamos JL, Weis WI. The beta-catenin destruction complex. Cold Spring Harb 
Perspect Biol. 2013 Jan;5(1):a007898. 
10. Burgess AW, Faux MC, Layton MJ, Ramsay RG. Wnt signaling and colon 
tumorigenesis--a view from the periphery. Experimental cell research. 2011 Nov 
15;317(19):2748-58. 
11. Brocardo M, Henderson BR. APC shuttling to the membrane, nucleus and 
beyond. Trends Cell Biol. 2008 Dec;18(12):587-96. 
12. Lui C, Mills K, Brocardo MG, Sharma M, Henderson BR. APC as a mobile 
scaffold: regulation and function at the nucleus, centrosomes, and mitochondria. 
IUBMB life. 2012 Mar;64(3):209-14. 
13. Brocardo M, Lei Y, Tighe A, Taylor SS, Mok MT, Henderson BR. 
Mitochondrial targeting of adenomatous polyposis coli protein is stimulated by 
truncating cancer mutations: regulation of Bcl-2 and implications for cell survival. J 
Biol Chem. 2008 Feb 29;283(9):5950-9. 
14. Boland ML, Chourasia AH, Macleod KF. Mitochondrial dysfunction in cancer. 
Front Oncol. 2013;3:292. 
15. Contreras L, Drago I, Zampese E, Pozzan T. Mitochondria: the calcium 
connection. Biochim Biophys Acta. 2010 Jun-Jul;1797(6-7):607-18. 
16. Tait SW, Green DR. Mitochondria and cell signalling. J Cell Sci. 2012 Feb 
15;125(Pt 4):807-15. 
References 
227 
17. McBride HM, Neuspiel M, Wasiak S. Mitochondria: more than just a 
powerhouse. Curr Biol. 2006 Jul 25;16(14):R551-60. 
18. Desai SP, Bhatia SN, Toner M, Irimia D. Mitochondrial localization and the 
persistent migration of epithelial cancer cells. Biophys J. 2013 May 7;104(9):2077-88. 
19. Zhao J, Zhang J, Yu M, Xie Y, Huang Y, Wolff DW, et al. Mitochondrial 
dynamics regulates migration and invasion of breast cancer cells. Oncogene. 2013 
Oct;32(40):4814-24. 
20. Miyoshi Y, Nagase H, Ando H, Horii A, Ichii S, Nakatsuru S, et al. Somatic 
mutations of the APC gene in colorectal tumors: mutation cluster region in the APC 
gene. Human molecular genetics. 1992 Jul;1(4):229-33. 
21. Lal G, Gallinger S. Familial adenomatous polyposis. Seminars in surgical 
oncology. 2000 Jun;18(4):314-23. 
22. Neufeld KL, Zhang F, Cullen BR, White RL. APC-mediated downregulation of 
beta-catenin activity involves nuclear sequestration and nuclear export. EMBO reports. 
2000 Dec;1(6):519-23. 
23. Henderson BR, Fagotto F. The ins and outs of APC and beta-catenin nuclear 
transport. EMBO Rep. 2002 Sep;3(9):834-9. 
24. Zhang F, White RL, Neufeld KL. Phosphorylation near nuclear localization 
signal regulates nuclear import of adenomatous polyposis coli protein. Proc Natl Acad 
Sci U S A. 2000 Nov 7;97(23):12577-82. 
25. Galea MA, Eleftheriou A, Henderson BR. ARM domain-dependent nuclear 
import of adenomatous polyposis coli protein is stimulated by the B56 alpha subunit of 
protein phosphatase 2A. J Biol Chem. 2001 Dec 7;276(49):45833-9. 
26. Jimbo T, Kawasaki Y, Koyama R, Sato R, Takada S, Haraguchi K, et al. 
Identification of a link between the tumour suppressor APC and the kinesin 
superfamily. Nat Cell Biol. 2002 Apr;4(4):323-7. 
27. Sharma M, Leung L, Brocardo M, Henderson J, Flegg C, Henderson BR. 
Membrane localization of adenomatous polyposis coli protein at cellular protrusions: 
targeting sequences and regulation by beta-catenin. J Biol Chem. 2006 Jun 
23;281(25):17140-9. 
28. Zumbrunn J, Kinoshita K, Hyman AA, Nathke IS. Binding of the adenomatous 
polyposis coli protein to microtubules increases microtubule stability and is regulated 
by GSK3 beta phosphorylation. Curr Biol. 2001 Jan 9;11(1):44-9. 
29. Mimori-Kiyosue Y, Shiina N, Tsukita S. Adenomatous polyposis coli (APC) 
protein moves along microtubules and concentrates at their growing ends in epithelial 
cells. The Journal of cell biology. 2000 Feb 7;148(3):505-18. 
30. Breitman M, Zilberberg A, Caspi M, Rosin-Arbesfeld R. The armadillo repeat 
domain of the APC tumor suppressor protein interacts with Striatin family members. 
Biochim Biophys Acta. 2008 Oct;1783(10):1792-802. 
References 
228 
31. Brocardo M, Nathke IS, Henderson BR. Redefining the subcellular location and 
transport of APC: new insights using a panel of antibodies. EMBO Rep. 2005 
Feb;6(2):184-90. 
32. Cadigan KM, Peifer M. Wnt signaling from development to disease: insights 
from model systems. Cold Spring Harb Perspect Biol. 2009 Aug;1(2):a002881. 
33. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006 
Nov 3;127(3):469-80. 
34. Cong F, Schweizer L, Varmus H. Wnt signals across the plasma membrane to 
activate the beta-catenin pathway by forming oligomers containing its receptors, 
Frizzled and LRP. Development. 2004 Oct;131(20):5103-15. 
35. Niehrs C. The complex world of WNT receptor signalling. Nature reviews 
Molecular cell biology. 2012 Dec;13(12):767-79. 
36. Seeling JM, Miller JR, Gil R, Moon RT, White R, Virshup DM. Regulation of 
beta-catenin signaling by the B56 subunit of protein phosphatase 2A. Science. 1999 Mar 
26;283(5410):2089-91. 
37. Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, Polakis P. Binding of 
GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. 
Science. 1996 May 17;272(5264):1023-6. 
38. Liu J, Xing Y, Hinds TR, Zheng J, Xu W. The third 20 amino acid repeat is the 
tightest binding site of APC for beta-catenin. Journal of molecular biology. 2006 Jun 
30;360(1):133-44. 
39. Eklof Spink K, Fridman SG, Weis WI. Molecular mechanisms of beta-catenin 
recognition by adenomatous polyposis coli revealed by the structure of an APC-beta-
catenin complex. EMBO J. 2001 Nov 15;20(22):6203-12. 
40. Behrens J, Jerchow BA, Wurtele M, Grimm J, Asbrand C, Wirtz R, et al. 
Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and 
GSK3beta. Science. 1998 Apr 24;280(5363):596-9. 
41. Spink KE, Polakis P, Weis WI. Structural basis of the Axin-adenomatous 
polyposis coli interaction. EMBO J. 2000 May 15;19(10):2270-9. 
42. Schneikert J, Ruppert JG, Behrens J, Wenzel EM. different Roles for the axin 
interactions with the SAMP versus the second twenty amino acid repeat of adenomatous 
polyposis coli. PLoS One. 2014;9(4):e94413. 
43. Xing Y, Clements WK, Kimelman D, Xu W. Crystal structure of a beta-
catenin/axin complex suggests a mechanism for the beta-catenin destruction complex. 
Genes Dev. 2003 Nov 15;17(22):2753-64. 
44. Ha NC, Tonozuka T, Stamos JL, Choi HJ, Weis WI. Mechanism of 
phosphorylation-dependent binding of APC to beta-catenin and its role in beta-catenin 
degradation. Molecular cell. 2004 Aug 27;15(4):511-21. 
References 
229 
45. Su Y, Fu C, Ishikawa S, Stella A, Kojima M, Shitoh K, et al. APC is essential 
for targeting phosphorylated beta-catenin to the SCFbeta-TrCP ubiquitin ligase. 
Molecular cell. 2008 Dec 5;32(5):652-61. 
46. Yang J, Zhang W, Evans PM, Chen X, He X, Liu C. Adenomatous polyposis 
coli (APC) differentially regulates beta-catenin phosphorylation and ubiquitination in 
colon cancer cells. The Journal of biological chemistry. 2006 Jun 30;281(26):17751-7. 
47. Mendoza-Topaz C, Mieszczanek J, Bienz M. The Adenomatous polyposis coli 
tumour suppressor is essential for Axin complex assembly and function and opposes 
Axin's interaction with Dishevelled. Open biology. 2011 Nov;1(3):110013. 
48. Henderson BR. Nuclear-cytoplasmic shuttling of APC regulates beta-catenin 
subcellular localization and turnover. Nat Cell Biol. 2000 Sep;2(9):653-60. 
49. Rosin-Arbesfeld R, Townsley F, Bienz M. The APC tumour suppressor has a 
nuclear export function. Nature. 2000 Aug 31;406(6799):1009-12. 
50. Hamada F, Bienz M. The APC tumor suppressor binds to C-terminal binding 
protein to divert nuclear beta-catenin from TCF. Dev Cell. 2004 Nov;7(5):677-85. 
51. Sierra J, Yoshida T, Joazeiro CA, Jones KA. The APC tumor suppressor 
counteracts beta-catenin activation and H3K4 methylation at Wnt target genes. Genes 
Dev. 2006 Mar 1;20(5):586-600. 
52. Etienne-Manneville S. APC in cell migration. Adv Exp Med Biol. 2009;656:30-
40. 
53. Akiyama T, Kawasaki Y. Wnt signalling and the actin cytoskeleton. Oncogene. 
2006 Dec 4;25(57):7538-44. 
54. Nathke I. Cytoskeleton out of the cupboard: colon cancer and cytoskeletal 
changes induced by loss of APC. Nat Rev Cancer. 2006 Dec;6(12):967-74. 
55. Sakamoto Y, Boeda B, Etienne-Manneville S. APC binds intermediate filaments 
and is required for their reorganization during cell migration. The Journal of cell 
biology. 2013 Feb 4;200(3):249-58. 
56. Okada K, Bartolini F, Deaconescu AM, Moseley JB, Dogic Z, Grigorieff N, et 
al. Adenomatous polyposis coli protein nucleates actin assembly and synergizes with 
the formin mDia1. J Cell Biol. 2010 Jun 28;189(7):1087-96. 
57. Kawasaki Y, Senda T, Ishidate T, Koyama R, Morishita T, Iwayama Y, et al. 
Asef, a link between the tumor suppressor APC and G-protein signaling. Science. 2000 
Aug 18;289(5482):1194-7. 
58. Watanabe T, Wang S, Noritake J, Sato K, Fukata M, Takefuji M, et al. 
Interaction with IQGAP1 links APC to Rac1, Cdc42, and actin filaments during cell 
polarization and migration. Dev Cell. 2004 Dec;7(6):871-83. 
References 
230 
59. Matsumine A, Ogai A, Senda T, Okumura N, Satoh K, Baeg GH, et al. Binding 
of APC to the human homolog of the Drosophila discs large tumor suppressor protein. 
Science. 1996 May 17;272(5264):1020-3. 
60. Munemitsu S, Souza B, Muller O, Albert I, Rubinfeld B, Polakis P. The APC 
gene product associates with microtubules in vivo and promotes their assembly in vitro. 
Cancer Res. 1994 Jul 15;54(14):3676-81. 
61. Su LK, Burrell M, Hill DE, Gyuris J, Brent R, Wiltshire R, et al. APC binds to 
the novel protein EB1. Cancer Res. 1995 Jul 15;55(14):2972-7. 
62. Murawala P, Tripathi MM, Vyas P, Salunke A, Joseph J. Nup358 interacts with 
APC and plays a role in cell polarization. J Cell Sci. 2009 Sep 1;122(Pt 17):3113-22. 
63. Kita K, Wittmann T, Nathke IS, Waterman-Storer CM. Adenomatous polyposis 
coli on microtubule plus ends in cell extensions can promote microtubule net growth 
with or without EB1. Mol Biol Cell. 2006 May;17(5):2331-45. 
64. Vicente-Manzanares M, Horwitz AR. Cell migration: an overview. Methods in 
molecular biology. 2011;769:1-24. 
65. Kroboth K, Newton IP, Kita K, Dikovskaya D, Zumbrunn J, Waterman-Storer 
CM, et al. Lack of adenomatous polyposis coli protein correlates with a decrease in cell 
migration and overall changes in microtubule stability. Mol Biol Cell. 2007 
Mar;18(3):910-8. 
66. Sansom OJ, Reed KR, Hayes AJ, Ireland H, Brinkmann H, Newton IP, et al. 
Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, and migration. 
Genes Dev. 2004 Jun 15;18(12):1385-90. 
67. Askham JM, Moncur P, Markham AF, Morrison EE. Regulation and function of 
the interaction between the APC tumour suppressor protein and EB1. Oncogene. 2000 
Apr 6;19(15):1950-8. 
68. Jaulin F, Kreitzer G. KIF17 stabilizes microtubules and contributes to epithelial 
morphogenesis by acting at MT plus ends with EB1 and APC. The Journal of cell 
biology. 2010 Aug 9;190(3):443-60. 
69. Pfister AS, Hadjihannas MV, Rohrig W, Schambony A, Behrens J. Amer2 
protein interacts with EB1 protein and adenomatous polyposis coli (APC) and controls 
microtubule stability and cell migration. The Journal of biological chemistry. 2012 Oct 
12;287(42):35333-40. 
70. Wen Y, Eng CH, Schmoranzer J, Cabrera-Poch N, Morris EJ, Chen M, et al. 
EB1 and APC bind to mDia to stabilize microtubules downstream of Rho and promote 
cell migration. Nat Cell Biol. 2004 Sep;6(9):820-30. 
71. Nakamura M, Zhou XZ, Lu KP. Critical role for the EB1 and APC interaction in 
the regulation of microtubule polymerization. Curr Biol. 2001 Jul 10;11(13):1062-7. 
References 
231 
72. Moseley JB, Bartolini F, Okada K, Wen Y, Gundersen GG, Goode BL. 
Regulated binding of adenomatous polyposis coli protein to actin. The Journal of 
biological chemistry. 2007 Apr 27;282(17):12661-8. 
73. Kawasaki Y, Sato R, Akiyama T. Mutated APC and Asef are involved in the 
migration of colorectal tumour cells. Nature cell biology. 2003 Mar;5(3):211-5. 
74. Reilein A, Nelson WJ. APC is a component of an organizing template for 
cortical microtubule networks. Nature cell biology. 2005 May;7(5):463-73. 
75. Etienne-Manneville S, Manneville JB, Nicholls S, Ferenczi MA, Hall A. Cdc42 
and Par6-PKCzeta regulate the spatially localized association of Dlg1 and APC to 
control cell polarization. The Journal of cell biology. 2005 Sep 12;170(6):895-901. 
76. Manneville JB, Jehanno M, Etienne-Manneville S. Dlg1 binds GKAP to control 
dynein association with microtubules, centrosome positioning, and cell polarity. The 
Journal of cell biology. 2010 Nov 1;191(3):585-98. 
77. Collin L, Schlessinger K, Hall A. APC nuclear membrane association and 
microtubule polarity. Biol Cell. 2008 Apr;100(4):243-52. 
78. Rusan NM, Peifer M. Original CIN: reviewing roles for APC in chromosome 
instability. The Journal of cell biology. 2008 Jun 2;181(5):719-26. 
79. Kaplan KB, Burds AA, Swedlow JR, Bekir SS, Sorger PK, Nathke IS. A role for 
the Adenomatous Polyposis Coli protein in chromosome segregation. Nat Cell Biol. 
2001 Apr;3(4):429-32. 
80. Green RA, Kaplan KB. Chromosome instability in colorectal tumor cells is 
associated with defects in microtubule plus-end attachments caused by a dominant 
mutation in APC. J Cell Biol. 2003 Dec 8;163(5):949-61. 
81. Deka J, Herter P, Sprenger-Haussels M, Koosch S, Franz D, Muller KM, et al. 
The APC protein binds to A/T rich DNA sequences. Oncogene. 1999 Oct 
7;18(41):5654-61. 
82. Brocardo MG, Borowiec JA, Henderson BR. Adenomatous polyposis coli 
protein regulates the cellular response to DNA replication stress. Int J Biochem Cell 
Biol. 2011 Sep;43(9):1354-64. 
83. Schneikert J, Behrens J. Truncated APC is required for cell proliferation and 
DNA replication. Int J Cancer. 2006 Jul 1;119(1):74-9. 
84. Jaiswal AS, Narayan S. A novel function of adenomatous polyposis coli (APC) 
in regulating DNA repair. Cancer Lett. 2008 Nov 28;271(2):272-80. 
85. Benchabane H, Ahmed Y. The adenomatous polyposis coli tumor suppressor 
and Wnt signaling in the regulation of apoptosis. Adv Exp Med Biol. 2009;656:75-84. 
86. Chen T, Yang I, Irby R, Shain KH, Wang HG, Quackenbush J, et al. Regulation 
of caspase expression and apoptosis by adenomatous polyposis coli. Cancer Res. 2003 
Aug 1;63(15):4368-74. 
References 
232 
87. Qian J, Perchiniak EM, Sun K, Groden J. The mitochondrial protein hTID-1 
partners with the caspase-cleaved adenomatous polyposis cell tumor suppressor to 
facilitate apoptosis. Gastroenterology. 2010 Apr;138(4):1418-28. 
88. Su LK, Johnson KA, Smith KJ, Hill DE, Vogelstein B, Kinzler KW. Association 
between wild type and mutant APC gene products. Cancer Res. 1993 Jun 
15;53(12):2728-31. 
89. Joslyn G, Richardson DS, White R, Alber T. Dimer formation by an N-terminal 
coiled coil in the APC protein. Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11109-13. 
90. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, et al. 
Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon 
carcinoma. Science. 1997 Mar 21;275(5307):1784-7. 
91. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, et al. 
Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or 
APC. Science. 1997 Mar 21;275(5307):1787-90. 
92. Chiurillo MA. Role of the Wnt/beta-catenin pathway in gastric cancer: An in-
depth literature review. World journal of experimental medicine. 2015 May 20;5(2):84-
102. 
93. Song L, Li Y, He B, Gong Y. Development of Small Molecules Targeting the 
Wnt Signaling Pathway in Cancer Stem Cells for the Treatment of Colorectal Cancer. 
Clinical colorectal cancer. 2015 Feb 17. 
94. Rosin-Arbesfeld R, Ihrke G, Bienz M. Actin-dependent membrane association 
of the APC tumour suppressor in polarized mammalian epithelial cells. EMBO J. 2001 
Nov 1;20(21):5929-39. 
95. Lesko AC, Goss KH, Yang FF, Schwertner A, Hulur I, Onel K, et al. The APC 
tumor suppressor is required for epithelial cell polarization and three-dimensional 
morphogenesis. Biochim Biophys Acta. 2015 Mar;1854(3):711-23. 
96. Nelson SA, Li Z, Newton IP, Fraser D, Milne RE, Martin DM, et al. 
Tumorigenic fragments of APC cause dominant defects in directional cell migration in 
multiple model systems. Disease models & mechanisms. 2012 Nov;5(6):940-7. 
97. Lamprecht SA, Lipkin M. Migrating colonic crypt epithelial cells: primary 
targets for transformation. Carcinogenesis. 2002 Nov;23(11):1777-80. 
98. Moss SF, Liu TC, Petrotos A, Hsu TM, Gold LI, Holt PR. Inward growth of 
colonic adenomatous polyps. Gastroenterology. 1996 Dec;111(6):1425-32. 
99. Mahmoud NN, Boolbol SK, Bilinski RT, Martucci C, Chadburn A, Bertagnolli 
MM. Apc gene mutation is associated with a dominant-negative effect upon intestinal 
cell migration. Cancer Res. 1997 Nov 15;57(22):5045-50. 
100. Kawasaki Y, Tsuji S, Muroya K, Furukawa S, Shibata Y, Okuno M, et al. The 
adenomatous polyposis coli-associated exchange factors Asef and Asef2 are required 
for adenoma formation in Apc(Min/+)mice. EMBO reports. 2009 Dec;10(12):1355-62. 
References 
233 
101. Faux MC, Ross JL, Meeker C, Johns T, Ji H, Simpson RJ, et al. Restoration of 
full-length adenomatous polyposis coli (APC) protein in a colon cancer cell line 
enhances cell adhesion. Journal of cell science. 2004 Jan 26;117(Pt 3):427-39. 
102. Thompson SL, Compton DA. Examining the link between chromosomal 
instability and aneuploidy in human cells. The Journal of cell biology. 2008 Feb 
25;180(4):665-72. 
103. Draviam VM, Xie S, Sorger PK. Chromosome segregation and genomic 
stability. Current opinion in genetics & development. 2004 Apr;14(2):120-5. 
104. Fodde R, Kuipers J, Rosenberg C, Smits R, Kielman M, Gaspar C, et al. 
Mutations in the APC tumour suppressor gene cause chromosomal instability. Nat Cell 
Biol. 2001 Apr;3(4):433-8. 
105. Green RA, Wollman R, Kaplan KB. APC and EB1 function together in mitosis 
to regulate spindle dynamics and chromosome alignment. Mol Biol Cell. 2005 
Oct;16(10):4609-22. 
106. Martino-Echarri E, Henderson BR, Brocardo MG. Targeting the DNA 
replication checkpoint by pharmacologic inhibition of Chk1 kinase: a strategy to 
sensitize APC mutant colon cancer cells to 5-fluorouracil chemotherapy. Oncotarget. 
2014 Oct 30;5(20):9889-900. 
107. Huang X, Guo B. Adenomatous polyposis coli determines sensitivity to histone 
deacetylase inhibitor-induced apoptosis in colon cancer cells. Cancer Res. 2006 Sep 
15;66(18):9245-51. 
108. Dihlmann S, Kloor M, Fallsehr C, von Knebel Doeberitz M. Regulation of 
AKT1 expression by beta-catenin/Tcf/Lef signaling in colorectal cancer cells. 
Carcinogenesis. 2005 Sep;26(9):1503-12. 
109. Mezhybovska M, Wikstrom K, Ohd JF, Sjolander A. The inflammatory 
mediator leukotriene D4 induces beta-catenin signaling and its association with 
antiapoptotic Bcl-2 in intestinal epithelial cells. The Journal of biological chemistry. 
2006 Mar 10;281(10):6776-84. 
110. Mezhybovska M, Yudina Y, Abhyankar A, Sjolander A. Beta-catenin is 
involved in alterations in mitochondrial activity in non-transformed intestinal epithelial 
and colon cancer cells. British journal of cancer. 2009 Nov 3;101(9):1596-605. 
111. Johannsen DL, Ravussin E. The role of mitochondria in health and disease. 
Current Opinion in Pharmacology. [doi: DOI: 10.1016/j.coph.2009.09.002]. 
2009;9(6):780-6. 
112. Chen C, Paw BH. Cellular and mitochondrial iron homeostasis in vertebrates. 
Biochim Biophys Acta. 2012 Sep;1823(9):1459-67. 
113. Mena NP, Urrutia PJ, Lourido F, Carrasco CM, Nunez MT. Mitochondrial iron 
homeostasis and its dysfunctions in neurodegenerative disorders. Mitochondrion. 2015 
Mar;21:92-105. 
References 
234 
114. Scheffler IE. Mitochondria: Wiley; 2011. 
115. Desideri E, Vegliante R, Ciriolo MR. Mitochondrial dysfunctions in cancer: 
genetic defects and oncogenic signaling impinging on TCA cycle activity. Cancer 
letters. 2015 Jan 28;356(2 Pt A):217-23. 
116. Serra D, Mera P, Malandrino MI, Mir JF, Herrero L. Mitochondrial fatty acid 
oxidation in obesity. Antioxidants & redox signaling. 2013 Jul 20;19(3):269-84. 
117. Huttemann M, Lee I, Samavati L, Yu H, Doan JW. Regulation of mitochondrial 
oxidative phosphorylation through cell signaling. Biochim Biophys Acta. 2007 
Dec;1773(12):1701-20. 
118. Smeitink J, van den Heuvel L, DiMauro S. The genetics and pathology of 
oxidative phosphorylation. Nature reviews Genetics. 2001 May;2(5):342-52. 
119. Chaban Y, Boekema EJ, Dudkina NV. Structures of mitochondrial oxidative 
phosphorylation supercomplexes and mechanisms for their stabilisation. Biochim 
Biophys Acta. 2014 Apr;1837(4):418-26. 
120. Papa S, Martino P, Capitanio G, Gaballo A, De Rasmo D, Signorile A, et al. The 
Oxidative Phosphorylation System in Mammalian Mitochondria. In: Scatena R, Bottoni 
P, Giardina B, editors. Advances in Mitochondrial Medicine: Springer Netherlands; 
2012. p. 3-37. 
121. Walsh C, Barrow S, Voronina S, Chvanov M, Petersen OH, Tepikin A. 
Modulation of calcium signalling by mitochondria. Biochim Biophys Acta. 2009 
Nov;1787(11):1374-82. 
122. Graier WF, Frieden M, Malli R. Mitochondria and Ca(2+) signaling: old guests, 
new functions. Pflugers Archiv : European journal of physiology. 2007 Dec;455(3):375-
96. 
123. Hajnoczky G, Csordas G, Das S, Garcia-Perez C, Saotome M, Sinha Roy S, et 
al. Mitochondrial calcium signalling and cell death: approaches for assessing the role of 
mitochondrial Ca2+ uptake in apoptosis. Cell calcium. 2006 Nov-Dec;40(5-6):553-60. 
124. Gincel D, Zaid H, Shoshan-Barmatz V. Calcium binding and translocation by 
the voltage-dependent anion channel: a possible regulatory mechanism in mitochondrial 
function. Biochem J. 2001 Aug 15;358(Pt 1):147-55. 
125. Rapizzi E, Pinton P, Szabadkai G, Wieckowski MR, Vandecasteele G, Baird G, 
et al. Recombinant expression of the voltage-dependent anion channel enhances the 
transfer of Ca2+ microdomains to mitochondria. The Journal of cell biology. 2002 Nov 
25;159(4):613-24. 
126. Kirichok Y, Krapivinsky G, Clapham DE. The mitochondrial calcium uniporter 
is a highly selective ion channel. Nature. 2004 Jan 22;427(6972):360-4. 
127. Alonso MT, Villalobos C, Chamero P, Alvarez J, Garcia-Sancho J. Calcium 
microdomains in mitochondria and nucleus. Cell calcium. 2006 Nov-Dec;40(5-6):513-
25. 
References 
235 
128. Gunter TE, Pfeiffer DR. Mechanisms by which mitochondria transport calcium. 
The American journal of physiology. 1990 May;258(5 Pt 1):C755-86. 
129. Scorziello A, Savoia C, Sisalli MJ, Adornetto A, Secondo A, Boscia F, et al. 
NCX3 regulates mitochondrial Ca(2+) handling through the AKAP121-anchored 
signaling complex and prevents hypoxia-induced neuronal death. Journal of cell 
science. 2013 Dec 15;126(Pt 24):5566-77. 
130. Li MX, Dewson G. Mitochondria and apoptosis: emerging concepts. 
F1000prime reports. 2015;7:42. 
131. Lopez J, Tait SW. Mitochondrial apoptosis: killing cancer using the enemy 
within. British journal of cancer. 2015 Mar 17;112(6):957-62. 
132. Gillies LA, Kuwana T. Apoptosis regulation at the mitochondrial outer 
membrane. Journal of cellular biochemistry. 2014 Apr;115(4):632-40. 
133. Willis SN, Adams JM. Life in the balance: how BH3-only proteins induce 
apoptosis. Current opinion in cell biology. 2005 Dec;17(6):617-25. 
134. Reubold TF, Eschenburg S. A molecular view on signal transduction by the 
apoptosome. Cellular signalling. 2012 Jul;24(7):1420-5. 
135. Tait SW, Ichim G, Green DR. Die another way--non-apoptotic mechanisms of 
cell death. Journal of cell science. 2014 May 15;127(Pt 10):2135-44. 
136. Lartigue L, Kushnareva Y, Seong Y, Lin H, Faustin B, Newmeyer DD. Caspase-
independent mitochondrial cell death results from loss of respiration, not cytotoxic 
protein release. Mol Biol Cell. 2009 Dec;20(23):4871-84. 
137. Lin MY, Sheng ZH. Regulation of mitochondrial transport in neurons. 
Experimental cell research. 2015 May 15;334(1):35-44. 
138. Sheng ZH. Mitochondrial trafficking and anchoring in neurons: New insight and 
implications. J Cell Biol. 2014 Mar 31;204(7):1087-98. 
139. Chaturvedi RK, Flint Beal M. Mitochondrial diseases of the brain. Free Radic 
Biol Med. 2013 Oct;63:1-29. 
140. Corrado M, Scorrano L, Campello S. Mitochondrial dynamics in cancer and 
neurodegenerative and neuroinflammatory diseases. International journal of cell 
biology. 2012;2012:729290. 
141. Sheng ZH, Cai Q. Mitochondrial transport in neurons: impact on synaptic 
homeostasis and neurodegeneration. Nature reviews Neuroscience. 2012 Feb;13(2):77-
93. 
142. Campello S, Lacalle RA, Bettella M, Manes S, Scorrano L, Viola A. 
Orchestration of lymphocyte chemotaxis by mitochondrial dynamics. J Exp Med. 2006 
Dec 25;203(13):2879-86. 
References 
236 
143. Guo X, Macleod GT, Wellington A, Hu F, Panchumarthi S, Schoenfield M, et 
al. The GTPase dMiro is required for axonal transport of mitochondria to Drosophila 
synapses. Neuron. 2005 Aug 4;47(3):379-93. 
144. Stowers RS, Megeath LJ, Gorska-Andrzejak J, Meinertzhagen IA, Schwarz TL. 
Axonal transport of mitochondria to synapses depends on milton, a novel Drosophila 
protein. Neuron. 2002 Dec 19;36(6):1063-77. 
145. Brickley K, Smith MJ, Beck M, Stephenson FA. GRIF-1 and OIP106, members 
of a novel gene family of coiled-coil domain proteins: association in vivo and in vitro 
with kinesin. J Biol Chem. 2005 Apr 15;280(15):14723-32. 
146. Fransson A, Ruusala A, Aspenstrom P. Atypical Rho GTPases have roles in 
mitochondrial homeostasis and apoptosis. J Biol Chem. 2003 Feb 21;278(8):6495-502. 
147. Cox RT, Spradling AC. Milton controls the early acquisition of mitochondria by 
Drosophila oocytes. Development. 2006 Sep;133(17):3371-7. 
148. Fransson S, Ruusala A, Aspenstrom P. The atypical Rho GTPases Miro-1 and 
Miro-2 have essential roles in mitochondrial trafficking. Biochem Biophys Res 
Commun. 2006 Jun 2;344(2):500-10. 
149. Glater EE, Megeath LJ, Stowers RS, Schwarz TL. Axonal transport of 
mitochondria requires milton to recruit kinesin heavy chain and is light chain 
independent. J Cell Biol. 2006 May 22;173(4):545-57. 
150. MacAskill AF, Brickley K, Stephenson FA, Kittler JT. GTPase dependent 
recruitment of Grif-1 by Miro1 regulates mitochondrial trafficking in hippocampal 
neurons. Mol Cell Neurosci. 2009 Mar;40(3):301-12. 
151. Hurd DD, Saxton WM. Kinesin mutations cause motor neuron disease 
phenotypes by disrupting fast axonal transport in Drosophila. Genetics. 1996 
Nov;144(3):1075-85. 
152. Wang X, Winter D, Ashrafi G, Schlehe J, Wong YL, Selkoe D, et al. PINK1 and 
Parkin Target Miro for Phosphorylation and Degradation to Arrest Mitochondrial 
Motility. Cell. 2011 Nov 11;147(4):893-906. 
153. Wang X, Schwarz TL. The mechanism of Ca2+ -dependent regulation of 
kinesin-mediated mitochondrial motility. Cell. 2009 Jan 9;136(1):163-74. 
154. Brickley K, Stephenson FA. Trafficking kinesin protein (TRAK)-mediated 
transport of mitochondria in axons of hippocampal neurons. J Biol Chem. 2011 May 
20;286(20):18079-92. 
155. Smith MJ, Pozo K, Brickley K, Stephenson FA. Mapping the GRIF-1 binding 
domain of the kinesin, KIF5C, substantiates a role for GRIF-1 as an adaptor protein in 
the anterograde trafficking of cargoes. J Biol Chem. 2006 Sep 15;281(37):27216-28. 
156. Pekkurnaz G, Trinidad JC, Wang X, Kong D, Schwarz TL. Glucose regulates 
mitochondrial motility via Milton modification by O-GlcNAc transferase. Cell. 2014 Jul 
3;158(1):54-68. 
References 
237 
157. Tsai PI, Course MM, Lovas JR, Hsieh CH, Babic M, Zinsmaier KE, et al. 
PINK1-mediated phosphorylation of Miro inhibits synaptic growth and protects 
dopaminergic neurons in Drosophila. Scientific reports. 2014;4:6962. 
158. Saotome M, Safiulina D, Szabadkai G, Das S, Fransson A, Aspenstrom P, et al. 
Bidirectional Ca2+-dependent control of mitochondrial dynamics by the Miro GTPase. 
Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20728-33. 
159. Macaskill AF, Rinholm JE, Twelvetrees AE, Arancibia-Carcamo IL, Muir J, 
Fransson A, et al. Miro1 is a calcium sensor for glutamate receptor-dependent 
localization of mitochondria at synapses. Neuron. 2009 Feb 26;61(4):541-55. 
160. Li Y, Lim S, Hoffman D, Aspenstrom P, Federoff HJ, Rempe DA. HUMMR, a 
hypoxia- and HIF-1alpha-inducible protein, alters mitochondrial distribution and 
transport. J Cell Biol. 2009 Jun 15;185(6):1065-81. 
161. Serrat R, Lopez-Domenech G, Mirra S, Quevedo M, Garcia-Fernandez J, Ulloa 
F, et al. The non-canonical Wnt/PKC pathway regulates mitochondrial dynamics 
through degradation of the arm-like domain-containing protein Alex3. PLoS One. 
2013;8(7):e67773. 
162. Misko A, Jiang S, Wegorzewska I, Milbrandt J, Baloh RH. Mitofusin 2 is 
necessary for transport of axonal mitochondria and interacts with the Miro/Milton 
complex. J Neurosci. 2010 Mar 24;30(12):4232-40. 
163. Lopez-Domenech G, Serrat R, Mirra S, D'Aniello S, Somorjai I, Abad A, et al. 
The Eutherian Armcx genes regulate mitochondrial trafficking in neurons and interact 
with Miro and Trak2. Nat Commun. 2012;3:814. 
164. Yi M, Weaver D, Hajnoczky G. Control of mitochondrial motility and 
distribution by the calcium signal: a homeostatic circuit. The Journal of cell biology. 
2004 Nov 22;167(4):661-72. 
165. Liu S, Sawada T, Lee S, Yu W, Silverio G, Alapatt P, et al. Parkinson's disease-
associated kinase PINK1 regulates Miro protein level and axonal transport of 
mitochondria. PLoS genetics. 2012;8(3):e1002537. 
166. Birsa N, Norkett R, Wauer T, Mevissen TE, Wu HC, Foltynie T, et al. Lysine 27 
ubiquitination of the mitochondrial transport protein Miro is dependent on serine 65 of 
the Parkin ubiquitin ligase. J Biol Chem. 2014 May 23;289(21):14569-82. 
167. Morlino G, Barreiro O, Baixauli F, Robles-Valero J, Gonzalez-Granado JM, 
Villa-Bellosta R, et al. Miro-1 links mitochondria and microtubule Dynein motors to 
control lymphocyte migration and polarity. Mol Cell Biol. 2014 Apr;34(8):1412-26. 
168. Russo GJ, Louie K, Wellington A, Macleod GT, Hu F, Panchumarthi S, et al. 
Drosophila Miro is required for both anterograde and retrograde axonal mitochondrial 
transport. J Neurosci. 2009 Apr 29;29(17):5443-55. 
169. van Spronsen M, Mikhaylova M, Lipka J, Schlager MA, van den Heuvel DJ, 
Kuijpers M, et al. TRAK/Milton motor-adaptor proteins steer mitochondrial trafficking 
to axons and dendrites. Neuron. 2013 Feb 6;77(3):485-502. 
References 
238 
170. Ligon LA, Steward O. Role of microtubules and actin filaments in the 
movement of mitochondria in the axons and dendrites of cultured hippocampal neurons. 
The Journal of comparative neurology. 2000 Nov 20;427(3):351-61. 
171. Morris RL, Hollenbeck PJ. Axonal transport of mitochondria along microtubules 
and F-actin in living vertebrate neurons. The Journal of cell biology. 1995 
Dec;131(5):1315-26. 
172. Langford GM. Actin- and microtubule-dependent organelle motors: 
interrelationships between the two motility systems. Current opinion in cell biology. 
1995 Feb;7(1):82-8. 
173. Perez-Olle R, Lopez-Toledano MA, Goryunov D, Cabrera-Poch N, Stefanis L, 
Brown K, et al. Mutations in the neurofilament light gene linked to Charcot-Marie-
Tooth disease cause defects in transport. Journal of neurochemistry. 2005 
May;93(4):861-74. 
174. Uttam J, Hutton E, Coulombe PA, Anton-Lamprecht I, Yu QC, Gedde-Dahl T, 
Jr., et al. The genetic basis of epidermolysis bullosa simplex with mottled pigmentation. 
Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9079-84. 
175. Winter L, Abrahamsberg C, Wiche G. Plectin isoform 1b mediates 
mitochondrion-intermediate filament network linkage and controls organelle shape. The 
Journal of cell biology. 2008 Jun 16;181(6):903-11. 
176. Cho KI, Cai Y, Yi H, Yeh A, Aslanukov A, Ferreira PA. Association of the 
kinesin-binding domain of RanBP2 to KIF5B and KIF5C determines mitochondria 
localization and function. Traffic. 2007 Dec;8(12):1722-35. 
177. Patil H, Cho KI, Lee J, Yang Y, Orry A, Ferreira PA. Kinesin-1 and 
mitochondrial motility control by discrimination of structurally equivalent but distinct 
subdomains in Ran-GTP-binding domains of Ran-binding protein 2. Open Biol. 2013 
Mar;3(3):120183. 
178. Cai Q, Gerwin C, Sheng ZH. Syntabulin-mediated anterograde transport of 
mitochondria along neuronal processes. J Cell Biol. 2005 Sep 12;170(6):959-69. 
179. Nangaku M, Sato-Yoshitake R, Okada Y, Noda Y, Takemura R, Yamazaki H, et 
al. KIF1B, a novel microtubule plus end-directed monomeric motor protein for transport 
of mitochondria. Cell. 1994 Dec 30;79(7):1209-20. 
180. Wozniak MJ, Melzer M, Dorner C, Haring HU, Lammers R. The novel protein 
KBP regulates mitochondria localization by interaction with a kinesin-like protein. 
BMC Cell Biol. 2005;6:35. 
181. Tanaka K, Sugiura Y, Ichishita R, Mihara K, Oka T. KLP6: a newly identified 
kinesin that regulates the morphology and transport of mitochondria in neuronal cells. J 
Cell Sci. 2011 Jul 15;124(Pt 14):2457-65. 
182. Pilling AD, Horiuchi D, Lively CM, Saxton WM. Kinesin-1 and Dynein are the 
primary motors for fast transport of mitochondria in Drosophila motor axons. Mol Biol 
Cell. 2006 Apr;17(4):2057-68. 
References 
239 
183. Jimenez-Mateos EM, Gonzalez-Billault C, Dawson HN, Vitek MP, Avila J. 
Role of MAP1B in axonal retrograde transport of mitochondria. Biochem J. 2006 Jul 
1;397(1):53-9. 
184. Trinczek B, Ebneth A, Mandelkow EM, Mandelkow E. Tau regulates the 
attachment/detachment but not the speed of motors in microtubule-dependent transport 
of single vesicles and organelles. Journal of cell science. 1999 Jul;112 ( Pt 14):2355-67. 
185. Chen Y, Sheng ZH. Kinesin-1-syntaphilin coupling mediates activity-dependent 
regulation of axonal mitochondrial transport. The Journal of cell biology. 2013 Jul 
22;202(2):351-64. 
186. Kang JS, Tian JH, Pan PY, Zald P, Li C, Deng C, et al. Docking of axonal 
mitochondria by syntaphilin controls their mobility and affects short-term facilitation. 
Cell. 2008 Jan 11;132(1):137-48. 
187. Pathak D, Sepp KJ, Hollenbeck PJ. Evidence that myosin activity opposes 
microtubule-based axonal transport of mitochondria. J Neurosci. 2010 Jun 
30;30(26):8984-92. 
188. Quintero OA, DiVito MM, Adikes RC, Kortan MB, Case LB, Lier AJ, et al. 
Human Myo19 is a novel myosin that associates with mitochondria. Curr Biol. 2009 
Dec 15;19(23):2008-13. 
189. Attwell D, Laughlin SB. An energy budget for signaling in the grey matter of the 
brain. Journal of cerebral blood flow and metabolism : official journal of the 
International Society of Cerebral Blood Flow and Metabolism. 2001 Oct;21(10):1133-
45. 
190. Varadi A, Cirulli V, Rutter GA. Mitochondrial localization as a determinant of 
capacitative Ca2+ entry in HeLa cells. Cell calcium. 2004 Dec;36(6):499-508. 
191. Escobar-Henriques M, Anton F. Mechanistic perspective of mitochondrial 
fusion: tubulation vs. fragmentation. Biochim Biophys Acta. 2013 Jan;1833(1):162-75. 
192. Chan DC. Fusion and fission: interlinked processes critical for mitochondrial 
health. Annual review of genetics. 2012;46:265-87. 
193. Chan DC. Mitochondrial fusion and fission in mammals. Annual review of cell 
and developmental biology. 2006;22:79-99. 
194. Hall AR, Burke N, Dongworth RK, Hausenloy DJ. Mitochondrial fusion and 
fission proteins: novel therapeutic targets for combating cardiovascular disease. British 
journal of pharmacology. 2014 Apr;171(8):1890-906. 
195. da Silva AF, Mariotti FR, Maximo V, Campello S. Mitochondria dynamism: of 
shape, transport and cell migration. Cell Mol Life Sci. 2014 Jun;71(12):2313-24. 
196. Song Z, Ghochani M, McCaffery JM, Frey TG, Chan DC. Mitofusins and OPA1 
mediate sequential steps in mitochondrial membrane fusion. Mol Biol Cell. 2009 
Aug;20(15):3525-32. 
References 
240 
197. Rojo M, Legros F, Chateau D, Lombes A. Membrane topology and 
mitochondrial targeting of mitofusins, ubiquitous mammalian homologs of the 
transmembrane GTPase Fzo. Journal of cell science. 2002 Apr 15;115(Pt 8):1663-74. 
198. Legros F, Lombes A, Frachon P, Rojo M. Mitochondrial fusion in human cells is 
efficient, requires the inner membrane potential, and is mediated by mitofusins. Mol 
Biol Cell. 2002 Dec;13(12):4343-54. 
199. Zorzano A, Liesa M, Sebastian D, Segales J, Palacin M. Mitochondrial fusion 
proteins: dual regulators of morphology and metabolism. Seminars in cell & 
developmental biology. 2010 Aug;21(6):566-74. 
200. de Brito OM, Scorrano L. Mitofusin 2 tethers endoplasmic reticulum to 
mitochondria. Nature. 2008 Dec 4;456(7222):605-10. 
201. Cipolat S, Rudka T, Hartmann D, Costa V, Serneels L, Craessaerts K, et al. 
Mitochondrial rhomboid PARL regulates cytochrome c release during apoptosis via 
OPA1-dependent cristae remodeling. Cell. 2006 Jul 14;126(1):163-75. 
202. Delettre C, Lenaers G, Griffoin JM, Gigarel N, Lorenzo C, Belenguer P, et al. 
Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in 
dominant optic atrophy. Nature genetics. 2000 Oct;26(2):207-10. 
203. Ishihara N, Fujita Y, Oka T, Mihara K. Regulation of mitochondrial morphology 
through proteolytic cleavage of OPA1. Embo j. 2006 Jul 12;25(13):2966-77. 
204. Delettre C, Griffoin JM, Kaplan J, Dollfus H, Lorenz B, Faivre L, et al. 
Mutation spectrum and splicing variants in the OPA1 gene. Human genetics. 2001 
Dec;109(6):584-91. 
205. Akepati VR, Muller EC, Otto A, Strauss HM, Portwich M, Alexander C. 
Characterization of OPA1 isoforms isolated from mouse tissues. Journal of 
neurochemistry. 2008 Jul;106(1):372-83. 
206. Smirnova E, Griparic L, Shurland DL, van der Bliek AM. Dynamin-related 
protein Drp1 is required for mitochondrial division in mammalian cells. Mol Biol Cell. 
2001 Aug;12(8):2245-56. 
207. Mears JA, Lackner LL, Fang S, Ingerman E, Nunnari J, Hinshaw JE. 
Conformational changes in Dnm1 support a contractile mechanism for mitochondrial 
fission. Nature structural & molecular biology. 2011 Jan;18(1):20-6. 
208. Friedman JR, Lackner LL, West M, DiBenedetto JR, Nunnari J, Voeltz GK. ER 
tubules mark sites of mitochondrial division. Science. 2011 Oct 21;334(6054):358-62. 
209. Pedrola L, Espert A, Wu X, Claramunt R, Shy ME, Palau F. GDAP1, the protein 
causing Charcot-Marie-Tooth disease type 4A, is expressed in neurons and is associated 
with mitochondria. Human molecular genetics. 2005 Apr 15;14(8):1087-94. 
210. Tondera D, Czauderna F, Paulick K, Schwarzer R, Kaufmann J, Santel A. The 
mitochondrial protein MTP18 contributes to mitochondrial fission in mammalian cells. 
Journal of cell science. 2005 Jul 15;118(Pt 14):3049-59. 
References 
241 
211. Karbowski M, Jeong SY, Youle RJ. Endophilin B1 is required for the 
maintenance of mitochondrial morphology. The Journal of cell biology. 2004 Sep 
27;166(7):1027-39. 
212. Lokireddy S, Wijesoma Isuru W, Teng S, Bonala S, Gluckman Peter D, 
McFarlane C, et al. The Ubiquitin Ligase Mul1 Induces Mitophagy in Skeletal Muscle 
in Response to Muscle-Wasting Stimuli. Cell metabolism. 2012 11/7/;16(5):613-24. 
213. Yun J, Puri R, Yang H, Lizzio MA, Wu C, Sheng ZH, et al. MUL1 acts in 
parallel to the PINK1/parkin pathway in regulating mitofusin and compensates for loss 
of PINK1/parkin. eLife. 2014;3:e01958. 
214. Ziviani E, Tao RN, Whitworth AJ. Drosophila parkin requires PINK1 for 
mitochondrial translocation and ubiquitinates mitofusin. Proc Natl Acad Sci U S A. 
2010 Mar 16;107(11):5018-23. 
215. Eura Y, Ishihara N, Oka T, Mihara K. Identification of a novel protein that 
regulates mitochondrial fusion by modulating mitofusin (Mfn) protein function. Journal 
of cell science. 2006 Dec 1;119(Pt 23):4913-25. 
216. Hoppins S, Edlich F, Cleland MM, Banerjee S, McCaffery JM, Youle RJ, et al. 
The soluble form of Bax regulates mitochondrial fusion via MFN2 homotypic 
complexes. Molecular cell. 2011 Jan 21;41(2):150-60. 
217. Choi SY, Huang P, Jenkins GM, Chan DC, Schiller J, Frohman MA. A common 
lipid links Mfn-mediated mitochondrial fusion and SNARE-regulated exocytosis. 
Nature cell biology. 2006 Nov;8(11):1255-62. 
218. Head B, Griparic L, Amiri M, Gandre-Babbe S, van der Bliek AM. Inducible 
proteolytic inactivation of OPA1 mediated by the OMA1 protease in mammalian cells. 
The Journal of cell biology. 2009 Dec 28;187(7):959-66. 
219. Song Z, Chen H, Fiket M, Alexander C, Chan DC. OPA1 processing controls 
mitochondrial fusion and is regulated by mRNA splicing, membrane potential, and 
Yme1L. The Journal of cell biology. 2007 Aug 27;178(5):749-55. 
220. Merkwirth C, Dargazanli S, Tatsuta T, Geimer S, Lower B, Wunderlich FT, et 
al. Prohibitins control cell proliferation and apoptosis by regulating OPA1-dependent 
cristae morphogenesis in mitochondria. Genes Dev. 2008 Feb 15;22(4):476-88. 
221. An HJ, Cho G, Lee JO, Paik SG, Kim YS, Lee H. Higd-1a interacts with Opa1 
and is required for the morphological and functional integrity of mitochondria. Proc 
Natl Acad Sci U S A. 2013 Aug 6;110(32):13014-9. 
222. Yoon Y, Krueger EW, Oswald BJ, McNiven MA. The mitochondrial protein 
hFis1 regulates mitochondrial fission in mammalian cells through an interaction with 
the dynamin-like protein DLP1. Mol Cell Biol. 2003 Aug;23(15):5409-20. 
223. Zhao J, Liu T, Jin S, Wang X, Qu M, Uhlen P, et al. Human MIEF1 recruits 
Drp1 to mitochondrial outer membranes and promotes mitochondrial fusion rather than 
fission. Embo j. 2011 Jul 20;30(14):2762-78. 
References 
242 
224. Otera H, Wang C, Cleland MM, Setoguchi K, Yokota S, Youle RJ, et al. Mff is 
an essential factor for mitochondrial recruitment of Drp1 during mitochondrial fission in 
mammalian cells. The Journal of cell biology. 2010 Dec 13;191(6):1141-58. 
225. Liu T, Yu R, Jin SB, Han L, Lendahl U, Zhao J, et al. The mitochondrial 
elongation factors MIEF1 and MIEF2 exert partially distinct functions in mitochondrial 
dynamics. Experimental cell research. 2013 Nov 1;319(18):2893-904. 
226. Palmer CS, Osellame LD, Laine D, Koutsopoulos OS, Frazier AE, Ryan MT. 
MiD49 and MiD51, new components of the mitochondrial fission machinery. EMBO 
reports. 2011 Jun;12(6):565-73. 
227. Fang L, Hemion C, Goldblum D, Meyer P, Orgul S, Frank S, et al. Inactivation 
of MARCH5 prevents mitochondrial fragmentation and interferes with cell death in a 
neuronal cell model. PLoS One. 2012;7(12):e52637. 
228. Karbowski M, Neutzner A, Youle RJ. The mitochondrial E3 ubiquitin ligase 
MARCH5 is required for Drp1 dependent mitochondrial division. The Journal of cell 
biology. 2007 Jul 2;178(1):71-84. 
229. Wang H, Song P, Du L, Tian W, Yue W, Liu M, et al. Parkin ubiquitinates Drp1 
for proteasome-dependent degradation: implication of dysregulated mitochondrial 
dynamics in Parkinson disease. The Journal of biological chemistry. 2011 Apr 
1;286(13):11649-58. 
230. Cribbs JT, Strack S. Reversible phosphorylation of Drp1 by cyclic AMP-
dependent protein kinase and calcineurin regulates mitochondrial fission and cell death. 
EMBO reports. 2007 Oct;8(10):939-44. 
231. Chang CR, Blackstone C. Cyclic AMP-dependent protein kinase 
phosphorylation of Drp1 regulates its GTPase activity and mitochondrial morphology. 
The Journal of biological chemistry. 2007 Jul 27;282(30):21583-7. 
232. Cereghetti GM, Stangherlin A, Martins de Brito O, Chang CR, Blackstone C, 
Bernardi P, et al. Dephosphorylation by calcineurin regulates translocation of Drp1 to 
mitochondria. Proc Natl Acad Sci U S A. 2008 Oct 14;105(41):15803-8. 
233. Wasiak S, Zunino R, McBride HM. Bax/Bak promote sumoylation of DRP1 and 
its stable association with mitochondria during apoptotic cell death. The Journal of cell 
biology. 2007 May 7;177(3):439-50. 
234. Braschi E, Zunino R, McBride HM. MAPL is a new mitochondrial SUMO E3 
ligase that regulates mitochondrial fission. EMBO reports. 2009 Jul;10(7):748-54. 
235. Zunino R, Schauss A, Rippstein P, Andrade-Navarro M, McBride HM. The 
SUMO protease SENP5 is required to maintain mitochondrial morphology and 
function. Journal of cell science. 2007 Apr 1;120(Pt 7):1178-88. 
236. Tondera D, Grandemange S, Jourdain A, Karbowski M, Mattenberger Y, Herzig 
S, et al. SLP-2 is required for stress-induced mitochondrial hyperfusion. Embo j. 2009 
Jun 3;28(11):1589-600. 
References 
243 
237. Babbar M, Sheikh MS. Metabolic Stress and Disorders Related to Alterations in 
Mitochondrial Fission or Fusion. Molecular and cellular pharmacology. 2013;5(3):109-
33. 
238. Mishra P, Chan DC. Mitochondrial dynamics and inheritance during cell 
division, development and disease. Nature reviews Molecular cell biology. 2014 
Oct;15(10):634-46. 
239. Chen H, Vermulst M, Wang YE, Chomyn A, Prolla TA, McCaffery JM, et al. 
Mitochondrial fusion is required for mtDNA stability in skeletal muscle and tolerance of 
mtDNA mutations. Cell. 2010 Apr 16;141(2):280-9. 
240. Chen H, Chomyn A, Chan DC. Disruption of fusion results in mitochondrial 
heterogeneity and dysfunction. The Journal of biological chemistry. 2005 Jul 
15;280(28):26185-92. 
241. Rossignol R, Faustin B, Rocher C, Malgat M, Mazat JP, Letellier T. 
Mitochondrial threshold effects. Biochem J. 2003 Mar 15;370(Pt 3):751-62. 
242. Taylor RW, Turnbull DM. Mitochondrial DNA mutations in human disease. 
Nature reviews Genetics. 2005 May;6(5):389-402. 
243. Kim I, Rodriguez-Enriquez S, Lemasters JJ. Selective degradation of 
mitochondria by mitophagy. Archives of biochemistry and biophysics. 2007 Jun 
15;462(2):245-53. 
244. Narendra D, Tanaka A, Suen DF, Youle RJ. Parkin is recruited selectively to 
impaired mitochondria and promotes their autophagy. The Journal of cell biology. 2008 
Dec 1;183(5):795-803. 
245. Narendra DP, Jin SM, Tanaka A, Suen DF, Gautier CA, Shen J, et al. PINK1 is 
selectively stabilized on impaired mitochondria to activate Parkin. PLoS biology. 2010 
Jan;8(1):e1000298. 
246. Chan NC, Salazar AM, Pham AH, Sweredoski MJ, Kolawa NJ, Graham RL, et 
al. Broad activation of the ubiquitin-proteasome system by Parkin is critical for 
mitophagy. Human molecular genetics. 2011 May 1;20(9):1726-37. 
247. Tanaka A, Cleland MM, Xu S, Narendra DP, Suen DF, Karbowski M, et al. 
Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by 
Parkin. The Journal of cell biology. 2010 Dec 27;191(7):1367-80. 
248. Gomes LC, Di Benedetto G, Scorrano L. During autophagy mitochondria 
elongate, are spared from degradation and sustain cell viability. Nat Cell Biol. 2011 
May;13(5):589-98. 
249. Frank S, Gaume B, Bergmann-Leitner ES, Leitner WW, Robert EG, Catez F, et 
al. The role of dynamin-related protein 1, a mediator of mitochondrial fission, in 
apoptosis. Dev Cell. 2001 Oct;1(4):515-25. 
250. Breckenridge DG, Stojanovic M, Marcellus RC, Shore GC. Caspase cleavage 
product of BAP31 induces mitochondrial fission through endoplasmic reticulum 
References 
244 
calcium signals, enhancing cytochrome c release to the cytosol. The Journal of cell 
biology. 2003 Mar 31;160(7):1115-27. 
251. Suen DF, Norris KL, Youle RJ. Mitochondrial dynamics and apoptosis. Genes 
Dev. 2008 Jun 15;22(12):1577-90. 
252. Germain M, Mathai JP, McBride HM, Shore GC. Endoplasmic reticulum BIK 
initiates DRP1-regulated remodelling of mitochondrial cristae during apoptosis. Embo j. 
2005 Apr 20;24(8):1546-56. 
253. Cassidy-Stone A, Chipuk JE, Ingerman E, Song C, Yoo C, Kuwana T, et al. 
Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax/Bak-
dependent mitochondrial outer membrane permeabilization. Dev Cell. 2008 
Feb;14(2):193-204. 
254. Scorrano L. Keeping mitochondria in shape: a matter of life and death. European 
journal of clinical investigation. 2013 Aug;43(8):886-93. 
255. Turnbull DM, Rustin P. Genetic and biochemical intricacy shapes mitochondrial 
cytopathies. Neurobiology of disease. 2015 Feb 12. 
256. Katsetos CD, Koutzaki S, Melvin JJ. Mitochondrial dysfunction in 
neuromuscular disorders. Seminars in pediatric neurology. 2013 Sep;20(3):202-15. 
257. Chen L, Winger AJ, Knowlton AA. Mitochondrial dynamic changes in health 
and genetic diseases. Molecular biology reports. 2014 Nov;41(11):7053-62. 
258. Saxton WM, Hollenbeck PJ. The axonal transport of mitochondria. Journal of 
cell science. 2012 May 1;125(Pt 9):2095-104. 
259. Cartoni R, Martinou JC. Role of mitofusin 2 mutations in the physiopathology 
of Charcot-Marie-Tooth disease type 2A. Experimental neurology. 2009 
Aug;218(2):268-73. 
260. Votruba M. Molecular genetic basis of primary inherited optic neuropathies. Eye 
(London, England). 2004 Nov;18(11):1126-32. 
261. Yan MH, Wang X, Zhu X. Mitochondrial defects and oxidative stress in 
Alzheimer disease and Parkinson disease. Free radical biology & medicine. 2013 
Sep;62:90-101. 
262. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current 
concepts of cancer metabolism. Nat Rev Cancer. 2011 May;11(5):325-37. 
263. Cantor JR, Sabatini DM. Cancer cell metabolism: one hallmark, many faces. 
Cancer discovery. 2012 Oct;2(10):881-98. 
264. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of 
cancer: metabolic reprogramming fuels cell growth and proliferation. Cell metabolism. 
2008 Jan;7(1):11-20. 
References 
245 
265. Al-Mehdi AB, Pastukh VM, Swiger BM, Reed DJ, Patel MR, Bardwell GC, et 
al. Perinuclear mitochondrial clustering creates an oxidant-rich nuclear domain required 
for hypoxia-induced transcription. Science signaling. 2012 Jul 3;5(231):ra47. 
266. Lennon FE, Salgia R. Mitochondrial dynamics: biology and therapy in lung 
cancer. Expert opinion on investigational drugs. 2014 May;23(5):675-92. 
267. Chiche J, Rouleau M, Gounon P, Brahimi-Horn MC, Pouyssegur J, Mazure NM. 
Hypoxic enlarged mitochondria protect cancer cells from apoptotic stimuli. Journal of 
cellular physiology. 2010 Mar;222(3):648-57. 
268. Tighe A, Johnson VL, Taylor SS. Truncating APC mutations have dominant 
effects on proliferation, spindle checkpoint control, survival and chromosome stability. 
J Cell Sci. 2004 Dec 15;117(Pt 26):6339-53. 
269. Barth AI, Siemers KA, Nelson WJ. Dissecting interactions between EB1, 
microtubules and APC in cortical clusters at the plasma membrane. J Cell Sci. 2002 Apr 
15;115(Pt 8):1583-90. 
270. Koutsopoulos OS, Laine D, Osellame L, Chudakov DM, Parton RG, Frazier AE, 
et al. Human Miltons associate with mitochondria and induce microtubule-dependent 
remodeling of mitochondrial networks. Biochim Biophys Acta. 2010 May;1803(5):564-
74. 
271. Frederick RL, Shaw JM. Moving mitochondria: establishing distribution of an 
essential organelle. Traffic. 2007 Dec;8(12):1668-75. 
272. Hirokawa N, Noda Y, Tanaka Y, Niwa S. Kinesin superfamily motor proteins 
and intracellular transport. Nat Rev Mol Cell Biol. 2009 Oct;10(10):682-96. 
273. Hirokawa N, Noda Y. Intracellular transport and kinesin superfamily proteins, 
KIFs: structure, function, and dynamics. Physiol Rev. 2008 Jul;88(3):1089-118. 
274. Klopfenstein DR, Vale RD, Rogers SL. Motor protein receptors: moonlighting 
on other jobs. Cell. 2000 Nov 10;103(4):537-40. 
275. Wozniak MJ, Bola B, Brownhill K, Yang YC, Levakova V, Allan VJ. Role of 
kinesin-1 and cytoplasmic dynein in endoplasmic reticulum movement in VERO cells. J 
Cell Sci. 2009 Jun 15;122(Pt 12):1979-89. 
276. Nakata T, Hirokawa N. Point mutation of adenosine triphosphate-binding motif 
generated rigor kinesin that selectively blocks anterograde lysosome membrane 
transport. J Cell Biol. 1995 Nov;131(4):1039-53. 
277. Rosa-Ferreira C, Munro S. Arl8 and SKIP act together to link lysosomes to 
kinesin-1. Dev Cell. 2011 Dec 13;21(6):1171-8. 
278. Chang J, Lee S, Blackstone C. Protrudin binds atlastins and endoplasmic 
reticulum-shaping proteins and regulates network formation. Proc Natl Acad Sci U S A. 
2013 Sep 10;110(37):14954-9. 
References 
246 
279. Stauber T, Simpson JC, Pepperkok R, Vernos I. A role for kinesin-2 in COPI-
dependent recycling between the ER and the Golgi complex. Curr Biol. 2006 Nov 
21;16(22):2245-51. 
280. Brown CL, Maier KC, Stauber T, Ginkel LM, Wordeman L, Vernos I, et al. 
Kinesin-2 is a motor for late endosomes and lysosomes. Traffic. 2005 Dec;6(12):1114-
24. 
281. Etienne-Manneville S, Hall A. Cdc42 regulates GSK-3beta and adenomatous 
polyposis coli to control cell polarity. Nature. 2003 Feb 13;421(6924):753-6. 
282. Jordan MA, Thrower D, Wilson L. Effects of vinblastine, podophyllotoxin and 
nocodazole on mitotic spindles. Implications for the role of microtubule dynamics in 
mitosis. Journal of cell science. 1992 Jul;102 ( Pt 3):401-16. 
283. Coue M, Brenner SL, Spector I, Korn ED. Inhibition of actin polymerization by 
latrunculin A. FEBS letters. 1987 Mar 23;213(2):316-8. 
284. Tanaka Y, Kanai Y, Okada Y, Nonaka S, Takeda S, Harada A, et al. Targeted 
disruption of mouse conventional kinesin heavy chain, kif5B, results in abnormal 
perinuclear clustering of mitochondria. Cell. 1998 Jun 26;93(7):1147-58. 
285. Cui H, Dong M, Sadhu DN, Rosenberg DW. Suppression of kinesin expression 
disrupts adenomatous polyposis coli (APC) localization and affects beta-catenin 
turnover in young adult mouse colon (YAMC) epithelial cells. Experimental cell 
research. 2002 Oct 15;280(1):12-23. 
286. Henthorn KS, Roux MS, Herrera C, Goldstein LS. A role for kinesin heavy 
chain in controlling vesicle transport into dendrites in Drosophila. Mol Biol Cell. 2011 
Nov;22(21):4038-46. 
287. Aoki K, Taketo MM. Adenomatous polyposis coli (APC): a multi-functional 
tumor suppressor gene. J Cell Sci. 2007 Oct 1;120(Pt 19):3327-35. 
288. Hanson CA, Miller JR. Non-traditional roles for the Adenomatous Polyposis 
Coli (APC) tumor suppressor protein. Gene. 2005 Nov 21;361:1-12. 
289. Caldwell CM, Green RA, Kaplan KB. APC mutations lead to cytokinetic 
failures in vitro and tetraploid genotypes in Min mice. J Cell Biol. 2007 Sep 
24;178(7):1109-20. 
290. Um JW, Min DS, Rhim H, Kim J, Paik SR, Chung KC. Parkin ubiquitinates and 
promotes the degradation of RanBP2. The Journal of biological chemistry. 2006 Feb 
10;281(6):3595-603. 
291. Poulogiannis G, McIntyre RE, Dimitriadi M, Apps JR, Wilson CH, Ichimura K, 
et al. PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate 
adenoma development in Apc mutant mice. Proc Natl Acad Sci U S A. 2010 Aug 
24;107(34):15145-50. 
292. Prevarskaya N, Skryma R, Shuba Y. Calcium in tumour metastasis: new roles 
for known actors. Nat Rev Cancer. 2011 Aug;11(8):609-18. 
References 
247 
293. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 Jan 7;100(1):57-
70. 
294. Pate KT, Stringari C, Sprowl-Tanio S, Wang K, TeSlaa T, Hoverter NP, et al. 
Wnt signaling directs a metabolic program of glycolysis and angiogenesis in colon 
cancer. EMBO J. 2014 Jul 1;33(13):1454-73. 
295. Zheng J. Energy metabolism of cancer: Glycolysis versus oxidative 
phosphorylation (Review). Oncology letters. 2012 Dec;4(6):1151-7. 
296. Roderick HL, Cook SJ. Ca2+ signalling checkpoints in cancer: remodelling 
Ca2+ for cancer cell proliferation and survival. Nat Rev Cancer. 2008 May;8(5):361-75. 
297. Whitfield JF. Calcium, calcium-sensing receptor and colon cancer. Cancer 
letters. 2009 Mar 8;275(1):9-16. 
298. Togo T. Ca(2+) regulates the subcellular localization of adenomatous polyposis 
coli tumor suppressor protein. Biochem Biophys Res Commun. 2009 Oct 9;388(1):12-6. 
299. Liu W, Shen SM, Zhao XY, Chen GQ. Targeted genes and interacting proteins 
of hypoxia inducible factor-1. International journal of biochemistry and molecular 
biology. 2012;3(2):165-78. 
300. Kuwai T, Kitadai Y, Tanaka S, Onogawa S, Matsutani N, Kaio E, et al. 
Expression of hypoxia-inducible factor-1alpha is associated with tumor vascularization 
in human colorectal carcinoma. International journal of cancer Journal international du 
cancer. 2003 Jun 10;105(2):176-81. 
301. Myant KB, Cammareri P, McGhee EJ, Ridgway RA, Huels DJ, Cordero JB, et 
al. ROS production and NF-kappaB activation triggered by RAC1 facilitate WNT-
driven intestinal stem cell proliferation and colorectal cancer initiation. Cell stem cell. 
2013 Jun 6;12(6):761-73. 
302. Yoon JC, Ng A, Kim BH, Bianco A, Xavier RJ, Elledge SJ. Wnt signaling 
regulates mitochondrial physiology and insulin sensitivity. Genes Dev. 2010 Jul 
15;24(14):1507-18. 
303. Meijering E, Dzyubachyk O, Smal I. Methods for cell and particle tracking. 
Methods Enzymol. 2012;504:183-200. 
304. Ally S, Larson AG, Barlan K, Rice SE, Gelfand VI. Opposite-polarity motors 
activate one another to trigger cargo transport in live cells. J Cell Biol. 2009 Dec 
28;187(7):1071-82. 
305. Holthuis JC, Ungermann C. Cellular microcompartments constitute general 
suborganellar functional units in cells. Biological chemistry. 2013 Feb;394(2):151-61. 
306. Guzun R, Kaambre T, Bagur R, Grichine A, Usson Y, Varikmaa M, et al. 
Modular organization of cardiac energy metabolism: energy conversion, transfer and 
feedback regulation. Acta physiologica. 2015 Jan;213(1):84-106. 
References 
248 
307. Matsuda S, Nakanishi A, Minami A, Wada Y, Kitagishi Y. Functions and 
characteristics of PINK1 and Parkin in cancer. Frontiers in bioscience. 2015;20:491-
501. 
308. Fardini Y, Dehennaut V, Lefebvre T, Issad T. O-GlcNAcylation: A New Cancer 
Hallmark? Frontiers in endocrinology. 2013;4:99. 
309. Mi W, Gu Y, Han C, Liu H, Fan Q, Zhang X, et al. O-GlcNAcylation is a novel 
regulator of lung and colon cancer malignancy. Biochim Biophys Acta. 2011 
Apr;1812(4):514-9. 
310. Yang YR, Jang HJ, Yoon S, Lee YH, Nam D, Kim IS, et al. OGA 
heterozygosity suppresses intestinal tumorigenesis in Apc(min/+) mice. Oncogenesis. 
2014;3:e109. 
311. Park MK, Ashby MC, Erdemli G, Petersen OH, Tepikin AV. Perinuclear, 
perigranular and sub-plasmalemmal mitochondria have distinct functions in the 
regulation of cellular calcium transport. EMBO J. 2001 Apr 17;20(8):1863-74. 
312. Liu C, Hermann TE. Characterization of ionomycin as a calcium ionophore. J 
Biol Chem. 1978 Sep 10;253(17):5892-4. 
313. MacLeod RJ, Hayes M, Pacheco I. Wnt5a secretion stimulated by the 
extracellular calcium-sensing receptor inhibits defective Wnt signaling in colon cancer 
cells. American journal of physiology Gastrointestinal and liver physiology. 2007 
Jul;293(1):G403-11. 
314. Ying J, Li H, Yu J, Ng KM, Poon FF, Wong SC, et al. WNT5A exhibits tumor-
suppressive activity through antagonizing the Wnt/beta-catenin signaling, and is 
frequently methylated in colorectal cancer. Clinical cancer research : an official journal 
of the American Association for Cancer Research. 2008 Jan 1;14(1):55-61. 
315. Brakeman JS, Gu SH, Wang XB, Dolin G, Baraban JM. Neuronal localization of 
the Adenomatous polyposis coli tumor suppressor protein. Neuroscience. 
1999;91(2):661-72. 
316. Bhat RV, Baraban JM, Johnson RC, Eipper BA, Mains RE. High levels of 
expression of the tumor suppressor gene APC during development of the rat central 
nervous system. J Neurosci. 1994 May;14(5 Pt 2):3059-71. 
317. Lang J, Maeda Y, Bannerman P, Xu J, Horiuchi M, Pleasure D, et al. 
Adenomatous polyposis coli regulates oligodendroglial development. J Neurosci. 2013 
Feb 13;33(7):3113-30. 
318. Fancy SP, Baranzini SE, Zhao C, Yuk DI, Irvine KA, Kaing S, et al. 
Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the 
mammalian CNS. Genes Dev. 2009 Jul 1;23(13):1571-85. 
319. Imura T, Wang X, Noda T, Sofroniew MV, Fushiki S. Adenomatous polyposis 
coli is essential for both neuronal differentiation and maintenance of adult neural stem 
cells in subventricular zone and hippocampus. Stem cells. 2010 Nov;28(11):2053-64. 
References 
249 
320. Yokota Y, Kim WY, Chen Y, Wang X, Stanco A, Komuro Y, et al. The 
adenomatous polyposis coli protein is an essential regulator of radial glial polarity and 
construction of the cerebral cortex. Neuron. 2009 Jan 15;61(1):42-56. 
321. Votin V, Nelson WJ, Barth AI. Neurite outgrowth involves adenomatous 
polyposis coli protein and beta-catenin. Journal of cell science. 2005 Dec 15;118(Pt 
24):5699-708. 
322. Koester MP, Muller O, Pollerberg GE. Adenomatous polyposis coli is 
differentially distributed in growth cones and modulates their steering. J Neurosci. 2007 
Nov 14;27(46):12590-600. 
323. Steketee MB, Moysidis SN, Weinstein JE, Kreymerman A, Silva JP, Iqbal S, et 
al. Mitochondrial dynamics regulate growth cone motility, guidance, and neurite growth 
rate in perinatal retinal ganglion cells in vitro. Investigative ophthalmology & visual 
science. 2012;53(11):7402-11. 
324. Arrazola MS, Silva-Alvarez C, Inestrosa NC. How the Wnt signaling pathway 
protects from neurodegeneration: the mitochondrial scenario. Frontiers in cellular 
neuroscience. 2015;9:166. 
325. Harvey A, Gibson T, Lonergan T, Brenner C. Dynamic regulation of 
mitochondrial function in preimplantation embryos and embryonic stem cells. 
Mitochondrion. 2011 Sep;11(5):829-38. 
326. Ishihara N, Nomura M, Jofuku A, Kato H, Suzuki SO, Masuda K, et al. 
Mitochondrial fission factor Drp1 is essential for embryonic development and synapse 
formation in mice. Nature cell biology. 2009 Aug;11(8):958-66. 
327. Alavi MV, Bette S, Schimpf S, Schuettauf F, Schraermeyer U, Wehrl HF, et al. 
A splice site mutation in the murine Opa1 gene features pathology of autosomal 
dominant optic atrophy. Brain : a journal of neurology. 2007 Apr;130(Pt 4):1029-42. 
328. Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC. Mitofusins 
Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for 
embryonic development. The Journal of cell biology. 2003 Jan 20;160(2):189-200. 
329. Moser AR, Shoemaker AR, Connelly CS, Clipson L, Gould KA, Luongo C, et 
al. Homozygosity for the Min allele of Apc results in disruption of mouse development 
prior to gastrulation. Developmental dynamics : an official publication of the American 
Association of Anatomists. 1995 Aug;203(4):422-33. 
330. Oshima M, Oshima H, Kitagawa K, Kobayashi M, Itakura C, Taketo M. Loss of 
Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice 
carrying a truncated Apc gene. Proc Natl Acad Sci U S A. 1995 May 9;92(10):4482-6. 
331. Yokoyama N, Hayashi N, Seki T, Pante N, Ohba T, Nishii K, et al. A giant 
nucleopore protein that binds Ran/TC4. Nature. 1995 Jul 13;376(6536):184-8. 
332. Wu J, Matunis MJ, Kraemer D, Blobel G, Coutavas E. Nup358, a 
cytoplasmically exposed nucleoporin with peptide repeats, Ran-GTP binding sites, zinc 
References 
250 
fingers, a cyclophilin A homologous domain, and a leucine-rich region. The Journal of 
biological chemistry. 1995 Jun 9;270(23):14209-13. 
333. Lee MW, Bassiouni R, Sparrow NA, Iketani A, Boohaker RJ, Moskowitz C, et 
al. The CT20 peptide causes detachment and death of metastatic breast cancer cells by 
promoting mitochondrial aggregation and cytoskeletal disruption. Cell Death Dis. 
2014;5:e1249. 
334. Zhou H, Zhang B, Zheng J, Yu M, Zhou T, Zhao K, et al. The inhibition of 
migration and invasion of cancer cells by graphene via the impairment of mitochondrial 
respiration. Biomaterials. 2014 Feb;35(5):1597-607. 
 
 
 
